Anlage 2

Transcription

Anlage 2

Anlage 1
Bewertung und Extraktion von Therapiestudien
Nr. Feld
Hinweise für die Bearbeitung
1
Quelle
Fox PA, Nathan M, Francis N, Singh N, Weir J, Dixon G,
Barton SE, Bower M. A double-blind, randomized
controlled trial of the use of imiquimod cream for the
treatment of anal canal high-grade anal intraepithelial
neoplasia in HIV-positive MSM on HAART, with longterm follow-up data including the use of open-label
imiquimod. AIDS 2010, 24:2331-2335
2
Studientyp vom Autor
bezeichnet als
prospektive, doppel-blinde, randomisierte, kontrollierte
Studie
3
Studientyp nach
Durchsicht
Zuordnung zu einem der folgenden Studientypen:
X Therapiestudie mit randomisierter Vergleichsgruppe
□ Therapiestudie mit nicht-randomisierter
Vergleichsgruppe
□ Therapiestudie mit Vergleichen über Zeit und Ort (z. B.
historische Kontrollen)
□ Fallkontrollstudien
□ Kohortenstudien
□ Therapiestudie ohne Vergleichsgruppen (auch „VorherNachher-Studien“)
□ Fallserie
□ Fallbericht / Kasuistik (case report)
□ Nicht eindeutig zuzuordnen
4
Formale Evidenzkriterien
gemäß SIGN
Hier folgt eine formale Zuordnung zu den Evidenzstufen
gemäß SIGN:
□ 1++: Qualitativ hochwertige Metaanalyse bzw.
systematischer Review von RCTs oder RCT mit sehr
geringem Risiko von Bias
X 1+: Gut durchgeführte Metaanalyse bzw. systematischer
Review von RCTs oder RCT mit geringem Risiko von
Bias
□ 1-: Metaanalyse bzw. systematischer Review von RCTs
oder RCT mit hohem Risiko von Bias
□ 2++: Qualitativ hochwertiger systematischer Review von
Fallkontroll- oder Kohortenstudien
Qualitativ hochwertige Fallkontroll- oder Kohortenstudie
mit sehr geringem Risiko von Confounding, Bias oder
Zufallsschwankungen und hoher Wahrscheinlichkeit, dass
der Zusammenhang kausal ist
□ 2+: Gut durchgeführte Fallkontroll- oder Kohortenstudie
mit einem niedrigen Risiko von Confounding, Bias oder
Zufallsschwankungen und einer mittleren Wahrscheinlichkeit, dass der Zusammenhang kausal ist
□ 2-: Fallkontroll- oder Kohortenstudie mit hohem Risiko
von Confounding, Bias oder Zufallsschwankungen und
einem signifikanten Risiko, dass der Zusammenhang nicht
kausal ist
Nr. Feld
□ 3: Andere Studien wie Einzelfallberichte, Fallserien
□ 4: Expertenmeinung
5
Bezugsrahmen
Hintergrund (Kontext) der Publikation: Intraepitheliale
anale Dysplasien (AIN) treten bei HIV-positiven Patienten
häufig auf und können sich zum Analkarzinom
weiterentwickeln. Die zur Zeit für die Behandlung der AIN
verwendeten Methoden (z.B. Laser, Trichloressigsäure
oder chirurgische Exzision) haben eine hohe Rückfallquote
und sind für die Patienten belastend.
Die Studie wurde in 2 Kliniken des NHS Trust (Chelsea und
Westminster Hospital) in England durchgeführt.
Unterstützt wurde sie von der Firma 3M Health Care Ltd.,
die das Verum und das Placebo in äußerlich gleicher
Verpackung zur Verfügung stellte und für die
Randomisierung verantwortlich war.
6
Indikation
Indikation: hochgradige anale intraepitheliale Neoplasie
bei HIV-Patienten
Behandlungsziel: Rückbildung der Neoplasie zu normalem
Analepithel oder zu niedriggradiger analer
intraepithelialer Neoplasie
7
Fragestellung / Zielsetzung
Klinische Studie mit der Fragestellung, ob Imiquimod
effektiver als Placebo in der Behandlung von
intraepithelialen analen Dysplasien bei HIV-Patienten ist.
Langzeit-Nachbeobachtung zur Ermittlung der
Rückfallquote. Erhebung der Nebenwirkungen zum
Vergleich mit anderen Behandlungsmethoden
8
Relevante Ein- und
Ausschlusskriterien
Einschlusskriterien: - hochgradige anale intraepitheliale
Dysplasie (HSIL), - HIV-positiv, - HAART seit mind. 3
Monaten, - CD4-Zellzahl mindestens 100/µl, - keine
vorangegangene Behandlung des Anus mit Imiquimod.
Alle Patienten sind männlich und MSM.
9
Prüfintervention
Selbstapplikation eines halben Sachets Imiquimod
3x/Woche für 4 Monate, anschließend hochauflösende
Anoskopie (HRA) zur Befunderhebung, im weiteren Verlauf
½ jährliche HRA zur weiteren Verlaufskontrolle. NonRespondern wurde im Anschluss an die Behandlung, die
Fortführung mit open-label Imiquimod für weitere 4
Monate angeboten.
10
Vergleichsintervention
Selbstapplikation eines halben Sachets Placebo 3x/Woche
für 4 Monate, anschließend hochauflösende Anoskopie
(HRA) zur Befunderhebung. Im Anschluss wurde den
Patienten die Verum-Therapie angeboten (wie unter Punkt
9 aufgeführt), im weiteren Verlauf ½ jährliche HRA zur
weiteren Verlaufskontrolle
11
Evtl. weitere
Behandlungsgruppen
keine
12
Studiendesign
Anzahl der Behandlungsarme
Typus:
X Parallelgruppendesign
□ Cross-Over Design
□ Prae-Post-Vergleich
□ Sonstige:.........................
2
Nr. Feld
Geplante Fallzahl: 120 Patienten
Wurde eine Fallzahlplanung (Power-Kalkulation)
durchgeführt? Ja. Bei einer angenommenen
Verbesserungsrate von 25% in der Verumgruppe und 5% in
der Placebogruppe wären 116 Patienten nötig gewesen um
eine Signifikanz von 5% und eine Sicherheit von 80% zu
erreichen.
Bei einer angenommenen Verbesserungsrate von 40% in
der Verumgruppe und 0% in der Placebogruppe wären 50
Patienten nötig gewesen um eine Signifikanz von 5% und
eine Sicherheit von 90% zu erreichen.
Waren Interimanalysen geplant? nein
13
Subgruppen
Enthält die Studie Subgruppen, die für die Fragestellung an
die Kommission relevant sind?
X keine relevanten Subgruppen
□ prospektiv geplante Subgruppenauswertung
□ post hoc definierte oder in Auswertung gefundene
Subgruppen
Subgruppen ggf. benennen
14
Zahl der Zentren
An der Studie nahmen 2 Kliniken teil.
15
Randomisierung
Die Firma 3M Health Care Ltd. ermöglichte die
Randomisierung durch die Herstellung von äußerlich
gleich verpacktem Verum und Placebo. Es wurde eine
Randomisierungssequenz erstellt und die Patienten
bekamen in der Reihenfolge ihrer Teilnahme die jeweils
nächste Nummer zugeteilt.
16
Concealment
(„Maskierung“ der
Randomisierung)
Die Randomisierung erfolgte maskiert, Behandler und
Behandelte erfuhren erst nach Ablauf der 4
Behandlungsmonate, ob sie Verum oder Placebo erhalten
hatten.
17
Verblindung der
Behandlung
Erfolgte eine Verblindung der Behandlung?
□ Nein, offene Behandlung
□ Patienten verblindet
□ Behandler verblindet
X Patienten und Behandler verblindet
Patienten erhielten Sachets mit Studiennummern. Ob es
sich dabei um Verum oder Placebo hielt war nicht
erkennbar.
18
Beobachtungsdauer
Behandlungsdauer: 4 Monate, danach Follow-up alle 6
Monate. Die Nachbeobachtungszeit betrug durchschnittlich
36 Monate / nach den 4 verblindeten Behandlungsmonaten
wurde allen Teilnehmern eine (Weiter-)Behandlung mit
open-label Imiquimod angeboten mit Follow-up wie oben.
19
Primäre Zielkriterien
Primäres Zielkriterium: Rückbildung der HSIL in normales
Analepithel oder in niedriggradige anale intraepitheliale
Dysplasie (LSIL).
Wichtig war der lange Nachbeobachtungszeitraum von
durchschnittlich 3 Jahren, da von anderen
Behandlungsmethoden hohe Rückfallquoten bekannt sind.
Die Nachbeobachtung wurde mittels ½-jährlicher HRA
durchgeführt. Die Befunde wurden jeweils von 2
verschiedenen Pathologen erhoben. Bei ungleichen
Befunden wurde der jeweils pathologischere gewertet.
3
Nr. Feld
20
Sekundäre Zielkriterien
Dauer der Befundbesserung
21
Statistische Methoden für
die Analyse der primären
Endpunkte
χ² = 8,78 unter Anwendung der Yates Korrektur mit einem
Freiheitsgrad, P = 0,003
22
Anzahl der behandelten
Patienten
Es wurden 64 Patienten in die Studie aufgenommen, davon
haben 53 die Studie auch komplett durchgeführt. 28
Patienten in der Imiquimod-Gruppe, 25 Patienten in der
Placebo-Gruppe.
Geplant waren ursprünglich 120 Patienten. Mangels
randomisierter Studienmedikation konnten jedoch nicht
mehr als 64 Patienten behandelt werden.
23
Zahl und Charakteristika
der eingeschlossenen und
ausgewerteten Patienten
Sind die Ausfälle von Studienteilnehmern (Drop-outs)
dokumentiert und begründet? Es gab 11 drop-outs, 5 davon
haben die Anwendung der Studienmedikation gar nicht erst
begonnen, 1 Patient aus der Placebogruppe entwickelte ein
Analkarzinom, 1 Patient der Verumgruppe brach wegen
UAW ab, 5 Patienten brachen die Therapie nach wenigen
Wochen ab. Häufigst genannter Grund hierfür:
Unzufriedenheit mit der Situation mit 50-%iger
Wahrscheinlichkeit ein Placebo zu erhalten.
Wie wurde in der Analyse mit Drop-outs verfahren? Dropouts wurden nicht in die Analyse aufgenommen. Es erfolgte
eine per protocol Analyse. Es gibt keine Hinweise auf
systematische und relevante Unterschiede zwischen den
Drop-outs und den durchgängig behandelten Patienten.
Darstellung des Patientenflusses nach dem CONSORTFlussdiagramm? nein, tabellarische Darstellung mit
vergleichbarem Informationsgehalt, siehe unten.
24
Vergleichbarkeit der
Behandlungsgruppen
Dokumentation: Liegen die Angaben, getrennt nach
Behandlungsgruppen, in tabellarischer Form
nachvollziehbar vor (z. B. zu Alter, Geschlecht, relevante
prognostische Faktoren, Begleittherapien etc.)? Ja
Gibt es relevante Unterschiede zwischen den
Behandlungsgruppen? Nein
Wurden die Gruppen bis auf die Intervention gleich
behandelt (Behandlungsgleichheit)? Ja
25
Ergebnisse
Darstellung der Ergebnisse s. u.
Vorrangig sollten hier die Ergebnisse aus der Intention-totreat-Analyse der primären Zielkriterien dargestellt
werden; zusätzlich klinisch besonders relevante
Zielkriterien sowie solche, die in mehreren Studien erhoben
wurden; Angaben soweit verfügbar, eigene Berechnungen
kennzeichnen; für mehrere Studien mit gleichen
Zielkriterien kann es sinnvoll sein, eine gemeinsame
Tabelle anzulegen. Vergleich zu Annahmen bei
Fallzahlplanung.
26
Unerwünschte
Therapiewirkung
Berücksichtigung von unerwünschten Therapiewirkungen,
Risiken und Komplikationen: Dosisfestlegung auf ein
halbes Sachet um Resorption im Rektum (und dadurch
systemische UAW) zu minimieren / nur ein Studienabbruch
in der Verum-Gruppe wegen UAW
4
27
Fazit der Autoren
Die Studie zeigt, dass Imiquimod alleine oder in
Kombination mit anderen Behandlungsmethoden
hochgradige AIN dauerhaft verbessern oder heilen kann.
Der Beweis, dass dadurch auch die Entstehung von
Analkarzinomen verhindert werden kann, steht allerdings
noch aus.
28
Abschließende Bewertung
durch den Bearbeiter
Die vorliegende Publikation wird
X berücksichtigt
□ nicht berücksichtigt
Wenn nicht berücksichtigt: Gründe angeben:
□ Klinisch relevante Patientengruppen nicht berücksichtigt
□ Klinisch relevante Alternativen zum Einsatz der
Technologie nicht berücksichtigt
□ Der in der Studie abgebildete Entwicklungsstatus der
Technologie entspricht nicht mehr heutigen Ansprüchen
□ Keine (patienten-)relevanten Endpunkte
□ Nicht auf den deutschen Versorgungskontext übertragbar
□ Erheblich eingeschränkte Validität der Ergebnisse
aufgrund schwerwiegender Mängel im Studiendesign
□ Es liegen aussagekräftigere Studien vor.
□ Sonstige Gründe – und zwar:
Ergebnisdarstellung für dichotome Zielkriterien
Anzahl Patienten mit
Verbesserung o. Heilung / Anzahl
Zielkriterium aller Patienten
Verum
Erfolg nach 12 / 28 (43%)
4-monatiger
Behandlung
Kontrolle
1 / 25 (4%)
Schätzer und
Maß für
95% KonfidenzGruppenintervall für
unterschied Gruppenunterschied
p-Wert
(optional)
Odds Ratio 2.13-152.35
= 18
0,003
Zu Feld 23+24:
5
Zu Feld 25:
6
Anlage 2
PubMed-MedLine Recherche vom 11. Januar 2011
Suche nach: anal + imiquimod => 38 Treffer
1. AIDS. 2010 Sep 24;24(15):2331-5.
A double-blind, randomized controlled trial of the use of imiquimod cream for the
treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive
MSM on HAART, with long-term follow-up data including the use of open-label
imiquimod.
Fox PA, Nathan M, Francis N, Singh N, Weir J, Dixon G, Barton SE, Bower M.
Chelsea and Westminster Hospital NHS Trust, London, UK. [email protected]
OBJECTIVE: To determine whether imiquimod was more effective than placebo for the
treatment of high-grade anal canal intraepithelial neoplasia (HG-ACIN).
DESIGN: Double-blind, randomized placebo-controlled clinical trial.
METHODS: Sixty-four HIV-positive patients were randomized to self-application of
imiquimod cream or matched placebo into the anal canal three times a week for 4
months. Response was assessed by cytology, high-resolution anoscopy and biopsy 2
months after therapy. All patients who failed to resolve were offered treatment
with open-label imiquimod for a further 4 months.
RESULTS: Fifty-three patients completed the study, of which 28 patients were on
active drug and 25 patients on placebo. In the imiquimod group, four patients
resolved and eight patients downgraded to low-grade squamous intraepithelial
lesion (LSIL) with a median follow-up of 33 months. In the placebo group, one
patient resolved. Imiquimod was significantly associated with a positive outcome
(P = 0.003). Only one patient discontinued owing to side effects. Twenty-one
patients entered a second open-label phase of treatment. Five of these patients
cleared their anal canal intraepithelial neoplasia (ACIN) and four patients
downgraded to LSIL. The overall mean duration of follow-up was 36 months. During
this extended follow-up period, 61% have exhibited sustained absence of
high-grade squamous intraepithelial lesion (HSIL).
CONCLUSION: This study demonstrates the effectiveness of imiquimod for the
treatment of ACIN, and the benefit of prolonged or repeated treatments. This form
of therapy is likely to be especially valuable for patients with widespread
multifocal ACIN who are otherwise difficult to treat, and should be considered as
an adjunct to ablative therapy.
PMID: 20729710 [PubMed - in process]
2. Clin Colon Rectal Surg. 2009 May;22(2):127-35.
Malignancies of the anal margin and perianal skin.
Wietfeldt ED, Thiele J.
Department of Surgery, Southern Illinois University School of Medicine,
Springfield, Illinois, USA.
Malignancies of the anal margin and perianal skin are relatively uncommon
lesions, comprising 3 to 4% of all anorectal malignancies. Commonly included in
this group of cancers are Bowen's disease (intraepithelial squamous cell cancer),
perianal Paget's disease (intraepithelial adenocarcinoma), invasive squamous cell
cancer, basal cell cancer, and malignant melanoma. Buschke-Lowenstein tumor, or
giant condyloma acuminatum, is not always included because this lesion is
technically benign, although it displays aggressive local invasive behavior that
makes it difficult to manage. Complaints are usually nonspecific, such as itching
or burning, bleeding, pain, drainage, or a mass. Proper diagnosis requires a high
index of suspicion on the part of the surgeon. Innocent local irritations will
resolve in a short time with appropriate therapy; those that persist must be
biopsied for tissue diagnosis. Wide local excision is the mainstay of treatment
for early stage tumors as it preserves continence and obtains adequate local
control. Adjunct therapies have been utilized in more advanced or recurrent
lesions, including radiotherapy, photodynamic therapy, and imiquimod. All have
met with a fair amount of success in controlling local disease; however, the
number of patients treated in each instance is small, making it difficult to
design an evidence-based treatment strategy. Invasion and metastasis are
relatively rare in this group of neoplasms; perianal Paget's disease has the
highest risk of associated underlying neoplasm. The most important consideration
in developing a treatment strategy is which strategy would achieve the best
clinical result with the least morbidity to the patient.
PMCID: PMC2780245
PMID: 20436838 [PubMed]
3. Colorectal Dis. 2010 Mar 10. [Epub ahead of print]
What Should We Do About Anal Condyloma and Anal Intraepithelial Neoplasia?
Results of a Survey.
Dindo D, Nocito A, Schettle M, Clavien PA, Hahnloser D.
Department of Surgery, Division of Visceral and Transplantation Surgery,
University Hospital, CH-8091 Zurich, Switzerland.
Abstract Aim: The incidence of human papilloma virus (HPV) related anal infection
and invasive anal squamous cell cancer is increasing dramatically. At present
there is a lack of standardization regarding diagnosis, treatment and
surveillance of patients with anal HPV infection. Method: An internet-based
survey was sent to members of international, surgical and dermatological
societies. Answers were obtained from 1017 dermatologists and 393 colorectal
surgeons (n=1410). Results: More dermatologists than surgeons provided
non-invasive treatment of anal condyloma with 5% imiquimod (80.4 percent vs. 28.2
percent; P<0.001) whereas the situation is reversed for surgical excision (56.8
percent vs. 91.3 percent; P<0.001). To detect dyplastic lesions, 42.0 percent of
surgeons used acetic acid only, 23.2 percent use this in combination with
high-resolution anoscopy (HRA) and 19.5 percent applied intra-anal cytological
smears. Similarly, 64.6 percent of dermatologists applied acetic acid only, 16.5
percent combined acetic acid with HRA, and 30.2 percent performed intra-anal
cytological smears (all P<0.001 compared to surgeons). The therapy for anal
intraepithelial lesions was not influenced by the grade of dysplasia but it was
by immune status. Conclusions: There were significant differences in practice
between colorectal surgeons and dermatologists. These findings highlight the need
for international and cross-disciplinary clinical guidelines.
PMID: 20236146 [PubMed - as supplied by publisher]
4. Surg Clin North Am. 2010 Feb;90(1):99-112, Table of Contents.
Condyloma and other infections including human immunodeficiency virus.
Lee PK, Wilkins KB.
UMDNJ-Robert Wood Johnson University Hospital, New Brunswick, NJ, USA.
Sexually transmitted diseases (STDs) are a common public health problem and as
such may be more common in a surgical practice than is believed. The recognition
that a virus can be responsible for a cancer has profound significant public
health implications. This article reviews the presentation and management of the
more common perianal STDs including human immunodeficiency virus, as well as the
pathogenesis and management of anal intraepithelial neoplasia.
PMID: 20109635 [PubMed - indexed for MEDLINE]
5. Int J STD AIDS. 2010 Jan;21(1):8-16.
More than a decade on: review of the use of imiquimod in lower anogenital
intraepithelial neoplasia.
Mahto M, Nathan M, O'Mahony C.
Department of Genitourinary Medicine, Cheshire East Community Health (Central and
Eastern Cheshire PCT), Assura Health and Wellness Centre, Sunderland Street,
Macclesfield SK11 6JL. [email protected]
To assess the effectiveness of 5% imiquimod cream (IQ) in the treatment of
vulvar, penile and anal intraepithelial neoplasias (VIN, PIN and AIN), we
searched Medline, Embase, PubMed and Cochrane Library databases. With regard to
VIN there were two randomized controlled trials (RCTs), eight uncontrolled/cohort
studies, nine case reports and one review article. Use of IQ in PIN and AIN were
only supported by cohort studies (two each for PIN and AIN) and case reports (15
for PIN and 3 for AIN). On pooled analysis of RCTs, uncontrolled and cohort
studies, the mean complete response (CR) rate for VIN, PIN and AIN were 51%, 70%
and 48%, respectively. The mean partial response (PR) rate for VIN, PIN and AIN
were 25%, 30% and 34% respectively. The recurrence (RR) rate for VIN, PIN and AIN
were 16%, 0% and 36%, respectively. The follow-up period for VIN, PIN and AIN
ranged from 2 to 32 months, 10 to 12 months and 11 to 39 months, respectively.
Although the results for PIN look the best, the strongest evidence regarding
efficacy of IQ in anogenital intraepithelial neoplasia is for VIN supported by
RCTs. Evidence for use of IQ in AIN was essentially limited to HIV-positive men
who have sex with men. IQ was reasonably well tolerated with side-effects being
managed with reduction in frequency of drug usage and/or rest periods. Based on
these results, IQ seems to be a safe mode of treatment and is possibly an
alternative to currently available methods of treatment. However, there are no
comparative studies assessing its efficacy against traditional modes of
treatment.
6. Vaccine. 2009 Apr 14;27(17):2326-34. Epub 2009 Feb 20.
Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like
particles.
Fraillery D, Zosso N, Nardelli-Haefliger D.
Institute of Microbiology, Centre Hospitalier Universitaire Vaudois and
University of Lausanne, Bugnon 48, CH-1011 Lausanne, Switzerland.
Human papillomavirus (HPV) vaccines based on L1 virus-like particle (VLP) can
prevent genital HPV infection and associated lesions after three intramuscular
injections. Needle-free administration might facilitate vaccine implementation,
especially in developing countries. Here we have investigated rectal and vaginal
administration of HPV16 L1 VLPs in mice and their ability to induce anti-VLP and
HPV16-neutralizing antibodies in serum and in genital, rectal and oral
secretions. Rectal and vaginal immunizations were not effective in the absence of
adjuvant. Cholera toxin was able to enhance systemic and mucosal anti-VLPs
responses after rectal immunization, but not after vaginal immunization. Rectal
immunization with Resiquimod and to a lesser extent Imiquimod, but not
monophosphoryl lipid A, induced anti-HPV16 VLP antibodies in serum and
secretions. Vaginal immunization was immunogenic only if administered in mice
treated with nonoxynol-9, a disrupter of the cervico-vaginal epithelium. Our
findings show that rectal and vaginal administration of VLPs can induce
significant HPV16-neutralizing antibody levels in secretions, despite the fact
that low titers are induced in serum. Imidazoquinolines, largely used to treat
genital and anal warts, and nonoxonol-9, used as genital microbicide/spermicide
were identified as adjuvants that could be safely used by the rectal or vaginal
route, respectively.
7. Acta Dermatovenerol Alp Panonica Adriat. 2009 Mar;18(1):7-11.
Proctoscopy should be mandatory in men that have sex with men with external
anogenital warts.
Mlakar B.
RoZna Dolina Surgical Centre, Department for Abdominal Surgery and Proctology,
RoZna dolina cesta IV/45, 1000 Ljubljana, Slovenia.
INTRODUCTION: The aim of this study was to evaluate anal pathology in men having
sex with men (MSM) seen at our proctology outpatient clinics.
METHODS: The charts of 74 MSM treated by the author between January 2002 and
April 2006 were reviewed.
RESULTS: Three of 74 patients (4%) had proctitis and 96% had anogenital
condylomata acuminata (warts). 49 out of 71 (69%) had external anogenital as well
as intra-anal warts and 13 (18%) had only intra-anal warts. In 14 an intra-anal
dysplasia and in 2 patients intra-anal verrucous carcinomas were detected. The
average duration of disease before referral to our institutions was more than 9
months. Half of the patients were previously treated for anogenital warts with
ointments and suppositories at other institutions, including 17 that were
"treated" with ointments and/or suppositories for hemorrhoids prescribed by
family physicians. The patients mostly had widespread disease and sixty-nine of
them required surgery. In the follow-up period there was no recurrence of warts
and only itching was observed in 31 (44%) patients. Therapy with imiquimod was
introduced for 3 months in twenty-two cases with intra-anal dysplasia. No major
side effects were noticed despite intra-anal use.
CONCLUSION: Proctoscopy and histological examination of intra-anal lesions in
cases of external anogenital warts should be mandatory in MSM patients. I would
like to encourage other physicians to use this approach, which enables detection
of intra-anal warts, dysplasia, and even carcinoma in the asymptomatic stage.
8. Dermatol Online J. 2009 Jan 15;15(1):14.
Comparison of podophyllotoxin and imiquimod as anal condyloma acuminata therapy.
Krishna S.
Comment on:
Dermatol Online J. 2008;14(12):8.
Herein we revisit the published evidence for comparison of the efficacy of
imiquimod and podophyllotoxin for anal condyloma acuminata.
9. J Dtsch Dermatol Ges. 2008 Nov;6(11):925-34. Epub 2008 Apr 12.
Anal intraepithelial neoplasia in HIV infection.
[Article in English, German]
Kreuter A, Brockmeyer NH, Altmeyer P, Wieland U; German Competence Network
HIV/AIDS.
Department of Dermatology, Ruhr University Bochum, Germany. [email protected]
Human papillomavirus (HPV) infections belong to the most common sexually
transmitted infections worldwide. While the immune system eliminates most HPV
infections over time in immunocompetent individuals, HPV infections tend to
persist in immunodeficient individuals. In HIV-infected men who have sex with men
(MSM), anal HPV prevalence is more than 90% and infections with multiple HPV
types are common. Consequently, HPV-associated anogenital malignancies occur with
high frequency in patients with HIV infection. Anal intraepithelial neoplasia
(AIN) is a potential precursor lesion of squamous cell carcinoma of the anus.
Like its cervical counterpart, cervical intraepithelial neoplasia (CIN), AIN is
causally linked to persistent infections with high-risk HPV types such as HPV16
or HPV18. As AIN and CIN share distinct biological similar-ities, AIN screenings
analogous to Pap smear programs for CIN have been recommended in high-risk
populations to reduce the incidence of anal carcinoma. These screenings include
cytological analysis followed by high resolution anoscopy in case of anal
dysplasia. Treatment guidelines for AIN are not yet available. Therapeutic
strategies can be divided into topical (e.g. trichloroacetic acid,
podophyllotoxin, imiquimod, photodynamic therapy) and ablative (e. g. surgical
excision, laser ablation, infrared coagulation, electrocautery) measures.
However, controlled studies on AIN treatment have not been performed. The impact
of HPV vaccination on AIN development will also need to be assessed. Long-term
follow-up of these patients is essential to gain more insight into the natural
history of anogenital HPV infection in HIV-positive MSM.
10. J Invest Dermatol. 2008 Aug;128(8):2078-83. Epub 2008 Feb 14.
Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained
clearance of anal intraepithelial neoplasia in HIV-infected men.
Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Stücker M, Altmeyer P,
Swoboda J, Pfister H, Wieland U; German Competence Network HIV/AIDS.
Collaborators: Adam A, Schewe K, Weitner L, Aratesh K, Arendt G, Bartz C, Behrens
G, Beichert M, Bieniek B, Cordes C, Bochow M, Brockmeyer N, Buchholz B, Bogner
JR, Buhk T, Clad A, Dannecker M, Dupke S, von Einsiedel R, Esser S, Faetkenheuer
G, Fischer K, Freiwald M, Friebe-Hoffmann U, Fenske S, Funk M, Ganschow R,
Gingelmaier A, Glaunsinger T, Goebel FD, Gölz J, Grosch-Wörner I, Haberl A,
Hamouda O, Harrer T, Hartmann M, Hartl H, Hölscher M, Hower M, Husstedt IW,
Jansen K, Jäger H, Jessen H, Jessen A, Karwat M, Klausen G, Kirchhoff F, Knechten
H, Köppe S, Kreuter A, Kuhlmann B, Langer P, Lauenroth-Mai, Lehmacher W, Lehmann
M, Levin C, Lübke M, Maschke M, Marcus U, Mauss S, Meyerhans A, Meyer-Olson D,
ter Meulen V, Michalik C, Moll A, Mosthaf FA, Mutz A, Neuen-Jacob E, Niehues T,
Oette M, Paulus U, Plettenberg A, Potthoff A, Racz P, Racz K, Rasokat H, Rausch
M, Reichelt D, Reitter A, Rieke A, Rockstroh J, Salzberger B, Schafberger A,
Schauer J, Schlote F, Schmidt B, Schranz D, Scholten S, Schuler C, Schwab M,
Schmidt W, Schmidt R, Schwarze S, Siffert W, Skaletz-Rorowski A,
Sonnenberg-Schwan U, Sopper S, Spengler U, Staszewski S, Steffan E, Stellbrink
HJ, Stoll M, Goecke T, Taubert S, Telschik A, Ulmer A, Ullrich R, Uberla K,
Usadel S, Vogel M, Wagner R, Walter H, Warnatz K, Wasem J, Wiesel W, Von
Weizsäcker K, Wieland U, Wintergerst U, Wolf E, Wolf H, Wünsche T, Wyen Ch, Zeitz
M, Zylka-Menhorn V.
1Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.
Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated
precursor lesion of anal carcinoma, is highly prevalent in HIV-infected men
having sex with men (MSM). This prospective follow-up study evaluated the
long-term results of imiquimod treatment of AIN in 19 HIV-infected MSM.
Standardized follow-up examinations included high-resolution anoscopy, anal
cytology/histology, HPV typing, and DNA load determination for HPV types 16, 18,
31, and 33. Mean follow-up time was 30.3 months. A total of 74% (14/19) of the
patients remained free of AIN at the previously treated site. Five patients (26%)
had recurrent high-grade AIN after a mean time of 24.6 months. At the end of
follow-up, the numbers of HPV types as well as high-risk HPV-DNA loads were
significantly lower than before therapy. During follow-up, 58% of all patients
(11/19) developed new anal cytological abnormalities in previously normal,
untreated anal regions. 55% of these new AIN lesions were high-grade lesions and
most of them were located intra-anally and associated with high-risk HPV types
not detectable before therapy. These results demonstrate that imiquimod leads to
a high rate of long-term clearance of AIN in HIV-positive men together with a
prolonged decrease of high-risk HPV-DNA load. However, new AIN lesions associated
with previously undetected HPV types frequently occur in untreated areas.
11. Dermatol Online J. 2008 Dec 15;14(12):8.
Intra-anal condyloma: surgical or topical treatment?
Dianzani C, Pierangeli A, Avola A, Borzomati D, Persichetti P, Degener AM.
Department of Dermatology, "Campus Biomedico," University of Rome, Italy.
[email protected]
Comment in:
Dermatol Online J. 2009;15(1):14.
Human Papillomavirus infections are the strongest risk factors for genital cancer
and are the causative agents of anogenital warts. Although the viral types
associated with condylomata usually do not cause carcinoma, in women with a
history of these lesions there is an increased risk of intraepithelial neoplasia
and cancer. Generally the lesions are not life-threatening, but they provoke
significant morbidity, are difficult to treat, and are a source of psychosocial
stress. Thus, condylomata represent not only a health problem for the patient but
also an economic burden for the society. Considering the individual episodes of
care, men experience a longer duration of the lesions and incur greater costs
than women. We report a case of a male patient with external and intra-anal
condyloma resistant to laser therapy. Initially, surgical intervention appeared
required because of florid and intra-anal growth. HPV DNA testing and sequencing
revealed the presence of HPV 6. After initial discomfort, the lesions were
successfully cleared with topical imiquimod 5 percent cream therapy.
12. Br J Dermatol. 2007 Dec;157 Suppl 2:52-5.
Evaluation of imiquimod for the therapy of external genital and anal warts in
comparison with destructive therapies.
Schöfer H.
Department of Dermatology and Venerology, University Hospital, J.W. Goethe
University, Theodor-Stern-Kai 7, 60590 Frankfurt/M, Germany.
[email protected]
External genital and anal warts (acuminate condyloma) were the first medical
indication the topical immune response modifier imiquimod was approved for in
1997. Since then, many placebo controlled randomized clinical trials have
demonstrated the efficacy and safety of this synthetic imidazoquinoline derivate
for the treatment of different human papillomavirus infections and tumours.
Treatment modalities for genital warts (5% cream, three times weekly, minimum
duration 4 weeks, control of side-effects) have been optimized and assured by
further clinical trials and meta-analyses. For a few years clinical studies
focussed on the long-term efficacy of the immunomodulatory therapy (sustained
clearance from warts) and most recent studies compared the efficacy of ablative,
destructive and imiquimod monotherapy as well as combination therapies.
13. Dis Colon Rectum. 2007 Dec;50(12):2173-9.
Earlier eradication of intra-anal warts with argon plasma coagulator combined
with imiquimod cream compared with argon plasma coagulator alone: a prospective,
randomized trial.
Viazis N, Vlachogiannakos J, Vasiliadis K, Theodoropoulos I, Saveriadis A,
Karamanolis DG.
2nd Department of Gastroenterology, Evangelismos Hospital, 59 Niriidon Street,
17561 P. Faliro, Athens, Greece. [email protected]
PURPOSE: Despite the increasing incidence of condylomata acuminate, optimal
treatment of anal warts is still undecided. This prospective, randomized study
was designed to compare the efficacy of combined argon plasma coagulation and
imiquimod cream vs. argon plasma coagulation alone in the management of
intra-anal warts.
METHODS: From October 2002 to March 2005, 49 patients with intra-anal warts were
randomly assigned to argon plasma coagulation plus imiquimod cream (n = 24) vs.
argon plasma coagulation alone (n = 25). Therapeutic sessions were repeated until
the elimination of the warts. Efficacy of therapy was defined as the time needed
for eradication. All patients were followed up for a mean period of 12 months for
signs of recurrence.
RESULTS: Elimination of warts was achieved earlier in patients receiving
combination therapy compared with those receiving monotherapy with argon plasma
coagulation (62.5 +/- 5.4 days vs. 91.2 +/- 6.4 days; P = 0.0016). A subgroup
analysis performed in HIV-positive patients showed similar results (combination
therapy 95 +/- 22.6 days; monotherapy 124.3 +/- 20.7 days; P = 0.033); however,
in HIV-positive patients warts were eradicated later compared with HIV-negative
patients (110.8 +/- 25.7 days vs. 65 +/- 25.4 days; P < 0.0001). No major
complications were observed in our study population. After the follow-up period,
recurrence of warts was evident in 22.7 percent of patients in the combination
group compared with 34.7 percent of patients in the monotherapy group (P = 0.51).
Recurrence was significantly higher in HIV-positive patients compared with
HIV-negative patients (P = 0.0039).
CONCLUSIONS: Combination therapy with argon plasma coagulator plus imiquimod
cream results in earlier clearance of intra-anal warts in both immunocompetent
and immunocompromised patients; however, it does not affect the rate of
recurrence.
14. J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1054-60.
Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of
HIV-positive patients treated with imiquimod for anogenital warts and anal
Sanclemente G, Herrera S, Tyring SK, Rady PL, Zuleta JJ, Correa LA, He Q, Wolff
JC.
Dermatology Section, Department of Internal Medicine, University of Antioquia,
Medellín, Colombia. [email protected]
OBJECTIVE: To evaluate the efficacy of 5% imiquimod in HIV-positive male patients
with anogenital warts or anal intraepithelial neoplasia (AIN), and to elucidate
whether human papillomavirus (HPV) type and viral load were important for
clinical outcome and recurrences.
METHODS: Thirty-seven patients with histologically proven anogenital warts or AIN
were enrolled. Topical 5% imiquimod was applied three times per week for more
than 8 h overnight for 16 weeks, although patients were allowed to continue
therapy for 4 more weeks if they did not have complete clearance of lesions.
RESULTS: Mean age was 34 years. The perianal area was the main lesion location.
Thirty-three patients had CD4 counts of < 500 cells/mm(3). Eighteen patients had
a histopathological diagnosis of AIN-1. Main HPV types detected corresponded to
low-risk HPV types. At 20 weeks of therapy, 46% patients achieved total clearance
whereas 14 patients had > 50% clearance. Recurrence was observed in 5 of 17
patients who cleared. Clearance was not influenced by patients' CD4 counts, wart
location, HIV viral load or HPV viral load.
CONCLUSIONS: The assumption that visible perianal warts are benign lesions in
HIV-positive patients has to be reevaluated since an important number of such
lesions could correspond to low-grade anal disease, which in turn could progress
to high-grade anal disease or cancer. In addition, our results in this
preliminary study indicate that imiquimod appears to be effective in treating AIN
in HIV-positive patients. Further studies are needed to document its utility to
prevent high-grade dysplasia and/or anal cancer.
15. Br J Dermatol. 2007 Sep;157(3):523-30. Epub 2007 Jun 15.
p16ink4a expression decreases during imiquimod treatment of anal intraepithelial
neoplasia in human immunodeficiency virus-infected men and correlates with the
decline of lesional high-risk human papillomavirus DNA load.
Kreuter A, Wieland U, Gambichler T, Altmeyer P, Pfister H, Tenner-Racz K, Racz P,
Potthoff A, Brockmeyer NH; for the German Network of Competence HIV/AIDS.
Department of Dermatology and Allergology, Ruhr-University Bochum, Gudrunstrasse
56, D-44791 Bochum, Germany. [email protected]
BACKGROUND: Human papillomavirus (HPV)-associated anogenital cancers and their
precursor lesions occur in excess in human immunodeficiency virus (HIV)-infected
patients despite the initiation of highly active antiretroviral therapy. In this
context, a drastically increased relative risk for anal intraepithelial neoplasia
(AIN) exists in HIV-infected men having sex with men (MSM). In a pilot study,
imiquimod, a topical immune response modifier, has been reported to be beneficial
in the treatment of AIN.
OBJECTIVES: To investigate the role of several biomarkers as potential adjuncts
in the course of imiquimod treatment for AIN, and to determine whether these
markers correlate with the course of high-risk HPV DNA load during imiquimod
therapy.
METHODS: Immunohistochemical staining was performed for p16(ink4a),
minichromosome maintenance protein (MCM), Ki67, proliferating cell nuclear
antigen (PCNA) and p21(waf1) expression before and after 16 weeks of imiquimod
treatment for AIN. High-risk HPV DNA load determinations were performed by
real-time polymerase chain reaction with type-specific primers and probes for HPV
types 16, 18, 31 and 33.
RESULTS: Histopathological and virological analyses were performed in 21
HIV-infected MSM with histologically confirmed AIN. Eighteen (86%) patients had a
complete histological clearance of AIN after imiquimod therapy. As previously
shown, lesional high-risk HPV DNA load significantly decreased during imiquimod
therapy. Moreover, a significant decline of p16(ink4a), Ki67, MCM and PCNA
expression after treatment was observed, while p21(waf1) expression changed
nonsignificantly after imiquimod therapy. A significant correlation between the
course of high-risk HPV DNA load and p16(ink4a) expression was observed during
imiquimod treatment of AIN, whereas the decline of high-risk HPV DNA load did not
significantly correlate with MCM, Ki67, PCNA or p21(waf1) expression.
CONCLUSIONS: The significant decrease in p16(ink4a) expression in correlation
with the drop of lesional high-risk HPV load suggests that p16(ink4a) may be a
useful adjunct for the evaluation of treatment response in HPV-associated
malignancies and their precursor lesions.
16. Med Sci Monit. 2007 Jun;13(6):CS75-7.
A therapeutic approach to perianal extramammary Paget's disease: topical
imiquimod can be useful to prevent or defer surgery.
Vereecken P, Awada A, Ghanem G, Marques da Costa C, Larsimont D, Simoens C,
Mendes da Costa P, Hendlisz A.
Departments of Dermatology, CHU-Brugmann Hospital, Brussels, Belgium.
[email protected]
BACKGROUND: Extramammary Paget's disease (EMPD) is a rare skin disease which can
be limited to the epidermis and can sometimes also be associated with underlying
carcinomas. At clinical examination, lesions are well-defined eczematous areas
and have been described typically in the anogenital region. Surgery is the
cornerstone treatment.
CASE REPORT: In this report the case of a 66-year-old patient presenting with a
long-lasting EMPD of perianal region without deep gastrointestinal neoplasia is
described. Because of the extension of the lesion, surgery should have led to
abdominoperineal amputation, but the patient rejected this option. Three months
of daily application of topical imiquimod was prescribed as an alternative
treatment. Biopsy-confirmed complete regression could be observed thereafter, and
no recurrence has been noted during a 12-month follow-up.
CONCLUSIONS: This successful treatment of a perianal-located EMPD by topical
imiquimod warrants further investigations.
17. Transpl Infect Dis. 2008 Feb;10(1):56-8. Epub 2007 May 19.
Giant anal condylomatosis after allogeneic bone marrow transplantation: a rare
complication of human papilloma virus infection.
Ganguly N, Waller S, Stasik CJ, Skikne BS, Ganguly S.
Department of Medicine, The University of Kansas Medical Center, Kansas City,
Kansas 66160, USA. [email protected]
Condyloma acuminata or genital warts are caused by human papilloma virus (HPV).
Ongoing proliferation of HPV in patients with congenital or acquired
immunodeficiency states leads to the development of rapidly progressive and
sometimes locally invasive tumor with or without dysplasia. Aggressive treatment,
diagnostic immuno-typing, and follow-up are necessary in patients with ongoing
immunosuppression. We report a case of giant ano-genital condylomatosis due to
HPV types 6 and 11 in a patient with chronic myeloid leukemia after allogeneic
bone marrow transplantation. The tumor was successfully treated with surgical
excision and local application of 5% imiquimod cream.
18. Int J Dermatol. 2007 Mar;46(3):318-9.
Successful treatment of perianal Bowen's disease with imiquimod.
van Egmond S, Hoedemaker C, Sinclair R.
University of Melbourne Department of Medicine (Dermatology), St. Vincent's
Hospital, Fitzroy, Australia.
Although perianal Bowen's disease (BD) is a relatively uncommon malignancy, it is
being detected with increasing frequency. It has a strong tendency for local
recurrence and treatment remains controversial. The effectiveness of different
treatment modalities, ranging from aggressive wide local excision with skin
grafting to the application of a topical immune response modifier, remains
uncertain. To our knowledge only two cases of perianal BD, successfully treated
with imiquimod, have been reported. We wish to present the third case,
effectively treated with imiquimod.
19. Arch Dermatol. 2006 Nov;142(11):1438-44.
Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men.
Wieland U, Brockmeyer NH, Weissenborn SJ, Hochdorfer B, Stücker M, Swoboda J,
Altmeyer P, Pfister H, Kreuter A.
Institute of Virology, University of Cologne, Cologne, Germany.
OBJECTIVE: To evaluate the treatment of anal intraepithelial neoplasia (AIN) with
the local immune response modifier imiquimod in human immunodeficiency virus
(HIV)-positive men who have sex with men (MSM).
DESIGN: Prospective, nonrandomized, open-label pilot study, with a mean follow-up
time of 9(1/2) months.
SETTING: Dermatology department of a university hospital. Patients Twenty-eight
consecutive HIV-positive MSM with histologically confirmed perianal (n = 23) or
intra-anal (n = 5) AIN. Intervention Overnight treatment with self-applied
imiquimod cream (perianal AIN) or suppositories (intra-anal AIN) 3 times a week
for 16 weeks.
MAIN OUTCOME MEASURES: Response to treatment was documented using clinical,
cytologic, and histologic criteria. Human papillomavirus (HPV) typing and HPV DNA
load determination for the high-risk HPV types 16, 18, 31, and 33 were performed.
RESULTS: Seventeen (61%) of all 28 patients included in the study and 17 (77%) of
the 22 patients with AIN, who applied imiquimod as instructed, showed clinical
and histologic clearance at the end of therapy. Four patients had residual AIN
and 1 patient did not improve. Clinical response was accompanied by a sharp
decline in HPV DNA loads and by a reduction in the number of HPV types, but
long-term HPV clearance was rarely achieved. In the follow-up period, AIN cleared
in 3 patients with residual AIN. Fourteen (78%) of 18 imiquimod responders with
at least 5 five months of follow-up had a normal cytologic and clinical picture
at the end of the follow-up period. Three primary responders developed a
recurrence. In 6 noncompliant patients, there was no clinical or morphological
improvement and the HPV DNA loads remained high.
CONCLUSIONS: Imiquimod appears to be a safe and effective treatment option for
AIN in HIV-positive MSM. Clinical response is accompanied by a significant
decrease in high-risk HPV DNA load. These results should encourage controlled
randomized studies of imiquimod treatment of AIN.
20. Ann Urol (Paris). 2006 Jun;40(3):175-8.
[Buschke-Löwenstein tumour: diagnosis and treatment].
[Article in French]
Lévy A, Lebbe C.
Service de dermatologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010
Paris, France. [email protected]
Buschke-Löwenstein tumour is classified as a verrucous carcinoma. It presents
like an exophytic tumour of the genital or peri-anal area, with ulceration and
sometimes fistulae and sinuses. It is preferentially seen in men and
immunocompromised patients. Histological appearance is not far from condyloma
acuminata, but with a tendency to compress and displace deeper tissues, without
basement membrane disruption. HPV types 6 or 11 are regularly found in
association with this tumour. Other STI have to be searched. Physical examination
and precise imagery are useful to chose the right treatment regimen. Radical
excision is recommended to avoid malignant transformation, but has to be large
because of the high number of recurrences. Other treatment modalities such as
chemotherapy or imiquimod could be of interest to avoid mutilating surgical
interventions. A regular follow-up is necessary because of frequent recurrences
and possible malignant transformation.
21. Arch Dermatol. 2006 Feb;142(2):243-4.
5% imiquimod suppositories decrease the DNA load of intra-anal HPV types 6 and 11
in HIV-infected men after surgical ablation of condylomata acuminata.
Kreuter A, Brockmeyer NH, Weissenborn SJ, Wafaisade A, Pfister H, Altmeyer P,
Wieland U; German Competence Network HIV/AIDS.
22. Curr Opin Infect Dis. 2006 Feb;19(1):62-6.
Human papillomavirus and anal intraepithelial neoplasia.
Fox PA.
Department of HIV and Genitourinary Medicine, Chelsea and Westminster Hospital,
London, UK. [email protected]
PURPOSE OF REVIEW: A review of recent developments in the understanding of the
natural history of anal squamous carcinoma arising from areas of high-grade anal
RECENT FINDINGS: Anal intraepithelial neoplasia is a consequence of chronic human
papillomavirus infection in the anal canal and appears to be driven by high viral
loads of human papillomavirus. In men who have sex with men with multiple sexual
partners prevalent human papillomavirus infection does not decline with age, in
contrast to heterosexual patients. Anal intraepithelial neoplasia is equally
prevalent in different age groups of men who have sex with men, but in other
respects what is known of its natural history resembles that of cervical
intraepithelial neoplasia. Low-grade lesions frequently resolve, but high-grade
lesions are much more stable. HIV-positives who practise receptive anal
intercourse are at highest risk of anal intraepithelial neoplasia. Screening is
easy to perform using cytology; the limitations of anal cytology being similar to
those of cervical cytology. Patients with any grade of cytological abnormality
require further investigation, ideally with high-resolution anoscopy, every 6
months. Successful treatments for individual small to medium-sized high-grade
lesions include trichloroacetic acid, infra-red coagulation and laser. In
HIV-positive patients the development of new lesions elsewhere is very likely.
Topical agents for multifocal disease include imiquimod and cidofovir.
SUMMARY: There is a need for large prospective cohort studies in men who have sex
with men and HIV-positive patients to further our understanding of this disease
and to evaluate treatment strategies.
23. J Dtsch Dermatol Ges. 2005 Apr;3(4):271-5.
[Controlled layered removal of anogenital warts by argon-plasma coagulation].
[Article in German]
Weyandt GH, Benoit S, Becker JC, Bröcker EB, Hamm H.
Klinik und Poliklinik für Haut-und Geschlechtskrankheiten der Universität
Wurzburg. [email protected]
BACKGROUND: According to guidelines of the German STD Association, appropriate
treatment of extensive anogenital warts with comparable recurrence rates includes
cryotherapy, surgical excision, electrosurgery, CO2- and Nd:YAG-laser
vaporisation. All these procedures are associated with varying degrees of risk
for bleeding, release of potentially infectious aerosol, deep thermal
destruction, slow wound healing, and scarring.
METHODS: Using argon-plasma coagulation anogenital warts can be removed in layers
in a controlled manner. High frequency current flows through the argon plasma to
the tissue, allowing well-controlled, superficial tissue destruction.
RESULTS: From January 2001 to March 2003, 54 patients with extensive genital,
anal or anogenital warts were treated. After one treatment, 66% of the patients
remained disease-free in the following 4 months. Thirteen patients (24%) showed
early recurrence after 4 weeks, five patients (9%) at a later date. In these
patients, further treatment, in 9 cases combined with topical imiquimod cream,
were necessary for complete remission.
CONCLUSION: Compared to other therapeutic procedures, argon-plasma coagulation is
a better controlled, quick and low-risk option for the treatment of anogenital
warts. Depending on the type of involvement and individual risk factors,
postoperative treatment with topical imiquimod cream may be useful.
24. Clin Exp Obstet Gynecol. 2005;32(2):138-40.
Grade 3 vulvar and anal intraepithelial neoplasia in a HIV seropositive
child--therapeutic result: case report.
de Góis NM, Costa RR, Kesselring F, de Freitas VG, Ribalta JC, Kobata MP, Taha
NS.
Sector of Pathology of the Inferior Genital Tract, Department of Gynecology,
UNIFESP, Department of Gynecology, Hospital AC Camargo, São Paulo, Brazil.
A case report of a HIV seropositive 8-year-old child with vulvar and anal border
neoplasia, both grade 3, and the adopted therapeutic management are presented.
The mother reported the history of a progressively growing verrucous lesion in
the vulva since the age of three and a half years. On physical examination a
pigmented and elevated lesion was observed in the whole vulvar region extending
to the anal region and intergluteal sulcus. After biopsies and anatomic
pathological examination, antiretroviral therapy, adequate for age, and topical
application of podophyllotoxin associated with Thuya officinalis extract was
started. Three months afterwards vaporization and CO2 laser excision were
performed in five sequential sessions, thereafter associated with topical
imiquimod application. After the first two sessions of laser therapy early
relapses occurred. After four weeks of imiquimod use, already a significant
improvement of the lesions was observed, making the following laser therapy
sessions easier. We conclude that antiretroviral therapy associated with
podophyllotoxin and Thuya was not effective regarding regression of the lesions.
Laser therapy alone led to early relapses. The local use of imiquimod associated
with laser was effective in decreasing and controling the lesions.
25. Br J Surg. 2005 Mar;92(3):277-90.
Anal intraepithelial neoplasia.
Abbasakoor F, Boulos PB.
Department of Surgery, Royal Free and University College Medical School, London,
UK.
BACKGROUND: Anal intraepithelial neoplasia (AIN) is believed to be a precursor of
anal squamous cell cancer and its incidence is rising in high-risk groups,
particularly those infected with the human immunodeficiency virus (HIV). The
natural history of AIN is unclear and management strategies are lacking.
METHODS: This review is based on a literature search (Medline and PubMed) with
manual cross-referencing of all articles related to AIN.
RESULTS AND CONCLUSIONS: The aetiology of AIN is intricately linked with human
papilloma viruses. The pathological processes involved in the progression of AIN
are becoming clearer but the natural history, particularly the rate of
progression to invasive cancer, remains unknown. There is no standard management
for AIN and this is mainly due to difficulties in both diagnosis and treatment. A
variety of treatment options have been tried with varying success. Surgery is
associated with significant recurrence, particularly in HIV-positive patients.
Non surgical approaches with imiquimod, photodynamic therapy and vaccination are
appealing, and further work is required. Long-term follow-up of these patients is
essential until the natural history of AIN becomes clearer.
26. Ann Dermatol Venereol. 2004 Nov;131(11):947-51.
[Effects of imiquimod on latent human papillomavirus anal infection in
HIV-infected patients].
[Article in French]
Pelletier F, Drobacheff-Thiebaut C, Aubin F, Venier AG, Mougin C, Laurent R.
Service de Dermatologie, CHU Saint-Jacques, Besançon.
INTRODUCTION: High risk human papillomaviruses (HPV) have emerged as risk factors
for anal carcinoma particularly in HIV-infected patients who demonstrate a high
rate of anal HPV infection. Considering the relationship between the presence of
anal infection and the development of neoplastic lesions, we wished to assess the
capacity of imiquimod to eradicate latent HPV infection in HIV-infected patients.
PATIENTS AND METHODS: We conducted a prospective, randomized, double-blind and
vehicle controlled study. Two consecutive anal swabs were taken at 2 month
intervals and only patients with two consecutive tests positive for the detection
of HPV-DNA (Hybrid Capture II) were included. Patients with persistent latent HPV
infection were divided into 2 groups who applied imiquimod versus vehicle during
6 weeks. HPV-DNA presence was then investigated 2 and 4 months following the
onset of treatment.
RESULTS: Among the 80 HIV-infected patients, 26 (32.5 p. 100) had 2 positive
consecutive assays, and 19 patients were included in the study. After
randomization, 9 patients received imiquimod and 10 vehicle. There was no
significant difference between treatment groups according to the following
criteria: gender, route of HIV transmission, CDC stage, prior medical history of
sexually transmitted diseases or anogenital warts. 33.3 p. 100 (3/9) of patients
treated with imiquimod were negative at M2, whereas 100 p. 100 (10/10) vehicle
treated-patients remained positive (p=0.08). Similar results were observed at the
M4 visit.
DISCUSSION: Our study confirmed the increased prevalence of latent HPV-DNA
infection in HIV-infected patients. In spite of the low number of treated
patients, we did not observe a statistically significant decrease in HPV-DNA in
anal swabs from imiquimod-treated patients as compared to placebo-treated
patients.
27. J Am Acad Dermatol. 2004 Jun;50(6):980-1.
Treatment of anal intraepithelial neoplasia in patients with acquired HIV with
imiquimod 5% cream.
Kreuter A, Hochdorfer B, Stücker M, Altmeyer P, Weiland U, Conant MA, Brockmeyer
NH.
28. Minerva Ginecol. 2003 Dec;55(6):541-6.
[Topical imiquimod cream in the treatment of external anogenital warts: personal
experience].
[Article in Italian]
Senatori R, Dionisi B, Lippa P, Inghirami P.
Ambulatorio MST-AIED, Roma. [email protected]
AIM: The clinical effects of home-therapy with 5% imiquimod cream in the
treatment of cutaneous anogenital warts are evaluated.
METHODS: From March 2000 to January 2002, 57 women presenting clinical cutaneous
external genital and perianal warts were selected in the base-population observed
at our clinical of vulvar pathology and sexually transmitted diseases, AIED Rome.
The patients were divided into 2 groups: Group A, with new cutaneous viral
lesions and Group B with recurrent anogenital warts pre-treated with CO2-laser
therapy. A total of 36% (20) of all patients presented contemporaneous HPV
lesions of cervix and/or vaginal wall. The follow-up was carried out at 4 weeks,
3 months and 6 months, evaluating the safety, clinical efficacy and tolerance of
women. The Pearson chi2 test was used to evaluate trends significance. All
lesions were photo-documented.
RESULTS: Sixty-four per cent (64%) of the patients had complete clearance of
anogenital warts within 16 weeks, for 3 times per week self-application of
imiquimod, with clinical remission at short term (6/8 weeks) (chi2=1.42; p<0.05);
12% had partial clearance (<50%) and 20% had a clearance of about 75%. The
coexistent lesions of cervix and/or vaginal walls had a high remission (>50%) and
required surgical additional therapy with CO2-laser; 28% of patients (16/57)
experienced mild to moderate drug-related side effects. There was a significant
increase in the severity of local skin reactions due to the increased time and
number of applications.
CONCLUSION: These data confirm that imiquimod cream at the dose regimen of 3
times per week, is effective and well tolerated in the treatment of cutaneous
external warts and is associated to a reduction of coexistent mucous viral
lesions due to enhancement of local immune response.
29. Ther Umsch. 2003 Oct;60(10):595-604.
[Human papillomaviruses].
[Article in German]
Gross G.
Klinik und Poliklinik für Dermatologie und Venerologie, Universität Rostock,
Deutschland. [email protected]
Human papillomaviruses (HPV) infect exclusively the basal cells of the skin and
of mucosal epithelia adjacent to the skin such as the mouth, the upper
respiratory tract, the lower genital tract and the anal canal. HPV does not lead
to a viremia. Basically there are three different types of HPV infection:
Clinically visible lesions, subclinical HPV infections and latent HPV infections.
Distinct HPV types induce morphologically and prognostically different clinical
pictures. The most common HPV associated benign tumor of the skin is the common
wart. Infections of the urogenitoanal tract with specific HPV-types are
recognised as the most frequent sexually transmitted viral infections. So-called
"high-risk" HPV-types (HPV16, 18 and others) are regarded by the world health
organisation as important risk-factors for the development of genital cancer
(mainly cervical cancer), anal cancer and upper respiratory tract cancer in both
genders. Antiviral substances with a specific anti-HPV effect are so far unknown.
Conventional therapies of benign skin warts and of mucosal warts are mainly
nonspecific. They comprise tissue-destroying therapies such as electrocautery,
cryotherapy and laser. In addition cytotoxic substances such as podophyllotoxin
and systemic therapy with retinoids are in use. Systemically and topically
administered immunotherapies represent a new approach for treatment. Both
interferons and particularly the recently developed imiquimod, an
interferon-alpha and cytokine-inductor lead to better results and are better
tolerated then conventional therapies. HPV-specific vaccines have been developed
in the last 5 years and will be used in future for prevention and treatment of
benign and malignant HPV-associated tumors of the genitoanal tract in both sexes.
30. Pediatr Dermatol. 2003 Sep-Oct;20(5):440-2.
Imiquimod is highly effective for extensive, hyperproliferative condyloma in
children.
Majewski S, Pniewski T, Malejczyk M, Jablonska S.
Department of Dermatology and Venereology, Warsaw School of Medicine, Warsaw,
Poland.
We describe a dramatic response to imiquimod of long-lasting, highly
proliferative extensive perianal condylomas involving the anal canal in a
19-month-old girl. Her mother was free of condyloma and allegedly had no human
papillomavirus (HPV) infection during pregnancy. There was no evidence of sexual
abuse. Application of 5% imiquimod cream to the child every other day for 3 weeks
resulted in almost complete resolution of the warts, with total clearance within
another 2 weeks. The inflammatory reaction was moderate. Since there is still
discussion of whether imiquimod may be prescribed for small children, this case
of very extensive condyloma provides evidence that the compound is safe and
highly effective.
31. Tumori. 2003 Jul-Aug;89(4 Suppl):16-8.
[Perianal Bowen's disease: a case report and review of the literature].
[Article in Italian]
Bertagni A, Vagliasindi A, Ascari Raccagni A, Valmori L, Verdecchia GM.
UO di Chirurgia Generale II, Unità di Chirurgia Oncologica, Ospedale GB
Morgagni-L Pierantoni, Forlì.
Perianal Bowen's disease is a uncommon, slow growing, intraepidermal
squamous-cell carcinoma (carcinoma in situ) of the anal region and may be a
precursor to squamous carcinoma of the anus. It is associated with cervical and
vulvar intraepithelial neoplasia and have human papillomavirus as a common cause.
Both sexes and all races are affected, with the highest prevalence in patients
aged 20 to 45 years. The symptoms of anal Bowen's disease are unspecific and the
clinical findings are uncharacteristic and include pain, itching, bleeding and a
disturbing lump. Biopsy and histopathologic examination is required for diagnosis
and to distinguish other perianal dermatoses; thus an anogenital warts that fail
to respond to conventional therapy, or change in appearance, warrant a biopsy
and, where the technique is available, DNA typing to identify the viral pathogen.
Infact the etiologic agent, the human papillomavirus (HPV), has been classified
by DNA techniques into at least 42 types, of which 16 and 18 are considered to
carry a high risk for cancer. The intraoperative findings is a lesion at the
anocutaneous line: perianal or intra-anal tumor, erosion or ulceration as well as
lichenoid lesion or hyperpigmentation. The disease has a proclivity for
recurrence and there are many controversies concerning treatment that
effectiveness remains uncertain and range from aggressive wide local excision
with skin grafting when necessary to laser vaporization (argon or CO2),
radiotherapy or a new immune response modifier (Imiquimod). We report a case of a
50-years-old woman with recurrence of Bowen's disease associated with vulvar HPV
infection and review the literature.
32. Dermatology. 2003;207(1):119-22.
Treatment of verrucous carcinoma with imiquimod and CO2 laser ablation.
Heinzerling LM, Kempf W, Kamarashev J, Hafner J, Nestle FO.
University Hospital Zürich, Zürich, Switzerland.
An 82-year-old female patient presented with a large perianal hyperkeratotic
tumor extending into the anal canal. Staging did not reveal any metastatic
spread. Diagnosis of verrucous carcinoma or Buschke-Löwenstein tumor,
respectively, was based on typical clinical and histologic features. Moreover,
human papillomavirus 6b DNA sequences could be detected by PCR. Surgical excision
could not be performed due to the general health status of the patient; thus,
alternative therapy methods were necessary. Treatment with imiquimod cream 5%
(Aldara), a topical immune response modifier applied once a day and left for 12
h, led to significant partial tumor regression and clear demarcation of the
tumor. The remaining tumor, now feasible for treatment with CO2 laser, was
removed in two sessions in local anesthesia. In a third session, tumor parts in
the anal canal were vaporized. This case demonstrates that the combination of
imiquimod and CO2 laser ablation is an effective treatment option for verrucous
carcinoma.
33. J Eur Acad Dermatol Venereol. 2003 May;17(3):363-5.
Bowenoid papulosis successfully treated with imiquimod.
Loo WJ, Holt PJ.
34. Br J Dermatol. 2002 Oct;147(4):757-9.
Application of imiquimod by suppositories (anal tampons) efficiently prevents
recurrences after ablation of anal canal condyloma.
Kaspari M, Gutzmer R, Kaspari T, Kapp A, Brodersen JP.
Department of Dermatology and Allergology, Hannover Medical University,
Ricklinger Strasse 5, Germany. [email protected]
BACKGROUND: After surgical removal, anal canal condyloma (ACC) has a higher risk
of recurrence compared with extragenital warts.
OBJECTIVES: To reduce local recurrences of ACC using follow-up treatment with
imiquimod-containing suppositories (anal tampons).
METHODS: After ablation of ACC, 10 male patients received treatment with
imiquimod suppositories three times weekly for 3-4 months.
RESULTS: Treatment with imiquimod anal tampons was well tolerated. Early initial
recurrences in some patients cleared after treatment with the imiquimod
suppositories. Within a mean follow-up of 9 months no patient demonstrated
recurrence of ACC.
CONCLUSIONS: These data suggest that imiquimod anal tampons may represent a new
therapeutic option to prevent recurrences of ACC following ablative surgery.
35. J Reprod Med. 2002 May;47(5):395-8.
Treatment of vulvar intraepithelial neoplasia 2/3 with imiquimod.
Jayne CJ, Kaufman RH.
Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston,
Texas, USA.
OBJECTIVE: To retrospectively review the charts of 13 women diagnosed with vulvar
intraepithelial neoplasia (VIN) 2/3 treated with imiquimod and to evaluate the
efficacy of this treatment.
STUDY DESIGN: Retrospective review. All 13 women were treated and evaluated by a
single gynecologist. The extent of the lesions prior to treatment and the extent
and degree of improvement were documented. Biopsy confirmation of disease was
obtained for each individual. Response to treatment was categorized as complete
regression, at least 75% regression or not improved.
RESULTS: The mean duration of treatment was 3.3 months, and follow-up after
completion of therapy was 5.5 months. Eight of the 13 women had complete
regression of the VIN. Four patients demonstrated 75% regression of disease, and
in one diabetic woman no improvement was seen. In two women demonstrating 75%
lesion regression, invasive carcinoma of the vulva was found in the area of
residual disease. In one instance this was determined to be superficially
invasive squamous cell carcinoma (1 mm of invasion), and in the second an anal
tag was found to have invasive squamous cell carcinoma.
CONCLUSION: Medical management of VIN 2/3 with imiquimod is worth considering.
However, careful evaluation of the patient must be carried out prior to the
institution of therapy to exclude the presence of invasive squamous cell
carcinoma.
36. J Chir (Paris). 2001 Oct;138(5):277-80.
[Anal condyloma: its management is still difficult].
[Article in French]
Sultan S.
Service de Coloproctologie, Hôpital des Diaconesses, 18, rue du Sergent-Bauchat,
F 75012 Paris.
Anal condylomas result from papillomavirus infection, the most common sexually
transmitted disease. The principal risk is the development of cancer of the anal
canal. The risk of contamination is high, even after a single sexual contact. No
specific antiviral treatment is available and no consensus has been reached on
the appropriate treatment of anal condylomas. Despite the development of various
methods (interferon, imiquimod), electrocoagulation remains the treatment of
choice. Finally, regular follow-up and treatment of the partner(s) are essential.
37. Arch Dermatol. 2001 Jan;137(1):14-6.
Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell
carcinoma in situ in an HIV-1-positive man.
Pehoushek J, Smith KJ.
National Naval Medical Center, Bethesda, MD 20889-5600, USA.
38. Treat Rev. 1995 Nov;(no 20):7.
Warts treatment.
[No authors listed]
AIDS: New York University Medical Center is testing an
alpha-interferon-stimulating cream, imiquimod, for anal and genital wart
treatment. More information can be obtained by calling The Network at
(800)734-7104.
Anlage 3
DIMID/EMBASE – Recherche vom 11. Januar 2011
Suchschritt : FT=anal AND FT=imiquimod => 102 Treffer
» Volltext-Angebot »
2/1 von 102
DIMDI: EMBASE (EM00) © 2011 Elsevier B.V.
ND:
Autoren:
EM2010704199
Newsom-Davis T; Bower M
Titel:
HIV-associated anal cancer
Source:
F1000 Medicine Reports; VOL: 2 (1) /20101208/
http://f1000.com/reports/m/2/85/pdf
ANR:
M2-85
DOI:
10.3410/M2-85
PU:
Faculty of 1000 Ltd
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
EISSN:
1757-5931
Institution: Bower M, Department of Oncology, Chelsea, Westminster Hospital NHS
Foundation Trust, 369 Fulham Road, London SW10 9NH, United
Kingdom, [email protected]
COU:
United Kingdom
DT:
Journal Article
RN:
0041
Keywords
CT:
ANUS CANCER/*diagnosis; ANUS CANCER/*drug therapy; ANUS
CANCER/*epidemiology; ANUS CANCER/*etiology; ANUS
CANCER/*therapy; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/*drug therapy; AIDS PATIENT; ARTICLE;
BLEEDING/complication; CANCER DIAGNOSIS; CANCER
EPIDEMIOLOGY; CANCER SCREENING; COLONOSCOPY; CONDYLOMA
ACUMINATUM/drug therapy; HISTOLOGY; HUMAN; HUMAN
IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFRARED
RADIATION; SKIN DEFECT/drug therapy; STANDARDIZED INCIDENCE
RATIO; WART VIRUS; IMIQUIMOD/drug therapy;
IMIQUIMOD/pharmacology; TRICHLOROACETIC ACID/drug therapy;
WART VIRUS VACCINE/drug therapy
DN:
Gardasil/Merck, United States
MN:
Merck, United States
ET:
Cancer; Public Health, Social Medicine and Epidemiology; Clinical and
Experimental Pharmacology; Drug Literature Index; Gastroenterology
TE:
CR:
AB:
AU:
AU:
PU:
CNOTE:
imiquimod/99011-02-6; trichloroacetic acid/14357-05-2; trichloroacetic acid/7603-9
99011-02-6; 14357-05-2; 76-03-9
HIV-associated anal carcinoma, a non-AIDS-defining cancer, is a human
papillomavirus-associated malignancy with a spectrum of preinvasive changes.
The standardized incidence ratio for anal cancer in patients with HIV/AIDS is 2050. Algorithms for anal cancer screening include anal cytology followed by highresolution anoscopy for those with abnormal findings. Outpatient topical
treatments for anal intraepithelial neoplasia include infrared coagulation therapy,
trichloroacetic acid, and imiquimod. The development of cost-effective national
screening programs for HIV-associated anal cancer remains a challenge. © 2010
Faculty of 1000 Ltd.
Newsom-Davis T
Newsom-Davis Thomas
Department of Oncology, Chelsea, Westminster Hospital NHS Foundation Trust,
369 Fulham Road, London SW10 9NH, United Kingdom
Bower M
Bower Mark
[email protected]
Faculty of 1000 Ltd
34-42 Cleveland Street, London, W1T 4LB, United Kingdom
Copyright 2011 Elsevier B.V., All rights reserved.
2/2 von 102
ND:
Autoren:
EM2010544798
Forcier M; Musacchio N
Titel:
An overview of human papillomavirus infection for the
dermatologist: Disease, diagnosis, management, and prevention
Source:
Dermatologic Therapy; VOL: 23 (5); p. 458-476 /September-October 2010/
DOI:
10.1111/j.1529-8019.2010.01350.x
PU:
Blackwell Publishing Inc.
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
1396-0296
EISSN:
1529-8019
CO:
DETHF
Institution: Forcier M, Dr. Prof., Department of Pediatrics, Brown University, Hasbro and
Rhode Island Hospitals, Potter 200.2 593 Eddy Street, Providence, RI 02903,
United States, [email protected]
COU:
DT:
RN:
Keywords
CT:
UT:
DN:
MN:
ET:
TE:
CR:
AB:
AU:
United States
Review; Journal Article
0118
CONDYLOMA ACUMINATUM/*drug therapy; CONDYLOMA
ACUMINATUM/*surgery; CONDYLOMA ACUMINATUM/*therapy;
PAPILLOMAVIRUS INFECTION/*; BEDTIME DOSAGE; CANCER
PREVENTION; CRYOTHERAPY; DISEASE ASSOCIATION; HUMAN;
INCIDENCE; INFECTION PREVENTION; LASER SURGERY; REVIEW;
SCREENING; SEXUAL INTERCOURSE; SURGICAL TECHNIQUE;
UTERINE CERVIX CANCER/drug therapy; UTERINE CERVIX
CANCER/prevention; UTERINE CERVIX DISEASE; VACCINATION;
VAGINA CANCER; VIRUS TRANSMISSION; VULVA CANCER;
DICHLOROACETIC ACID/drug therapy; IMIQUIMOD/drug therapy;
INTERFERON/drug therapy; PLACEBO; PODOPHYLLIN/drug therapy;
PODOPHYLLOTOXIN/drug therapy; POLYPHENON E/drug therapy;
TRICHLOROACETIC ACID/drug therapy; WART VIRUS VACCINE/drug
therapy
anogenital; cervical cancer; condyloma; genital warts; HPV; human
papillomavirus; vaccine
Cervarix/Glaxo SmithKline, United Kingdom; Gardasil/Merck, United States
Glaxo SmithKline, United Kingdom; Merck, United States
Microbiology: Bacteriology, Mycology, Parasitology and Virology; Obstetrics and
Gynecology; Cancer; Public Health, Social Medicine and Epidemiology; Drug
Literature Index
dichloroacetic acid/13425-80-4; dichloroacetic acid/2156-56-1; dichloroacetic
acid/79-43-6; imiquimod/99011-02-6; podophyllin/9000-55-9;
podophyllotoxin/518-28-5; trichloroacetic acid/14357-05-2; trichloroacetic
acid/76-03-9
13425-80-4; 2156-56-1; 79-43-6; 99011-02-6; 9000-55-9; 518-28-5; 14357-05-2;
76-03-9
Genital human papillomavirus (HPV) is a common, usually transient,
dermatologic infection transmitted by genital contact that can cause a variety of
anogenital diseases, including warts (condyloma), dysplasia (cervical, vaginal,
vulvar, anal), and squamous cell carcinoma. A number of treatment modalities are
available to treat anogenital warts, both patient- and provider-applied. Treatment
is efficacious, but lesions can recur. Bivalent and quadrivalent vaccines are
approved to prevent HPV infection. Both are indicated to prevent cervical cancer,
while the quadrivalent vaccine is also approved to prevent vaginal/vulvar cancers
as well as genital warts in males and females. Providers should clearly explain the
natural history and potential sequelae of HPV disease, counsel patients on
prevention strategies, and recommend vaccination as an effective method of
prevention to their patients. © 2010 Wiley Periodicals, Inc.
Forcier M
Forcier Michelle
Department of Pediatrics, Brown University, Hasbro and Rhode Island Hospitals,
Potter 200.2 593 Eddy Street, Providence, RI 02903, United States
[email protected]
AU:
PU:
CNOTE:
Musacchio N
Musacchio Najah
Department of Pediatrics, Brown University, Hasbro and Rhode Island Hospitals,
Potter 200.2 593 Eddy Street, Providence, RI 02903, United States
Blackwell Publishing Inc.
350 Main Street, Malden, MA 02148, United States
2/3 von 102
ND:
Autoren:
EM2010539809
Fox PA; Nathan M; Francis N; Singh N; Weir J; Dixon G; Barton SE; Bower M
Titel:
A double-blind, randomized controlled trial of the use of imiquimod
cream for the treatment of anal canal high-grade anal intraepithelial
neoplasia in HIV-positive MSM on HAART, with long-term followup data including the use of open-label imiquimod
Source:
AIDS; VOL: 24 (15); p. 2331-2335 /20100924/
DOI:
10.1097/QAD.0b013e32833d466c
PU:
Lippincott Williams and Wilkins
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
0269-9370
EISSN:
1473-5571
CO:
AIDSE
Institution: Fox PA, Chelsea and Westminster Hospital NHS Trust, 369 Fulham Road,
London SW10 9NH, United Kingdom, [email protected]
COU:
United Kingdom
DT:
Journal Article
JSC:
E.5.3 ... Virology; E.4.1 ... Allergy & Clinical Immunology
RN:
0010
Keywords
CT:
ANUS TUMOR/*drug therapy; HIGH GRADE ANAL CANAL
INTRAEPITHELIAL NEOPLASIA/*drug therapy; HIGHLY ACTIVE
ANTIRETROVIRAL THERAPY/*; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/*; PRECANCER AND CANCER-IN-SITU/*drug therapy;
ADULT; ARTICLE; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL
TRIAL; CONTROLLED STUDY; CREAM; CYTOLOGY; DOUBLE BLIND
PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP;
HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION; HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS; LOW GRADE SQUAMOUS
INTRAEPITHELIAL LESION; MAJOR CLINICAL STUDY; MALE; MALE
HOMOSEXUAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED
UT:
ET:
TE:
CR:
AB:
AU:
AU:
AU:
AU:
TRIAL; RECTOSCOPY; TREATMENT OUTCOME; TREATMENT
RESPONSE; UNSPECIFIED SIDE EFFECT/side effect; IMIQUIMOD/*adverse
drug reaction; IMIQUIMOD/*clinical trial; IMIQUIMOD/*drug therapy;
IMIQUIMOD/*rectal drug administration; PLACEBO
anal intraepithelial neoplasia; high-grade squamous intraepithelial lesion;
imiquimod; low-grade squamous intraepithelial lesion; placebo-controlled studies
Microbiology: Bacteriology, Mycology, Parasitology and Virology; Cancer; Drug
Literature Index; Adverse Reactions Titles; Gastroenterology
imiquimod/99011-02-6
99011-02-6
Objective: To determine whether imiquimod was more effective than placebo for
the treatment of high-grade anal canal intraepithelial neoplasia (HG-ACIN).
Design: Double-blind, randomized placebo-controlled clinical trial. Methods:
Sixty-four HIV-positive patients were randomized to self-application of
imiquimod cream or matched placebo into the anal canal three times a week for 4
months. Response was assessed by cytology, high-resolution anoscopy and biopsy
2 months after therapy. All patients who failed to resolve were offered treatment
with open-label imiquimod for a further 4 months. Results: Fifty-three patients
completed the study, of which 28 patients were on active drug and 25 patients on
placebo. In the imiquimod group, four patients resolved and eight patients
downgraded to low-grade squamous intraepithelial lesion (LSIL) with a median
follow-up of 33 months. In the placebo group, one patient resolved. Imiquimod
was significantly associated with a positive outcome (P = 0.003). Only one patient
discontinued owing to side effects. Twenty-one patients entered a second openlabel phase of treatment. Five of these patients cleared their anal canal
intraepithelial neoplasia (ACIN) and four patients downgraded to LSIL. The
overall mean duration of follow-up was 36 months. During this extended followup period, 61% have exhibited sustained absence of high-grade squamous
intraepithelial lesion (HSIL). Conclusion: This study demonstrates the
effectiveness of imiquimod for the treatment of ACIN, and the benefit of
prolonged or repeated treatments. This form of therapy is likely to be especially
valuable for patients with widespread multifocal ACIN who are otherwise difficult
to treat, and should be considered as an adjunct to ablative therapy. © 2010
Wolters Kluwer Health | Lippincott Williams & Wilkins.
Fox PA
Fox Paul A.
Chelsea and Westminster Hospital NHS Trust, 369 Fulham Road, London SW10
9NH, United Kingdom
[email protected]
Nathan M
Nathan Mayura
Homerton Hospital NHS Trust, United Kingdom
Francis N
Francis Nicholas
Department of Cellular Pathology, Imperial College Healthcare NHS Trust,
United Kingdom
Singh N
AU:
AU:
AU:
AU:
PU:
CNOTE:
Singh Naveena
Department of Pathology, Barts and the London NHS Trust, London, United
Kingdom
Weir J
Weir Justin
United Kingdom
Dixon G
Dixon Glen
United Kingdom
Barton SE
Barton Simon E.
9NH, United Kingdom
Bower M
Bower Mark
9NH, United Kingdom
250 Waterloo Road, London, SE1 8RD, United Kingdom
2/4 von 102
ND:
Autoren:
EM2010459680
Oon SF; Hanly A; Winter DC
Titel:
Pap smears for men: A vision of the future?
Source:
Irish Journal of Medical Science; VOL: 179 (3); p. 459-462 /September 2010/
DOI:
10.1007/s11845-009-0340-6
PU:
Springer London
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
0021-1265
CO:
IJMSA
Institution: Oon SF, Department of Colorectal Surgery, St. Vincent's University Hospital, Elm
Park, Dublin 4, Ireland, [email protected]
COU:
Ireland
DT:
Journal Article
JSC:
C.0 ... Clinical Medicine
RN:
0007
Keywords
CT:
ANAL INTRAEPITHELIAL NEOPLASM/*diagnosis; ANAL
INTRAEPITHELIAL NEOPLASM/*epidemiology; ANAL INTRAEPITHELIAL
NEOPLASM/*etiology; ANAL INTRAEPITHELIAL NEOPLASM/*prevention;
ANAL SQUAMOUS CARCINOMA/*diagnosis; ANAL SQUAMOUS
CARCINOMA/*epidemiology; ANAL SQUAMOUS CARCINOMA/*etiology;
ANAL SQUAMOUS CARCINOMA/*prevention; ANAL SQUAMOUS
INTRAEPITHELIAL LESION/*diagnosis; ANAL SQUAMOUS
INTRAEPITHELIAL LESION/*epidemiology; ANAL SQUAMOUS
INTRAEPITHELIAL LESION/*etiology; ANAL SQUAMOUS
INTRAEPITHELIAL LESION/*prevention; ANUS CARCINOMA/*diagnosis;
ANUS CARCINOMA/*epidemiology; ANUS CARCINOMA/*etiology; ANUS
CARCINOMA/*prevention; CONDYLOMA/*diagnosis; CONDYLOMA/*drug
therapy; CONDYLOMA/*etiology; CONDYLOMA/*surgery;
PAPANICOLAOU TEST/*; PERIANAL CONDYLOMATA/*diagnosis;
PERIANAL CONDYLOMATA/*etiology; PERIANAL
CONDYLOMATA/*surgery; ABLATION THERAPY; ADULT; ANUS
TUMOR/diagnosis; ANUS TUMOR/epidemiology; ANUS TUMOR/etiology;
ANUS TUMOR/prevention; ARTICLE; CANCER RISK; CANCER
SCREENING; CARBON DIOXIDE LASER; CASE REPORT; CLINICAL
PRACTICE; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY;
CURETTAGE; EXCISION; FEMALE; HEALTH CARE COST; HIGH RISK
POPULATION; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY
VIRUS INFECTED PATIENT; IMMUNOMODULATION; INFRARED
RADIATION; LOW LEVEL LASER THERAPY; MALE; MALE
HOMOSEXUAL; NEODYMIUM LASER; PRACTICE GUIDELINE; SEXUAL
TRANSMISSION; SEXUALLY TRANSMITTED DISEASE/epidemiology;
SEXUALLY TRANSMITTED DISEASE/prevention; SQUAMOUS CELL
CARCINOMA/diagnosis; SQUAMOUS CELL CARCINOMA/epidemiology;
SQUAMOUS CELL CARCINOMA/etiology; SQUAMOUS CELL
CARCINOMA/prevention; UTERINE CERVIX CANCER/diagnosis; UTERINE
CERVIX CANCER/epidemiology; UTERINE CERVIX CANCER/etiology;
UTERINE CERVIX CANCER/prevention; WART VIRUS; WOUND
CLOSURE; ADRENALIN/drug administration; ADRENALIN/drug combination;
ADRENALIN/drug therapy; ADRENALIN/topical drug administration; ALPHA
INTERFERON/drug therapy; ANTIBIOTIC AGENT/drug administration;
ANTIBIOTIC AGENT/drug therapy; ANTIBIOTIC AGENT/topical drug
administration; BCG VACCINE/drug administration; BCG VACCINE/drug
therapy; BCG VACCINE/topical drug administration; CIDOFOVIR/drug
administration; CIDOFOVIR/drug therapy; CIDOFOVIR/topical drug
administration; FLUOROURACIL/drug administration; FLUOROURACIL/drug
combination; FLUOROURACIL/drug therapy; FLUOROURACIL/topical drug
administration; IMIQUIMOD/drug therapy; PODOPHYLLIN/drug
administration; PODOPHYLLIN/drug therapy; PODOPHYLLIN/topical drug
administration; TRICHLOROACETIC ACID/drug administration;
TRICHLOROACETIC ACID/drug therapy; TRICHLOROACETIC ACID/topical
drug administration
UT:
AIN; Anal cancer; Anal intraepithelial neoplasm; Anal squamous carcinoma;
Anal squamous intraepithelial lesion; ASIL; Perianal condylomata; Screening
ET:
TE:
CR:
AB:
AU:
AU:
AU:
PU:
CNOTE:
Microbiology: Bacteriology, Mycology, Parasitology and Virology; Cancer;
Public Health, Social Medicine and Epidemiology; Drug Literature Index;
Gastroenterology
adrenalin/51-43-4; adrenalin/55-31-2; adrenalin/6912-68-1; cidofovir/113852-372; fluorouracil/51-21-8; imiquimod/99011-02-6; podophyllin/9000-55-9;
trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9
51-43-4; 55-31-2; 6912-68-1; 113852-37-2; 51-21-8; 99011-02-6; 9000-55-9;
14357-05-2; 76-03-9
Background: Anal intraepithelial neoplasia (AIN) rarely receives as much
publicity as its neighbouring orifice, the cervix. As in the cervix, intraepithelial
neoplasias are precursors to cancer in the anal canal. AIN and cervical interstitial
neoplasia (CIN) undergo dysplasia as a consequence of human papillomavirus
(HPV) infection. Since the advent of screening with the Pap smear in CIN,
cervical cancer has plummeted to a fifth of its initial incidence. Anal cancer,
however, has been rising, with a predilection for human immunodeficiency virusinfected men. HPV causes a squamous epithelial dysplasia and converts healthy
tissue into AINs of increasing severity until anal cancer manifests. Clinical case:
This article describes a clinical case of anogenital HPV infection refractory to
medical and surgical therapy. It also describes an effective surgical excision
technique associated with a good cosmetic outcome. Conclusions: The paper
concludes by briefly discussing the implications of a national screening
programme against AIN in the future. © 2009 Royal Academy of Medicine in
Ireland.
Oon SF
Oon SF
Department of Colorectal Surgery, St. Vincent's University Hospital, Elm Park,
Dublin 4, Ireland
[email protected]
Hanly A
Hanly A
Dublin 4, Ireland
[email protected]
Winter DC
Winter DC
Dublin 4, Ireland
[email protected]
Springer London
The Guildway, Old Portsmouth Road, Artington, Guildford, GU3 1LP, United
Kingdom
2/5 von 102
ND:
Autoren:
EM2010331200
Park IU; Palefsky JM
Titel:
Evaluation and management of anal intraepithelial neoplasia in
HIV-negative and HIV-positive men who have sex with men
Source:
Current Infectious Disease Reports; VOL: 12 (2); p. 126-133 /March 2010/
DOI:
10.1007/s11908-010-0090-7
PU:
Current Science Ltd
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
1523-3847
CO:
CIDRC
Institution: Park IU, Department of Family and Community Medicine, University of
California San Francisco, San Francisco, CA 94143, United
States, [email protected]
COU:
United States
DT:
JSC:
E.5 ... Clinical Microbiology
RN:
0046
Keywords
CT:
ANAL INTRAEPITHELIAL NEOPLASIA/*diagnosis; ANAL
INTRAEPITHELIAL NEOPLASIA/*disease management; ANAL
INTRAEPITHELIAL NEOPLASIA/*drug therapy; ANAL INTRAEPITHELIAL
NEOPLASIA/*epidemiology; ANAL INTRAEPITHELIAL
NEOPLASIA/*prevention; ANAL INTRAEPITHELIAL NEOPLASIA/*surgery;
ANAL INTRAEPITHELIAL NEOPLASIA/*therapy; ANUS
CANCER/*diagnosis; ANUS CANCER/*disease management; ANUS
CANCER/*drug therapy; ANUS CANCER/*epidemiology; ANUS
CANCER/*prevention; ANUS CANCER/*surgery; ANUS CANCER/*therapy;
MALE HOMOSEXUAL/*; ANTICOAGULANT THERAPY;
BLEEDING/complication; CANCER DIAGNOSIS; CANCER INCIDENCE;
CANCER SCREENING; CANCER SURGERY; CANCER THERAPY;
CARBON DIOXIDE LASER; CAUTERIZATION; COST EFFECTIVENESS
ANALYSIS; CYTOLOGY; DIAGNOSTIC IMAGING; DRUG EFFICACY;
FOLLOW UP; HUMAN IMMUNODEFICIENCY VIRUS INFECTED
PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
PAIN/complication; RECTUM BIOPSY; REVIEW; CARBON DIOXIDE;
IMIQUIMOD/pharmacoeconomics; LIQUID NITROGEN/pharmacoeconomics;
TRICHLOROACETIC ACID/pharmacoeconomics; WART VIRUS
VACCINE/drug therapy; WART VIRUS VACCINE/pharmacoeconomics
UT:
Anal cancer; Anal intraepithelial neoplasia; HIV; Human papillomavirus;
Prevention; Screening
ET:
Microbiology: Bacteriology, Mycology, Parasitology and Virology; Public Health,
Social Medicine and Epidemiology; Health Policy, Economics and Management;
Drug Literature Index; Gastroenterology
TE:
CR:
AB:
AU:
AU:
PU:
CNOTE:
carbon dioxide/124-38-9; carbon dioxide/58561-67-4; imiquimod/99011-02-6;
124-38-9; 58561-67-4; 99011-02-6; 14357-05-2; 76-03-9
The incidence of human papillomavirus (HPV)- associated anal cancer in men
who have sex with men (MSM) is striking and has not been mitigated by the use
of highly active antiretroviral therapy. Detection and treatment of highgrade anal
intraepithelial neoplasia (HGAIN) may reduce the incidence of anal cancer. Anal
cytology is a useful tool to detect HGAIN; annual screening of HIV-positive
MSM and biennial screening of HIV-negative MSM appears to be costeffective.
MSMwith abnormal cytology should be referred for high-resolution anoscopy and
biopsy. Individuals with HGAIN should receive treatment; treatment modalities
for HGAIN demonstrate moderate efficacy and are usually well tolerated, but
greater study is required to determine which treatment is optimal. Large
prospective studies are needed to document the efficacy of screening and
treatment of HGAIN on anal cancer incidence. The HPV vaccine holds promise
for primary prevention of anal cancer in MSM, but significant implementation
challenges remain. © The Author(s) 2010.
Park IU
Park Ina U.
Department of Family and Community Medicine, University of California San
Francisco, San Francisco, CA 94143, United States
[email protected]
Palefsky JM
Palefsky Joel M.
Department of Medicine, University of California San Francisco, San Francisco,
CA 94143, United States
[email protected]
Current Science Ltd
34-42 Cleveland Street, London, W1P 6LB, United Kingdom
2/6 von 102
ND:
Autoren:
EM2010305523
Ma B; Xu Y; Hung C-F; Wu T-C
Titel:
HPV and therapeutic vaccines: Where are we in 2010?
Source:
DOI:
PU:
SU:
Sprache:
AL:
CY:
ISSN:
Current Cancer Therapy Reviews; VOL: 6 (2); p. 81-103 /2010/
10.2174/157339410791202583
Bentham Science Publishers B.V.
EMBASE
English
English
Netherlands
1573-3947
Institution: Wu T-C, Department of Pathology, The Johns Hopkins University School of
Medicine, CRBII 309, 1550 Orleans Street, Baltimore, Maryland 21231, United
COU:
United States
DT:
Journal Article
RN:
0202
Keywords
CT:
UTERINE CERVIX CANCER/*drug therapy; WART VIRUS/*; ABSENCE OF
SIDE EFFECTS/side effect; ANAL INTRAEPITHELIAL NEOPLASIA/drug
therapy; ANORECTAL INTRAEPITHELIAL NEOPLASIA/drug therapy;
ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN
PRESENTATION; ARTICLE; CANCER IMMUNIZATION; CANCER
RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL
BASED GENE THERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL;
CONDYLOMA/drug therapy; CYTOTOXIC T LYMPHOCYTE; DNA
REPLICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG
MEGADOSE; DRUG POTENCY; DRUG SAFETY; ELECTROPORATION;
EPITHELIUM TUMOR/drug therapy; FEVER/side effect; GENE GUN; HIGH
GRADE SQUAMOUS INTRAEPITHELIAL/drug therapy; HUMAN;
HYPOTENSION/side effect; IMMUNOGENICITY; IMMUNOMODULATION;
LACTOBACILLUS PLANTARUM; LACTOCOCCUS LACTIS; LISTERIA
MONOCYTOGENES; MOLECULAR BIOLOGY; PAPILLOMATOSIS/drug
therapy; PRIORITY JOURNAL; RECURRENT CANCER/drug therapy;
REPLICON; RESPIRATORY PAPILLOMATOSIS/drug therapy;
SALMONELLA ENTERICA; SINGLE DRUG DOSE; TREATMENT
RESPONSE; UNSPECIFIED SIDE EFFECT/side effect; UTERINE CERVIX
CARCINOMA IN SITU/drug therapy; VACCINIA VIRUS; VAGINAL
INTRAEPITHELIAL NEOPLASIA/drug therapy; VIRION; VIRUS ENTRY;
VIRUS LIKE AGENT; VULVAR INTRAEPITHELIAL NEOPLASIA/drug
therapy; WART VIRUS VACCINE/*adverse drug reaction; WART VIRUS
VACCINE/*clinical trial; WART VIRUS VACCINE/*drug combination; WART
VIRUS VACCINE/*drug dose; WART VIRUS VACCINE/*drug therapy; WART
VIRUS VACCINE/*intradermal drug administration; WART VIRUS
VACCINE/*intramuscular drug administration; WART VIRUS
VACCINE/*intraurethral drug administration; WART VIRUS
VACCINE/*intrauterine drug administration; WART VIRUS
VACCINE/*intravenous drug administration; WART VIRUS
VACCINE/*subcutaneous drug administration; ADXS 11 001/adverse drug
reaction; ADXS 11 001/clinical trial; ADXS 11 001/drug therapy; ADXS 11
001/intravenous drug administration; AMOLIMOGENE BEPIPLASMID/clinical
trial; AMOLIMOGENE BEPIPLASMID/drug therapy; AMOLIMOGENE
BEPIPLASMID/intramuscular drug administration; APIGENIN/drug
combination; BACTERIAL VECTOR; DENDRITIC CELL VACCINE/clinical
trial; DENDRITIC CELL VACCINE/drug combination; DENDRITIC CELL
VACCINE/drug therapy; DENDRITIC CELL VACCINE/subcutaneous drug
administration; DNA VACCINE/drug combination; DNA VACCINE/intradermal
drug administration; DNA VACCINE/intramuscular drug administration; E2
PROTEIN/clinical trial; E2 PROTEIN/drug comparison; E2 PROTEIN/drug
therapy; E2 PROTEIN/intraurethral drug administration; E2
PROTEIN/intrauterine drug administration; EPIGALLOCATECHIN
UT:
DN:
MN:
ET:
TE:
CR:
AB:
AU:
GALLATE/drug combination; FLT3 LIGAND; FLUOROURACIL/drug
comparison; FLUOROURACIL/drug therapy; HEAT SHOCK PROTEIN 70;
HLA ANTIGEN/endogenous compound; IMIQUIMOD/drug combination;
IMIQUIMOD/drug therapy; INTERLEUKIN 2/drug combination;
INTERLEUKIN 2/drug therapy; KEYHOLE LIMPET HEMOCYANIN/drug
combination; KEYHOLE LIMPET HEMOCYANIN/drug therapy; LYSOSOME
ASSOCIATED MEMBRANE PROTEIN 1; NUCLEIC ACID; PROTEIN
E6/endogenous compound; PROTEIN E7/endogenous compound; SGN
00101/clinical trial; SGN 00101/drug therapy; SGN 00101/subcutaneous drug
administration; TG 4001/clinical trial; TG 4001/drug therapy; TG
4001/subcutaneous drug administration; TUMOR CELL VACCINE;
UNCLASSIFIED DRUG; UNINDEXED DRUG; VGX 3100/clinical trial; VGX
3100/drug therapy; VIRUS ANTIGEN/endogenous compound; VIRUS
DNA/endogenous compound; VIRUS RNA/endogenous compound; VIRUS
VECTOR; ZYC 101/clinical trial; ZYC 101/drug therapy; ZYC 101/intramuscular
drug administration; ZYC 101/subcutaneous drug administration
Cervical cancer; Clinical trials; Hpv; Therapeutic vaccine
Cervarix/Glaxo SmithKline; Gardasil/Merck; Sgn 00101/Nventa; Tg
4001/Hoffmann La Roche; Tg 4001/Transgene; Zyc 101/Eisai
Eisai; Glaxo SmithKline; Hoffmann La Roche; Merck; Nventa; Transgene
Gynecology; Immunology, Serology and Transplantation; Drug Literature Index;
Adverse Reactions Titles
Flt3 ligand/171404-15-2; apigenin/520-36-5; epigallocatechin gallate/989-51-5;
fluorouracil/51-21-8; imiquimod/99011-02-6; interleukin 2/85898-30-2
171404-15-2; 520-36-5; 989-51-5; 51-21-8; 99011-02-6; 85898-30-2
The discovery of human papillomavirus (HPV) as a necessary etiological factor
for cervical cancer has spurred the development of preventive and therapeutic
HPV vaccines for the control of HPV-associated malignancies including cervical,
vulvar, vaginal, and a subset of head and neck cancers. The commercial
preventive HPV vaccines, Gardasil and Cervarix, use HPV virus-like particles to
generate neutralizing antibodies against HPV major capsid protein L1. However,
they do not exert therapeutic effects on existing lesions and are unlikely to have an
immediate impact on the prevalence of cervical cancer due to their cost and
limited availability in developing countries, which account for more than 80% of
cervical cancers. Thus, there is an urgent need for therapeutic HPV vaccines.
Therapeutic HPV vaccines can eliminate pre- existing lesions and infections by
generating cellular immunity against HPV-infected cells. HPV E6 and E7
oncoproteins represent ideal targets for therapeutic intervention because of their
constitutive expression in HPV-associated tumors and their crucial role in the
induction and maintenance of HPV-associated disease. This review discusses the
current progress of various therapeutic HPV vaccine approaches, including live
vector-based, peptide/protein-based, nucleic acid-based and cell-based vaccines
targeting E6 and/or E7 antigens, and their future prospects for the control of HPVassociated malignancies. © 2010 Bentham Science Publishers Ltd.
Ma B
Ma Barbara
Department of Pathology, The Johns Hopkins University School of Medicine,
CRBII 309, 1550 Orleans Street, Baltimore, Maryland 21231, United States
AU:
AU:
AU:
PU:
CNOTE:
Xu Y
Xu Yijie
Hung C-F
Hung Chien-Fu
Wu T-C
Wu T-C
CRBII 309, 1550 Orleans Street, Baltimore, Maryland 21231, United States;
Departments of Obstetrics and Gynecology, The Johns Hopkins Medical
Institutions, Baltimore, MD, United States; Departments of Molecular
Microbiology and Immunology, The Johns Hopkins Medical Institutions,
Baltimore, MD, United States; Departments of Oncology, The Johns Hopkins
Medical Institutions, Baltimore, MD, United States
[email protected]
Bentham Science Publishers B.V.
P.O. Box 294, Bussum, 1400 AG, Netherlands
2/7 von 102
ND:
Autoren:
EM2010068534
Mahto M; Nathan M; O'Mahony C
Titel:
More than a decade on: Review of the use of imiquimod in lower
anogenital intraepithelial neoplasia
Source:
International Journal of STD and AIDS; VOL: 21 (1); p. 8-16 /January 2010/
http://ijsa.rsmjournals.com/cgi/reprint/21/1/8
DOI:
10.1258/ijsa.2009.009309
PU:
Royal Society of Medicine Press Ltd
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
0956-4624
CO:
INSAE
Institution: Mahto M, Dr., Department of Genitourinary Medicine, Cheshire East Community
Health (Central and Eastern Cheshire PCT), Assura Health and Wellness Centre,
Sunderland Street, Macclesfield SK11 6JL, United
COU:
United Kingdom
DT:
JSC:
C.5 ... Dermatology & Venereology; B.2 ... Public Health; E.5 ... Clinical
Microbiology
0069
RN:
Keywords
CT:
ANUS CARCINOMA/*drug therapy; INTRAEPITHELIAL ANAL
NEOPLASIA/*drug therapy; INTRAEPITHELIAL PENILE NEOPLASIA/*drug
therapy; INTRAEPITHELIAL VULVAR NEOPLASIA/*; PENIS
CARCINOMA/*drug therapy; VULVA CARCINOMA/*drug therapy; CANCER
RECURRENCE; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT
ANALYSIS; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE;
EMBASE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS
INFECTED PATIENT; INTRAEPITHELIAL VULVAR CARCINOMA/drug
therapy; MALE HOMOSEXUAL; MEDLINE; PRIORITY JOURNAL;
REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT/side
effect; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*drug therapy;
IMIQUIMOD/*topical drug administration
UT:
Anal intraepithelial neoplasia; Anogenital; Imiquimod; Intraepithelial neoplasia;
Penile intraepithelial neoplasia; Vulvar intraepithelial neoplasia
DN:
Aldara; Zartra
ET:
Obstetrics and Gynecology; Urology and Nephrology; Drug Literature Index;
Adverse Reactions Titles; Gastroenterology
TE:
CR:
99011-02-6
AB:
To assess the effectiveness of 5% imiquimod cream (IQ) in the treatment of
vulvar, penile and anal intraepithelial neoplasias (VIN, PIN and AIN), we
searched Medline, Embase, PubMed and Cochrane Library databases. With regard
to VIN there were two randomized controlled trials (RCTs), eight
uncontrolled/cohort studies, nine case reports and one review article. Use of IQ in
PIN and AIN were only supported by cohort studies (two each for PIN and AIN)
and case reports (15 for PIN and 3 for AIN). On pooled analysis of RCTs,
uncontrolled and cohort studies, the mean complete response (CR) rate for VIN,
PIN and AIN were 51%, 70% and 48%, respectively. The mean partial response
(PR) rate for VIN, PIN and AIN were 25%, 30% and 34% respectively. The
recurrence (RR) rate for VIN, PIN and AIN were 16%, 0% and 36%, respectively.
The follow-up period for VIN, PIN and AIN ranged from 2 to 32 months, 10 to 12
months and 11 to 39 months, respectively. Although the results for PIN look the
best, the strongest evidence regarding efficacy of IQ in anogenital intraepithelial
neoplasia is for VIN supported by RCTs. Evidence for use of IQ in AIN was
essentially limited to HIV-positive men who have sex with men. IQ was
reasonably well tolerated with side-effects being managed with reduction in
frequency of drug usage and/or rest periods. Based on these results, IQ seems to
be a safe mode of treatment and is possibly an alternative to currently available
methods of treatment. However, there are no comparative studies assessing its
efficacy against traditional modes of treatment.
AU:
Mahto M
Mahto M
Department of Genitourinary Medicine, Cheshire East Community Health
AU:
AU:
PU:
CNOTE:
(Central and Eastern Cheshire PCT), Assura Health and Wellness Centre,
Sunderland Street, Macclesfield SK11 6JL, United Kingdom
[email protected]
Nathan M
Nathan M
Department of Sexual Health, Homerton Hospital NHS Trust, Homerton Row,
London E9 6SR, United Kingdom
O'Mahony C
O'Mahony C
Department of Sexual Health (Genitourinary Medicine), Countess of Chester
Foundation Trust Hospital, Liverpool Road, Chester CH2 1UL, United Kingdom
P.O. Box 9002, London, W1A 0ZA, United Kingdom
2/8 von 102
ND:
Autoren:
EM2010089410
Van Kemseke C
Titel:
Sexually transmitted diseases and anorectum
Source:
Acta Gastro-Enterologica Belgica; VOL: 72 (4); p. 413-419 /2009/
PU:
Universa Press
SU:
EMBASE
Sprache: English
AL:
English
CY:
Belgium
ISSN:
0001-5644
CO:
AGEBA
Institution: Van Kemseke C, Department of Gatroenterology, Centre Hospitalier Universitaire
de Liège, Domaine Universitaire du Sart Tilman B35, 4000 Liège,
Belgium, [email protected]
COU:
Belgium
DT:
Conference Paper; Journal Article
JSC:
C.1.8 ... Gastroenterology
RN:
0051
Keywords
CT:
SEXUALLY TRANSMITTED DISEASE/*diagnosis; SEXUALLY
TRANSMITTED DISEASE/*disease management; ANUS; CHLAMYDIA
TRACHOMATIS; CLINICAL FEATURE; CONDYLOMA
ACUMINATUM/diagnosis; CONDYLOMA ACUMINATUM/disease
management; CONDYLOMA ACUMINATUM/drug therapy; CONDYLOMA
ACUMINATUM/etiology; CONDYLOMA ACUMINATUM/surgery;
CONFERENCE PAPER; CONSULTATION; CRYOTHERAPY; DIAGNOSTIC
DN:
ET:
TE:
TEST; DRUG SUBSTITUTION; DRUG WITHDRAWAL;
ELECTROCOAGULATION; EPIDEMIC; EXCISION; GASTROINTESTINAL
SYMPTOM/side effect; GONOCOCCAL URETHRITIS/diagnosis;
GONOCOCCAL URETHRITIS/disease management; GONOCOCCAL
URETHRITIS/drug resistance; GONOCOCCAL URETHRITIS/drug therapy;
GONOCOCCAL URETHRITIS/etiology; GONORRHEA/diagnosis;
GONORRHEA/disease management; GONORRHEA/drug resistance;
GONORRHEA/drug therapy; GONORRHEA/etiology; HERPES
SIMPLEX/diagnosis; HERPES SIMPLEX/disease management; HERPES
SIMPLEX/drug therapy; HERPES SIMPLEX/etiology; HERPES SIMPLEX
VIRUS 1; HERPES SIMPLEX VIRUS 2; HERXHEIMER REACTION/side
effect; HETEROSEXUALITY; HIGH RISK BEHAVIOR; HUMAN; HUMAN
IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE;
LYMPHOGRANULOMA VENEREUM/diagnosis; LYMPHOGRANULOMA
VENEREUM/disease management; LYMPHOGRANULOMA
VENEREUM/drug therapy; LYMPHOGRANULOMA
VENEREUM/epidemiology; LYMPHOGRANULOMA VENEREUM/etiology;
LYMPHOGRANULOMA VENEREUM/prevention; NEISSERIA
GONORRHOEAE; PATHOGENESIS; PUBLIC HEALTH PROBLEM;
RECTUM; RISK ASSESSMENT; SECONDARY SYPHILIS/drug therapy;
SEXUAL BEHAVIOR; SINGLE DRUG DOSE; SYPHILIS/diagnosis;
SYPHILIS/disease management; SYPHILIS/drug therapy;
SYPHILIS/epidemiology; SYPHILIS/etiology; SYPHILIS/prevention;
TREPONEMA PALLIDUM; WART VIRUS; ACICLOVIR/drug therapy;
ACICLOVIR/oral drug administration; ANALGESIC AGENT; ANTIPYRETIC
AGENT; AZITHROMYCIN/adverse drug reaction; AZITHROMYCIN/drug
therapy; AZITHROMYCIN/oral drug administration; BENZATHINE
PENICILLIN/adverse drug reaction; BENZATHINE PENICILLIN/drug therapy;
BENZATHINE PENICILLIN/intramuscular drug administration;
CEFOTAXIME/drug therapy; CEFTRIAXONE/drug combination;
CEFTRIAXONE/drug therapy; CEFTRIAXONE/intramuscular drug
administration; CIPROFLOXACIN/drug therapy; CIPROFLOXACIN/oral drug
administration; DOXYCYCLINE/drug combination; DOXYCYCLINE/drug
therapy; DOXYCYCLINE/oral drug administration; ERYTHROMYCIN/drug
therapy; ERYTHROMYCIN/oral drug administration; FLUOROURACIL/drug
therapy; IMIQUIMOD/drug therapy; OFLOXACIN/drug therapy;
OFLOXACIN/oral drug administration; PENICILLIN G/adverse drug reaction;
PENICILLIN G/drug therapy; PENICILLIN G/intravenous drug administration;
PODOPHYLLIN/drug therapy; POVIDONE IODINE; SPECTINOMYCIN/drug
therapy; VALACICLOVIR/drug therapy; WART VIRUS VACCINE/drug
therapy
Cervarix; Ciproxine; Claforan; Gardasil; Imiquimod; Rocephine; Tarivid;
Trobicin
Gynecology; Public Health, Social Medicine and Epidemiology; Drug Literature
Index; Adverse Reactions Titles
aciclovir/59277-89-3; azithromycin/83905-01-5; benzathine penicillin/1538-09-6;
cefotaxime/63527-52-6; cefotaxime/64485-93-4; ceftriaxone/73384-59-5;
ceftriaxone/74578-69-1; ciprofloxacin/85721-33-1; doxycycline/10592-13-9;
doxycycline/17086-28-1; doxycycline/564-25-0; erythromycin/114-07-8;
CR:
AB:
AU:
PU:
CNOTE:
erythromycin/70536-18-4; fluorouracil/51-21-8; imiquimod/99011-02-6;
ofloxacin/82419-36-1; penicillin G/1406-05-9; penicillin G/61-33-6;
podophyllin/9000-55-9; povidone iodine/25655-41-8; spectinomycin/1695-77-8;
spectinomycin/21736-83-4; spectinomycin/23312-56-3; valaciclovir/124832-26-4
59277-89-3; 83905-01-5; 1538-09-6; 63527-52-6; 64485-93-4; 73384-59-5;
74578-69-1; 85721-33-1; 10592-13-9; 17086-28-1; 564-25-0; 114-07-8; 7053618-4; 51-21-8; 99011-02-6; 82419-36-1; 1406-05-9; 61-33-6; 9000-55-9; 2565541-8; 1695-77-8; 21736-83-4; 23312-56-3; 124832-26-4
Sexually transmitted diseases (STD) are a major public health problem because
their incidence is increasing worldwide despite prevention campaigns and because
they raise the risk of HIV infection. Anorectal localisations of STD are common
among men who have sex with men (MSM) but can also be seen among
heterosexuals (men or women). Transmission of such infections is due to anal sex
or to other sexual behaviours like "fisting". Although some pathogens (like
Human Papillomavirus-HPV) are common in gastroenterologist/proctologist
consultations, others are not so well-known. Furthermore during the last years,
sexual risky behaviours have led to resurgence of old affections (like syphilis) or
to emergence of unknown diseases (like lymphogranuloma venereum) in our
countries. This presentation tends to focus on clinical manifestation, diagnosis and
treatment of different STD : HPV, Herpes Simplex Virus, Neisseria gonorrhoeae,
Chlamydia trachomatis (in particularly lymphogranuloma venereum) and
Treponema pallidum.
Van Kemseke C
Van Kemseke C
Department of Gastroenterology, ULG CHU Liège
[email protected]
Universa Press
Hoenderstraat 24, Wetteren, B-9230, Belgium
2/9 von 102
ND:
Autoren:
EM2010009060
Garrett K; Kalady MF
Titel:
Anal Neoplasms
Source:
DOI:
PU:
SU:
Sprache:
AL:
CY:
ISSN:
CO:
PII:
Surgical Clinics of North America; VOL: 90 (1); p. 147-161 /February 2010/
10.1016/j.suc.2009.09.008
W.B. Saunders
EMBASE
English
English
United States
0039-6109
SCNAA
S0039610909001261
Institution: Kalady MF, Dr., Department of Colorectal Surgery, Digestive Disease Institute,
9500 Euclid Avenue, Cleveland, OH 44195, United States, [email protected]
COU:
United States
DT:
JSC:
D.1 ... General & Abdominal Surgery
RN:
0105
Keywords
CT:
ANUS CANCER/*drug therapy; ANUS INTRAEPITHELIAL
NEOPLASIA/diagnosis; ANUS INTRAEPITHELIAL NEOPLASIA/drug
therapy; ANUS INTRAEPITHELIAL NEOPLASIA/etiology; ANUS
TUMOR/diagnosis; ANUS TUMOR/drug therapy; ANUS TUMOR/etiology;
BASAL CELL CARCINOMA/diagnosis; BASAL CELL CARCINOMA/surgery;
CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER
RECURRENCE/surgery; CANCER SURGERY; CARCINOGENESIS/etiology;
CLINICAL TRIAL; COLON ADENOCARCINOMA/diagnosis; COLON
ADENOCARCINOMA/drug therapy; COLON
ADENOCARCINOMA/radiotherapy; COLON ADENOCARCINOMA/surgery;
COLON ADENOCARCINOMA/therapy; CONTINUOUS INFUSION;
CYTOLOGY; DIAGNOSTIC IMAGING; DISEASE COURSE; DOSE
RESPONSE; DRUG DOSE SEQUENCE; EXTERNAL BEAM
RADIOTHERAPY; GASTROINTESTINAL STROMAL TUMOR/drug therapy;
GASTROINTESTINAL STROMAL TUMOR/surgery; HUMAN; KAPOSI
SARCOMA/radiotherapy; LYMPH NODE METASTASIS/complication;
LYMPH NODE METASTASIS/surgery; MELANOMA/diagnosis;
MELANOMA/surgery; NEUROENDOCRINE TUMOR/drug therapy;
NEUROENDOCRINE TUMOR/radiotherapy; NEUROENDOCRINE
TUMOR/surgery; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL;
RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CANCER/surgery;
REPEATED DRUG DOSE; REVIEW; SALVAGE THERAPY;
SARCOMA/diagnosis; SARCOMA/surgery; SINGLE DRUG DOSE;
SQUAMOUS CELL CARCINOMA/diagnosis; SQUAMOUS CELL
CARCINOMA/drug therapy; SQUAMOUS CELL CARCINOMA/radiotherapy;
SQUAMOUS CELL CARCINOMA/surgery; SURGICAL TECHNIQUE;
TREATMENT INDICATION; VERRUCOUS CARCINOMA/diagnosis;
VERRUCOUS CARCINOMA/drug therapy; VERRUCOUS
CARCINOMA/radiotherapy; VERRUCOUS CARCINOMA/surgery; ALPHA
INTERFERON/drug therapy; CAPECITABINE/drug therapy;
CETUXIMAB/drug therapy; CISPLATIN/drug comparison; CISPLATIN/drug
therapy; ETOPOSIDE/drug therapy; FLUOROURACIL/drug combination;
FLUOROURACIL/drug comparison; FLUOROURACIL/drug dose;
FLUOROURACIL/drug therapy; FLUOROURACIL/topical drug administration;
IMATINIB/drug therapy; IMIQUIMOD/drug therapy; IMIQUIMOD/topical
drug administration; INTERFERON/drug therapy; MITOMYCIN/drug
combination; MITOMYCIN/drug comparison; MITOMYCIN/drug therapy;
MITOMYCIN C/clinical trial; MITOMYCIN C/drug dose; MITOMYCIN C/drug
therapy; MITOMYCIN C/intravenous drug administration; OXALIPLATIN/drug
therapy; PODOPHYLLIN/drug therapy; PODOPHYLLIN/topical drug
administration
UT:
Anal canal; Anal cancer; Anal margin; Carcinoma in-situ; Epidermoid cancer;
Squamous cell carcinoma
DN:
ET:
TE:
CR:
AB:
AU:
AU:
PU:
CNOTE:
Gleevec
Cancer; Drug Literature Index; Gastroenterology
capecitabine/154361-50-9; cetuximab/205923-56-4; cisplatin/15663-27-1;
cisplatin/26035-31-4; cisplatin/96081-74-2; etoposide/33419-42-0;
fluorouracil/51-21-8; imatinib/152459-95-5; imatinib/220127-57-1;
imiquimod/99011-02-6; mitomycin/1404-00-8; mitomycin C/50-07-7; mitomycin
C/74349-48-7; oxaliplatin/61825-94-3; podophyllin/9000-55-9
154361-50-9; 205923-56-4; 15663-27-1; 26035-31-4; 96081-74-2; 33419-42-0;
51-21-8; 152459-95-5; 220127-57-1; 99011-02-6; 1404-00-8; 50-07-7; 74349-487; 61825-94-3; 9000-55-9
A variety of lesions comprise tumors of the anal canal, with carcinoma in situ and
epidermoid cancers being the most common. Less common anal neoplasms
include adenocarcinoma, melanoma, gastrointestinal stromal cell tumors,
neuroendocrine tumors, and Buschke-Lowenstein tumors. Treatment strategies are
based on anatomic location and histopathology. In this article different tumors and
management of each, including a brief review of local excision for rectal cancer,
are discussed in turn. © 2010 Elsevier Inc. All rights reserved.
Garrett K
Garrett Kelly
Department of Colorectal Surgery, Digestive Disease Institute, 9500 Euclid
Avenue, Cleveland, OH 44195, United States
Kalady MF
Kalady Matthew F.
Department of Colorectal Surgery, Digestive Disease Institute, 9500 Euclid
Avenue, Cleveland, OH 44195, United States; Department of Cancer Biology,
9500 Euclid Avenue, Cleveland, OH 44195, United States
[email protected]
W.B. Saunders
Independence Square West, Philadelphia, PA 19106-3399, United States
2/10 von 102
ND:
Autoren:
EM2010006172
Lee PK; Wilkins KB
Titel:
Condyloma and Other Infections Including Human
Immunodeficiency Virus
Source:
DOI:
PU:
SU:
Sprache:
AL:
CY:
Surgical Clinics of North America; VOL: 90 (1); p. 99-112 /February 2010/
10.1016/j.suc.2009.09.005
W.B. Saunders
EMBASE
English
English
United States
ISSN:
0039-6109
CO:
SCNAA
PII:
S0039610909001236
Institution: Wilkins KB, Dr., UMDNJ-Robert Wood Johnson University Hospital, New
Brunswick, NJ, United States, [email protected]
COU:
United States
DT:
JSC:
RN:
0042
Keywords
CT:
CONDYLOMA/*diagnosis; CONDYLOMA/*drug therapy;
CONDYLOMA/*epidemiology; CONDYLOMA/*etiology; HUMAN
IMMUNODEFICIENCY VIRUS INFECTION/*etiology; ANUS
CANCER/diagnosis; ANUS CANCER/epidemiology; ANUS CANCER/etiology;
ANUS CANCER/surgery; ANUS CANCER/therapy; ANUS
INTRAEPITHELIAL NEOPLASIA/diagnosis; ANUS INTRAEPITHELIAL
NEOPLASIA/epidemiology; ANUS INTRAEPITHELIAL
NEOPLASIA/etiology; ANUS INTRAEPITHELIAL NEOPLASIA/surgery;
ANUS INTRAEPITHELIAL NEOPLASIA/therapy; BACTERIUM CULTURE;
BEDTIME DOSAGE; BIOPSY; CLINICAL FEATURE; CLINICAL TRIAL;
DOSE RESPONSE; ENTERITIS/diagnosis; ENTERITIS/drug therapy;
ENTERITIS/etiology; GENITAL ULCER/diagnosis; GENITAL
ULCER/etiology; GIARDIASIS/drug therapy; GONORRHEA/diagnosis;
GONORRHEA/drug therapy; GONORRHEA/etiology; GRANULOMA
INGUINALE/diagnosis; GRANULOMA INGUINALE/drug therapy;
GRANULOMA INGUINALE/etiology; HERPES SIMPLEX VIRUS 1; HERPES
SIMPLEX VIRUS 2; HERPES VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL
THERAPY; HUMAN; LYMPHOGRANULOMA VENEREUM/diagnosis;
LYMPHOGRANULOMA VENEREUM/drug therapy; LYMPHOGRANULOMA
VENEREUM/epidemiology; LYMPHOGRANULOMA VENEREUM/etiology;
NONHUMAN; PRIORITY JOURNAL; PROCTITIS/diagnosis;
PROCTITIS/drug therapy; PROCTITIS/etiology; PROCTOCOLITIS/diagnosis;
PROCTOCOLITIS/drug therapy; PROCTOCOLITIS/etiology; REVIEW; RISK
FACTOR; SEXUALLY TRANSMITTED DISEASE/etiology;
SIGMOIDOSCOPY; SINGLE DRUG DOSE; SQUAMOUS CELL
CARCINOMA/drug therapy; SYPHILIS/diagnosis; SYPHILIS/drug therapy;
SYPHILIS/etiology; ULCUS MOLLE/diagnosis; ULCUS MOLLE/drug therapy;
ULCUS MOLLE/etiology; VIRUS INFECTION/drug therapy; WART VIRUS;
ACICLOVIR/drug therapy; ACICLOVIR/oral drug administration;
AZITHROMYCIN/drug dose; AZITHROMYCIN/drug therapy;
AZITHROMYCIN/oral drug administration; BENZATHINE PENICILLIN/drug
dose; BENZATHINE PENICILLIN/drug therapy; BENZATHINE
PENICILLIN/intramuscular drug administration; CEFIXIME/drug therapy;
CEFIXIME/oral drug administration; CEFTRIAXONE/drug dose;
CEFTRIAXONE/drug therapy; CEFTRIAXONE/intramuscular drug
administration; CIPROFLOXACIN/drug therapy; CIPROFLOXACIN/oral drug
administration; COTRIMOXAZOLE/drug therapy; COTRIMOXAZOLE/oral
drug administration; DICHLOROACETIC ACID/drug therapy;
DIIODOHYDROXYQUIN/drug therapy; DIIODOHYDROXYQUIN/oral drug
UT:
ET:
TE:
CR:
AB:
AU:
AU:
administration; DOXYCYCLINE/drug therapy; DOXYCYCLINE/oral drug
administration; ERYTHROMYCIN/drug therapy; ERYTHROMYCIN/oral drug
administration; ERYTHROMYCIN ETHYLSUCCINATE/drug therapy;
ERYTHROMYCIN ETHYLSUCCINATE/oral drug administration;
FAMCICLOVIR/drug therapy; FAMCICLOVIR/oral drug administration;
IMIQUIMOD/clinical trial; IMIQUIMOD/drug dose; IMIQUIMOD/drug
therapy; LEVOFLOXACIN/drug therapy; LEVOFLOXACIN/oral drug
administration; METRONIDAZOLE/drug therapy; METRONIDAZOLE/oral
drug administration; OFLOXACIN/drug therapy; OFLOXACIN/oral drug
administration; PODOPHYLLIN/drug therapy; TETRACYCLINE/drug therapy;
TETRACYCLINE/oral drug administration; TINIDAZOLE/drug dose;
TINIDAZOLE/drug therapy; TINIDAZOLE/oral drug administration;
TRICHLOROACETIC ACID/drug therapy; VALACICLOVIR/drug therapy;
VALACICLOVIR/oral drug administration
Anal intraepithelial neoplasia; High resolution anoscopy; Human papillomavirus;
Perianal sexually transmitted diseases
Microbiology: Bacteriology, Mycology, Parasitology and Virology; Dermatology
and Venereology; Drug Literature Index; Gastroenterology
aciclovir/59277-89-3; azithromycin/83905-01-5; benzathine penicillin/1538-09-6;
cefixime/79350-37-1; ceftriaxone/73384-59-5; ceftriaxone/74578-69-1;
ciprofloxacin/85721-33-1; cotrimoxazole/8064-90-2; dichloroacetic acid/1342580-4; dichloroacetic acid/2156-56-1; dichloroacetic acid/79-43-6;
diiodohydroxyquin/8054-64-6; diiodohydroxyquin/83-73-8; doxycycline/1059213-9; doxycycline/17086-28-1; doxycycline/564-25-0; erythromycin/114-07-8;
erythromycin/70536-18-4; erythromycin ethylsuccinate/1264-62-6;
famciclovir/104227-87-4; imiquimod/99011-02-6; levofloxacin/100986-85-4;
levofloxacin/138199-71-0; metronidazole/39322-38-8; metronidazole/443-48-1;
ofloxacin/82419-36-1; podophyllin/9000-55-9; tetracycline/23843-90-5;
tetracycline/60-54-8; tetracycline/64-75-5; tinidazole/19387-91-8; trichloroacetic
acid/14357-05-2; trichloroacetic acid/76-03-9; valaciclovir/124832-26-4
59277-89-3; 83905-01-5; 1538-09-6; 79350-37-1; 73384-59-5; 74578-69-1;
85721-33-1; 8064-90-2; 13425-80-4; 2156-56-1; 79-43-6; 8054-64-6; 83-73-8;
10592-13-9; 17086-28-1; 564-25-0; 114-07-8; 70536-18-4; 1264-62-6; 10422787-4; 99011-02-6; 100986-85-4; 138199-71-0; 39322-38-8; 443-48-1; 82419-361; 9000-55-9; 23843-90-5; 60-54-8; 64-75-5; 19387-91-8; 14357-05-2; 76-03-9;
124832-26-4
Sexually transmitted diseases (STDs) are a common public health problem and as
such may be more common in a surgical practice than is believed. The recognition
that a virus can be responsible for a cancer has profound significant public health
implications. This article reviews the presentation and management of the more
common perianal STDs including human immunodeficiency virus, as well as the
pathogenesis and management of anal intraepithelial neoplasia. © 2010 Elsevier
Inc. All rights reserved.
Lee PK
Lee Peter K.
UMDNJ-Robert Wood Johnson University Hospital, New Brunswick, NJ, United
States; 5965 E. Broad Street, Suite 120, Columbus, OH 43213, United States
Wilkins KB
Wilkins Kirsten Bass
PU:
CNOTE:
UMDNJ-Robert Wood Johnson University Hospital, New Brunswick, NJ, United
States; 3900 Park Avenue, Suite 101, Edison, NJ 08820, United States
[email protected]
W.B. Saunders
2/11 von 102
ND:
Autoren:
EM2009634138
Graziottin A
Titel:
HPV infection in women: Clinical consequences, psychosexual
impact and the chances of prevention
Source:
Italian Journal of Gynaecology and Obstetrics; VOL: 21 (3); p. 141-151 /2009/
http://www.sigo.it/Documenti/Journal/italianjournal3_09.pdf
PU:
S.I.G.O. Publishing Co
SU:
EMBASE
Sprache: English
AL:
English; Italian
CY:
Italy
ISSN:
1121-8339
CO:
IJGOE
Institution: Graziottin A, Center of Gynecology and Medical Sexology, H. San Raffaele
Resnati, Milan, Italy
COU:
Italy
DT:
JSC:
C.4 ... Obstetrics & Gynecology
RN:
0053
Keywords
CT:
CONDYLOMA ACUMINATUM/*diagnosis; CONDYLOMA
ACUMINATUM/*drug therapy; CONDYLOMA
ACUMINATUM/*epidemiology; CONDYLOMA ACUMINATUM/*etiology;
CONDYLOMA ACUMINATUM/*prevention; CONDYLOMA
ACUMINATUM/*therapy; PSYCHOSEXUAL DISORDER/*complication;
ANAL INTRAEPITHELIAL NEOPLASIA/complication; ANAL
INTRAEPITHELIAL NEOPLASIA/diagnosis; ANAL INTRAEPITHELIAL
NEOPLASIA/epidemiology; ANGER; ANUS CANCER/complication; ANUS
CANCER/diagnosis; ANUS CANCER/epidemiology; ANXIETY; CLINICAL
FEATURE; CLINICAL TRIAL; CRYOTHERAPY;
DEPRESSION/complication; DISEASE ASSOCIATION; DISTRESS
SYNDROME/complication; DRUG INDICATION; FEMALE; HUMAN;
HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE
18; INFECTION PREVENTION; LASER SURGERY; MALIGNANT
TRANSFORMATION; NONHUMAN; PAPANICOLAOU TEST;
PRECANCER/drug therapy; PRIMARY PREVENTION; RECURRENT
UT:
ET:
TE:
CR:
AB:
AU:
INFECTION/complication; REVIEW; RISK ASSESSMENT; SECONDARY
PREVENTION; UTERINE CERVIX CANCER/complication; UTERINE
CERVIX CANCER/diagnosis; UTERINE CERVIX CANCER/drug therapy;
UTERINE CERVIX CANCER/etiology; UTERINE CERVIX
CANCER/prevention; VIRUS DETECTION; VIRUS GENOME; WOMEN'S
HEALTH; ALPHA INTERFERON/clinical trial; ALPHA INTERFERON/drug
therapy; ALPHA INTERFERON/intramuscular drug administration;
IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration;
PODOPHYLLOTOXIN/drug therapy; PODOPHYLLOTOXIN/topical drug
administration; TRICHLOROACETIC ACID/drug therapy;
TRICHLOROACETIC ACID/topical drug administration; WART VIRUS
VACCINE/drug therapy; WART VIRUS VACCINE/intramuscular drug
administration
Anal HPV infection; Cervical cancer; Genital warts; HPV; HPV vaccine;
Intraepithelial neoplasia; Psychosexual issues
Gynecology; Cancer; Public Health, Social Medicine and Epidemiology; Drug
Literature Index
imiquimod/99011-02-6; podophyllotoxin/518-28-5; trichloroacetic acid/14357-052; trichloroacetic acid/76-03-9
99011-02-6; 518-28-5; 14357-05-2; 76-03-9
Introduction. Human Papillomavirus (HPV) infection is the most common genital
viral infection in humans. It is highly prevalent and increasing, due to promiscuity
and unprotected sex. HPV is a wide family of DNA viruses, which may cause
benign skin and mucosal tumours (genital, anal or oral warts), intraepithelial
neoplasias and/or malignant cancers in different organs. Women are more
susceptible to the oncogenic effect of HPVs, mostly at the genital site. Aims. This
paper analyses the main characteristics of HPVs, the clinical consequences of their
infections in women, with the current epidemiology; some highlights on the actual
measure of prevention, with a focus on the psychosexual consequences of HPV
infections. Conclusion. The HR-HPVs (High Risk Human Papillomavirus) have
been causally related to several cancers in human (cervical, vulvar, vaginal, anal),
and the LR-HPV (Low Risk Human Papillomavirus) types related mainly to a
benign sexually transmitted disease: genital warts. Primary measures of prevention
such as vaccination can protect against a panel of HPV related diseases, while
secondary prevention, such as pap test or HPV test are specific for a precocious
diagnosis, and is currently standardized as a screening measure, only in the field
of cervical cancer. To guarantee the most effective preventive strategies both
measures had to continue together. Psychosexual vulnerability increases with
number of recurrences of HPV infections. Depression, anxiety and anger are the
emotions most frequently reported. However, no specific correlation has been
proved so far between HPV infection and a specific female sexual disorder. A
practical approach is offered to the reader with clinically relevant tips, useful in
his/her daily practice, when dealing with HPV infected women and couples. ©
Copyright 2009, CIC Edizioni Internazionali.
Graziottin A
Graziottin A
Center of Gynecology and Medical Sexology, H. San Raffaele Resnati, Milan,
Italy
PU:
CNOTE:
S.I.G.O. Publishing Co
Via dei Soldati 25, Rome, 00186, Italy
2/12 von 102
ND:
Autoren:
EM2009602532
Kolodziejczak M; Ciesielski P; Nawrocki G
Titel:
Co nowego w chorobach odbytu i kanalu odbytu
What is new in anus and anal canal diseases
Source:
Gastroenterologia Polska; VOL: 16 (2); p. 163-169 /2009/
http://www.cornetis.com.pl/pliki/download.php?issn=12329886&rok=2009&numer=2&str_p=163
PU:
Cornetis
SU:
EMBASE
Sprache: Polish
AL:
English; Polish
CY:
Poland
ISSN:
1232-9886
CO:
GASPF
Institution: Kolodziejczak M, Dr., Oddzial Chirurgii Ogólnej Z Pododzialem Proktologii
Szpitala na Solcu, ul. Solec 93, 00-382 Warszawa, Poland, [email protected]
COU:
Poland
DT:
JSC:
RN:
0040
Keywords
CT:
ANUS DISEASE/*; ANUS; ANUS CANCER/drug therapy; ANUS
FISSURE/drug therapy; ANUS FISSURE/surgery; ANUS FISTULA;
CONDYLOMA; CONSERVATIVE TREATMENT; CROHN DISEASE/drug
therapy; FECES INCONTINENCE; HEMORRHOID/surgery;
HEMORRHOIDECTOMY; HUMAN; NUCLEAR MAGNETIC RESONANCE
IMAGING; PERIANAL ABSCESS; PRACTICE GUIDELINE; RECTOSCOPY;
REVIEW; ANTIINFLAMMATORY AGENT; BOTULINUM TOXIN A/drug
therapy; IMIQUIMOD/drug therapy; INFLIXIMAB/drug therapy;
METRONIDAZOLE; MITOMYCIN/drug therapy
UT:
Anal cancer; Anal fissure; Crohn's disease; Haemorrhoids; Incontinence
ET:
Microbiology: Bacteriology, Mycology, Parasitology and Virology; Surgery;
TE:
botulinum toxin A/93384-43-1; imiquimod/99011-02-6; infliximab/170277-31-3;
metronidazole/39322-38-8; metronidazole/443-48-1; mitomycin/1404-00-8
CR:
93384-43-1; 99011-02-6; 170277-31-3; 39322-38-8; 443-48-1; 1404-00-8
AB:
In recent years there has been a significant progress in the diagnostics and therapy
of diseases of anus and anal canal. The progress in diagnostics includes both
AU:
AU:
AU:
PU:
CNOTE:
advancement in imaging diagnostics, such as 2D and 3D ultrasonography or MRI,
and improvement in functional examinations, such as non-invasive EMG. In the
surgical treatment of proctological diseases, as in other fields of surgery,
development of minimally invasive techniques is observed. On the other hand,
however, many surgeons are going back to old treatment methods, changing only
some technical details. It is not always possible to evaluate the efficacy of such
methods explicitly, mainly because of a short period of observation and the fact
that the groups of patients are not always homogeneous. This article discusses
advancements in the treatment of such inflammatory diseases as anal fissure,
haemorrhoids, abscesses, fistulas, condylomas and ano-rectal Crohn's disease.
Major changes have been observed in the surgical treatment of anal fistules. Due
to the large percentage of complications related to the surgical treatment of anal
fistules, for a few years there have been attempts to use conservative methods of
treatment of this disease. Such methods include tissue glue and so called "plugs",
which are used to close the internal ostium of the fistula. Progress in the treatment
of ano-rectal Crohn's disease mainly includes introduction of anti-inflammatory
medicines of a newer generation, and the most recent novelty is biological
treatment. In addition, current guidelines in the diagnostics and treatment of
incontinence have been discussed, as well as contemporary trends in the
management of patients with anal cancers. The article provides a review of the
current literature on the treatment of proctological inflammatory diseases and anal
cancers. Copyright © 2009 Cornetis.
Ciesielski P
Ciesielski Przemyslaw
Oddzial Chirurgii Ogólnej Szpitala Powiatowego W Wolominie
Kolodziejczak M
Kolodziejczak Malgorzata
Oddzial Chirurgii Ogólnej Z Pododzialem Proktologii Szpitala na Solcu, ul. Solec
93, 00-382 Warszawa, Poland
[email protected]
Nawrocki G
Nawrocki Grzegorz
Oddzial Chirurgii Kliniki Onkologicznej, Centrum Onkologii - Instytut Im. Marii
Sklodowskiej-Curie W Warszawie
Cornetis
ul. Dlugosza 2-6, Wroclaw, 51-162, Poland
2/13 von 102
ND:
Autoren:
EM2009465878
Palefsky JM
Titel:
Anal cancer prevention in HIV-positive men and women
Source:
DOI:
Current Opinion in Oncology; VOL: 21 (5); p. 433-438 /September 2009/
10.1097/CCO.0b013e32832f511a
PU:
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
1040-8746
CO:
CUOOE
Institution: Palefsky JM, Dr., Department of Medicine, University of California, San
Francisco, Box 0126, 505 Parnassus Ave, San Francisco, CA 94143, United
COU:
United States
DT:
JSC:
C.1.3.1 ... Clinical Oncology
RN:
0017
Keywords
CT:
ANUS CANCER/*disease management; ANUS CANCER/*drug therapy; ANUS
CANCER/*epidemiology; ANUS CANCER/*prevention; ANUS
CANCER/*radiotherapy; ANUS CANCER/*surgery; CANCER
PREVENTION/*; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/*drug therapy; ANAL INTRAEPITHELIAL NEOPLASIA/disease
management; ANAL INTRAEPITHELIAL NEOPLASIA/drug therapy; ANAL
INTRAEPITHELIAL NEOPLASIA/surgery; ANAL INTRAEPITHELIAL
NEOPLASIA/therapy; CANCER GROWTH; CANCER INCIDENCE; CANCER
RADIOTHERAPY; CANCER SCREENING; CAUTERIZATION; CLINICAL
TRIAL; COLPOSCOPY; CONDYLOMA/disease management;
CONDYLOMA/drug therapy; CONDYLOMA/surgery; CONDYLOMA/therapy;
CRYOTHERAPY; DISEASE ASSOCIATION; HIGHLY ACTIVE
ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; LOW
LEVEL LASER THERAPY; MALE HOMOSEXUAL; PRIORITY JOURNAL;
REVIEW; SURGICAL TECHNIQUE; TREATMENT FAILURE; UTERINE
CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU/diagnosis;
UTERINE CERVIX CARCINOMA IN SITU/surgery; UTERINE CERVIX
CYTOLOGY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT/drug
therapy; CATECHIN/drug therapy; CATECHIN/topical drug administration;
IMIQUIMOD/clinical trial; IMIQUIMOD/drug therapy; IMIQUIMOD/topical
drug administration; LIQUID NITROGEN; PODOPHYLLOTOXIN/drug therapy;
PODOPHYLLOTOXIN/topical drug administration; SINECATECHIN
DERIVATIVE/drug therapy; SINECATECHIN DERIVATIVE/topical drug
administration; TRICHLOROACETIC ACID; UNCLASSIFIED DRUG
UT:
Anal cancer; Anal intraepithelial neoplasia; Cancer prevention; HIV; Human
papillomavirus; Screening
ET:
Cancer; Public Health, Social Medicine and Epidemiology; Immunology,
Serology and Transplantation; Drug Literature Index; Gastroenterology
TE:
catechin/13392-26-2; catechin/154-23-4; imiquimod/99011-02-6;
acid/76-03-9
CR:
13392-26-2; 154-23-4; 99011-02-6; 518-28-5; 14357-05-2; 76-03-9
AB:
AU:
PU:
CNOTE:
PURPOSE OF REVIEW: The incidence of human papillomavirus-associated anal
cancer is unacceptably high among HIV-positive men who have sex with men,
and possibly in HIV-positive women. Unlike most other malignancies occurring in
the HIV-positive population, anal cancer is potentially preventable, using methods
similar to those used to prevent cervical cancer in women. This review discusses
the issues around screening to prevent anal cancer. RECENT FINDINGS: Recent
studies show that the incidence of anal cancer has increased since the introduction
of highly active antiretroviral therapy in this population and now exceeds the
highest incidence of cervical cancer among women reported anywhere in the
world. SUMMARY: The high incidence of anal cancer among HIV-positive
individuals must not be ignored, since it may be preventable. Given the current
evidence and analogy with the cervical cancer prevention model, many clinicians
believe that identification and treatment of high-grade anal intraepithelial
neoplasia to prevent anal cancer are warranted. When the expertise to do so exists,
this is a reasonable approach, particularly if coupled with efforts to optimize
further screening and treatment approaches, as well as efforts to document the
efficacy of high-grade anal intraepithelial neoplasia treatment to reduce the
incidence of anal cancer. © 2009 Lippincott Williams & Wilkins, Inc.
Palefsky JM
Palefsky Joel M.
Department of Medicine, University of California, San Francisco, Box 0126, 505
Parnassus Ave, San Francisco, CA 94143, United States
[email protected]
530 Walnut Street, Philadelphia, PA 19106-3621, United States
2/14 von 102
ND:
Autoren:
EM2009395225
Fox P
Titel:
Anal cancer screening in men who have sex with men
Source:
Current Opinion in HIV and AIDS; VOL: 4 (1); p. 64-67 /January 2009/
DOI:
10.1097/COH.0b013e32831a6fe0
PU:
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
1746-630X
EISSN:
1746-6318
Institution: Fox P, Dr., Chelsea and Westminster Hospital, St. Stephen's Centre, 369 Fulham
Road, London SW10 9NH, United Kingdom, [email protected]
COU:
United Kingdom
DT:
RN:
0025
Keywords
CT:
ANUS CANCER/*; CANCER SCREENING/*; MALE HOMOSEXUAL/*;
ANAL CYTOLOGY; ANUS INTRAEPITHELIAL NEOPLASIA/diagnosis;
ANUS INTRAEPITHELIAL NEOPLASIA/drug therapy; ANUS
INTRAEPITHELIAL NEOPLASIA/therapy; CANCER RISK; CONDYLOMA
ACUMINATUM; CYTOLOGY; DIGITAL RECTAL EXAMINATION; DRUG
EFFICACY; DYSPLASIA/diagnosis; DYSPLASIA/drug therapy;
DYSPLASIA/therapy; HIGH RESOLUTION ANOSCOPY; HIGHLY ACTIVE
ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY
VIRUS INFECTION; INTESTINE ENDOSCOPY; PRIORITY JOURNAL;
REVIEW; SELF EXAMINATION; SENSITIVITY AND SPECIFICITY; VIRUS
LOAD; WART VIRUS; CYCLIN DEPENDENT KINASE INHIBITOR 2A;
PLACEBO; TRICHLOROACETIC ACID/drug therapy
UT:
Anal cancer; Anal cytology; Anal intraepithelial neoplasia; Natural history;
Treatment
ET:
Dermatology and Venereology; Cancer; Public Health, Social Medicine and
Epidemiology; Drug Literature Index; Gastroenterology
TE:
CR:
99011-02-6; 14357-05-2; 76-03-9
AB:
Purpose of review: To determine whether current evidence and expert opinion
support the routine use of anal cytology and high-resolution anoscopy in men who
have sex with men. Recent findings: Most recently published guidelines do not
recommend routine anal cytology, but anal cancer is undoubtedly a serious and
growing problem for HIV-positive patients. Two recent cohort studies have
provided data that suggest that the precursor lesion (highgrade squamous
intraepithelial lesion) might not be more prevalent in patients on highly active
antiretroviral therapy than in historical pre-highly active antiretroviral therapy
cohorts or in HIV-negative men who have sex with men. If substantiated by
further studies, this would make it easier to focus intervention with highresolution anoscopy on a smaller group of patients. This would be helpful because
high-resolution anoscopy remains a resource that is both costly and difficult to
access in most countries. The sensitivity and specificity of anal cytology is poor
and adjuncts to cytology such as p16ink4a staining and human papillomavirus
viral loads might be utilized to further reduce the number of patients requiring
high-resolution anoscopy. Despite the burden of high-grade squamous
intraepithelial lesion in HIV negative men who have sex with men, anal cancer
remains uncommon in this group. Summary: Although routine anal cytology is
not advisable for men who have sex with men at present, be they HIV positive or
negative, clinicians should be regularly performing digital rectal examination in
those at high risk of anal cancer, both to facilitate early detection of anal cancer
and in the interests of health promotion. © 2009 Wolters Kluwer Health |
Lippincott Williams & Wilkins.
AU:
Fox P
Fox Paul
Chelsea and Westminster Hospital, St. Stephen's Centre, 369 Fulham Road,
London SW10 9NH, United Kingdom
PU:
CNOTE:
[email protected]
2/15 von 102
ND:
Autoren:
EM2009395223
Palefsky J
Titel:
Human papillomavirus-related disease in people with HIV
Source:
Current Opinion in HIV and AIDS; VOL: 4 (1); p. 52-56 /January 2009/
DOI:
10.1097/COH.0b013e32831a7246
PU:
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
1746-630X
EISSN:
1746-6318
Institution: Palefsky J, Dr. Prof., Department of Medicine, University of California, 505
Parnassus Ave, Box 0126, San Francisco, CA 94143, United
COU:
United States
DT:
RN:
0036
Keywords
CT:
ANUS CANCER/*epidemiology; ANUS CANCER/*prevention; HUMAN
IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; UTERINE
CERVIX CANCER/*epidemiology; WART VIRUS/*; ANUS
INTRAEPITHELIAL NEOPLASIA/drug therapy; ANUS INTRAEPITHELIAL
NEOPLASIA/surgery; ANUS INTRAEPITHELIAL NEOPLASIA/therapy;
CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING;
CONDYLOMA ACUMINATUM/drug therapy; DISEASE ASSOCIATION;
DRUG MECHANISM; DYSPLASIA/drug therapy; DYSPLASIA/surgery;
DYSPLASIA/therapy; HUMAN; MALE HOMOSEXUAL; MORBIDITY;
MOUTH CANCER; PENIS CANCER; PREVALENCE; PRIORITY JOURNAL;
REVIEW; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION;
ANTIRETROVIRUS AGENT/drug therapy; IMIQUIMOD/drug therapy;
IMIQUIMOD/pharmacology; IMIQUIMOD/topical drug administration
UT:
Anal cancer; Anal intraepithelial neoplasia; Cervical cancer; Cervical
intraepithelial neoplasia; Human papillomavirus
ET:
Obstetrics and Gynecology; Cancer; Immunology, Serology and Transplantation;
Drug Literature Index; Gastroenterology
TE:
CR:
AB:
AU:
PU:
CNOTE:
99011-02-6
Purpose of review: The incidence of human papillomavirus (HPV)-related cancers
has increased among people with HIV infection compared with the general
population. This review will describe recent findings in HPV-associated cancer
incidence since the introduction of antiretroviral therapy, HPV/disease prevalence
at sites other than cervix and anus, and recent data on screening and treatment of
anal intraepithelial neoplasia. Recent findings: Consistent with high prevalence of
anogenital HPV infection, new data on cervical intraepithelial neoplasia and anal
intraepithelial neoplasia in HIV-positive men and women show that the incidence
of cervical cancer has not declined since the introduction of antiretroviral therapy
and that the incidence of anal cancer is rising. Several studies also highlight high
rates of HPV infection and HPV-associated disease at sites other than the cervix
and anus, including the penis and the mouth. Treatment methods for anal
intraepithelial neoplasia have been described and show reasonable efficacy.
Summary: New data imply that the problem of HPV-related cancers will not
decline among HIV-positive men and women in the antiretroviral therapy era,
highlighting the need to perform studies to determine if screening and treatment of
anal intraepithelial neoplasia will prevent development of anal cancer. Recent
data show progress in both these areas. © 2009 Wolters Kluwer Health |
Palefsky J
Palefsky Joel
Department of Medicine, University of California, 505 Parnassus Ave, Box 0126,
San Francisco, CA 94143, United States
[email protected]
2/16 von 102
ND:
Autoren:
EM2009329201
Coremans G; Snoeck R
Titel:
Cidofovir: Clinical experience and future perspectives on an acyclic
nucleoside phosphonate analog of cytosine in the treatment of
refractory and premalignant HPV-associated anal lesions
Source:
Expert Opinion on Pharmacotherapy; VOL: 10 (8); p. 1343-1352 /June 2009/
http://www.informapharmascience.com/doi/pdf/10.1517/14656560902960154
10.1517/14656560902960154
Informa Healthcare
EMBASE
English
English
United Kingdom
1465-6566
DOI:
PU:
SU:
Sprache:
AL:
CY:
ISSN:
CO:
EOPHF
Institution: Coremans G, University Hospital Gasthuisberg, Department of Gastroenterology,
Herestraat 49, 3000 Leuven, Belgium, [email protected]
COU:
Belgium
DT:
JSC:
A.1.1 ... Clinical Pharmacology
RN:
0063
Keywords
CT:
ACUMINATUM/*surgery; CONDYLOMA ACUMINATUM/*therapy;
PRECANCER/*; VIRUS INFECTION/*drug therapy; VIRUS
INFECTION/*surgery; VIRUS INFECTION/*therapy; ANAL LESION/drug
therapy; ANTIVIRAL ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE;
BOWEN DISEASE/drug therapy; CLINICAL TRIAL; DISEASE
ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG
BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG
DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER/side
effect; DRUG FORMULATION; DRUG INDUCED HEADACHE/side effect;
DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG
TOLERABILITY; FATIGUE/side effect; GLOMERULUS FILTRATION RATE;
HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/drug therapy;
LESIONS AND DEFECTS/drug therapy; LONG TERM CARE; MAXIMUM
PLASMA CONCENTRATION; MYALGIA/side effect; NEOPLASM/drug
therapy; NEPHROTOXICITY/side effect; NONHUMAN; PENIS DISEASE/drug
therapy; PROTEINURIA/side effect; RECURRENT INFECTION/drug therapy;
REVIEW; UTERINE CERVIX CARCINOMA IN SITU/drug therapy; UTERINE
CERVIX DYSPLASIA/drug therapy; VULVA DISEASE/drug therapy;
CIDOFOVIR/*adverse drug reaction; CIDOFOVIR/*clinical trial;
CIDOFOVIR/*drug combination; CIDOFOVIR/*drug concentration;
CIDOFOVIR/*drug dose; CIDOFOVIR/*drug therapy; CIDOFOVIR/*drug
toxicity; CIDOFOVIR/*intralesional drug administration;
CIDOFOVIR/*intravenous drug administration; CIDOFOVIR/*pharmacokinetics;
CIDOFOVIR/*pharmacology; CIDOFOVIR/*subconjunctival drug
administration; CIDOFOVIR/*topical drug administration; ACYCLIC
NUCLEOSIDE; ALPHA2 INTERFERON/adverse drug reaction; ALPHA2
INTERFERON/drug therapy; ALPHA2 INTERFERON/pharmacology; ALPHA2
INTERFERON/topical drug administration; CYTOSINE;
FLUOROURACIL/drug therapy; FLUOROURACIL/pharmacology;
IMIQUIMOD/drug therapy; IMIQUIMOD/pharmacology; PHOSPHONIC
ACID DERIVATIVE; PHOTOSENSITIZING AGENT/drug therapy;
ZIDOVUDINE/drug combination; ZIDOVUDINE/drug therapy
UT:
AIN; Antiviral activity; Apoptosis; Cidofovir; Condylomata acuminata; HPMPC;
HPV-associated anogenital lesions; Nephrotoxicity; Phosphorylated metabolites
ET:
Gynecology; Dermatology and Venereology; Drug Literature Index; Adverse
Reactions Titles
TE:
cidofovir/113852-37-2; cytosine/71-30-7; fluorouracil/51-21-8; imiquimod/9901102-6; zidovudine/30516-87-1
CR:
113852-37-2; 71-30-7; 51-21-8; 99011-02-6; 30516-87-1
AB:
AU:
AU:
PU:
CNOTE:
Background: Cidofovir, a nucleotide analog with antiviral activity against a broad
range of DNA viruses including human papilloma viruses (HPV), is available off
label to clinicians. Objective: To provide a better knowledge of pharmacology and
effects when topically applied. Methods: After reviewing the chemistry,
physiology, and animal studies, an overview of clinical studies is provided.
Results/conclusions: Cidofovir, as a result of its antiviral and antiproliferative
activity and its ability to induce apoptosis, can offer a solution for the treatment of
severe recurrent HPV-induced lesions. It can also be used to attempt to treat
dysplastic lesions and as an adjuvant treatment. The long-lasting antiviral activity
allows infrequent dosing. As a rule, cidofovir applied on the skin is well tolerated,
even in long-term treatment. The dose-limiting nephrotoxicity of the drug is not a
concern in patients with a glomerular filtration rate within the normal range.
Cidofovir has clearly influenced the landscape of refractory and dysplastic
anogenital condylomata acuminata and its use has increased over the last decade.
However, further controlled clinical trials are needed to assess the role of
cidofovir and its derivatives. © 2009 Informa UK Ltd. All rights reserved.
Coremans G
Coremans Georges
University Hospital Gasthuisberg, Department of Gastroenterology, Herestraat 49,
3000 Leuven, Belgium
[email protected]
Snoeck R
Snoeck Robert
Rega Institute for Medical Research, KU Leuven, Belgium
Informa Healthcare
Telephone House, 69 - 77 Paul Street, EC2A 4LQ, United Kingdom
2/17 von 102
ND:
Autoren:
EM2009322231
Longacre TA; Kong CS; Welton ML
Titel:
Diagnostic problems in anal pathology
Source:
Advances in Anatomic Pathology; VOL: 15 (5); p. 263-278 /September 2008/
DOI:
10.1097/PAP.0b013e318183234b
PU:
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
1072-4109
EISSN:
1533-4031
PII:
0012548020080900000002
Institution: Longacre TA, Dr., Department of Pathology, Stanford University, School of
Medicine, 300 Pasteur Drive, Stanford, CA 94305, United
United States
E.7 ... Anatomy, Histology, Cytology & Anthropology
0073
COU:
DT:
JSC:
RN:
Keywords
CT:
ANUS DISEASE/*diagnosis; ANUS DISEASE/*epidemiology; ANUS
DISEASE/*etiology; DIAGNOSTIC VALUE/*; ACQUIRED IMMUNE
DEFICIENCY SYNDROME; ADENOCARCINOMA/diagnosis; ANAL
CANAL; ANAL CONDYLOMA/diagnosis; ANOPLASTY; ANUS
CANCER/diagnosis; ANUS CARCINOMA/epidemiology; ANUS
CARCINOMA/etiology; ANUS INTERCOURSE; BASAL CELL
CARCINOMA/diagnosis; CANCER DIAGNOSIS; CANCER INCIDENCE;
CANCER RISK; CANCER SURGERY; CIGARETTE SMOKING; CLINICAL
EVALUATION; CLINICAL PROTOCOL; CONDYLOMA/diagnosis;
CONDYLOMA ACUMINATUM/diagnosis; CYTOLOGY; DIAGNOSTIC
ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION;
DYSPLASIA; GENITAL TRACT CANCER; HEMORRHOIDECTOMY; HIGH
RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN
IMMUNODEFICIENCY VIRUS; HYPERPLASIA/diagnosis; IMMUNE
DEFICIENCY; INFECTION RISK; INVASIVE CARCINOMA;
MELANOMA/diagnosis; NEUROENDOCRINE TUMOR/diagnosis;
NOMENCLATURE; NONHUMAN; PATHOLOGIST; PATIENT
ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RECTUM BIOPSY;
REVIEW; SCREENING; SERODIAGNOSIS; SMALL CELL
CARCINOMA/diagnosis; SQUAMOUS CELL CARCINOMA/epidemiology;
METAPLASIA/diagnosis; TUMOR DIFFERENTIATION; VERRUCOUS
CARCINOMA/diagnosis; VERRUCOUS CARCINOMA/surgery; VIRUS
INFECTION/drug therapy; VIRUS TYPING; WART VIRUS; BIOLOGICAL
MARKER/endogenous compound; CYCLIN DEPENDENT KINASE
INHIBITOR 2A/endogenous compound; IMIQUIMOD/drug therapy;
IMIQUIMOD/topical drug administration
UT:
Anal carcinoma; Anal dysplasia; Anal intraepithelial neoplasia; Buschke and
Lowenstein; Condyloma acuminatum; HPV; Human papilloma virus; p16; ProEx
C; Verrucous carcinoma
ET:
Microbiology: Bacteriology, Mycology, Parasitology and Virology; Internal
Medicine; Cancer; Public Health, Social Medicine and Epidemiology; Drug
Literature Index; Gastroenterology
TE:
CR:
99011-02-6
AB:
Anal squamous cell carcinoma and its precursor lesions are increasing in
incidence in the United States and Europe. This trend predates human
immunodeficiency virus/acquired immune deficiency syndrome and has been
associated with persistent high-risk human papilloma virus (HPV) genotype
infection, previous lower genital tract dysplasia/carcinoma, high frequency
anoreceptive intercourse, heavy cigarette smoking, immunosuppression in solid
organ transplant and immune disorders, and human immunodeficiency virus
AU:
AU:
AU:
PU:
CNOTE:
seropositivity. Screening protocols for at-risk patients are under active
investigation and pathologists are often asked to assess anal canal and perianal
biopsies for the presence of dysplasia and/or invasive carcinoma. Because
underdiagnosis and overdiagnosis of anal cancer and precancer may lead to
inappropriate treatment, it is important for the pathologist to be aware of current
screening strategies, specific risk lesions, and the role of pathology in initial
diagnosis and evaluation of anal biopsy and/or resection specimens. Standardized
histologic criteria and uniform terminology should be used for reporting all anal
canal and perianal squamous intraepithelial lesions. HPV subtyping, anal
cytology, and recently identified biomarkers, such as p16 and Becton Dickinson
ProEx C may provide additional information in problematic cases, but it is
important to be aware of the limitations of these assays. HPV has been linked to
all the major histologic subtypes of anal carcinoma (eg, basaloid, cloacogenic,
transitional, etc.) and this association is strongest for anal canal lesions. With the
possible exception of the microcystic pattern, histologic subtype does not seem to
predict prognosis; and anal squamous cell carcinomas should be classified as
either keratinizing or nonkeratinizing. Poorly differentiated squamous cell
carcinomas have a worse prognosis and should be distinguished from poorly
differentiated adenocarcinoma, melanoma, and neuroendocrine tumors. Very well
differentiated squamous cell carcinoma with pushing margins (so-called giant
condyloma of Buschke and Lowenstein) should be classified as verrucous
carcinoma; this tumor shows aggressive local infiltration but does not metastasize.
As all anal condylomata may harbor foci of high-grade dysplasia or invasive
carcinoma, careful sectioning and complete histologic examination is required. ©
2008 Lippincott Williams & Wilkins, Inc.
Longacre TA
Longacre Teri A.
Department of Pathology, Stanford University, School of Medicine, 300 Pasteur
Drive, Stanford, CA 94305, United States
[email protected]
Kong CS
Kong Christina S.
Department of Pathology, Stanford University, School of Medicine, 300 Pasteur
Drive, Stanford, CA 94305, United States
Welton ML
Welton Mark L.
Department of Surgery, Stanford University, Stanford, CA, United States
2/18 von 102
ND:
Autoren:
EM2009302522
Gibbon KL; Ekeowa-Anderson AL; Leigh IM
Titel:
External anogenital premalignant and malignant disease
Source:
Cancer Treatment and Research; VOL: 146; p. 279-298 /2009/
BTI:
Skin Cancer after Organ Transplantation
DOI:
10.1007/978-0-387-78574-5_23
PU:
Springer Science and Business Media Netherlands
SU:
EMBASE
Sprache: English
AL:
English
CY:
Netherlands
ISSN:
0927-3042
ISBN:
9780387785738
Institution: Gibbon KL, Barts and the London NHS Trust, London, E1 1BB, United Kingdom
COU:
United Kingdom
DT:
Review; Book Series
RN:
0090
Keywords
CT:
ANOGENITAL INTRAEPITHELIAL NEOPLASIA/*drug therapy;
ANOGENITAL INTRAEPITHELIAL NEOPLASIA/*prevention; GENITAL
TRACT TUMOR/*drug therapy; GENITAL TRACT TUMOR/*prevention;
ANAL INTRAEPITHELIAL NEOPLASIA/drug therapy; ANAL
INTRAEPITHELIAL NEOPLASIA/surgery; ANUS CANCER/drug therapy;
ANUS TUMOR/drug therapy; ANUS TUMOR/surgery; CANCER
CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER
RADIOTHERAPY; CANCER RISK; CHEMOSURGERY; CLINICAL TRIAL;
DISEASE ASSOCIATION; GRAFT RECIPIENT; HUMAN; ORGAN
TRANSPLANTATION; PENILE INTRAEPITHELIAL NEOPLASIA; PENIS
TUMOR; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL
CARCINOMA; UTERINE CERVIX CANCER/drug therapy; UTERINE
CERVIX CANCER/prevention; UTERINE CERVIX CARCINOMA IN SITU;
VAGINAL INTRAEPITHELIAL NEOPLASIA/drug therapy; VAGINAL
INTRAEPITHELIAL NEOPLASIA/prevention; VAGINAL
INTRAEPITHELIAL NEOPLASIA/surgery; VERRUCA VULGARIS/drug
therapy; VERRUCA VULGARIS/prevention; VULVA TUMOR/drug therapy;
VULVA TUMOR/prevention; VULVA TUMOR/surgery; VULVAR
INTRAEPITHELIAL NEOPLASIA/drug therapy; VULVAR
INTRAEPITHELIAL NEOPLASIA/prevention; VULVAR INTRAEPITHELIAL
NEOPLASIA/surgery; CIDOFOVIR/drug combination; CIDOFOVIR/drug
therapy; CIDOFOVIR/topical drug administration; COVAL;
FLUOROURACIL/drug combination; FLUOROURACIL/drug therapy;
FLUOROURACIL/topical drug administration; HEAT SHOCK PROTEIN
E7/drug development; HEAT SHOCK PROTEIN E7/drug therapy;
IMIQUIMOD/clinical trial; IMIQUIMOD/drug therapy; IMIQUIMOD/topical
drug administration; INTERFERON/drug combination; INTERFERON/drug
therapy; ISOTRETINOIN/drug combination; ISOTRETINOIN/drug therapy;
ISOTRETINOIN/oral drug administration; MITOMYCIN C/drug combination;
MITOMYCIN C/drug therapy; RECOMBINANT PROTEIN/drug development;
RECOMBINANT PROTEIN/drug therapy; RETINOID/drug therapy;
RETINOID/oral drug administration; TRICHLOROACETIC ACID/drug therapy;
TRICHLOROACETIC ACID/topical drug administration; UNCLASSIFIED
DN:
MN:
ET:
TE:
CR:
AB:
AU:
AU:
AU:
PU:
CNOTE:
DRUG; WART VIRUS VACCINE/clinical trial; WART VIRUS VACCINE/drug
therapy
Cervarix/Glaxo SmithKline; Coval; Gardasil/Sanofi Pasteur
Glaxo SmithKline; Sanofi Pasteur
Dermatology and Venereology; Cancer; Immunology, Serology and
Transplantation; Urology and Nephrology; Drug Literature Index
cidofovir/113852-37-2; fluorouracil/51-21-8; imiquimod/99011-02-6;
isotretinoin/4759-48-2; mitomycin C/50-07-7; mitomycin C/74349-48-7;
113852-37-2; 51-21-8; 99011-02-6; 4759-48-2; 50-07-7; 74349-48-7; 14357-05-2;
76-03-9
The external anogenital area comprises the anus, perianal skin, and the adjacent
external genitalia including the vulva and vaginal introitus in the female, and the
penis and scrotum in the male. Immunosuppressed organ transplant recipients
(OTR) are prone to viral infections, and have an increased incidence of human
papillomavirus (HPV) associated premalignant and malignant neoplasms, which
specifically target the anogenital tract. The cumulative risk of the development of
a solid-organ neoplasm is 5-6% [1-3]. Nearly all of these neoplasms occur on a
background of premalignant disease (i.e., carcinoma in situ). The most common
presentation of anogenital disease in OTR is condyloma accuminata or genital
viral warts and these are regarded as a marker of immunosuppression in this
group. © 2009 Springer US.
Gibbon KL
Gibbon Karen L.
Barts and the London NHS Trust, London, E1 1BB, United Kingdom
Ekeowa-Anderson AL
Ekeowa-Anderson Arucha L.
Royal London Hospital, Whitechapel, London, E1 1BB, United Kingdom
Leigh IM
Leigh Irene M.
College of Medicine, Dentistry and Nursing, University of Dundee, Ninewells
Hospital and Medical School, Dundee DD1 9YS, United Kingdom
Springer Science and Business Media Netherlands
Van Godewijckstraat 30, Dordrecht, 3311, Netherlands
2/19 von 102
ND:
Autoren:
EM2009259014
Stier EA; Baranoski AS
Titel:
Human papillomavirus-related diseases in HIV-infected individuals
Source:
DOI:
PU:
Current Opinion in Oncology; VOL: 20 (5); p. 541-546 /September 2008/
10.1097/CCO.0b013e3283094ed8
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
1040-8746
CO:
CUOOE
Institution: Stier EA, Dr., Department of Obstetrics and Gynecology, Boston University
School of Medicine, Boston Medical Center, 85 East Concord Street, Boston, MA
02118, United States, [email protected]
COU:
United States
DT:
JSC:
C.1.3.1 ... Clinical Oncology
RN:
0049
Keywords
CT:
HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; WART
VIRUS/*; ANAL DYSPLASIA/therapy; ANUS CANCER/drug therapy; ANUS
CANCER/radiotherapy; ANUS DISEASE/therapy; BLOOD TOXICITY/side
effect; CANCER INCIDENCE; CARCINOGENESIS/etiology; CONDYLOMA
ACUMINATUM/drug therapy; CONDYLOMA ACUMINATUM/etiology;
DYSPLASIA/therapy; GASTROINTESTINAL TOXICITY/side effect; HIGHLY
ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN
IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN
PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18;
INTENSITY MODULATED RADIATION THERAPY; NONHUMAN;
OROPHARYNX CANCER/etiology; PREVALENCE; PRIORITY JOURNAL;
REVIEW; SKIN TOXICITY/side effect; TREATMENT OUTCOME; UTERINE
CERVIX CANCER/drug therapy; UTERINE CERVIX CANCER/etiology;
UTERINE CERVIX CANCER/prevention; UTERINE CERVIX CARCINOMA
IN SITU/drug therapy; UTERINE CERVIX CARCINOMA IN SITU/etiology;
UTERINE CERVIX CARCINOMA IN SITU/prevention; UTERINE CERVIX
DYSPLASIA/etiology; ANTIRETROVIRUS AGENT/drug therapy;
CISPLATIN/adverse drug reaction; CISPLATIN/drug combination;
CISPLATIN/drug therapy; FLUOROURACIL/adverse drug reaction;
FLUOROURACIL/drug combination; FLUOROURACIL/drug therapy;
MITOMYCIN/adverse drug reaction; MITOMYCIN/drug combination;
MITOMYCIN/drug therapy; WART VIRUS VACCINE/drug therapy
UT:
Cervical and anal dysplasia; HIV; Human papillomavirus
ET:
Gynecology; Cancer; Drug Literature Index; Adverse Reactions Titles
TE:
cisplatin/15663-27-1; cisplatin/26035-31-4; cisplatin/96081-74-2; fluorouracil/5121-8; imiquimod/99011-02-6; mitomycin/1404-00-8
CR:
15663-27-1; 26035-31-4; 96081-74-2; 51-21-8; 99011-02-6; 1404-00-8
AB:
Purpose of review To present recent publications in human papillomavirusassociated diseases and their relationship to HIV-infected patients. Recent findings
Studies assessing geographic variations in human papillomavirus types and
prevalence in cervical dysplasia and cancer in HIV-infected women suggest that
AU:
AU:
PU:
CNOTE:
although human papillomavirus types 16 and 18 dominate, multiple other human
papillomavirus types may play a role in carcinogenesis. Anal dysplasia and cancer
incidence continues to rise in the highly active antiretroviral therapy era; however,
data on outcomes following therapy for anal dysplasia (infrared coagulator, highresolution anoscopy-guided ablation) and anal cancer (chemoradiation and
possibly intensity-modulated radiation therapy) have been encouraging. Oral
human papillomavirus may be associated with lower genital tract human
papillomavirus infection and may have implications in the development of
oropharyngeal cancer. Summary As HIV-infected patients in the highly active
antiretroviral therapy era continue to have high rates of cervical and anal cancer, it
is important to continue screening efforts and treatment of preinvasive disease.
Treatment options for anal dysplasia and anal cancer in HIV-infected individuals
are expanding and may lead to decreased morbidity and mortality. Trials assessing
safety and immunogenicity of the human papillomavirus quadrivalent vaccine in
people with HIV have started enrollment, and if successful, may prevent many
human papillomavirus-associated cancers. © 2008 Wolters Kluwer Health |
Stier EA
Stier Elizabeth A.
Department of Obstetrics and Gynecology, Boston University School of Medicine,
Boston Medical Center, Boston, MA, United States; Department of Obstetrics and
Gynecology, Boston University School of Medicine, Boston Medical Center, 85
East Concord Street, Boston, MA 02118, United States
[email protected]
Baranoski AS
Baranoski Amy S.
Section of Infectious Diseases, Boston University School of Medicine, Boston
Medical Center, Boston, MA, United States
2/20 von 102
ND:
Autoren:
EM2009202399
Handisurya A; Schellenbacher C; Kirnbauer R
Titel:
Erkrankungen durch humane Papillomviren (HPV)
Diseases caused by human papillomaviruses (HPV): Academy CME
Source:
JDDG - Journal of the German Society of Dermatology; VOL: 7 (5); p. 453-467
/May 2009/
10.1111/j.1610-0387.2009.06988.x
Blackwell Publishing Ltd
EMBASE
German; English
English; German
DOI:
PU:
SU:
Sprache:
AL:
CY:
United Kingdom
ISSN:
1610-0379
EISSN:
1610-0387
CO:
JJDDA
Institution: Handisurya A, Dr., M.D. Medical University Vienna, Department of
Dermatology, Division of Immunology Allergy and Infectious Diseases,
Währinger Gürtel 18-20, A-1090 Vienna,
Austria, [email protected]
COU:
Austria
DT:
JSC:
C.5 ... Dermatology & Venereology
RN:
0011
Keywords
CT:
WART VIRUS/*; ADD ON THERAPY; BONE MARROW SUPPRESSION/side
effect; BOWEN DISEASE; BOWENOID PAPULOSIS; BUTCHER WART;
CAUTERIZATION; COLPOSCOPY; CONDYLOMA ACUMINATUM/drug
therapy; CONDYLOMA ACUMINATUM/prevention; CONDYLOMA
ACUMINATUM/surgery; CONDYLOMA ACUMINATUM/therapy;
CRYOTHERAPY; DNA DETERMINATION; EPIDERMODYSPLASIA
VERRUCIFORMIS; FEVER/side effect; FOCAL EPITHELIUM
HYPERPLASIA; HEADACHE/side effect; HISTOLOGY; HUMAN; HUMAN
INFLAMMATION/side effect; KERATOLYSIS; LARYNX
PAPILLOMATOSIS; LASER SURGERY; MALE HOMOSEXUAL;
MYALGIA/side effect; NONHUMAN; OPEN READING FRAME; PAIN/side
effect; PATHOGENESIS; PHYLOGENY; POLYMERASE CHAIN REACTION;
RECTOSCOPY; REVIEW; SEROLOGY; SEXUALLY TRANSMITTED
DISEASE; SKIN CANCER; SKIN PRURITUS/side effect; SQUAMOUS CELL
CARCINOMA; TAXONOMY; URETHROSCOPY; VERRUCA
VULGARIS/drug therapy; VERRUCA VULGARIS/surgery; VERRUCA
VULGARIS/therapy; VIRUS GENOME; VIRUS LIKE AGENT; VIRUS
TRANSMISSION; ACETIC ACID/drug therapy; ACETIC ACID/topical drug
administration; CAPSID PROTEIN; CIDOFOVIR/adverse drug reaction;
CIDOFOVIR/drug therapy; FLUOROURACIL/adverse drug reaction;
FLUOROURACIL/drug therapy; IMIQUIMOD/drug therapy;
INTERFERON/adverse drug reaction; INTERFERON/drug therapy;
INTERFERON/intralesional drug administration; INTERFERON/topical drug
administration; PODOPHYLLOTOXIN/drug therapy; WART VIRUS
VACCINE/drug therapy
UT:
Condylomata acuminata; Epidermodysplasia verruciformis; HPV vaccine; Human
papillomavirus; Skin warts
DN:
Cervarix/Glaxo SmithKline; Gardasil/Labaz
MN:
Glaxo SmithKline; Labaz
ET:
and Venereology; Immunology, Serology and Transplantation; Drug Literature
TE:
acetic acid/127-08-2; acetic acid/127-09-3; acetic acid/64-19-7; acetic acid/71-501; cidofovir/113852-37-2; fluorouracil/51-21-8; imiquimod/99011-02-6;
CR:
AB:
AU:
AU:
AU:
PU:
CNOTE:
podophyllotoxin/518-28-5
127-08-2; 127-09-3; 64-19-7; 71-50-1; 113852-37-2; 51-21-8; 99011-02-6; 51828-5
Human papillomaviruses (HPV) are non-enveloped tumor viruses with a double
stranded DNA approximately 8 kilobases in length. The viral genome is enclosed
by a spherical capsid with icosahedral symmetry and a diameter of about 55 nm.
More than 100 HPV types have been identified. They infect the squamous
epithelia of skin and mucosa and usually cause benign papillomas or warts.
Persistent infection with high-risk oncogenic HPV causes all cervical cancers,
most anal cancers, and a subset of vulvar, vaginal, penile and oropha-ryngeal
cancers. In recent years cutaneous beta-HPV types have been associated with the
pathogenesis of non-melanoma skin cancers. Two prophylactic HPV vaccines
based on virus-like particles (VLP) are licensed. These are up to 100% effective in
preventing HPV 16 and HPV 18 infections and associated genital lesions in
women, who have not been previously infected with these types. One vaccine also
prevents genital warts caused by HPV 6 and HPV 11. © Blackwell Verlag GmbH,
Berlin.
Handisurya A
Handisurya Alessandra
Division of Immunology, Allergy and Infectious Diseases, Department of
Dermatology, Medical University of Vienna, Austria; M.D. Medical University
Vienna, Department of Dermatology, Division of Immunology Allergy and
Infectious Diseases, Währinger Gürtel 18-20, A-1090 Vienna, Austria
[email protected]
Schellenbacher C
Schellenbacher Christina
Dermatology, Medical University of Vienna, Austria
Kirnbauer R
Kirnbauer Reinhard
Dermatology, Medical University of Vienna, Austria
9600 Garsington Road, Oxford, OX4 2XG, United Kingdom
2/21 von 102
ND:
Autoren:
EM2009198456
Mlakar B
Titel:
Proctoscopy should be mandatory in men that have sex with men
with external anogenital warts
Source:
Acta Dermatovenerologica Alpina, Pannonica et Adriatica; VOL: 18 (1); p. 7-11
/March 2009/
Slovenian Medical Society
PU:
SU:
EMBASE
Sprache: English
AL:
English
CY:
Slovenia
ISSN:
1318-4458
CO:
ADPAE
Institution: Mlakar B, Dr., Rozna Dolina Surgical Centre, Department for Abdominal Surgery
and Proctology, Rozna dolina cesta IV/45, 1000 Ljubljana, Slovenia
COU:
Slovenia
DT:
Journal Article
JSC:
RN:
0019
Keywords
CT:
ACUMINATUM/*surgery; RECTOSCOPY/*; ADULT; AGED; ARTICLE;
BURNING SENSATION/side effect; DISEASE DURATION; DRUG
WITHDRAWAL; DYSPLASIA; FLU LIKE SYNDROME/side effect; FOLLOW
UP; HUMAN; LEUKOPENIA/side effect; MAJOR CLINICAL STUDY; MALE;
MALE HOMOSEXUAL; PROCTITIS/drug therapy; RECURRENCE RISK;
SINGLE DRUG DOSE; VERRUCOUS CARCINOMA; ALPHA
INTERFERON/subcutaneous drug administration; AZITHROMYCIN/drug
combination; AZITHROMYCIN/drug therapy; AZITHROMYCIN/oral drug
administration; CIPROFLOXACIN/drug combination; CIPROFLOXACIN/drug
therapy; IMIQUIMOD/adverse drug reaction; IMIQUIMOD/drug therapy;
IMIQUIMOD/rectal drug administration
UT:
Condylomata acuminata; Intra-anal dysplasia; Proctoscopy; Recurrence; Sexually
transmitted diseases; Therapy with imiquimod; Verrucous carcinoma
ET:
and Venereology; Drug Literature Index; Adverse Reactions Titles
TE:
azithromycin/83905-01-5; ciprofloxacin/85721-33-1; imiquimod/99011-02-6
CR:
83905-01-5; 85721-33-1; 99011-02-6
AB:
Introduction: The aim of this study was to evaluate anal pathology in men having
sex with men (MSM) seen at our proctology outpatient clinics. Methods: The
charts of 74 MSM treated by the author between January 2002 and April 2006
were reviewed. Results: Three of 74 patients (4%) had proctitis and 96% had
anogenital condylomata acuminata (warts). 49 out of 71 (69%) had external
anogenital as well as intra-anal warts and 13 (18%) had only intra-anal warts. In
14 an intra-anal dysplasia and in 2 patients intra-anal verrucous carcinomas were
detected. The average duration of disease before referral to our institutions was
more than 9 months. Half of the patients were previously treated for anogenital
warts with ointments and suppositories at other institutions, including 17 that were
"treated" with ointments and/or suppositories for hemorrhoids prescribed by
family physicians. The patients mostly had widespread disease and sixty-nine of
them required surgery. In the follow-up period there was no recurrence of warts
and only itching was observed in 31 (44%) patients. Therapy with imiquimod was
introduced for 3 months in twenty-two cases with intra-anal dysplasia. No major
side effects were noticed despite intra-anal use. Conclusion: Proctoscopy and
AU:
PU:
CNOTE:
histological examination of intra-anal lesions in cases of external anogenital warts
should be mandatory in MSM patients. I would like to encourage other physicians
to use this approach, which enables detection of intra-anal warts, dysplasia, and
even carcinoma in the asymptomatic stage.
Mlakar B
Mlakar Bostjan
Rozna Dolina Surgical Centre, Department for Abdominal Surgery and
Proctology, Rozna dolina cesta IV/45, 1000 Ljubljana, Slovenia; Zdrav Splet
Surgical Center, Outpatient Proctology Clinic, Lackova 54, 2000 Maribor,
Slovenia
Slovenian Medical Society
Komenskega 4, Ljubljana, 61000, Slovenia
2/22 von 102
ND:
Autoren:
EM2009168185
Kreutei A; Wieland U
Titel:
Human papillomavirus-associated diseases in HIV-infected men who
have sex with men
Source:
Current Opinion in Infectious Diseases; VOL: 22 (2); p. 109-114 /April 2009/
DOI:
10.1097/QCO.0b013e3283229fc8
PU:
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
0951-7375
CO:
COIDE
Institution: Kreutei A, Department of Dermatology, Ruhr University Bochum, Gudrunstr. 56,
44791 Bochum, Germany, [email protected]
COU:
Germany
DT:
Journal Article
JSC:
RN:
0040
Keywords
CT:
HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*etiology; SEXUAL
BEHAVIOR/*; WART VIRUS/*; ANAL CONDYLOMA; ANAL
DYSPLASIA/diagnosis; ANOSCOPY; ANUS CANCER/drug therapy; ANUS
CANCER/epidemiology; ANUS CANCER/etiology; ANUS
CANCER/radiotherapy; ANUS DISEASE/diagnosis; ANUS TUMOR/diagnosis;
ANUS TUMOR/drug therapy; ANUS TUMOR/epidemiology; ANUS
TUMOR/etiology; ANUS TUMOR/surgery; ANUS TUMOR/therapy; ARTICLE;
CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER
UT:
ET:
TE:
CR:
AB:
AU:
RADIOTHERAPY; CANCER SCREENING; CONDYLOMA; CYTOLOGY;
DIAGNOSTIC PROCEDURE; HETEROSEXUAL MALE; HIGHLY ACTIVE
ANTIRETROVIRAL THERAPY; HISTORY; HUMAN; HUMAN
IMMUNODEFICIENCY VIRUS; INFORMATION; INTROSPECTION;
MEDICAL LITERATURE; MOUTH INFECTION/epidemiology; MOUTH
INFECTION/etiology; PENIS DISEASE/etiology; PENIS INFECTION/etiology;
PENIS INFECTION/surgery; PENIS INFECTION/therapy; POPULATION;
PRACTICE GUIDELINE; RISK; TREATMENT OUTCOME;
ANTINEOPLASTIC AGENT/drug therapy; ANTIRETROVIRUS AGENT/drug
therapy; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration;
LIQUID NITROGEN/drug therapy; LIQUID NITROGEN/topical drug
administration; PODOPHYLLOTOXIN/drug therapy;
PODOPHYLLOTOXIN/topical drug administration; TRICHLOROACETIC
ACID/drug therapy; TRICHLOROACETIC ACID/topical drug administration
Anal; Anal cancer; HIV; Human papillomavirus infection; Men who have sex
with men; Oral intraepithelial neoplasia; Penile
Microbiology: Bacteriology, Mycology, Parasitology and Virology; Psychiatry;
Drug Literature Index
99011-02-6; 518-28-5; 14357-05-2; 76-03-9
Purpose of review Persistent human papillomavirus (HPV) infection is very
frequent in HIV-positive men who have sex with men. This review summarizes
recent data on papillomavirus-induced anal intraepithelial neoplasia and anal
cancer in these patients. Moreover, data are provided on penile and oral HPVassociated diseases, for which only limited information is available in the
literature. Recent findings The incidence of anal intraepithelial neoplasia rises in
HIV-positive men who have sex with men despite the introduction of highly
active antiretroviral therapy. Increasing evidence indicates that high-grade lesions
can progress to anal cancer over time. Anal cytology has been recommended as
the primary screening tool for anal dysplasia in the at-risk population. Individuals
with abnormal cytology should undergo high-resolution anoscopy to appropriately
identify and treat dysplastic lesions. Anal cancer has become one of the most
common non-AIDS-defining tumors in HIV-infected individuals. In the era of
highly active antiretroviral therapy, the outcome of combined chemoradiotherapy
in HIV-positive individuals with anal cancer is similar to that in HIV-negative
persons. Penile and oral HPV-associated diseases seem to be more frequent in
HIV-positive men than reported for HIV-negative heterosexual men. Summary
Diagnostic and therapeutic guidelines should be implemented for at-risk
populations for anal dysplasia/anal cancer, such as HIV-positive men who have
sex with men. More study is required to get better insights into the natural history
of penile and oral HPV-associated benign and malignant lesions. 2009 Wolters
Kluwer Health | Lippincott Williams & Wilkins.
Kreutei A
Kreutei Alexander
Department of Dermatology, Ruhr University Bochum, Bochum, Germany;
Department of Dermatology, Ruhr University Bochum, Gudrunstr. 56, 44791
Bochum, Germany
[email protected]
AU:
PU:
CNOTE:
Wieland U
Wieland Ulrike
Institute of Virology, University of Köln, Cologne, Germany
2/23 von 102
ND:
Autoren:
EM2009153775
Palefsky JM; Rubin M
Titel:
The Epidemiology of Anal Human Papillomavirus and Related
Neoplasia
Source:
Obstetrics and Gynecology Clinics of North America; VOL: 36 (1); p. 187-200
/March 2009/
DOI:
10.1016/j.ogc.2009.02.003
PU:
W.B. Saunders
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
0889-8545
CO:
OGCAE
PII:
S0889854509000084
Institution: Palefsky JM, Dr., Division of Infectious Disease, Department of Medicine,
University of California, Box 0126, Room M1203, San Francisco, CA 94143,
United States, [email protected]
COU:
United States
DT:
JSC:
RN:
0049
Keywords
CT:
INTRAEPITHELIAL NEOPLASIA/*epidemiology; ANAL
INTRAEPITHELIAL NEOPLASIA/*etiology; ANAL INTRAEPITHELIAL
NEOPLASIA/*prevention; ANAL INTRAEPITHELIAL NEOPLASIA/*surgery;
ANAL INTRAEPITHELIAL NEOPLASIA/*therapy; ANUS
CANCER/*diagnosis; ANUS CANCER/*epidemiology; ANUS
CANCER/*etiology; ANUS CANCER/*prevention; ANUS CANCER/*surgery;
ANUS CANCER/*therapy; UTERINE CERVIX CANCER/*epidemiology;
UTERINE CERVIX CANCER/*etiology; UTERINE CERVIX
CANCER/*prevention; UTERINE CERVIX CANCER/*surgery; UTERINE
CERVIX CANCER/*therapy; VERRUCA VULGARIS/*drug therapy;
VERRUCA VULGARIS/*epidemiology; VERRUCA VULGARIS/*therapy;
UT:
ET:
TE:
CR:
AB:
AU:
AU:
PU:
CNOTE:
WART VIRUS/*; ALGORITHM; ANOSCOPY; BIOPSY; CANCER
CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER PREVENTION;
CANCER RISK; CANCER SCREENING; CANCER SURGERY;
CAUTERIZATION; COLPOSCOPY; CONDYLOMA/drug therapy;
CRYOTHERAPY; CYTODIAGNOSIS; CYTOLOGY; DIAGNOSTIC
PROCEDURE; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HIGH
RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS
INFECTED PATIENT; HUMAN PAPILLOMAVIRUS TYPE 16; INFECTION
RISK; LOW LEVEL LASER THERAPY; MASS SCREENING; PRIORITY
JOURNAL; REVIEW; RISK FACTOR; SCREENING; UTERINE CERVIX
CYTOLOGY; DICHLOROACETIC ACID/drug therapy; GREEN TEA
EXTRACT/drug therapy; IMIQUIMOD/drug therapy;
PODOPHYLLOTOXIN/drug therapy; TRICHLOROACETIC ACID/drug therapy
Anal cytology; Geriatric; High resolution anoscopy (HRA); Human
papillomavirus (HPV); Management
Microbiology: Bacteriology, Mycology, Parasitology and Virology; Cancer;
Public Health, Social Medicine and Epidemiology
dichloroacetic acid/13425-80-4; dichloroacetic acid/2156-56-1; dichloroacetic
acid/79-43-6; imiquimod/99011-02-6; podophyllotoxin/518-28-5; trichloroacetic
acid/14357-05-2; trichloroacetic acid/76-03-9
13425-80-4; 2156-56-1; 79-43-6; 99011-02-6; 518-28-5; 14357-05-2; 76-03-9
The relationship between cervical cancer and human papillomavirus (HPV) is well
known. Like cervical cancer, anal cancer is preceded by a series of precancerous
changes, raising the possibility that like cervical cancer, anal cancer can be
prevented. Further, given the known risk factors for anal cancer, prevention
efforts could be targeted to high-risk groups, providing a unique example of a
screening program targeted to high-risk individuals. This article describes the
epidemiology of anal HPV infection, anal intraepithelial neoplasia, and anal
cancer among men and women, as well as current efforts to prevent anal cancers.
© 2009 Elsevier Inc. All rights reserved.
Palefsky JM
Palefsky Joel M.
Division of Infectious Disease, Department of Medicine, University of California,
Box 0126, Room M1203, San Francisco, CA 94143, United States; Anal
Neoplasia Clinic, University of California Helen Diller Family Comprehensive
Cancer Center, San Francisco, CA, United States; Clinical and Translational
Research School of Medicine, CA, United States
[email protected]
Rubin M
Rubin Mary
Anal Neoplasia Clinic, University of California Helen Diller Family
Comprehensive Cancer Center, San Francisco, CA, United States; School of
Nursing, University of California, San Francisco, CA, United States
W.B. Saunders
2/24 von 102
ND:
Autoren:
EM2009126761
Fraillery D; Zosso N; Nardelli-Haefliger D
Titel:
Rectal and vaginal immunization of mice with human
papillomavirus L1 virus-like particles
Source:
Vaccine; VOL: 27 (17); p. 2326-2334 /20090414/
DOI:
10.1016/j.vaccine.2009.02.029
PU:
Elsevier Ltd
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
0264-410X
CO:
VACCD
PII:
S0264410X09002436
Institution: Nardelli-Haefliger D, Institute of Microbiology, Centre Hospitalier Universitaire
Vaudois, University of Lausanne, Bugnon 48, CH-1011 Lausanne,
Switzerland, [email protected]
COU:
Switzerland
DT:
Journal Article
JSC:
E.4 ... Immunology & Serology; E.5 ... Clinical Microbiology
RN:
0041
Keywords
CT:
DRUG ADMINISTRATION ROUTE/*; HUMAN PAPILLOMAVIRUS TYPE
16/*; IMMUNIZATION/*; VIRUS LIKE AGENT/*; ANIMAL EXPERIMENT;
ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BAGG
ALBINO MOUSE; CONDYLOMA ACUMINATUM/drug therapy; FEMALE;
MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL;
UTERINE CERVIX CANCER/drug therapy; UTERINE CERVIX
CANCER/etiology; UTERINE CERVIX CANCER/prevention; HUMAN
PAPILLOMA VIRUS TYPE 16 L1 VIRUS LIKE PARTICLE VACCINE/*drug
development; HUMAN PAPILLOMA VIRUS TYPE 16 L1 VIRUS LIKE
PARTICLE VACCINE/*drug therapy; HUMAN PAPILLOMA VIRUS TYPE 16
L1 VIRUS LIKE PARTICLE VACCINE/*intranasal drug administration;
HUMAN PAPILLOMA VIRUS TYPE 16 L1 VIRUS LIKE PARTICLE
VACCINE/*intravaginal drug administration; HUMAN PAPILLOMA VIRUS
TYPE 16 L1 VIRUS LIKE PARTICLE VACCINE/*oral drug administration;
HUMAN PAPILLOMA VIRUS TYPE 16 L1 VIRUS LIKE PARTICLE
VACCINE/*pharmaceutics; HUMAN PAPILLOMA VIRUS TYPE 16 L1 VIRUS
LIKE PARTICLE VACCINE/*rectal drug administration; HUMAN
PAPILLOMA VIRUS TYPE 16 L1 VIRUS LIKE PARTICLE
VACCINE/*subcutaneous drug administration; WART VIRUS VACCINE/*drug
development; WART VIRUS VACCINE/*drug therapy; WART VIRUS
VACCINE/*pharmaceutics; BICARBONATE; CHOLERA TOXIN/intranasal
drug administration; CHOLERA TOXIN/pharmaceutics; CHOLERA
UT:
DN:
MN:
ET:
TE:
CR:
AB:
AU:
AU:
TOXIN/rectal drug administration; ESTRADIOL/subcutaneous drug
administration; IMIQUIMOD/pharmaceutics; IMIQUIMOD/rectal drug
administration; IMMUNOGLOBULIN A ANTIBODY/endogenous compound;
IMMUNOGLOBULIN G ANTIBODY/endogenous compound;
IMMUNOLOGICAL ADJUVANT/pharmaceutics;
MEDROXYPROGESTERONE ACETATE/subcutaneous drug administration;
NEUTRALIZING ANTIBODY/endogenous compound; NONOXINOL
9/intravaginal drug administration; NONOXINOL 9/pharmaceutics;
RESIQUIMOD/drug therapy; RESIQUIMOD/intranasal drug administration;
RESIQUIMOD/pharmaceutics; RESIQUIMOD/rectal drug administration;
RESIQUIMOD/subcutaneous drug administration; UNCLASSIFIED DRUG
Human papillomavirus virus-like particles; Mucosal immunity; Rectal and vaginal
immunization
Aldara/Glaxo SmithKline Biologicals, Belgium; Conceptrol/Advanced Care,
United States; Depo Provera/Pfizer, Switzerland; R 848/huang lisheng pharmatec,
China
Advanced Care, United States; Glaxo SmithKline Biologicals, Belgium; huang
lisheng pharmatec, China; Pfizer, Switzerland; Sigma
Microbiology: Bacteriology, Mycology, Parasitology and Virology; Immunology,
Serology and Transplantation; Drug Literature Index; Pharmacy
bicarbonate/144-55-8; bicarbonate/71-52-3; estradiol/50-28-2; imiquimod/9901102-6; medroxyprogesterone acetate/71-58-9; nonoxinol 9/96827-50-8;
resiquimod/144875-48-9
144-55-8; 71-52-3; 50-28-2; 99011-02-6; 71-58-9; 96827-50-8; 144875-48-9
Human papillomavirus (HPV) vaccines based on L1 virus-like particle (VLP) can
prevent genital HPV infection and associated lesions after three intramuscular
injections. Needle-free administration might facilitate vaccine implementation,
especially in developing countries. Here we have investigated rectal and vaginal
administration of HPV16 L1 VLPs in mice and their ability to induce anti-VLP
and HPV16-neutralizing antibodies in serum and in genital, rectal and oral
secretions. Rectal and vaginal immunizations were not effective in the absence of
adjuvant. Cholera toxin was able to enhance systemic and mucosal anti-VLPs
responses after rectal immunization, but not after vaginal immunization. Rectal
immunization with Resiquimod and to a lesser extent Imiquimod, but not
monophosphoryl lipid A, induced anti-HPV16 VLP antibodies in serum and
secretions. Vaginal immunization was immunogenic only if administered in mice
treated with nonoxynol-9, a disrupter of the cervico-vaginal epithelium. Our
findings show that rectal and vaginal administration of VLPs can induce
significant HPV16-neutralizing antibody levels in secretions, despite the fact that
low titers are induced in serum. Imidazoquinolines, largely used to treat genital
and anal warts, and nonoxonol-9, used as genital microbicide/spermicide were
identified as adjuvants that could be safely used by the rectal or vaginal route,
respectively. © 2009 Elsevier Ltd. All rights reserved.
Fraillery D
Fraillery Dominique
Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, University of
Lausanne, Bugnon 48, CH-1011 Lausanne, Switzerland
Zosso N
AU:
PU:
CNOTE:
Zosso Nathalie
Nardelli-Haefliger D
Nardelli-Haefliger Denise
[email protected]
Elsevier Ltd
Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom
2/25 von 102
ND:
Autoren:
EM2009108873
Graziottin A; Serafini A
Titel:
HPV infection in women: Psychosexual impact of genital warts and
intraepithelial lesions
Source:
Journal of Sexual Medicine; VOL: 6 (3); p. 633-645 /2009/
DOI:
10.1111/j.1743-6109.2008.01151.x
PU:
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
1743-6095
EISSN:
1743-6109
Institution: Graziottin A, Dr., H. San Raffaele Resnati Center of Gynecology and Medical
Sexology, Via Enrico Panzacchi 6, 20123 Milano,
Italy, [email protected]
COU:
Italy
DT:
JSC:
C.4 ... Obstetrics & Gynecology; D.5 ... Urological Surgery
RN:
0074
Keywords
CT:
ACUMINATUM/*etiology; CONDYLOMA ACUMINATUM/*prevention;
CONDYLOMA ACUMINATUM/*surgery; CONDYLOMA
ACUMINATUM/*therapy; PSYCHOSEXUAL DISORDER/*; ANGER;
ANXIETY; CARBON DIOXIDE LASER; CLINICAL PRACTICE; CLINICAL
TRIAL; DEPRESSION; DNA VIRUS; DYSPAREUNIA; FEMALE; FEMALE
SEXUAL DYSFUNCTION; HUMAN; LASER SURGERY; LOW LEVEL
LASER THERAPY; MEDICAL RESEARCH; MEDLINE; PATHOGENESIS;
UT:
ET:
TE:
CR:
AB:
AU:
PATIENT COUNSELING; PRIORITY JOURNAL; RECURRENT VIRUS
INFECTION/etiology; REVIEW; SEXUAL BEHAVIOR; SEXUAL
FUNCTION; SEXUALLY TRANSMITTED DISEASE/etiology;
THERMOCOAGULATION; UTERINE CERVIX CARCINOMA IN SITU/drug
therapy; UTERINE CERVIX CARCINOMA IN SITU/etiology; UTERINE
CERVIX CARCINOMA IN SITU/prevention; VULVAR VESTIBULITIS;
VULVODYNIA; WART VIRUS; ALPHA INTERFERON/clinical trial; ALPHA
INTERFERON/drug therapy; ALPHA INTERFERON/intramuscular drug
administration; IMIQUIMOD/drug therapy; WART VIRUS VACCINE/drug
therapy
Anal HPV Infection; Anxiety; Cervical Cancer; Depression; Dyspareunia; Female
Sexual Dysfunctions; Genital Warts; High-Risk Partners; HPV; HPV Vaccine;
Intraepithelial Neoplasia; Oral HPV Infection; Psychosexual Issues
Gynecology; Cancer; Public Health, Social Medicine and Epidemiology;
Psychiatry; Drug Literature Index
99011-02-6
Introduction. Genital Human Papillomavirus (HPV) infection is the most
commonly occurring sexually transmitted viral infection in humans. HPV is a
wide family of DNA viruses, which may cause benign skin and mucosal tumors
(genital, anal, or oral warts), intraepithelial neoplasias, and/ or malignant cancers
in different organs. Women are more susceptible to the oncogenic effect of HPVs,
mostly at the genital site on the uterine cervix. Aims. This review analyzes the
impact of: (i) genital warts (GWs) and their treatment; (ii) HPV-related genital,
oral, and anal precancerous lesions on women's sexual function. Methods. A
Medline search was carried out. Search terms were HPV, GWs, intraepithelial
neoplasia, cervical cancer, anal cancer, oral cancer, epidemiology, HPV risk
factors, sexual dysfunctions, desire disorders, arousal disorders, dyspareunia,
vulvar vestibulitis, vulvodynia, orgasmic difficulties, sexual repertoire, couple
sexual problems, depression, anxiety, pap smear, screening program, therapy, and
vaccines. Main Outcome Measures. Sexual consequences of HPV infection in
women, specifically GWs and intraepithelial HPV-related neoplasia. Results.
Psychosexual vulnerability increases with number of recurrences of HPV
infections. Depression, anxiety, and anger are the emotions most frequently
reported. However, to date, there is no conclusive evidence of a specific
correlation between HPV infection and a specific female sexual disorder. The
relationship between HPV and vulvar vestibulitis/ vulvodynia-related dyspareunia
seems not to be direct. Counseling problems, the role of anti-HPV vaccine, and the
concept of the high-risk partner are discussed. The reader is offered a practical
approach with clinically relevant recommendations that may prove useful in
his/her daily practice when dealing with HPV-infected women and couples.
Conclusion. The evidence of psychosexual consequences of HPV-related GWs
and intraepithelial lesions is limited. Specific research on the sexual impact of
GWs and intraepithelial HPV-related lesion in women is urgently needed. © 2009
International Society for Sexual Medicine.
Graziottin A
Graziottin Alessandra
H. San Raffaele Resnati Center of Gynecology and Medical Sexology, Via Enrico
AU:
PU:
CNOTE:
Panzacchi 6, 20123 Milano, Italy
[email protected]
Serafini A
Serafini Audrey
IRCCS San Raffaele Department of Obstetrics and Gynecology, Milan, Italy
2/26 von 102
ND:
Autoren:
EM2009080569
Marini A; Hengge UR
Titel:
Wichtige virale und bakterielle infektionen der haut und
schleimhäute
Important viral and bacterial infections of the skin and mucous
membrane
Source:
Internist; VOL: 50 (2); p. 160-170 /February 2009/
DOI:
10.1007/s00108-008-2209-6
PU:
Springer Verlag
SU:
EMBASE
Sprache: German
AL:
English; German
CY:
Germany
ISSN:
0020-9554
CO:
INTEA
Institution: Hengge UR, Dr. Prof., Klinik für Dermatologie, Heinrich-Heine-Universität,
Moorenstrae 5, 40225 Düsseldorf, Germany, [email protected]
COU:
Germany
DT:
JSC:
C.1 ... Internal Medicine
RN:
0015
Keywords
CT:
BACTERIAL SKIN DISEASE/*drug therapy; BACTERIAL SKIN
DISEASE/*etiology; SKIN INFECTION/*drug therapy; SKIN
INFECTION/*etiology; VIRAL SKIN DISEASE/*drug therapy; VIRAL SKIN
DISEASE/*etiology; ANUS CANCER; CONDYLOMA ACUMINATUM/drug
therapy; CRYOTHERAPY; CURETTAGE; DISEASE SEVERITY; ECTHYMA;
ERYSIPELAS; FASCIA; GENITAL HERPES; HERPES ZOSTER; HUMAN;
HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/etiology; IMMUNE DEFICIENCY; IMMUNE SYSTEM;
IMMUNOCOMPROMISED PATIENT; IMPETIGO; KAPOSI
SARCOMA/etiology; KERATOLYSIS/drug therapy; KERATOLYSIS/therapy;
UT:
ET:
TE:
CR:
AB:
AU:
LOW LEVEL LASER THERAPY; LYMPHADENITIS; LYMPHANGITIS;
MUSCLE NECROSIS; MYCOSIS; PENIS CANCER; PSEUDOMONAS
AERUGINOSA; REVIEW; SKIN NECROSIS; STAPHYLOCOCCUS;
STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS
PYOGENES; SURGICAL TECHNIQUE; UTERINE CERVIX CANCER;
VERRUCA VULGARIS/etiology; WART VIRUS; 5 (2 BROMOVINYL) 2'
DEOXYURIDINE/drug therapy; ACICLOVIR/drug therapy;
AZITHROMYCIN/drug therapy; CEFALEXIN/drug therapy; CEFAZOLIN/drug
therapy; CLINDAMYCIN/drug therapy; DICLOXACILLIN/drug therapy;
ERYTHROMYCIN/drug therapy; FAMCICLOVIR/drug therapy;
FLUCLOXACILLIN/drug therapy; GANCICLOVIR/drug therapy;
GENTAMICIN/drug therapy; IMIQUIMOD/drug therapy; NEOMYCIN/drug
therapy; OXACILLIN/drug therapy; PENICILLIN G/drug therapy;
PODOPHYLLIN/drug therapy; SALICYLIC ACID/drug therapy;
VALACICLOVIR/drug therapy
Bacterial infections; Herpes simplex virus; Human papillomavirus; Variella zoster
virus; Viral infections
Medicine; Dermatology and Venereology; Drug Literature Index
5 (2 bromovinyl) 2' deoxyuridine/69304-47-8; 5 (2 bromovinyl) 2'
deoxyuridine/82768-44-3; aciclovir/59277-89-3; azithromycin/83905-01-5;
cefalexin/15686-71-2; cefalexin/23325-78-2; cefazolin/25953-19-9;
cefazolin/27164-46-1; clindamycin/18323-44-9; dicloxacillin/13412-64-1;
dicloxacillin/3116-76-5; dicloxacillin/343-55-5; erythromycin/114-07-8;
erythromycin/70536-18-4; famciclovir/104227-87-4; flucloxacillin/1847-24-1;
flucloxacillin/5250-39-5; ganciclovir/82410-32-0; gentamicin/1392-48-9;
gentamicin/1403-66-3; gentamicin/1405-41-0; imiquimod/99011-02-6;
neomycin/11004-65-2; neomycin/1404-04-2; neomycin/1405-10-3;
neomycin/8026-22-0; oxacillin/1173-88-2; oxacillin/66-79-5; oxacillin/7240-38-2;
penicillin G/1406-05-9; penicillin G/61-33-6; podophyllin/9000-55-9; salicylic
acid/63-36-5; salicylic acid/69-72-7; valaciclovir/124832-26-4
69304-47-8; 82768-44-3; 59277-89-3; 83905-01-5; 15686-71-2; 23325-78-2;
25953-19-9; 27164-46-1; 18323-44-9; 13412-64-1; 3116-76-5; 343-55-5; 114-078; 70536-18-4; 104227-87-4; 1847-24-1; 5250-39-5; 82410-32-0; 1392-48-9;
1403-66-3; 1405-41-0; 99011-02-6; 11004-65-2; 1404-04-2; 1405-10-3; 8026-220; 1173-88-2; 66-79-5; 7240-38-2; 1406-05-9; 61-33-6; 9000-55-9; 63-36-5; 6972-7; 124832-26-4
Skin infections are more frequent in immunodeficient patients, seniors and infants
than in healthy individuals with an intact immune system. The severity of
infections ranges from localized, self-limiting cutaneous infections to widespread
necrosis of the skin, muscle, and fascia. The most frequent infections of the skin
and mucous membranes are caused by bacterial and viral infectious agents. Fungal
infection are also important especially in immunocompromised patients. In
particular, viruses play an important and increasing role in the development of
several tumors including HPV-associated cervical, anal and penile cancer or
HHV-8-induced Kaposi sarcoma. 2008 Springer Medizin Verlag.
Marini A
Marini A
Klinik für Dermatologie, Heinrich-Heine-Universität, Düsseldorf, Germany
AU:
PU:
CNOTE:
Hengge UR
Hengge UR
Klinik für Dermatologie, Heinrich-Heine-Universität, Düsseldorf, Germany;
Klinik für Dermatologie, Heinrich-Heine-Universität, Moorenstrae 5, 40225
Düsseldorf, Germany
[email protected]
Springer Verlag
Tiergartenstrasse 17, Heidelberg, D-69121, Germany
2/27 von 102
ND:
Autoren:
EM2009054032
Krishna S
Titel:
Comparison of podophyllotoxin and imiquimod as anal condyloma
accuminata therapy
Source:
Dermatology Online Journal; VOL: 15 (1) /January 2009/
http://dermatology-s10.cdlib.org/1501/letters/podophyllotoxin/krishna.html
ANR:
14
PU:
Dermatology Online Journal
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
EISSN:
1087-2108
Institution: Krishna S, Faculty of Medicine, Imperial College London, United
COU:
United Kingdom
DT:
Journal Article
JSC:
RN:
0012
Keywords
CT:
CONDYLOMA ACUMINATUM/*drug therapy; ARTICLE; DRUG EFFICACY;
DRUG MECHANISM; DRUG SAFETY; HUMAN; NECROSIS;
PODOPHYLLUM; TREATMENT CONTRAINDICATION; UNSPECIFIED
SIDE EFFECT/side effect; IMIQUIMOD/*adverse drug reaction;
IMIQUIMOD/*drug comparison; IMIQUIMOD/*drug therapy;
IMIQUIMOD/*topical drug administration; PODOPHYLLOTOXIN/*adverse
drug reaction; PODOPHYLLOTOXIN/*drug comparison;
PODOPHYLLOTOXIN/*drug therapy; PODOPHYLLOTOXIN/*pharmacology;
PODOPHYLLOTOXIN/*topical drug administration
ET:
Dermatology and Venereology; Drug Literature Index; Adverse Reactions Titles
TE:
imiquimod/99011-02-6; podophyllotoxin/518-28-5
CR:
AB:
AU:
PU:
CNOTE:
99011-02-6; 518-28-5
imiquimod and podophyllotoxin for anal condyloma accuminata 2009
Dermatology Online Journal.
Krishna S
Krishna Sreedhar
Faculty of Medicine, Imperial College London, United Kingdom
[email protected]
United States
2/28 von 102
ND:
Autoren:
EM2009040569
Gervaz P; Buchs N; Morel P
Titel:
Diagnosis and management of anal cancer
Source:
Current Gastroenterology Reports; VOL: 10 (5); p. 502-506 /2008/
DOI:
10.1007/s11894-008-0092-x
PU:
Current Science Ltd
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
1522-8037
CO:
CGRUA
Institution: Gervaz P, Dr., Clinique de Chirurgie Viscérale, Hôpital Cantonal Universitaire de
Genève, Rue Micheli-du-Crest 24, 1211 Genève,
Switzerland, [email protected]
COU:
Switzerland
DT:
JSC:
RN:
0045
Keywords
CT:
CANCER/*prevention; ANUS CANCER/*radiotherapy; ANUS
CANCER/*surgery; BLOOD TOXICITY/side effect; CANCER SCREENING;
CLINICAL TRIAL; DRUG TOLERABILITY; HIGH RISK PATIENT;
HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/diagnosis; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/drug therapy; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/prevention; IMMUNOCOMPETENCE; INTENSITY
MODULATED RADIATION THERAPY; MONOTHERAPY; PATIENT CARE
PLANNING; PRECANCER; REVIEW; SQUAMOUS CELL
DN:
MN:
ET:
TE:
CR:
AB:
AU:
AU:
AU:
PU:
CARCINOMA/diagnosis; SQUAMOUS CELL CARCINOMA/drug therapy;
SQUAMOUS CELL CARCINOMA/prevention; SQUAMOUS CELL
CARCINOMA/radiotherapy; SQUAMOUS CELL CARCINOMA/surgery;
SURVIVAL RATE; TREATMENT OUTCOME; ANTIRETROVIRUS
AGENT/drug therapy; CISPLATIN/clinical trial; CISPLATIN/drug combination;
CISPLATIN/drug therapy; FLUOROURACIL/drug combination;
FLUOROURACIL/drug therapy; IMIQUIMOD/drug therapy;
IMIQUIMOD/topical drug administration; MITOMYCIN C/adverse drug
reaction; MITOMYCIN C/clinical trial; MITOMYCIN C/drug combination;
MITOMYCIN C/drug therapy; PROTEIN E7/clinical trial; PROTEIN E7/drug
therapy; PROTEIN E7/subcutaneous drug administration; SGN 00101/clinical
trial; SGN 00101/drug therapy; SGN 00101/subcutaneous drug administration;
UNCLASSIFIED DRUG; WART VIRUS VACCINE/drug therapy
Gardasil/Merck and Co, United States; Sgn 00101
Merck and Co, United States
Cancer; Public Health, Social Medicine and Epidemiology; Drug Literature Index;
cisplatin/15663-27-1; cisplatin/26035-31-4; cisplatin/96081-74-2; fluorouracil/5121-8; imiquimod/99011-02-6; mitomycin C/50-07-7; mitomycin C/74349-48-7
15663-27-1; 26035-31-4; 96081-74-2; 51-21-8; 99011-02-6; 50-07-7; 74349-48-7
During the past three decades, anal cancer has served as a paradigm for the
successful application of chemoradiation to solid tumors. Since the early 1990s,
the increasing incidence of anal cancer in homosexual men has highlighted the
causative role of oncogenic human papillomavirus infection. This review focuses
on significant trends and developments in the management of patients with
squamous cell carcinoma of the anal canal, emphasizing three major aspects of
diagnosis and treatment: routine screening and eradication of premalignant lesions
in high-risk individuals; outcome of chemoradiation therapy in HIV-positive
individuals in the era of highly active antiretroviral therapy; and potential
improvements in chemoradiation protocols through improved radiation delivery
technique and the combination of mitomycin with cisplatin in current prospective
randomized trials. Springer Science+Business Media, LLC 2008.
Gervaz P
Gervaz Pascal
Clinique de Chirurgie Viscérale, Hôpital Cantonal Universitaire de Genève, Rue
Micheli-du-Crest 24, 1211 Genève, Switzerland
[email protected]
Buchs N
Buchs Nicolas
Morel P
Morel Philippe
Current Science Ltd
34-42 Cleveland Street, London, W1P 6LB, United Kingdom
CNOTE:
2/29 von 102
ND:
Autoren:
EM2009013203
Dianzani C; Pierangeli A; Avola A; Borzomati D; Persichetti P; Degener AM
Titel:
Intra-anal condyloma: Surgical or topical treatment?
Source:
Dermatology Online Journal; VOL: 14 (12) /December 2008/
http://dermatologys10.cdlib.org/1412/case_presentations/intraanal_condyloma/dianzani.html
ANR:
8
PU:
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
EISSN:
1087-2108
Institution: Dianzani C, Department of Dermatology, Campus Biomedico, University of
Rome, Italy, [email protected]
COU:
Italy
DT:
Journal Article
JSC:
RN:
0010
Keywords
CT:
CONDYLOMA/*surgery; ADULT; ANUS; ARTICLE; CASE REPORT;
COLONOSCOPY; HETEROSEXUAL MALE; HUMAN; HYPERKERATOSIS;
LOW LEVEL LASER THERAPY; LYMPHOCYTE COUNT; MALE; SKIN
BIOPSY; ANTIINFLAMMATORY AGENT/drug therapy
ET:
Dermatology and Venereology; Drug Literature Index
AB:
history of these lesions there is an increased risk of intraepithelial neoplasia and
cancer. Generally the lesions are not life-threatening, but they provoke significant
morbidity, are difficult to treat, and are a source of psychosocial stress. Thus,
condylomata represent not only a health problem for the patient but also an
economic burden for the society. Considering the individual episodes of care, men
experience a longer duration of the lesions and incur greater costs than women.
We report a case of a male patient with external and intra-anal condyloma
resistant to laser therapy. Initially, surgical intervention appeared required because
of florid and intra-anal growth. HPV DNA testing and sequencing revealed the
presence of HPV 6. After initial discomfort, the lesions were successfully cleared
with topical imiquimod 5 percent cream therapy. © 2008 Dermatology Online
Journal.
AU:
AU:
AU:
AU:
AU:
AU:
PU:
CNOTE:
Dianzani C
Dianzani Caterina
Department of Dermatology, Campus Biomedico, University of Rome, Italy
[email protected]
Pierangeli A
Pierangeli Alessandra
Department of Experimental Medicine, Section of Virology, Sapienza University,
Rome, Italy
Avola A
Avola Alessandra
Department of Dermatology, Campus Biomedico, University of Rome, Italy
Borzomati D
Borzomati Domenico
General Surgery Campus Biomedico, University of Rome, Italy
Persichetti P
Persichetti Paolo
Plastic Surgery, Campus Biomedico, University of Rome, Italy
Degener AM
Degener Anna Marta
Department of Experimental Medicine, Section of Virology, Sapienza University,
Rome, Italy
United States
2/30 von 102
ND:
Autoren:
EM2008589814
Bussen S; Herold A; Schmittner M; Krammer H; Bussen D
Titel:
Koloproktologische erkrankungen in der schwangerschaft und dem
wochenbett
Coloproctologic disorders during pregnancy and in the postpartum
period
Source:
DOI:
PU:
SU:
Sprache:
AL:
CY:
ISSN:
CO:
Geburtshilfe und Frauenheilkunde; VOL: 68 (11); p. 1069-1073 /November 2008/
10.1055/s-2008-1039050
Georg Thieme Verlag
EMBASE
German
English; German
Germany
0016-5751
GEFRA
Institution: Bussen S, Dr., Rathausstr. 25, 68519 Viernheim, [email protected]
DT:
JSC:
RN:
0034
Keywords
CT:
COLORECTAL DISEASE/*; PREGNANCY/*; PUERPERIUM/*; ANUS
FISSURE; ANUS FISTULA; COLORECTAL CANCER; CONDYLOMA
ACUMINATUM; ENTERITIS; HEMORRHOID; HUMAN; MEDICAL CARE;
PERIANAL ABSCESS; REVIEW; THROMBOSIS; AZATHIOPRINE;
BOTULINUM TOXIN; BUPIVACAINE; CYCLOSPORIN; DICLOFENAC;
FLUOROURACIL; GLYCERYL TRINITRATE; HYDROCORTISONE;
IBUPROFEN; IMIQUIMOD; LIDOCAINE; MEPIVACAINE;
MERCAPTOPURINE; MESALAZINE; METHOTREXATE;
METHYLPREDNISOLONE; METRONIDAZOLE; PARACETAMOL;
PODOPHYLLIN; PREDNISOLONE; PROCAINE;
SALAZOSULFAPYRIDINE; TACROLIMUS
UT:
Anal fissure; Anal fistula; Colorectal cancer; Condylomata acuminata;
Haemorrhoids; Inflammatory bowel disease; Postpartum period; Pregnancy
ET:
Obstetrics and Gynecology; Radiology; Drug Literature Index; Gastroenterology
TE:
azathioprine/446-86-6; bupivacaine/18010-40-7; bupivacaine/2180-92-9;
bupivacaine/55750-21-5; cyclosporin/79217-60-0; diclofenac/15307-79-6;
diclofenac/15307-86-5; fluorouracil/51-21-8; glyceryl trinitrate/55-63-0;
hydrocortisone/50-23-7; ibuprofen/15687-27-1; imiquimod/99011-02-6;
lidocaine/137-58-6; lidocaine/24847-67-4; lidocaine/56934-02-2; lidocaine/73-789; mepivacaine/1722-62-9; mepivacaine/96-88-8; mercaptopurine/31441-78-8;
mercaptopurine/50-44-2; mercaptopurine/6112-76-1; mesalazine/89-57-6;
methotrexate/15475-56-6; methotrexate/59-05-2; methotrexate/7413-34-5;
methylprednisolone/6923-42-8; methylprednisolone/83-43-2;
metronidazole/39322-38-8; metronidazole/443-48-1; paracetamol/103-90-2;
podophyllin/9000-55-9; prednisolone/50-24-8; procaine/51-05-8; procaine/59-461; salazosulfapyridine/599-79-1; tacrolimus/104987-11-3
CR:
446-86-6; 18010-40-7; 2180-92-9; 55750-21-5; 79217-60-0; 15307-79-6; 1530786-5; 51-21-8; 55-63-0; 50-23-7; 15687-27-1; 99011-02-6; 137-58-6; 24847-67-4;
56934-02-2; 73-78-9; 1722-62-9; 96-88-8; 31441-78-8; 50-44-2; 6112-76-1; 8957-6; 15475-56-6; 59-05-2; 7413-34-5; 6923-42-8; 83-43-2; 39322-38-8; 443-481; 103-90-2; 9000-55-9; 50-24-8; 51-05-8; 59-46-1; 599-79-1; 104987-11-3
AB:
During pregnancy the anatomy and physiology of the pelvic floor and the perianal
region is modified, due to endocrine, metabolic and immunologic changes. This
can lead to a change in the observed incidence of coloproctologic disorders or an
alteration of pre-existing coloproctologic diseases. In patients requiring specific
treatment prior to or during pregnancy the possibility of adverse effects on the
antenatal or postnatal development of the child has to be considered carefully. It is
necessary to evaluate whether the therapeutic strategy needs to be modified or
even discontinued. The aim of this review is to present the current state of
knowledge on the medical care and treatment of coloproctologic disorders during
pregnancy. Diagnostic approaches and therapeutic options for haemorrhoids, anal
fissures, perianal thrombosis, perianal abscesses and fistulas, anogenitals warts,
colorectal malignomas and inflammatory bowel diseases are presented.
AU:
AU:
AU:
AU:
AU:
PU:
CNOTE:
Therapeutic options are discussed with regard to their applicability during
pregnancy and in the postpartum period. © Georg Thieme Verlag KG Stuttgart.
Krammer H
Krammer H
Magen-Darm-Praxis Mannheim
Bussen S
Bussen Stefanie
Konsiliarärztin der Universitäts-Frauenklinik Mannheim; Rathausstr. 25, 68519
Viernheim
[email protected]
Herold A
Herold A
End- und Dickdarmzentrum Mannheim
Schmittner M
Schmittner M
Klinik für Anästhesiologie und Operative Intensivmedizin, Universität Mannheim
Bussen D
Bussen D
End- und Dickdarmzentrum Mannheim
Georg Thieme Verlag
Rudigerstrasse 14, Stuttgart, D-70469, Germany
2/31 von 102
ND:
Autoren:
EM2008532390
De Parades V
Titel:
Pathologie anale: Des progrès indéniables
Anal pathology: Undeniable progress made
Source:
Revue du Praticien; VOL: 58 (16); p. 1751-1753 /20081031/
PU:
Huveaux France
SU:
EMBASE
Sprache: French
CY:
France
ISSN:
0035-2640
CO:
REPRA
Institution: De Parades V, Service de Proctologie Médico-interventionnelle, Groupe
Hospitalier Diaconesses Croix-Saint-Simon, Site Reuilly, 75012 Paris,
France, [email protected]
COU:
France
DT:
Short Survey; Journal Article
JSC:
Keywords
CT:
ANUS DISEASE/*epidemiology; ANUS DISEASE/*etiology; ANORECTAL
DISEASE; ANUS; COLON CROHN DISEASE/drug therapy;
CONDYLOMA/drug therapy; CULTURAL PERIOD; HEMORRHOID/etiology;
HOMOSEXUALITY; HUMAN; PREVALENCE; RECTOSCOPY; RELIGION;
SEXUAL BEHAVIOR; SHORT SURVEY; IMIQUIMOD/drug therapy;
NITRIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA
ANTIBODY/drug therapy
ET:
General Pathology and Pathological Anatomy; Drug Literature Index;
Gastroenterology
TE:
CR:
99011-02-6
AU:
De Parades V
De Parades Vincent
Service de Proctologie Médico-interventionnelle, Groupe Hospitalier Diaconesses
Croix-Saint-Simon, Site Reuilly, 75012 Paris, France; Service d'Hépatogastroentérologie, Hôpital Européen Georges-Pompidou, 75015 Paris, France
[email protected]
PU:
Huveaux France
114 Avenue Charles de Gaulle, Neuilly sur Seine, 92200, France
CNOTE: Copyright 2009 Elsevier B.V., All rights reserved.
2/32 von 102
ND:
Autoren:
EM2008513151
Kreuter A; Brockmeyer NH; Altmeyer P; Wieland U
Titel:
Anale intraepitheliale neoplasie bei HIV-infektion
Anal intraepithelial neoplasia in HIV infection
Source:
/November 2008/
DOI:
10.1111/j.1610-0387.2008.06737.x
PU:
SU:
EMBASE
Sprache: German; English
AL:
English; German
CY:
United Kingdom
ISSN:
1610-0379
EISSN:
1610-0387
CO:
JJDDA
Institution: Kreuter A, Dr. Prof., Klinik für Dermatologie und Allergologie, Ruhr-Universität
Bochum, Gudrunstraße 56, D-44791 Bochum, [email protected]
DT:
JSC:
RN:
0046
Keywords
CT:
NEOPLASIA/*surgery; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/*drug therapy; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/*epidemiology; NEOPLASM/*diagnosis; NEOPLASM/*drug
therapy; NEOPLASM/*surgery; CANCER CLASSIFICATION; CANCER
SCREENING; CANCER STAGING; CANCER SURGERY;
CAUTERIZATION; CLINICAL TRIAL; CYTOLOGY; FLU LIKE
SYNDROME/side effect; FOLLOW UP; HIGHLY ACTIVE
ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOCOMPETENCE;
INJECTION SITE REACTION/side effect; LASER SURGERY; MALE
HOMOSEXUAL; PATHOGENESIS; PHOTODYNAMIC THERAPY;
POSTOPERATIVE COMPLICATION/complication; REVIEW; UTERINE
CERVIX CARCINOMA IN SITU; WART VIRUS; ANTIRETROVIRUS
AGENT/drug therapy; IMIQUIMOD/adverse drug reaction;
IMIQUIMOD/clinical trial; IMIQUIMOD/drug therapy;
PODOPHYLLOTOXIN/drug therapy; SGN 00101/adverse drug reaction; SGN
00101/clinical trial; SGN 00101/drug therapy; TRICHLOROACETIC ACID/drug
therapy; UNCLASSIFIED DRUG; WART VIRUS VACCINE/drug therapy; ZYC
101/adverse drug reaction; ZYC 101/clinical trial; ZYC 101/drug therapy
UT:
Anal dysplasia; Anal intraepithelial neoplasia; High-resolution anoscopy; HIV
infection; Human papillomavirus
DN:
Sgn 00101; Zyc 101
ET:
Dermatology and Venereology; Cancer; Drug Literature Index; Adverse Reactions
Titles; Gastroenterology
TE:
CR:
99011-02-6; 518-28-5; 14357-05-2; 76-03-9
AB:
Human papillomavirus (HPV) infections belong to the most common sexually
transmitted infections worldwide. While the immune system eliminates most HPV
infections over time in immunocompetent individuals, HPV infections tend to
persist in immunodeficient individuals. In HIV-infected men who have sex with
men (MSM), anal HPV prevalence is more than 90% and infections with multiple
HPV types are common. Consequently, HPV-associated anogenital malignancies
occur with high frequency in patients with HIV infection. Anal intraepithelial
neoplasia (AIN) is a potential precursor lesion of squamous cell carcinoma of the
anus. Like its cervical counterpart, cervical intraepithelial neoplasia (CIN), AIN is
causally linked to persistent infections with high-risk HPV types such as HPV16
or HPV18. As AIN and CIN share distinct biological similar-ities, AIN screenings
analogous to Pap smear programs for CIN have been recommended in high-risk
populations to reduce the incidence of anal carcinoma. These screenings include
cytological analysis followed by high resolution anoscopy in case of anal
dysplasia. Treatment guidelines for AIN are not yet available. Therapeutic
strategies can be divided into topical (e.g. trichloroacetic acid, podophyllotoxin,
imiquimod, photodynamic therapy) and ablative (e. g. surgical excision, laser
ablation, infrared coagulation, electrocautery) measures. However, controlled
studies on AIN treatment have not been performed. The impact of HPV
AU:
AU:
AU:
AU:
PU:
CNOTE:
vaccination on AIN development will also need to be assessed. Long-term followup of these patients is essential to gain more insight into the natural history of
anogenital HPV infection in HIV-positive MSM. © The Authors.
Kreuter A
Kreuter Alexander
Department of Dermatology, Ruhr University Bochum, Germany; Klinik für
Dermatologie und Allergologie, Ruhr-Universität Bochum, Gudrunstraße 56, D44791 Bochum
[email protected]
Brockmeyer NH
Brockmeyer Norbert H.
Department of Dermatology, Ruhr University Bochum, Germany
Altmeyer P
Altmeyer Peter
Department of Dermatology, Ruhr University Bochum, Germany
Wieland U
Wieland Ulrike
Institute of Virology, University of Cologne, Germany
2/33 von 102
ND:
Autoren:
EM2008409082
Senéjoux A
Titel:
Traitement des condylomes anaux récidivants
Treatment of recurrent anal warts
Source:
Gastroenterologie Clinique et Biologique; VOL: 32 (5 SUPPL. PART 2); p. S231S234 /May 2008/
DOI:
10.1016/j.gcb.2008.04.015
PU:
Elsevier Masson SAS
SU:
EMBASE
Sprache: French
CY:
France
ISSN:
0399-8320
CO:
GCBID
PII:
S039983200800225X
Institution: Senéjoux A, Coloproctologie, hôpital Léopold-Bellan, 19, rue Vercingétorix,
75014 Paris, France, [email protected]
COU:
France
DT:
Journal Article
JSC:
RN:
0047
Keywords
CT:
ACUMINATUM/*surgery; ADULT; ARTICLE; BIOPSY; CASE REPORT;
COLPOSCOPY; ELECTROCOAGULATION; EXCISION; FEMALE;
GYNECOLOGICAL EXAMINATION; HUMAN; ONCOGENE;
PROCTOLOGY; RECURRENT DISEASE; YAG LASER; ALPHA
INTERFERON/drug therapy; ALPHA INTERFERON/intralesional drug
administration; CIDOFOVIR/drug therapy; CIDOFOVIR/topical drug
administration; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug
administration; PODOPHYLLIN/drug therapy; PODOPHYLLIN/topical drug
administration; TRICHLOROACETIC ACID/drug therapy;
TRICHLOROACETIC ACID/topical drug administration
ET:
Microbiology: Bacteriology, Mycology, Parasitology and Virology; Drug
TE:
cidofovir/113852-37-2; imiquimod/99011-02-6; podophyllin/9000-55-9;
CR:
113852-37-2; 99011-02-6; 9000-55-9; 14357-05-2; 76-03-9
AU:
Senéjoux A
Senéjoux A
Coloproctologie, hôpital Léopold-Bellan, 19, rue Vercingétorix, 75014 Paris,
France
[email protected]
PU:
Elsevier Masson SAS
62 rue Camille Desmoulins, Issy les Moulineaux Cedex, 92442, France
2/34 von 102
ND:
Autoren:
EM2008390004
Kreuter A; Brockmeyer NH; Weissenborn SJ; Gambichler T; Stücker M;
Altmeyer P; Pfister H; Wieland U
Titel:
Penile intraepithelial neoplasia is frequent in HIV-positive men with
anal dysplasia
Source:
Journal of Investigative Dermatology; VOL: 128 (9); p. 2316-2324 /September
2008/
ClinicalTrials.gov-NCT00365729
10.1038/jid.2008.72
Nature Publishing Group
EMBASE
English
English
United States
NCT:
DOI:
PU:
SU:
Sprache:
AL:
CY:
ISSN:
0022-202X
EISSN:
1523-1747
CO:
JIDEA
PII:
JID200872
Institution: Wieland U, Dr., Institute of Virology, University of Cologne, Fuerst-PuecklerStrasse 56, Koeln 50935, Germany, [email protected]
COU:
Germany
DT:
Journal Article
JSC:
RN:
0045
Keywords
CT:
ANAL INTRAEPITHELIAL NEOPLASIA/*drug therapy; ANAL
INTRAEPITHELIAL NEOPLASIA/*epidemiology; ANAL
INTRAEPITHELIAL NEOPLASIA/*surgery; ANUS CANCER/*drug therapy;
ANUS CANCER/*epidemiology; ANUS CANCER/*surgery; PENILE
INTRAEPITHELIAL NEOPLASIA/*epidemiology; PENILE
INTRAEPITHELIAL NEOPLASIA/*surgery; PENIS CANCER/*epidemiology;
PENIS CANCER/*surgery; ADULT; AGED; ARTICLE; CANCER GRADING;
CAUTERIZATION; CIRCUMCISION; CONTROLLED STUDY; CYTOLOGY;
DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN
IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS
TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR
CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PATIENT ATTITUDE;
PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS
LOAD; BETA GLOBIN/endogenous compound; CYCLIN DEPENDENT
KINASE INHIBITOR 2A/endogenous compound; IMIQUIMOD/drug therapy;
TRICHLOROACETIC ACID/drug therapy; VIRUS DNA/endogenous compound
ET:
and Venereology; Public Health, Social Medicine and Epidemiology; Urology and
Nephrology; Drug Literature Index
TE:
CR:
99011-02-6; 14357-05-2; 76-03-9
AB:
Anogenital human papillomavirus (HPV)-infection is common in HIV-infected
men who have sex with men (HIV+MSM). These patients have a strongly
increased risk of HPV-induced anal cancer and its precursor lesion, anal
intraepithelial neoplasia (AIN), and a moderately increased risk for penile cancer.
Only limited data exist on penile intraepithelial neoplasia (PIN) in HIV+MSM.
We determined the prevalence and evaluated the virologic characteristics of PIN
and AIN in 263 HIV+MSM. In case of histologically confirmed PIN (and AIN),
HPV-typing, HPV-DNA load determination, and immunohistochemical staining
for p16INK4a were performed. PIN was detected in 11 (4.2%) and
AIN in 156 (59.3%) patients. Ten PIN patients also had AIN within the
observation period. Four clinical types of PINs could be distinguished. High-riskalpha -HPV-DNA was found in 10 PIN lesions, with HPV16 being the most
frequent type. Infections with multiple HPV-types were common. All high-grade
lesions had high-risk-HPV-DNA-loads >=1 HPV-copy/ beta -globin-gene-copy.
Cutaneous beta -HPVs were found in PIN and AIN, but beta -HPV-DNA loads
AU:
AU:
AU:
AU:
AU:
AU:
AU:
AU:
PU:
CNOTE:
were very low, irrespective of the histological grade. p16INK4a
Expression was detectable in all PIN lesions and correlated both with the
histological grade and with high-risk HPV-DNA loads. In view of the PIN
prevalence found in our study, all HIV+MSM should be screened for PIN in
addition to AIN screening. © 2008 The Society for Investigative Dermatology.
Kreuter A
Kreuter Alexander
Department of Dermatology, Ruhr-University Bochum, Bochum, Germany
Brockmeyer NH
Weissenborn SJ
Weissenborn Soenke J.
Institute of Virology, University of Cologne, Koeln, Germany
Gambichler T
Gambichler Thilo
Stücker M
Stücker Markus
Altmeyer P
Altmeyer Peter
Pfister H
Pfister Herbert
Wieland U
Wieland Ulrike
Institute of Virology, University of Cologne, Koeln, Germany; Institute of
Virology, University of Cologne, Fuerst-Pueckler-Strasse 56, Koeln 50935,
Germany
[email protected]
Houndmills, Basingstoke, Hampshire, RG21 6XS, United Kingdom
2/35 von 102
ND:
Autoren:
EM2008355760
Bushby SA; Chauhan M
Titel:
Management of internal genital warts: Do we all agree? A postal
survey
Source:
International Journal of STD and AIDS; VOL: 19 (6); p. 367-369 /June 2008/
DOI:
10.1258/ijsa.2008.007292
PU:
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
0956-4624
CO:
INSAE
Institution: Bushby SA, Dr., Department of Genito-urinary Medicine, Sunderland Royal
Hospital, Kayll Road, Sunderland, Tyne and Wear SR4 7TP, United
COU:
United Kingdom
DT:
Journal Article
JSC:
Microbiology
RN:
0008
Keywords
CT:
ACUMINATUM/*surgery; ARTICLE; COLPOSCOPY; CRYOTHERAPY;
ELECTROSURGERY; HISTOPATHOLOGY; HUMAN; HUMAN
IMMUNODEFICIENCY VIRUS INFECTED PATIENT; PRIORITY
JOURNAL; RECTOSCOPY; RECTUM SURGERY; UNITED KINGDOM;
UROLOGIC SURGERY; UTERINE CERVIX CARCINOMA IN SITU;
IMIQUIMOD/drug therapy; TRICHLOROACETIC ACID/drug therapy
UT:
Anal intraepithelial neoplasia; HIV; Papillomavirus
ET:
Medicine; Obstetrics and Gynecology; Urology and Nephrology; Drug Literature
Index; Gastroenterology
TE:
CR:
99011-02-6; 14357-05-2; 76-03-9
AB:
A postal survey was undertaken to determine whether there was any consensus of
opinion regarding the management of internal genital warts in genitourinary
medicine clinics in the UK. Overall, 110 forms were returned (57% response). The
majority of clinics would refer patients with cervical warts for colposcopy
especially if the patient was over the age of 25 or HIV-positive. Proctoscopy or
anoscopy was performed in 60% of clinics for patients with perianal warts to
determine the presence of warts within the anal canal or rectum. Only 24% of
patients with intra-anal warts are referred directly to surgery for biopsy,
increasing to 61% if the patient has HIV infection. Cryotherapy is the main
treatment for all types of internal warts. Our findings suggest there is no
consensus and we recommend that all HIV-positive patients with anal or cervical
condyloma should be investigated for evidence of intraepithelial neoplasia.
AU:
Chauhan M
AU:
PU:
CNOTE:
Chauhan M
Department of Genito-urinary Medicine, Sunderland Royal Hospital, Kayll Road,
Sunderland, Tyne and Wear SR4 7TP, United Kingdom
Bushby SA
Bushby Stephen A.
Department of Genito-urinary Medicine, Sunderland Royal Hospital, Kayll Road,
Sunderland, Tyne and Wear SR4 7TP, United Kingdom
[email protected]
2/36 von 102
ND:
Autoren:
EM2008355739
Nathan M; Hickey N; Mayuranathan L; Vowler SL; Singh N
Titel:
Treatment of anal human papillomavirus-associated disease: A long
term outcome study
Source:
International Journal of STD and AIDS; VOL: 19 (7); p. 445-449 /July 2008/
DOI:
10.1258/ijsa.2007.007290
PU:
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
0956-4624
CO:
INSAE
Institution: Nathan M, Dr., Department of Sexual Health, Homerton University Hospital,
London E9 6SR, United Kingdom, [email protected]
COU:
United Kingdom
DT:
Journal Article
JSC:
Microbiology
RN:
0025
Keywords
CT:
ANAL INTRAEPITHELIAL NEOPLASIA/*drug therapy; ANAL
INTRAEPITHELIAL NEOPLASIA/*surgery; ANUS DISEASE/*drug therapy;
ANUS DISEASE/*surgery; CONDYLOMA ACUMINATUM/*; ADULT;
ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE;
HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/drug therapy;
HUMAN TISSUE; LASER SURGERY; MAJOR CLINICAL STUDY; MALE;
PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT
UT:
ET:
TE:
CR:
AB:
AU:
AU:
AU:
AU:
AU:
OUTCOME; WART VIRUS; ANTIRETROVIRUS AGENT/drug therapy;
IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug administration
Anal cancer screening; Anal intraepithelial neoplasia; Anal warts; Laser
treatment
and Venereology; Drug Literature Index
99011-02-6
Treatment for human papillomavirus (HPV)-associated anal canal disease has
been unsatisfactory. The objective of our study was to determine the treatment
outcome in our cohort with anal HPV disease. Overall, 181 patients were
evaluated over a median period of 19.1 months (range = 2.8-125.5). Eighty-eight
patients (48.6%) with high-grade anal intraepithelial neoplasia (AIN) and 82
patients (45.3%) with low-grade AIN underwent treatment. One hundred and
forty-one patients (77.9%) received laser ablative treatment as an outpatient
procedure. The treatment yielded cure, defined as a disease-free state at 12 months
after treatment, in 63.0% (114/181). Median time to cure for the cohort was 31.5
months (95% confidence interval: 23.0-40.0). Treatment outcome showed no
evidence of being affected by age, sexual preference, history of smoking or
presence of high-grade disease. Median time to cure was significantly affected by
a positive HIV status (P = 0.02) and the extent (volume) of the disease (P = 0.01).
Contrary to the current view that treatment of HPV-related anal disease is
difficult, unrewarding due to recurrences and may lead to substantial morbidity,
we demonstrate that effective treatment is possible for both low- and high-grade
AIN. These findings should help with the general desire to introduce screening for
AIN for at-risk groups.
Nathan M
Nathan Mayura
Department of Sexual Health, Homerton University Hospital, London E9 6SR,
United Kingdom
[email protected]
Hickey N
Hickey N
United Kingdom
Mayuranathan L
Mayuranathan L
United Kingdom
Vowler SL
Vowler SL
Centre for Applied Medical Statistics, Department of Public Health and Primary
Care, University of Cambridge, Cambridge CB2 0SR, United Kingdom
Singh N
Singh N
Department of Pathology, Barts and the London NHS Trust, London E1 1BB,
PU:
CNOTE:
United Kingdom
2/37 von 102
ND:
Autoren:
EM2008342149
Kreuter A; Potthoff A; Brockmeyer NH; Gambichler T; Stücker M; Altmeyer P;
Swoboda J; Pfister H; Wieland U
Titel:
Imiquimod leads to a decrease of human papillomavirus DNA and to
a sustained clearance of anal intraepithelial neoplasia in HIVinfected men
Source:
Journal of Investigative Dermatology; VOL: 128 (8); p. 2078-2083 /August 2008/
DOI:
10.1038/jid.2008.24
PU:
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
0022-202X
EISSN:
1523-1747
CO:
JIDEA
PII:
JID200824
Institution: Kreuter A, Prof., Department of Dermatology and Allergology, Ruhr-University
Bochum, Gudrunstrasse 56, Bochum 44791, Germany, [email protected]
COU:
Germany
DT:
Journal Article
JSC:
RN:
0030
Keywords
CT:
NEOPLASIA/*surgery; ANUS TUMOR/*diagnosis; ANUS TUMOR/*drug
therapy; ANUS TUMOR/*surgery; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/*drug therapy; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/*etiology; WART VIRUS/*; ANOSCOPY; ANUS; ARTICLE;
CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY;
CYTOLOGY; DIAGNOSTIC IMAGING; FOLLOW UP; HISTOLOGY;
HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT;
HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;
RISK; SEXUAL BEHAVIOR; TIME; VIRUS TYPING; IMIQUIMOD/*drug
therapy; VIRUS DNA/*; ANTIRETROVIRUS AGENT/drug therapy;
TRICHLOROACETIC ACID/drug therapy
DN:
MN:
ET:
TE:
CR:
AB:
AU:
AU:
AU:
AU:
AU:
AU:
Aldara/3M, Germany
3M, Germany
Microbiology: Bacteriology, Mycology, Parasitology and Virology; Drug
99011-02-6; 14357-05-2; 76-03-9
Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated
precursor lesion of anal carcinoma, is highly prevalent in HIV-infected men
having sex with men (MSM). This prospective follow-up study evaluated the
long-term results of imiquimod treatment of AIN in 19 HIV-infected MSM.
Standardized follow-up examinations included high-resolution anoscopy, anal
cytology/histology, HPV typing, and DNA load determination for HPV types 16,
18, 31, and 33. Mean follow-up time was 30.3 months. A total of 74% (14/19) of
the patients remained free of AIN at the previously treated site. Five patients
(26%) had recurrent high-grade AIN after a mean time of 24.6 months. At the end
of follow-up, the numbers of HPV types as well as high-risk HPV-DNA loads
were significantly lower than before therapy. During follow-up, 58% of all
patients (11/19) developed new anal cytological abnormalities in previously
normal, untreated anal regions. 55% of these new AIN lesions were high-grade
lesions and most of them were located intra-anally and associated with high-risk
HPV types not detectable before therapy. These results demonstrate that
imiquimod leads to a high rate of long-term clearance of AIN in HIV-positive
men together with a prolonged decrease of high-risk HPV-DNA load. However,
new AIN lesions associated with previously undetected HPV types frequently
occur in untreated areas. © 2008 The Society for Investigative Dermatology.
Swoboda J
Swoboda Jochen
Institute of Cytology, Bonn-Bad Godesberg, Germany
Kreuter A
Kreuter Alexander
Department of Dermatology, Ruhr-University Bochum, Bochum, Germany;
Department of Dermatology and Allergology, Ruhr-University Bochum,
Gudrunstrasse 56, Bochum 44791, Germany
[email protected]
Potthoff A
Potthoff Anja
Brockmeyer NH
Gambichler T
Gambichler Thilo
Stücker M
Stücker Markus
AU:
AU:
AU:
PU:
CNOTE:
Altmeyer P
Altmeyer Peter
Pfister H
Pfister Herbert
Wieland U
Wieland Ulrike
Houndmills, Basingstoke, Hampshire, RG21 6XS, United Kingdom
2/38 von 102
ND:
Autoren:
EM2008238467
Diaz ML
Titel:
Human Papilloma Virus - Prevention and Treatment
Source:
Obstetrics and Gynecology Clinics of North America; VOL: 35 (2); p. 199-217
/200806/
DOI:
10.1016/j.ogc.2008.03.002
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
0889-8545
CO:
OGCAE
PII:
S0889854508000193
Institution: Diaz ML, Dr., Section of Ambulatory Gynecology, Cleveland Clinic Florida, 2950
Cleveland Clinic Blvd, Weston, FL 33331, United States, [email protected]
COU:
United States
DT:
JSC:
RN:
0081
Keywords
CT:
CONDYLOMA ACUMINATUM/*disease management; CONDYLOMA
CONDYLOMA ACUMINATUM/*prevention; CONDYLOMA
ACUMINATUM/*surgery; WART VIRUS/*; ADENOCARCINOMA/diagnosis;
ADENOCARCINOMA/drug therapy; ADENOCARCINOMA/surgery;
ADENOCARCINOMA IN SITU/diagnosis; ADENOCARCINOMA IN
ET:
TE:
CR:
AB:
SITU/drug therapy; ADENOCARCINOMA IN SITU/surgery; ANAL
INTRAEPITHELIAL NEOPLASIA; ANUS CARCINOMA/drug therapy; ANUS
CARCINOMA/epidemiology; ANUS CARCINOMA/surgery; ANUS DISEASE;
BEDTIME DOSAGE; BRONCHOSCOPY; CANCER CHEMOTHERAPY;
CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK;
CANCER SCREENING; CANCER STAGING; CANCER SURGERY;
CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS
ANALYSIS; DISEASE ASSOCIATION; HUMAN; INCIDENCE; INFECTION
PREVENTION; PAPANICOLAOU TEST; PAPILLOMATOSIS/diagnosis;
PAPILLOMATOSIS/drug therapy; PAPILLOMATOSIS/epidemiology;
PAPILLOMATOSIS/etiology; PAPILLOMATOSIS/surgery; PRIMARY
PREVENTION; PRIORITY JOURNAL; RESPIRATORY RECURRENT
PAPILLOMATOSIS/diagnosis; RESPIRATORY RECURRENT
PAPILLOMATOSIS/drug therapy; RESPIRATORY RECURRENT
PAPILLOMATOSIS/epidemiology; RESPIRATORY RECURRENT
PAPILLOMATOSIS/etiology; RESPIRATORY RECURRENT
PAPILLOMATOSIS/surgery; REVIEW; SECONDARY PREVENTION; SKIN
IRRITATION/side effect; SQUAMOUS CELL CARCINOMA/epidemiology;
UTERINE CERVIX CANCER/diagnosis; UTERINE CERVIX
CANCER/epidemiology; UTERINE CERVIX CANCER/prevention; UTERINE
CERVIX CANCER/radiotherapy; UTERINE CERVIX CANCER/surgery;
UTERINE CERVIX CARCINOMA IN SITU/prevention; UTERINE CERVIX
CARCINOMA IN SITU/surgery; UTERINE CERVIX CYTOLOGY;
VACCINATION; VAGINA CARCINOMA/diagnosis; VAGINA
CARCINOMA/epidemiology; VAGINA CARCINOMA/radiotherapy; VAGINA
CARCINOMA/surgery; VAGINAL INTRAEPITHELIAL NEOPLASIA/drug
therapy; VAGINAL INTRAEPITHELIAL NEOPLASIA/epidemiology;
VAGINAL INTRAEPITHELIAL NEOPLASIA/surgery; VIRUS LIKE AGENT;
VIRUS STRAIN; VULVA CARCINOMA/diagnosis; VULVA
CARCINOMA/epidemiology; VULVA CARCINOMA/surgery; VULVA
DISEASE/drug therapy; VULVA DISEASE/surgery; VULVAR
INTRAEPITHELIAL NEOPLASIA/drug therapy; VULVAR
INTRAEPITHELIAL NEOPLASIA/surgery; ALPHA INTERFERON/drug
therapy; ANTINEOPLASTIC AGENT/drug therapy; CIDOFOVIR/drug therapy;
DICHLOROACETIC ACID/drug therapy; DICHLOROACETIC ACID/topical
drug administration; FLUOROURACIL/drug therapy; FLUOROURACIL/topical
drug administration; IMIQUIMOD/adverse drug reaction; IMIQUIMOD/drug
therapy; IMIQUIMOD/topical drug administration; NONSTEROID
ANTIINFLAMMATORY AGENT/oral drug administration; PLACEBO;
drug administration; WART VIRUS VACCINE/clinical trial; WART VIRUS
VACCINE/drug therapy; WART VIRUS VACCINE/pharmacoeconomics
Obstetrics and Gynecology; Cancer; Health Policy, Economics and Management;
Drug Literature Index; Adverse Reactions Titles; Internal Medicine
cidofovir/113852-37-2; dichloroacetic acid/13425-80-4; dichloroacetic acid/215656-1; dichloroacetic acid/79-43-6; fluorouracil/51-21-8; imiquimod/99011-02-6;
113852-37-2; 13425-80-4; 2156-56-1; 79-43-6; 51-21-8; 99011-02-6; 14357-05-2;
76-03-9
Knowledge regarding the relationship between the human papillomavirus (HPV)
AU:
CNOTE:
and many diseases continues to grow. Clinicians should not only understand how
to treat HPV-related diseases but offer strategies to prevent them. This
understanding encompasses patient education and counseling regarding
modifiable lifestyle factors and patient participation in organized secondary
screening programs. Finally, for the first time in history, patients may be offered
safe and effective vaccines that promise to have a dramatic impact on these
conditions. © 2008 Elsevier Inc. All rights reserved.
Diaz ML
Diaz Maria Lina
Section of Ambulatory Gynecology, Cleveland Clinic Florida, 2950 Cleveland
Clinic Blvd, Weston, FL 33331, United States
[email protected]
2/39 von 102
ND:
Autoren:
EM2008227984
Palefsky J
Titel:
Human papillomavirus and anal neoplasia
Source:
Current HIV/AIDS Reports; VOL: 5 (2); p. 78-85 /200805/
DOI:
10.1007/s11904-008-0013-5
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
1548-3568
EISSN:
1548-3576
Institution: Palefsky J, Dr., University of California, San Francisco, Box 0126, 505 Parnassus
Avenue, San Francisco, CA 94143, United States, [email protected]
COU:
United States
DT:
RN:
0057
Keywords
CT:
CANCER/*epidemiology; ANUS CANCER/*etiology; ANUS
CANCER/*prevention; ANUS CANCER/*surgery; WART VIRUS/*; ANUS
SURGERY; BASAL CELL; CANCER CHEMOTHERAPY; CANCER
DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER IMMUNIZATION;
CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER
SCREENING; CANCER STAGING; CANCER SURGERY; CANCER
SURVIVAL; CAUTERIZATION; CHLAMYDIA TRACHOMATIS; DIGITAL
RECTAL EXAMINATION; EPITHELIUM CELL; HIGH RISK POPULATION;
HUMAN; OVERALL SURVIVAL; RECTUM BIOPSY; REVIEW; TUMOR
BIOPSY; UTERINE CERVIX CANCER; IMIQUIMOD/drug therapy;
PODOPHYLLOTOXIN/drug therapy; WART VIRUS VACCINE/drug therapy
DN:
MN:
ET:
TE:
CR:
AB:
AU:
CNOTE:
Cervarix/Glaxo SmithKline, United States; Gardasil/Merck and Co, United States
Glaxo SmithKline, United States; Merck and Co, United States
Cancer; Public Health, Social Medicine and Epidemiology; Immunology,
Serology and Transplantation; Drug Literature Index; Gastroenterology
99011-02-6; 518-28-5
Anal cancer is a rare disease in the general population, but the incidence of anal
cancer is higher in certain at-risk groups, such as men who have sex with men
(MSM), and immunosuppressed individuals, including those with HIV infection.
Among HIV-positive MSM, the incidence of anal cancer may be as high as 10
times greater than current rates of cervical cancer in the general population of
women. Anal cancer is associated with human papillomavirus (HPV) infection
and may be preceded by high-grade anal intraepithelial neoplasia (HGAIN).
HGAIN and anal HPV infection are both highly prevalent in groups at risk for
anal cancer. Current issues include determining the effect of antiretroviral therapy
on the natural history of HGAIN and the incidence of anal cancer, optimizing
diagnostic and therapeutic approaches to HGAIN, and determining the potential
for prophylactic HPV vaccines to prevent anal HPV infection and anal cancer in
at-risk groups. Copyright © 2008 by Current Medicine Group LLC.
Palefsky J
Palefsky Joel
University of California, San Francisco, Box 0126, 505 Parnassus Avenue, San
Francisco, CA 94143, United States
[email protected]
2/40 von 102
ND:
Autoren:
EM2008183406
Karelovic D; Krzelj V; Pezelj D
Titel:
Genitalne infekcije uzrokovane ljudskim papilomavirusima u
pedijatriji
Pediatrics genital human papilomavirus infection
Source:
Paediatria Croatica, Supplement; VOL: 49 (1); p. 226-233 /2005/
SU:
EMBASE
Sprache: Croatian
AL:
English; Croatian
CY:
Croatia
ISSN:
1330-724X
Institution: Karelovic D, Dr., Klinika za Zenske Bolesti I Porode, Klinicka Bolnica Split,
Spinciceva 1, 21000 Split, [email protected]
DT:
Conference Paper; Journal Article
RN:
0087
Keywords
CT:
DN:
MN:
ET:
TE:
CR:
AB:
AU:
VERRUCA VULGARIS/*drug therapy; VERRUCA VULGARIS/*epidemiology;
VERRUCA VULGARIS/*surgery; VERRUCA VULGARIS/*therapy; WART
VIRUS/*; ADOLESCENT; ANTIMICROBIAL THERAPY; ANUS
CANCER/complication; CANCER PREVENTION; CAUTERIZATION;
CONDYLOMA; CONDYLOMA ACUMINATUM/drug therapy;
CONDYLOMA ACUMINATUM/epidemiology; CONDYLOMA
CONFERENCE PAPER; FEMALE GENITAL SYSTEM; HEALTH
PROGRAM; HUMAN; IMMUNOMODULATION; INCUBATION TIME;
MORPHOLOGY; MOUTH CANCER/complication; OROPHARYNX
CANCER/complication; PAPOVAVIRUS; PENIS CANCER/complication;
PROSTATE CANCER/complication; PUBLIC HEALTH PROBLEM;
RECURRENCE RISK; SEXUALLY TRANSMITTED DISEASE/etiology;
TREATMENT INDICATION; UTERINE CERVIX; UTERINE CERVIX
CANCER/complication; VULVA CANCER/complication; ALPHA
INTERFERON/drug therapy; BCG VACCINE/drug therapy; BETA
INTERFERON/drug therapy; CIDOFOVIR/drug therapy;
FLUOROURACIL/drug therapy; GAMMA INTERFERON/drug therapy;
IMIQUIMOD/drug therapy; PODOPHYLLIN/drug therapy;
PODOPHYLLOTOXIN/drug therapy; WART VIRUS VACCINE
Aldara; Podofilox
Glaxo SmithKline
Dermatology and Venereology; Public Health, Social Medicine and
Epidemiology; Drug Literature Index; Microbiology: Bacteriology, Mycology,
Parasitology and Virology; Internal Medicine; Pediatrics and Pediatric Surgery
cidofovir/113852-37-2; fluorouracil/51-21-8; gamma interferon/82115-62-6;
imiquimod/99011-02-6; podophyllin/9000-55-9; podophyllotoxin/518-28-5
113852-37-2; 51-21-8; 82115-62-6; 99011-02-6; 9000-55-9; 518-28-5
Human papillomaviruses (HPV) belong to the family Papovariridae and genus
Papillomavirus. Today more than 150 HPV types are known and approximately
40 types infect the female genital tract. Genital HPV infection is the most common
sexually transmitted disease. HPV infection of the uterine cervix can be found in
as many as 65% urban adolescent girls. Warts occur in 10% of children, with a
peak between the ages of 12 and 16. HPV infection is increasingly the subject of
investigation because it is the major factor for the development of cervical, vulvar,
anal and penile cancers but may also be implicated in the prostate cancer and
cancers of the oropharynx, oral cavity and gullet. HPV infection is a global public
health problem so every state should create prevention programs. The incubation
period of condylomata after exposure ranges from three weeks to eight months.
Most infections are often asymptomatic and transient. No antiviral drugs are
currently licensed for the treatment of HPV infection. Treatment choice depends
on the morphology, number, and distribution of genital warts. Treatement of
genital warts includes ablative therapy, immune modulations, chemical or physical
agents and antimicrobical therapy. From data literature HPV treatments can be
classified by mode of action as either patient - applied (home) or physician applied
(office) therapies. HPV vaccines are likely to become available in the next few
years and may become an important prevention tool.
Karelovic D
Karelovic Deni
AU:
AU:
CNOTE:
Klinika za Zenske Bolesti I Porode; Klinika za Zenske Bolesti I Porode, Klinicka
Bolnica Split, Spinciceva 1, 21000 Split
[email protected]
Krzelj V
Krzelj Vjekoslav
Klinika za Djecje Bolesti
Pezelj D
Pezelj Damir
Odjel za Kozne I Spolne Bolesti, Klinicka Bolnica Split
2/41 von 102
ND:
Autoren:
EM2008074944
Gross G; Ikenberg H; Petry KU; Pfister H; Schneede P; Schöfer H; Szeimies R-M
Titel:
Condylomata acuminata und andere HPV-assoziierte
krankheitsbilder von genitale, anus und harnröhre
Guideline for Condylomata acuminata and other HPV-associated
diseases of the genitals, the anus and the urethra
Source:
/200802/
DOI:
10.1111/j.1610-0387.2007.06659.x
SU:
EMBASE
Sprache: German
CY:
United Kingdom
ISSN:
1610-0379
EISSN:
1610-0387
CO:
JJDDA
Institution: Gross G, Dr. Prof., Klinik und Poliklinik für Dermatologie und Venerologie,
Klinikum der Universität Rostock AÖR, Augustenstraße 80-84, D-18055
Rostock, [email protected]
DT:
JSC:
Keywords
CT:
CONDYLOMA ACUMINATUM/*diagnosis; CONDYLOMA
CONDYLOMA ACUMINATUM/*prevention; WART VIRUS/*; ACETIC ACID
TEST; ANAL CANAL; ANAL COMPLAINT; ANAL INTRAEPITHELIAL
NEOPLASIA; ANTIVIRAL THERAPY; ANUS CARCINOMA; BOWEN
DISEASE; BOWENOID PAPULOSIS; CANCER INVASION; CARCINOMA
IN SITU; CHILDHOOD; CHLAMYDIA; CLINICAL EXAMINATION;
COLONOSCOPY; COLPOSCOPY; CONDOM; CRYOTHERAPY;
CYTOLOGY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE
ET:
TE:
CR:
AU:
AU:
AU:
AU:
AU:
AU:
AU:
CNOTE:
COURSE; DISEASE TRANSMISSION; EPITHELIUM TUMOR;
ERYTHROPLASIA; ERYTHROPLASIA QUEYRAT; FLUORESCENCE;
FLUORIDE TEST; GENITAL HERPES; GENITAL SYSTEM; HIGH RISK
PATIENT; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE
DEFICIENCY; IMMUNOASSAY; INTRAEPITHELIUM NEOPLASIA;
MOLECULAR BIOLOGY; MULTIPLE CANCER; NEWBORN INFECTION;
PENILE INTRAEPITHELIAL NEOPLASIA; PENIS TUMOR; PERIANAL
INTRAEPITHELIAL NEOPLASIA; PHOTODYNAMIC THERAPY;
PREGNANCY; PREVALENCE; PROPHYLAXIS; RECTOSCOPY; REVIEW;
SELF CARE; SEROLOGY; SEXUALITY; SEXUALLY TRANSMITTED
DISEASE; SURGICAL TECHNIQUE; SYMPTOM; SYPHILIS; TREATMENT
CONTRAINDICATION; TREATMENT INDICATION; TRICHOMONAS;
TUMOR LOCALIZATION; URETHRA; URETHROSCOPY; UTERINE
CERVIX; UTERINE CERVIX CARCINOMA; UTERINE CERVIX
CARCINOMA IN SITU; VACCINATION; VAGINA TUMOR; VAGINAL
INTRAEPITHELIAL NEOPLASIA; VULVA CARCINOMA; VULVAR
INTRAEPITHELIAL NEOPLASIA; BETA INTERFERON/drug therapy;
GREEN TEA EXTRACT; IMIQUIMOD/drug therapy
Dermatology and Venereology; Public Health, Social Medicine and
Epidemiology; Drug Literature Index; Microbiology: Bacteriology, Mycology,
Parasitology and Virology; General Pathology and Pathological Anatomy
99011-02-6
Gross G
Gross Gerd
Klinik und Poliklinik für Dermatologie und Venerologie, Klinikum der
Universität Rostock AÖR, Augustenstraße 80-84, D-18055 Rostock
[email protected]
Ikenberg H
Ikenberg Hans
Petry KU
Petry Karl Ulrich
Pfister H
Pfister Herbert
Schneede P
Schneede Peter
Schöfer H
Schöfer Helmut
Szeimies R-M
Szeimies Rolf-Markus
2/42 von 102
ND:
Autoren:
EM2008052215
Ganguly N; Waller S; Stasik CJ; Skikne BS; Ganguly S
Titel:
Giant anal condylomatosis after allogeneic bone marrow
transplantation: A rare complication of human papilloma virus
infection
Source:
Transplant Infectious Disease; VOL: 10 (1); p. 56-58 /200802/
DOI:
10.1111/j.1399-3062.2007.00233.x
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
1398-2273
EISSN:
1399-3062
CO:
TIDSF
Institution: Ganguly S, Dr., Department of Hematology, University of Kansas Medical
Center, MS 4038, 3901 Rainbow Blvd, Kansas City, KS 66160, United
COU:
United States
DT:
Journal Article
JSC:
D.4 ... Transplantation; E.5 ... Clinical Microbiology
RN:
0005
Keywords
CT:
CONDYLOMA/*complication; CONDYLOMA/*drug therapy;
CONDYLOMA/*etiology; CONDYLOMA/*surgery; GIANT ANAL
CONDYLOMATOSIS/*complication; GIANT ANAL
CONDYLOMATOSIS/*drug therapy; GIANT ANAL
CONDYLOMATOSIS/*etiology; GIANT ANAL
CONDYLOMATOSIS/*surgery; ADULT; ANAMNESIS; ARTICLE; BONE
MARROW TRANSPLANTATION; CASE REPORT; CLINICAL FEATURE;
GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; MALE;
PRIORITY JOURNAL; RECTUM SURGERY; VIRUS INFECTION; WART
VIRUS; IMIQUIMOD/drug therapy
ET:
Immunology, Serology and Transplantation; Drug Literature Index; Microbiology:
Bacteriology, Mycology, Parasitology and Virology; Gastroenterology; General
Pathology and Pathological Anatomy
TE:
CR:
99011-02-6
AB:
Condyloma acuminata or genital warts are caused by human papilloma virus
(HPV). Ongoing proliferation of HPV in patients with congenital or acquired
immunodeficiency states leads to the development of rapidly progressive and
sometimes locally invasive tumor with or without dysplasia. Aggressive treatment,
diagnostic immuno-typing, and follow-up are necessary in patients with ongoing
immunosuppression. We report a case of giant ano-genital condylomatosis due to
HPV types 6 and 11 in a patient with chronic myeloid leukemia after allogeneic
bone marrow transplantation. The tumor was successfully treated with surgical
excision and local application of 5% imiquimod cream. Copyright © Blackwell
AU:
AU:
AU:
AU:
AU:
CNOTE:
Munksgaard 2007.
Ganguly N
Ganguly N
Department of Medicine, University of Kansas Medical Center, Kansas City, KS,
United States
Waller S
Waller S
Department of Infectious Diseases, University of Kansas Medical Center, Kansas
City, KS, United States
Stasik CJ
Stasik CJ
Department of Pathology, University of Kansas Medical Center, Kansas City, KS,
United States
Skikne BS
Skikne BS
Ganguly S
Ganguly S
Department of Hematology, University of Kansas Medical Center, MS 4038, 3901
Rainbow Blvd, Kansas City, KS 66160, United States; Department of
Hematology, University of Kansas Medical Center, Kansas City, KS, United
States
[email protected]
2/43 von 102
ND:
Autoren:
EM2008026579
Fleshner PR; Chalasani S; Chang GJ; Levien DH; Hyman NH; Buie WD;
Bastawrous A; Sigurdson E; Kumar R; Steele S; Newstead R; Strong S; Phang T;
Tjandra J; Shellito P
Titel:
Practice parameters for anal squamous neoplasms
Source:
Diseases of the Colon and Rectum; VOL: 51 (1); p. 2-9 /200801/
DOI:
10.1007/s10350-007-9093-3
SU:
EMBASE
Sprache: English
CY:
United States
ISSN:
0012-3706
EISSN:
1530-0358
CO:
DICRA
Institution: Hyman NH, Dr., Fletcher Allen Health Care, 111 Colchester Avenue, Fletcher
301, Burlington, VT 05401, United States, [email protected]
COU:
United States
DT:
Journal Article
JSC:
RN:
0082
Keywords
CT:
NEOPLASIA/*surgery; ANAL INTRAEPITHELIAL NEOPLASIA/*therapy;
CANCER/*etiology; ANUS CANCER/*radiotherapy; ANUS CANCER/*surgery;
ANUS CANCER/*therapy; CARCINOMA IN SITU/*diagnosis; SQUAMOUS
CELL CARCINOMA/*diagnosis; SQUAMOUS CELL CARCINOMA/*drug
therapy; SQUAMOUS CELL CARCINOMA/*etiology; SQUAMOUS CELL
CARCINOMA/*radiotherapy; SQUAMOUS CELL CARCINOMA/*surgery;
SQUAMOUS CELL CARCINOMA/*therapy; ANOSCOPY; ARTICLE; BONE
MARROW TOXICITY/side effect; CANCER CHEMOTHERAPY; CANCER
CYTODIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING;
CANCER SURVIVAL; CLINICAL PRACTICE; COLONOSCOPY;
COLORECTAL CANCER/diagnosis; COLORECTAL CANCER/drug therapy;
COLORECTAL CANCER/etiology; COLORECTAL CANCER/radiotherapy;
COLORECTAL CANCER/surgery; COLORECTAL CANCER/therapy;
COLORECTAL SURGERY; COLOSTOMY; COMBINATION
CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; COST
EFFECTIVENESS ANALYSIS; ENDOSCOPIC BIOPSY; ENDOSCOPIC
ECHOGRAPHY; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY;
HEALTH CARE QUALITY; HIGHLY ACTIVE ANTIRETROVIRAL
THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED
PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION/drug
therapy; INGUINAL LYMPH NODE; LYMPH NODE
METASTASIS/complication; LYMPH NODE METASTASIS/radiotherapy;
MULTIMODALITY CANCER THERAPY; PHOTODYNAMIC THERAPY;
PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY;
PRACTICE GUIDELINE; PRECANCER; PREOPERATIVE EVALUATION;
PROGNOSIS; RADIATION DOSE; RECTUM ABDOMINOPERINEAL
RESECTION; SIGMOIDOSCOPY; SURGEON; TUMOR VOLUME;
UNSPECIFIED SIDE EFFECT/side effect; WART VIRUS;
CISPLATIN/*adverse drug reaction; CISPLATIN/*drug combination;
CISPLATIN/*drug therapy; FLUOROURACIL/*adverse drug reaction;
FLUOROURACIL/*drug administration; FLUOROURACIL/*drug combination;
FLUOROURACIL/*drug therapy; FLUOROURACIL/*topical drug
administration; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*drug
administration; IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug
administration; MITOMYCIN/*adverse drug reaction; MITOMYCIN/*drug
combination; MITOMYCIN/*drug therapy; ACETIC ACID;
ANTIRETROVIRUS AGENT/drug therapy; LUGOL
ET:
Cancer; Drug Literature Index; Adverse Reactions Titles; Gastroenterology;
Surgery
TE:
acetic acid/127-08-2; acetic acid/127-09-3; acetic acid/64-19-7; acetic acid/71-501; cisplatin/15663-27-1; cisplatin/26035-31-4; cisplatin/96081-74-2;
fluorouracil/51-21-8; imiquimod/99011-02-6; lugol/12298-68-9; mitomycin/140400-8
CR:
127-08-2; 127-09-3; 64-19-7; 71-50-1; 15663-27-1; 26035-31-4; 96081-74-2; 51-
AU:
AU:
AU:
AU:
AU:
AU:
AU:
AU:
AU:
AU:
AU:
AU:
AU:
AU:
AU:
CNOTE:
21-8; 99011-02-6; 12298-68-9; 1404-00-8
Fleshner PR
Fleshner Phillip R.
Steele S
Steele Scott
Newstead R
Newstead Raham
Strong S
Strong Scott
Phang T
Phang Terry
Tjandra J
Tjandra Joe
Shellito P
Shellito Paul
Chalasani S
Chalasani Sridhar
Chang GJ
Chang George J.
Levien DH
Levien David H.
Hyman NH
Hyman Neil H.
Fletcher Allen Health Care, 111 Colchester Avenue, Fletcher 301, Burlington, VT
05401, United States
[email protected]
Buie WD
Buie W. Donald
Bastawrous A
Bastawrous Amir
Sigurdson E
Sigurdson Elin
Kumar R
Kumar Ravin
2/44 von 102
ND:
Autoren:
EM2007613487
Viazis N; Vlachogiannakos J; Vasiliadis K; Theodoropoulos I; Saveriadis A;
Karamanolis DG
Titel:
Earlier eradication of intra-anal warts with argon plasma coagulator
combined with imiquimod cream compared with argon plasma
coagulator alone: A prospective, randomized trial
Source:
Diseases of the Colon and Rectum; VOL: 50 (12); p. 2173-2179 /200712/
DOI:
10.1007/s10350-007-9041-2
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
0012-3706
EISSN:
1530-0358
CO:
DICRA
Institution: Viazis N, Dr., 59 Niriidon Street, 17561 P. Faliro, Athens,
Greece, [email protected]
COU:
Greece
DT:
Journal Article
JSC:
RN:
0021
Keywords
CT:
ARGON PLASMA COAGULATION/*; ERADICATION THERAPY/*;
VERRUCA VULGARIS/*drug therapy; VERRUCA VULGARIS/*therapy;
ADULT; ARTICLE; BURNING SENSATION/side effect; CLINICAL
ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY; DRUG EFFICACY; ERYTHEMA/side effect;
FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS
INFECTED PATIENT; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED
PATIENT; MALE; PRURITUS/side effect; RECURRENT DISEASE;
IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*clinical trial;
IMIQUIMOD/*drug therapy
ET:
Dermatology and Venereology; Drug Literature Index; Adverse Reactions Titles;
Gastroenterology
TE:
CR:
99011-02-6
AB:
PURPOSE: Despite the increasing incidence of condylomata acuminate, optimal
treatment of anal warts is still undecided. This prospective, randomized study was
designed to compare the efficacy of combined argon plasma coagulation and
imiquimod cream vs. argon plasma coagulation alone in the management of intraanal warts. METHODS: From October 2002 to March 2005, 49 patients with
intra-anal warts were randomly assigned to argon plasma coagulation plus
imiquimod cream (n=24) vs. argon plasma coagulation alone (n=25). Therapeutic
sessions were repeated until the elimination of the warts. Efficacy of therapy was
defined as the time needed for eradication. All patients were followed up for a
mean period of 12 months for signs of recurrence. RESULTS: Elimination of
warts was achieved earlier in patients receiving combination therapy compared
with those receiving monotherapy with argon plasma coagulation (62.5±5.4 days
vs. 91.2±6.4 days; P=0.0016). A subgroup analysis performed in HIV-positive
patients showed similar results (combination therapy 95±22.6 days; monotherapy
AU:
AU:
AU:
AU:
AU:
AU:
CNOTE:
124.3±20.7 days; P=0.033); however, in HIV-positive patients warts were
eradicated later compared with HIV-negative patients (110.8±25.7 days vs.
65±25.4 days; P<0.0001). No major complications were observed in our study
population. After the follow-up period, recurrence of warts was evident in 22.7
percent of patients in the combination group compared with 34.7 percent of
patients in the monotherapy group (P=0.51). Recurrence was significantly higher
in HIV-positive patients compared with HIV-negative patients (P=0.0039).
CONCLUSIONS: Combination therapy with argon plasma coagulator plus
imiquimod cream results in earlier clearance of intra-anal warts in both
immunocompetent and immunocompromised patients; however, it does not affect
the rate of recurrence. © 2007 American Society of Colon and Rectal Surgeons.
Viazis N
Viazis Nikos
2nd Department of Gastroenterology, Evangelismos Hospital, Athens, Greece; 59
Niriidon Street, 17561 P. Faliro, Athens, Greece
[email protected]
Vlachogiannakos J
Vlachogiannakos John
2nd Department of Gastroenterology, Evangelismos Hospital, Athens, Greece
Vasiliadis K
Vasiliadis Konstantinos
Theodoropoulos I
Theodoropoulos Ioannis
Saveriadis A
Saveriadis Adamos
Karamanolis DG
Karamanolis Dimitrios G.
2/45 von 102
ND:
Autoren:
EM2007579514
Schöfer H
Titel:
Evaluation of imiquimod for the therapy of external genital and anal
warts in comparison with destructive therapies
Source:
DOI:
SU:
Sprache:
British Journal of Dermatology; VOL: 157 (SUPPL. 2); p. 52-55 /200712/
10.1111/j.1365-2133.2007.08274.x
EMBASE
English
AL:
English
CY:
United Kingdom
ISSN:
0007-0963
EISSN:
1365-2133
CO:
BJDEA
Institution: Schöfer H, Department of Dermatology and Venerology, University Hospital,
J.W. Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt/M,
Germany, [email protected]
COU:
Germany
DT:
Journal Article
JSC:
RN:
0025
Keywords
CT:
ANUS/*; CONDYLOMA ACUMINATUM/*complication; CONDYLOMA
ACUMINATUM/*drug therapy; CONDYLOMA ACUMINATUM/*etiology;
CONDYLOMA ACUMINATUM/*prevention; GENITAL SYSTEM/*;
VERRUCA VULGARIS/*complication; VERRUCA VULGARIS/*drug therapy;
VERRUCA VULGARIS/*etiology; VERRUCA VULGARIS/*prevention;
ARTICLE; BURNING SENSATION/side effect; CD4 LYMPHOCYTE COUNT;
CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE
STUDY; COST MINIMIZATION ANALYSIS; CREAM; DEPRESSION/side
effect; DRUG EFFICACY; DRUG FEVER/side effect; DRUG SAFETY; DRUG
SCREENING; DRUG TOLERABILITY; ERYTHEMA/side effect; FLU LIKE
SYNDROME/side effect; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION/drug therapy; HUMAN
HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOCOMPROMISED PATIENT;
IMMUNOMODULATION; INFLAMMATION/side effect; LONG TERM
CARE; MONOTHERAPY; OINTMENT; PAIN/side effect; PATIENT
COMPLIANCE; PRIORITY JOURNAL; PRURITUS/side effect; SKIN
INDURATION/side effect; SKIN MANIFESTATION/side effect; SKIN
ULCER/side effect; TAMPON; TOPICAL TREATMENT; TREATMENT
DURATION; VIRUS REPLICATION; IMIQUIMOD/*adverse drug reaction;
IMIQUIMOD/*clinical trial; IMIQUIMOD/*drug administration;
IMIQUIMOD/*drug comparison; IMIQUIMOD/*drug therapy;
IMIQUIMOD/*pharmacology; IMIQUIMOD/*topical drug administration;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT/drug therapy;
CYTOKINE/endogenous compound; IMIDAZOQUINOLINE
DERIVATIVE/drug therapy; IMIDAZOQUINOLINE
DERIVATIVE/pharmacology; IMIDAZOQUINOLINE DERIVATIVE/topical
drug administration; INTERFERON/adverse drug reaction; INTERFERON/drug
therapy; INTERFERON/topical drug administration; PEGINTERFERON/drug
therapy; PODOPHYLLOTOXIN/adverse drug reaction;
PODOPHYLLOTOXIN/drug comparison; PODOPHYLLOTOXIN/drug therapy
ET:
Medicine
TE:
CR:
AB:
AU:
CNOTE:
99011-02-6; 518-28-5
External genital and anal warts (acuminate condyloma) were the first medical
indication the topical immune response modifier imiquimod was approved for in
1997. Since then, many placebo controlled randomized clinical trials have
demonstrated the efficacy and safety of this synthetic imidazoquinoline derivate
for the treatment of different human papillomavirus infections and tumours.
Treatment modalities for genital warts (5% cream, three times weekly, minimum
duration 4 weeks, control of side-effects) have been optimized and assured by
further clinical trials and meta-analyses. For a few years clinical studies focussed
on the long-term efficacy of the immunomodulatory therapy (sustained clearance
from warts) and most recent studies compared the efficacy of ablative, destructive
and imiquimod monotherapy as well as combination therapies. © 2007 The
Author.
Schöfer H
Schöfer H
Department of Dermatology and Venerology, University Hospital, J.W. Goethe
University, Theodor-Stern-Kai 7, 60590 Frankfurt/M, Germany
[email protected]
2/46 von 102
ND:
Autoren:
EM2007497375
Monk BJ; Tewari KS
Titel:
The spectrum and clinical sequelae of human papillomavirus
infection
Source:
Gynecologic Oncology; VOL: 107 (2 SUPPL.); p. S6-S13 /200711/
DOI:
10.1016/j.ygyno.2007.07.076
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
0090-8258
EISSN:
1095-6859
CO:
GYNOA
PII:
S0090825807005719
Institution: Monk BJ, The Division of Gynecologic Oncology, Department of Obstetrics and
Gynecology, The Chao Family Comprehensive Cancer Center, 101 The City
Drive, Orange, CA 92868-3298, United States, [email protected]
COU:
United States
DT:
Journal Article
JSC:
C.4 ... Obstetrics & Gynecology; C.1.3.1 ... Clinical Oncology
RN:
0035
Keywords
CT:
CONDYLOMA/*drug therapy; CONDYLOMA/*therapy; SEXUALLY
TRANSMITTED DISEASE/*; UTERINE CERVIX CARCINOMA/*; VIRUS
INFECTION/*etiology; WART VIRUS/*; ANUS CANCER; ARTICLE;
CARCINOGENESIS; CHILD CARE; ESOPHAGUS CANCER; HIGH RISK
POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN
PAPILLOMAVIRUS TYPE 18; OROPHARYNX TUMOR;
PAPILLOMATOSIS/disease management; PENIS CANCER; POPULATION
RESEARCH; PRIORITY JOURNAL; SKIN BIOPSY; VAGINA CANCER;
VULVA CARCINOMA; WOMEN'S HEALTH; CATECHIN/drug therapy;
IMIQUIMOD/drug therapy; PODOPHYLLIN/drug therapy;
PODOPHYLLOTOXIN/drug therapy; VEREGEN/drug therapy
ET:
Obstetrics and Gynecology; Dermatology and Venereology; Cancer; Drug
Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and
Virology
TE:
catechin/13392-26-2; catechin/154-23-4; imiquimod/99011-02-6;
podophyllin/9000-55-9; podophyllotoxin/518-28-5
CR:
13392-26-2; 154-23-4; 99011-02-6; 9000-55-9; 518-28-5
AB:
Infection with the human papillomavirus (HPV) is the most common sexually
transmitted disease afflicting approximately 80% of the population. HPV infection
is an essential factor in cervical carcinogenesis and cervical carcinoma is the
second most common cause of cancer among women worldwide. In addition to
cervical cancer, other malignancies in both men and women such as esophageal,
oropharyngeal, and anal cancer have been causally associated with this virus.
Other gender-specific HPV-related cancers include penile, vulvar and vaginal
cancer. HPV-16 is the most common HPV type associated with a malignant
phenotype regardless of organ of origin. HPV-16 together with HPV-18 accounts
for approximately 70% of cervical cancers. Other non-oncogenic HPV types
including HPV types 6 and 11 are associated with over 90% of benign HPVrelated lesions such as genital warts and juvenile respiratory papillomatosis. ©
2007 Elsevier Inc. All rights reserved.
AU:
Monk BJ
Monk Bradley J.
The Division of Gynecologic Oncology, Department of Obstetrics and
Drive, Orange, CA 92868-3298, United States
[email protected]
AU:
Tewari KS
Tewari Krishnansu S.
The Division of Gynecologic Oncology, Department of Obstetrics and
Drive, Orange, CA 92868-3298, United States
2/47 von 102
ND:
EM2007415567
Autoren:
Sanclemente G; Herrera S; Tyring SK; Rady PL; Zuleta J-J; Correa L-A; He Q;
Wolff J-C
Titel:
Human papillomavirus (HPV) viral load and HPV type in the
clinical outcome of HIV-positive patients treated with imiquimod for
anogenital warts and anal intraepithelial neoplasia
Source:
Journal of the European Academy of Dermatology and Venereology; VOL: 21
(8); p. 1054-1060 /200709/
DOI:
10.1111/j.1468-3083.2007.02169.x
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
0926-9959
EISSN:
1468-3083
CO:
JEAVE
Institution: Sanclemente G, University of Antioquia, Clinica El Rosario, Carrera 20 # 2 Sur185, El Tesoro, Medellin, Colombia, [email protected]
COU:
Colombia
DT:
Journal Article
JSC:
RN:
0035
Keywords
CT:
ANUS TUMOR/*diagnosis; CONDYLOMA/*diagnosis; CONDYLOMA/*drug
therapy; EPITHELIUM TUMOR/*diagnosis; HUMAN IMMUNODEFICIENCY
VIRUS INFECTION/*; WART VIRUS/*; ADULT; ARTICLE; CD4
LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG EFFICACY;
FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN
TISSUE; MALE; MALIGNANT TRANSFORMATION; NONHUMAN;
OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE;
TREATMENT DURATION; TUMOR CLASSIFICATION; VIRUS
DETECTION; VIRUS LOAD; VIRUS STRAIN; IMIQUIMOD/*drug therapy;
IMIQUIMOD/*topical drug administration
ET:
Dermatology and Venereology; Urology and Nephrology; Drug Literature Index;
Microbiology: Bacteriology, Mycology, Parasitology and Virology;
Gastroenterology
TE:
CR:
99011-02-6
AB:
Objective: To evaluate the efficacy of 5% imiquimod in HIV-positive male
patients with anogenital warts or anal intraepithelial neoplasia (AIN), and to
elucidate whether human papillomavirus (HPV) type and viral load were
important for clinical outcome and recurrences. Methods: Thirty-seven patients
with histologically proven anogenital warts or AIN were enrolled. Topical 5%
imiquimod was applied three times per week for more than 8 h overnight for 16
weeks, although patients were allowed to continue therapy for 4 more weeks if
they did not have complete clearance of lesions. Results: Mean age was 34 years.
The perianal area was the main lesion location. Thirty-three patients had CD4
AU:
AU:
AU:
AU:
AU:
AU:
AU:
AU:
counts of < 500 cells/mm 3. Eighteen patients had a histopathological diagnosis of
AIN-1. Main HPV types detected corresponded to low-risk HPV types. At 20
weeks of therapy, 46% patients achieved total clearance whereas 14 patients had >
50% clearance. Recurrence was observed in 5 of 17 patients who cleared.
Clearance was not influenced by patients' CD4 counts, wart location, HIV viral
load or HPV viral load. Conclusions: The assumption that visible perianal warts
are benign lesions in HIV-positive patients has to be reevaluated since an
important number of such lesions could correspond to low-grade anal disease,
which in turn could progress to high-grade anal disease or cancer. In addition, our
results in this preliminary study indicate that imiquimod appears to be effective in
treating AIN in HIV-positive patients. Further studies are needed to document its
utility to prevent high-grade dysplasia and/or anal cancer. © 2007 The Authors
Journal compilation © 2007 European Academy of Dermatology and
Venereology.
Sanclemente G
Sanclemente G
Medellín, Colombia; Grid -Dermatology Section, Department of Internal
Medicine University of Antioquia, Medellín, Colombia; University of Antioquia,
Clinica El Rosario, Carrera 20 # 2 Sur-185, El Tesoro, Medellin, Colombia
[email protected]
Herrera S
Herrera S
Medellín, Colombia
Tyring SK
Tyring SK
Department of Dermatology, University of Texas Health Science Center, Houston,
TX, United States
Rady PL
Rady PL
TX, United States
Zuleta J-J
Zuleta J-J
Escuela de Investigacion Medica Aplicada-School of Medicine, University of
Antioquia, Medellín, Colombia
Correa L-A
Correa L-A
Medellín, Colombia
He Q
He Q
TX, United States
Wolff J-C
CNOTE:
Wolff J-C
Medellín, Colombia
2/48 von 102
ND:
Autoren:
EM2007401262
Kreuter A; Wieland U; Gambichler T; Altmeyer P; Pfister H; Tenner-Racz K;
Racz P; Potthoff A; Brockmeyer NH
Titel:
p16ink4a expression decreases during imiquimod
treatment of anal intraepithelial neoplasia in human
immunodeficiency virus-infected men and correlates with the decline
of lesional high-risk human papillomavirus DNA load
Source:
British Journal of Dermatology; VOL: 157 (3); p. 523-530 /200709/
DOI:
10.1111/j.1365-2133.2007.08004.x
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
0007-0963
EISSN:
1365-2133
CO:
BJDEA
Institution: Kreuter A, Department of Dermatology and Allergology, Ruhr-University
Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany, [email protected]
COU:
Germany
DT:
Journal Article
JSC:
RN:
0030
Keywords
CT:
ANUS INTRAEPITHELIAL TUMOR/*drug therapy; ANUS TUMOR/*drug
therapy; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT/*;
VIRUS LOAD/*; ARTICLE; CLINICAL ARTICLE; HISTOPATHOLOGY;
HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN
HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN TISSUE;
IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN
EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WART
VIRUS; IMIQUIMOD/*drug therapy; PROTEIN P16INK4A/*endogenous
compound; VIRUS DNA/*endogenous compound; CYCLIN DEPENDENT
KINASE INHIBITOR 1/endogenous compound; KI 67 ANTIGEN/endogenous
compound; MINICHROMOSOME MAINTENANCE PROTEIN/endogenous
compound
ET:
TE:
CR:
AB:
AU:
AU:
AU:
AU:
Transplantation; Drug Literature Index; Microbiology: Bacteriology, Mycology,
Parasitology and Virology
imiquimod/99011-02-6; minichromosome maintenance protein/290875-10-4
99011-02-6; 290875-10-4
Background: Human papillomavirus (HPV)-associated anogenital cancers and
their precursor lesions occur in excess in human immunodeficiency virus (HIV)infected patients despite the initiation of highly active antiretroviral therapy. In
this context, a drastically increased relative risk for anal intraepithelial neoplasia
(AIN) exists in HIV-infected men having sex with men (MSM). In a pilot study,
imiquimod, a topical immune response modifier, has been reported to be
beneficial in the treatment of AIN. Objectives: To investigate the role of several
biomarkers as potential adjuncts in the course of imiquimod treatment for AIN,
and to determine whether these markers correlate with the course of high-risk
HPV DNA load during imiquimod therapy. Methods: Immunohistochemical
staining was performed for p16ink4a, minichromosome maintenance
protein (MCM), Ki67, proliferating cell nuclear antigen (PCNA) and
p21waf1 expression before and after 16 weeks of imiquimod
treatment for AIN. High-risk HPV DNA load determinations were performed by
real-time polymerase chain reaction with type-specific primers and probes for
HPV types 16, 18, 31 and 33. Results: Histopathological and virological analyses
were performed in 21 HIV-infected MSM with histologically confirmed AIN.
Eighteen (86%) patients had a complete histological clearance of AIN after
imiquimod therapy. As previously shown, lesional high-risk HPV DNA load
significantly decreased during imiquimod therapy. Moreover, a significant
decline of p16ink4a, Ki67, MCM and PCNA expression after
treatment was observed, while p21waf1 expression changed
nonsignificantly after imiquimod therapy. A significant correlation between the
course of high-risk HPV DNA load and p16ink4a expression was
observed during imiquimod treatment of AIN, whereas the decline of high-risk
HPV DNA load did not significantly correlate with MCM, Ki67, PCNA or
p21waf1 expression. Conclusions: The significant decrease in
p16ink4a expression in correlation with the drop of lesional high-risk
HPV load suggests that p16 ink4a may be a useful adjunct for the
evaluation of treatment response in HPV-associated malignancies and their
precursor lesions. © 2007 The Authors.
Kreuter A
Kreuter A
Gudrunstrasse 56, D-44791 Bochum, Germany
[email protected]
Wieland U
Wieland U
Institute of Virology, University of Cologne, Cologne, Germany
Gambichler T
Gambichler T
Altmeyer P
AU:
AU:
AU:
AU:
AU:
CNOTE:
Altmeyer P
Pfister H
Pfister H
Institute of Virology, University of Cologne, Cologne, Germany
Tenner-Racz K
Tenner-Racz K
Bernhard-Nocht Institute for Tropical Diseases, Hamburg, Germany
Racz P
Racz P
Bernhard-Nocht Institute for Tropical Diseases, Hamburg, Germany
Potthoff A
Potthoff A
Brockmeyer NH
Brockmeyer NH
2/49 von 102
ND:
Autoren:
EM2007379879
Herat A; Whitfeld M; Hillman R
Titel:
Anal intraepithelial neoplasia and anal cancer in dermatological
practice
Source:
Australasian Journal of Dermatology; VOL: 48 (3); p. 143-155 /200708/
DOI:
10.1111/j.1440-0960.2007.00369.x
SU:
EMBASE
Sprache: English
AL:
English
CY:
Australia
ISSN:
0004-8380
EISSN:
1440-0960
CO:
AJDEB
Institution: Herat A, Dr., Department of Dermatology, Clatterbridge Hospital, Bebington,
Wirral CH63 4JY, United Kingdom, [email protected]
COU:
United Kingdom
DT:
JSC:
RN:
0113
Keywords
CT:
CANCER/*epidemiology; ANUS CANCER/*surgery; ANUS
CANCER/*therapy; BOWEN DISEASE/drug therapy; BOWEN
DISEASE/surgery; BOWENOID PAPULOSIS/drug therapy; CANCER
DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER SCREENING;
CLINICAL TRIAL; CONDYLOMA/drug therapy; EROSION/side effect;
ERYTHEMA/side effect; FLU LIKE SYNDROME/side effect; HIGH RISK
POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS
INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
IMMUNOSUPPRESSIVE TREATMENT; MEDICAL PRACTICE;
MORBIDITY; PATHOGENESIS; REVIEW; VAGINAL INTRAEPITHELIAL
NEOPLASIA/drug therapy; VERRUCA VULGARIS/drug therapy; VERRUCA
VULGARIS/etiology; VERRUCA VULGARIS/prevention; VULVA
TUMOR/drug therapy; AMINOLEVULINIC ACID/drug therapy;
AMINOLEVULINIC ACID/oral drug administration; AMINOLEVULINIC
ACID/topical drug administration; CIDOFOVIR/drug therapy;
CIDOFOVIR/topical drug administration; FLUOROURACIL/drug combination;
FLUOROURACIL/drug comparison; FLUOROURACIL/drug therapy;
FLUOROURACIL/topical drug administration; IMIQUIMOD/adverse drug
reaction; IMIQUIMOD/drug combination; IMIQUIMOD/drug comparison;
PHOTOSENSITIZING AGENT/drug therapy; PHOTOSENSITIZING
AGENT/oral drug administration; PODOPHYLLOTOXIN/drug therapy;
PODOPHYLLOTOXIN/topical drug administration; WART VIRUS
VACCINE/clinical trial; WART VIRUS VACCINE/drug therapy
ET:
Transplantation; Drug Literature Index; Adverse Reactions Titles
TE:
aminolevulinic acid/106-60-5; cidofovir/113852-37-2; fluorouracil/51-21-8;
CR:
106-60-5; 113852-37-2; 51-21-8; 99011-02-6; 518-28-5
AB:
Anal intraepithelial neoplasia is considered to be a precursor lesion of invasive
anal cancer. It is now increasingly recognized in high-risk groups, such as men
who have sex with men and HIV-infected patients. Human papillomaviruses are
considered to be an important aetiological agent in both anal intraepithelial
neoplasia and anal cancer. Dermatologists are likely to encounter these conditions
among the differential diagnoses to be considered in high-risk patients presenting
with perianal and anal lesions. Anal cancer rates are also increasing among the
HIV-infected and HIV-non-infected population. The successful treatment of anal
intraepithelial neoplasia may reduce the risk of subsequent development of anal
cancer. However, current therapies for anal intraepithelial neoplasia may be
associated with treatment-related morbidity and are not well validated. It is
currently not proven that they reduce the likelihood of the development of anal
cancer. Nevertheless, screening for anal intraepithelial neoplasia is being
advocated for high-risk groups and may become standard dermatological care for
these patients. In view of recent developments in the understanding of this
condition, this article reviews the current understanding of anal intraepithelial
neoplasia and its treatment from a dermatological perspective. © 2007 The
Australasian College of Dermatologists.
AU:
AU:
AU:
CNOTE:
Herat A
Herat Asoka
Skin and Cancer Foundation, Darlinghurst, NSW, Australia; Department of
Dermatology, Clatterbridge Hospital, Bebington, Wirral CH63 4JY, United
Kingdom
[email protected]
Whitfeld M
Whitfeld Margot
Skin and Cancer Foundation, Darlinghurst, NSW, Australia
Hillman R
Hillman Richard
Sexually Transmitted Infections Research Centre, Westmead Hospital, Sydney,
NSW, Australia
2/50 von 102
ND:
Autoren:
EM2007331548
Fradet-Turcotte A; Archambault J
Titel:
Recent advances in the search for antiviral agents against human
papillomaviruses
Source:
Antiviral Therapy; VOL: 12 (4); p. 431-451 /2007/
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
1359-6535
CO:
ANTHF
Institution: Archambault J, Laboratory of Molecular Virology, Institut de Recherches Cliniques de
Montréal, Montreal, Que., Canada, [email protected]
COU:
Canada
DT:
JSC:
A.1 ... Pharmacology & Drug Therapy
RN:
0192
Keywords
CT:
CONDYLOMA/*drug therapy; CONDYLOMA/*etiology; CONDYLOMA/*surgery;
VERRUCA VULGARIS/*drug therapy; VERRUCA VULGARIS/*etiology; VERRUCA
VULGARIS/*surgery; ANUS CANCER/drug therapy; CANCER SURGERY;
CLINICAL TRIAL; DNA REPLICATION; DNA SYNTHESIS; DRUG MECHANISM;
DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG
TARGETING; ELECTROSURGERY; EPISOME; HEAD AND NECK CANCER/drug
therapy; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN
PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN
DN:
MN:
ET:
TE:
CR:
AB:
PAPILLOMAVIRUS TYPE 6; PRIORITY JOURNAL; REVIEW; SEXUALLY
TRANSMITTED DISEASE/drug therapy; SKIN DEFECT/drug therapy; STRUCTURE
ACTIVITY RELATION; TRANSCRIPTION REGULATION; UTERINE CERVIX
CANCER/drug therapy; VIRUS REPLICATION; WART VIRUS; ANTIVIRUS
AGENT/*drug development; ANTIVIRUS AGENT/*drug therapy; ANTIVIRUS
AGENT/*pharmacology; CYTOTOXIC AGENT/*drug therapy; CYTOTOXIC
AGENT/*topical drug administration; VIRUS VACCINE/*drug development; VIRUS
VACCINE/*drug therapy; VIRUS VACCINE/*pharmacology; WART VIRUS
VACCINE/*drug therapy; WART VIRUS VACCINE/*pharmacology;
ARTEMISININ/pharmacology; BENZODIAZEPINE DERIVATIVE/pharmacology;
BIPHENYLSULPHONACETIC ACID INHIBITOR/drug analysis;
BIPHENYLSULPHONACETIC ACID INHIBITOR/pharmacology;
CARRAGEENAN/drug analysis; CARRAGEENAN/pharmacology; CYCLIN
DEPENDENT KINASE 2 INHIBITOR/pharmacology; DEPSIPEPTIDE/drug analysis;
DEPSIPEPTIDE/pharmacology; GLYCOPROTEIN E1/drug development;
GLYCOPROTEIN E1/pharmacology; GLYCOPROTEIN E2/drug development;
GLYCOPROTEIN E2/pharmacology; HISTONE DEACETYLASE INHIBITOR/drug
analysis; HISTONE DEACETYLASE INHIBITOR/pharmacology; IMIQUIMOD/drug
therapy; IMIQUIMOD/topical drug administration; INDANDIONE INHIBITOR/drug
analysis; INDANDIONE INHIBITOR/drug development; INDANDIONE
INHIBITOR/pharmacology; N (2 AMINOPHENYL) 4 (3
PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE/drug analysis;
N (2 AMINOPHENYL) 4 (3
PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE/pharmacology;
POLYAMIDE/drug therapy; POLYAMIDE/pharmacology; POLYPHENON E/drug
therapy; POLYPHENON E/topical drug administration; PROTEIN E6/drug
development; PROTEIN E6/pharmacology; PROTEIN E7/drug development; PROTEIN
E7/pharmacology; ROSCOVITINE/drug analysis; ROSCOVITINE/pharmacology;
VALPROATE MAGNESIUM/clinical trial; VALPROATE MAGNESIUM/drug
therapy; VALPROATE MAGNESIUM/pharmacology; VALPROIC ACID/drug
analysis; VALPROIC ACID/pharmacology; VORINOSTAT/drug analysis;
VORINOSTAT/pharmacology
Cervarix/Glaxo SmithKline, United Kingdom; Gardasil/Merck, United States;
Polyphenon E
Glaxo SmithKline, United Kingdom; Merck, United States
Dermatology and Venereology; Cancer; Clinical and Experimental Pharmacology; Drug
Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and Virology
artemisinin/63968-64-9; carrageenan/9000-07-1; carrageenan/9049-05-2;
carrageenan/9061-82-9; carrageenan/9064-57-7; imiquimod/99011-02-6;
polyamide/63428-83-1; roscovitine/186692-46-6; valproate magnesium/62959-43-7;
valproic acid/1069-66-5; valproic acid/99-66-1; vorinostat/149647-78-9
63968-64-9; 9000-07-1; 9049-05-2; 9061-82-9; 9064-57-7; 99011-02-6; 63428-83-1;
186692-46-6; 62959-43-7; 1069-66-5; 99-66-1; 149647-78-9
Infection by human papillomavirus (HPV) is extremely common and associated with the
development of benign warts or malignant lesions of the skin and mucosa. Infection by a
high-risk (oncogenic) anogenital HPV type, most often through sexual contacts, is the
starting point of virtually all cases of cervical cancers and the majority of anal cancers.
The same viral types are also increasingly being linked with a subset of head-and-neck
and non-melanoma skin cancers. Although prophylactic vaccines are now available to
protect against the four types most commonly found in cervical and anal cancers
AU:
AU:
CNOTE:
(HPV16 and HPV18) and anogenital warts (HPV6 and HPV11), these neither protect
against all genital HPVs nor are of therapeutic utility for already infected patients. Thus,
the need for antiviral agents to treat HPV-associated diseases remains great, but none
currently exist. This article reviews the recent progress made towards the development of
antiviral agents to treat HPV infections, from target identification and validation to the
discovery of lead compounds with therapeutic potential. Emphasis has been placed on
novel low-molecular-weight compounds that antagonize HPV proteins or, alternatively,
inhibit cellular proteins which have been usurped by papillomaviruses and are mediating
their pathogenic effects. © 2007 International Medical Press.
Fradet-Turcotte A
Fradet-Turcotte Amélie
Laboratory of Molecular Virology, Institut de Recherches Cliniques de Montréal,
Montreal, Que., Canada
Archambault J
Archambault Jacques
Laboratory of Molecular Virology, Institut de Recherches Cliniques de Montréal,
Montreal, Que., Canada; Department of Biochemistry, University of Montreal, Montreal,
Que., Canada
[email protected]
2/51 von 102
ND:
Autoren:
EM2007321114
Palefsky JM
Titel:
HPV infection in men
Source:
Disease Markers; VOL: 23 (4); p. 261-272 /2007/
BTI:
HUMAN PAPILLOMAVIRUSES AND CERVICAL CANCER
SU:
EMBASE
Sprache: English
AL:
English
CY:
Netherlands
ISSN:
0278-0240
CO:
DMARD
Institution: Palefsky JM, Dr., Box 0126, Department of Medicine, University of California,
San Francisco, 505 Parnassus Ave, San Francisco, CA 94143, United
COU:
United States
DT:
JSC:
RN:
0078
Keywords
CT:
VIRUS INFECTION/*drug therapy; VIRUS INFECTION/*etiology; ANUS
CANCER/drug therapy; ANUS CANCER/radiotherapy; ANUS DISEASE;
ET:
TE:
CR:
AB:
AU:
CNOTE:
CANCER RADIOTHERAPY; CANCER SCREENING; CARCINOGENESIS;
CONDYLOMA/drug therapy; DISEASE ASSOCIATION; DISEASE COURSE;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY;
MALE GENITAL SYSTEM; MALE HOMOSEXUAL; MORTALITY;
NONHUMAN; PENIS DISEASE/drug therapy; PENIS DISEASE/etiology;
PRIORITY JOURNAL; REVIEW; RISK FACTOR; SAMPLING; SEX
DIFFERENCE; SEXUAL TRANSMISSION; SEXUALITY; UTERINE
CERVIX; UTERINE CERVIX CANCER; WART VIRUS; WOMEN'S
HEALTH; ANTIRETROVIRUS AGENT/drug therapy; FLUOROURACIL/drug
therapy; IMIQUIMOD/drug therapy; INTERFERON/drug therapy; LIQUID
NITROGEN/drug therapy; PODOPHYLLOTOXIN/drug therapy;
drug administration; WART VIRUS VACCINE/drug therapy
Cancer; Urology and Nephrology; Drug Literature Index; General Pathology and
Pathological Anatomy
fluorouracil/51-21-8; imiquimod/99011-02-6; podophyllotoxin/518-28-5;
51-21-8; 99011-02-6; 518-28-5; 14357-05-2; 76-03-9
While much is known about the natural history of cervical human papillomavirus
(HPV) infection and its consequences, including cervical intraepithelial neoplasia
and cervical cancer, relatively little is known about the natural history of
anogenital HPV infection and diseases in men. In part this reflects difficulties in
penile sampling and visual assessment of penile lesions. Anal HPV infection and
disease also remain poorly understood. Although HPV is transmitted sexually and
infects the genitals of both sexes, the cervix remains biologically more vulnerable
to malignant transformation than does the penis or anus in men. An understanding
of male HPV infection is therefore important in terms of reducing transmission of
HPV to women and improving women's health. However, it is also important due
to the burden of disease in men, who may develop both penile and anal cancer,
particularly among HIV-positive men who have sex with men. Improved sampling
techniques of the male genitalia and cohort studies in progress should provide
important information on the natural history of anogenital HPV infection and
disease in men, including risk factors for HPV acquisition and transmission. The
impact of HPV vaccination in women on male anogenital HPV infection will also
need to be assessed. © 2007 - IOS Press and the authors. All rights reserved.
Palefsky JM
Palefsky Joel M.
Box 0126, Department of Medicine, University of California, San Francisco, 505
Parnassus Ave, San Francisco, CA 94143, United States; Department of Medicine,
University of California, San Francisco, CA 94143, United States
[email protected]
2/52 von 102
ND:
EM2007160777
Autoren:
Serarslan G
Titel:
Imiquimoda bagli siddetli ülserasyon
Severe genital ulceration induced by imiquimod: Letter to the editor
Source:
Turkiye Klinikleri Journal of Medical Sciences; VOL: 27 (1); p. 146-148 /200702/
SU:
EMBASE
Sprache: Turkish
AL:
English; Turkish
CY:
Turkey
ISSN:
1300-0292
Institution: Serarslan G, Dr., Dermatoloji AD, Mustafa Kemal Üniversitesi Tip Fakültesi,
Hatay, [email protected]
DT:
Journal Article
RN:
0010
Keywords
CT:
CONDYLOMA/*drug therapy; GENITAL ULCER/*diagnosis; GENITAL
ULCER/*side effect; ADULT; ANTIVIRAL ACTIVITY; ANUS; ARTICLE;
BURNING SENSATION/side effect; CASE REPORT; CLINICAL FEATURE;
CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG ACTIVITY;
ERYTHEMA/side effect; HUMAN; LOCAL SKIN REACTION/side effect;
MALE; PERINEUM; PRURITUS/side effect; WART VIRUS;
IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*drug therapy;
IMIQUIMOD/*pharmacology; IMIQUIMOD/*topical drug administration;
ALPHA INTERFERON/endogenous compound
ET:
Dermatology and Venereology; Clinical and Experimental Pharmacology; Drug
Literature Index; Adverse Reactions Titles; Microbiology: Bacteriology,
Mycology, Parasitology and Virology
TE:
CR:
99011-02-6
AB:
Genital warts are benign, proliferative tumours, caused by human papilloma
viruses, occurring in the genital, anal, perineal and/or perianal areas. Imiquimod
shows antiviral activity by stimulating the production of interferon- alpha and
various other cytokines and it is used for the topical treatment of genital warts.
Although local skin reactions including erythema, itching and burning may occur
after application of imiquimod, ulceration is not a common adverse reaction.
Here, we present a 25-year-old man with severe ulceration occurring after
application of imiquimod for genital wart. Copyright © 2007 by Türkiye
Klinikleri.
AU:
Serarslan G
Serarslan Gamze
Dermatoloji AD, Mustafa Kemal Üniversitesi Tip Fakültesi, Hatay
[email protected]
2/53 von 102
ND:
Autoren:
EM2007085779
Bonatti H; Aigner F; De Clercq E; Boesmueller C; Widschwendner A; Larcher C;
Margreiter R; Schneeberger S
Titel:
Local administration of cidofovir for human papilloma virus
associated skin lesions in transplant recipients
Source:
Transplant International; VOL: 20 (3); p. 238-246 /200703/
DOI:
10.1111/j.1432-2277.2006.00430.x
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
0934-0874
EISSN:
1432-2277
CO:
TRINE
Institution: Bonatti H, Department of General and Transplant Surgery, Innsbruck Medical
University, Anichstrasse 35, A-6020 Innsbruck,
Austria, [email protected]
COU:
Austria
DT:
Journal Article
JSC:
D.4 ... Transplantation
RN:
0046
Keywords
CT:
SKIN INFECTION/*drug therapy; SKIN INFECTION/*etiology; SKIN
INFECTION/*surgery; VERRUCA VULGARIS/*drug therapy; VERRUCA
VULGARIS/*etiology; VERRUCA VULGARIS/*side effect; VERRUCA
VULGARIS/*surgery; WART VIRUS/*; ADULT; ANUS DISEASE/drug
therapy; ANUS DISEASE/etiology; ANUS DISEASE/surgery; ARTICLE;
CLINICAL ARTICLE; CONDYLOMA/drug therapy; CONDYLOMA/etiology;
CONDYLOMA/surgery; CRYOTHERAPY; CYTOMEGALOVIRUS
INFECTION/drug therapy; DISEASE ASSOCIATION; DRUG EFFICACY;
DRUG SUBSTITUTION; FEMALE; GRAFT RECIPIENT; GRAFT
REJECTION/complication; GRAFT REJECTION/drug therapy; GRAFT
REJECTION/prevention; HUMAN; IMMUNOSUPPRESSIVE TREATMENT;
KIDNEY TRANSPLANTATION; LASER SURGERY; MALE; PENIS
DISEASE/drug therapy; PENIS DISEASE/etiology; PRIORITY JOURNAL;
TREATMENT FAILURE; TREATMENT OUTCOME; CIDOFOVIR/*drug
therapy; CIDOFOVIR/*intralesional drug administration; CIDOFOVIR/*topical
drug administration; ALEMTUZUMAB/drug therapy;
ALEMTUZUMAB/intravenous drug administration; AMPHOTERICIN B LIPID
COMPLEX; BASILIXIMAB/drug therapy; CALCINEURIN
INHIBITOR/adverse drug reaction; CALCINEURIN INHIBITOR/drug therapy;
GANCICLOVIR/drug therapy; IMIQUIMOD/drug therapy; MYCOPHENOLIC
ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE/drug therapy;
RAPAMYCIN/drug therapy; STEROID/drug therapy; TACROLIMUS/adverse
drug reaction; TACROLIMUS/drug therapy; THYMOCYTE ANTIBODY/drug
therapy; VALGANCICLOVIR/drug therapy
DN:
Aldara
ET:
TE:
CR:
AB:
AU:
AU:
AU:
AU:
AU:
Drug Literature Index; Adverse Reactions Titles; Microbiology: Bacteriology,
Mycology, Parasitology and Virology; Surgery
alemtuzumab/216503-57-0; cidofovir/113852-37-2; ganciclovir/82410-32-0;
imiquimod/99011-02-6; mycophenolic acid 2 morpholinoethyl ester/116680-01-4;
mycophenolic acid 2 morpholinoethyl ester/128794-94-5; prednisone/53-03-2;
rapamycin/53123-88-9; tacrolimus/104987-11-3; valganciclovir/175865-59-5;
valganciclovir/175865-60-8; valganciclovir/175865-61-9; valganciclovir/17586562-0; valganciclovir/175865-64-2; valganciclovir/175865-67-5
216503-57-0; 113852-37-2; 82410-32-0; 99011-02-6; 116680-01-4; 128794-94-5;
53-03-2; 53123-88-9; 104987-11-3; 175865-59-5; 175865-60-8; 175865-61-9;
175865-62-0; 175865-64-2; 175865-67-5
Human papilloma virus (HPV)-associated diseases are increasingly diagnosed in
solid organ recipients. Cidofovir (CDV) is a broad-spectrum antiviral agent with
activity against all human herpes viruses and HPV. From 2000-2004, a total of
1303 solid organ transplants (SOT) were performed at our center. Six transplant
recipients were treated with topical CDV for HPV-associated lesions. One cardiac
recipient responded to a single injection of CDV into his recurrent anal
condylomata. In a renal recipient with recurrent penile condylomata CDV was
injected into the lesions four times (2 week interval) until lesions regressed. One
renal recipient developed multiple vaginal and anal intradermal neoplasias, which
relapsed after laser ablation. The lesions were repeatedly injected with CDV and
completely disappeared. Two renal recipients with widespread verrucae vulgares
were treated with CDV gel, which resulted in regression of the lesions. One
patient developed donor derived verrucae vulgares on both transplanted hands,
which responded to CDV gel. Four of the six patients were switched from
calcineurin inhibitors (CNIs) to Sirolimus (SIR). CDV was found effective in the
treatment of HPV-associated skin lesions in SOT recipients. It needs to be
determined whether switch from CNIs to SIR might have contributed to the
beneficial effect of CDV. © 2007 The Authors.
Bonatti H
Bonatti Hugo
Department of General and Transplant Surgery, Innsbruck, Austria; Department of
General and Transplant Surgery, Innsbruck Medical University, Anichstrasse 35,
A-6020 Innsbruck, Austria
[email protected]
Aigner F
Aigner Felix
Department of General and Transplant Surgery, Innsbruck, Austria
De Clercq E
De Clercq Eric
Rega Institute for Medical Research, K.U.Leuven, Leuven, Belgium
Boesmueller C
Boesmueller Claudia
Widschwendner A
Widschwendner Andreas
Department of Gynecology, Medical University, Innsbruck, Austria
AU:
AU:
AU:
CNOTE:
Larcher C
Larcher Clara
Department of Microbiology, Hygiene and Social Medicine, Medical University,
Innsbruck, Austria
Margreiter R
Margreiter Raimund
Schneeberger S
Schneeberger Stefan
2/54 von 102
ND:
Autoren:
EM2007010407
Parés D; Mullerat J; Pera M
Titel:
Neoplasia intraepitelial anal
Anal intraepithelial neoplasia
Source:
Medicina Clinica; VOL: 127 (19); p. 749-755 /20061118/
DOI:
10.1157/13095527
SU:
EMBASE
Sprache: Spanish
AL:
English; Spanish
CY:
Spain
ISSN:
0025-7753
CO:
MCLBA
Institution: Parés D, Dr., Unidad de Cirugía Colorrectal, Hospital del Mar, Pg. Marítim, 2529, 08003 Barcelona, Spain, [email protected]
COU:
Spain
DT:
JSC:
RN:
0058
Keywords
CT:
ANUS TUMOR/*diagnosis; ANUS TUMOR/*drug therapy; ANUS
TUMOR/*surgery; ANAMNESIS; CANCER SCREENING; CANCER
SURGERY; CONDYLOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC
PROCEDURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN
IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE
TREATMENT; INCIDENCE; MEDICAL EDUCATION; REVIEW; RISK
FACTOR; SQUAMOUS CELL CARCINOMA; TUMOR LOCALIZATION;
UTERINE CERVIX CANCER; IMIQUIMOD/drug therapy
ET:
Cancer; Drug Literature Index; Gastroenterology; General Pathology and
Pathological Anatomy; Surgery
TE:
CR:
AB:
AU:
AU:
AU:
CNOTE:
99011-02-6
Human papillomavirus (HPV) is responsible for anal condylomata, anal
intraepithelial neoplasia (AIN) and anal squamous cell carcinoma. AIN is a
premalignant condition that can progress to invasive carcinoma through different
grades of severity of the disease called AIN I, AIN II and AIN III. This paper
looks at the current definition, diagnostic methods and management of AIN. The
incidence of AIN has increased significantly in the last decades. The groups at risk
are mainly patients with infection with human immunodeficiency virus,
immunossuppressed patients and patients affected by HPV related diseases (e.g.,
cervical cancer or anal condyloma). Accurate diagnosis of AIN lesions consists of
accurate grading and disease extension. Low grade AIN (AIN I) or in extensive
lesions, follow-up is advised to determine the possible evolution to anal squamous
cell carcinoma. In cases of more severe and localized lesions (AIN II and AIN III),
surgical resection should be considered if the predictive postoperative morbidity is
low. Screening programs for AIN are not currently in place and there might be
much effort to study the management of HPV in these patients.
Parés D
Parés David
Unidad de Cirugía Colorrectal, Hospital del Mar, Barcelona, Spain; Unidad de
Cirugía Colorrectal, Hospital del Mar, Pg. Marítim, 25-29, 08003 Barcelona,
Spain
[email protected]
Mullerat J
Mullerat José
Department of Surgery, Royal Free and University College Medical School,
Londres, United Kingdom
Pera M
Pera Miguel
Unidad de Cirugía Colorrectal, Hospital del Mar, Barcelona, Spain
2/55 von 102
ND:
Autoren:
EM2006578475
Kreuter A; Wieland U; Potthoff A; Altmeyer P; Brockmeyer N
Titel:
HPV-assoziierte tumoren bei HIV-infektion
HPV-associated tumours in HIV-infection
Source:
SU:
Sprache:
AL:
CY:
ISSN:
Medizinische Welt; VOL: 57 (11); p. 498-502 /200611/
EMBASE
German
English; German
Germany
0025-8512
CO:
MEWEA
Institution: Kreuter A, Prof. Dr., Klinik für Dermatologie und Allergologie, Ruhr-Universität
Bochum, Gudrunstr. 56, 44791 Bochum, Germany, [email protected]
COU:
Germany
DT:
Journal Article
JSC:
RN:
0005
Keywords
CT:
ANUS INTRAEPITHELIAL NEOPLASIA/*diagnosis; ANUS
INTRAEPITHELIAL NEOPLASIA/*epidemiology; ANUS INTRAEPITHELIAL
NEOPLASIA/*etiology; ANUS TUMOR/*diagnosis; ANUS
TUMOR/*epidemiology; ANUS TUMOR/*etiology; HUMAN
IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; ARTICLE;
CLINICAL TRIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS
INFECTED PATIENT; INCIDENCE; PREVALENCE; RISK ASSESSMENT;
UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;
ANTIRETROVIRUS AGENT/drug therapy
ET:
Public Health, Social Medicine and Epidemiology; Immunology, Serology and
Transplantation; Drug Literature Index; Gastroenterology; General Pathology and
AB:
Human papillomavirus (HPV)-infection belong to the most common sexually
transmitted diseases worldwide. HIV-infected men having sex with men (MSM)
are strongly associated with a higher prevalence of genital HPV-infecfion, a
higher incidence of anal intraepithelial neoplasia (AIN), and consecutively an
increased risk for anal cancer. Since the introduction of HMRT, the incidence of
several viral-associated neoplasias has significantly fallen in HIV-infected
individuals. At the beginning of the era of HAART, a justified hope existed that
just as well genitoanal HPV-related neoplasias would decrease based on the
success of HAART-induced immune restoration. However, HAART seems to
have only little impact on the natural history of AIN as observed in a cohort of
HIV-positive MSM before and after the initiation of HAART. As AIN and cancer
precursor lesions of the cervix, cervical intraepithelial neoplasia, share distinct
clinical similarities, cytologic smear testing for AIN has been recommended to
early detect and treat lesions. In on ongoing trial of the German competence
network on HIV/Aids in Bochum, clinical, cytological, virological, and
histological features of AIN and anol carcinoma are investigated. In this
collective, 89% of all patients had anal HPV-infection and 21% had histologically
confirmed AIN. To date, controlled clinical trials for the treatment of AIN ore still
missing and the literature on this subject is limited. Therefore, a German multicenter trial is currently on the way comparing ablative (electrofulgary and
infrared-coagulation) and topical (imiquimod cream and suppositories) strategies
in the management of AIN. © 2006 Schattauer GmbH.
AU:
Kreuter A
Kreuter Alexander
Dermatologische Klinik, Ruhr-Universität Bochum, Bochum, Germany; Klinik
für Dermatologie und Allergologie, Ruhr-Universität Bochum, Gudrunstr. 56,
44791 Bochum, Germany
AU:
AU:
AU:
AU:
CNOTE:
[email protected]
Wieland U
Wieland U
Institut der Virologie des Klinikums, Universität Köln
Potthoff A
Potthoff A
Dermatologische Klinik, Ruhr-Universität Bochum, Bochum, Germany
Altmeyer P
Altmeyer P
Brockmeyer N
Brockmeyer N
2/56 von 102
ND:
Autoren:
EM2006574875
Wieland U; Brockmeyer NH; Weissenborn SJ; Hochdorfer B; Stücker M;
Swoboda J; Altmeyer P; Pfister H; Kreuter A
Titel:
Imiquimod treatment of anal intraepithelial neoplasia in HIVpositive men
Source:
Archives of Dermatology; VOL: 142 (11); p. 1438-1444 /2006/
http://archderm.ama-assn.org/cgi/reprint/142/11/1438
NCT:
DOI:
10.1001/archderm.142.11.1438
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
0003-987X
EISSN:
0003-987X
CO:
ARDEA
Institution: Kreuter A, Dr., Department of Dermatology and Allergology, Ruhr University
Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany, [email protected]
COU:
Germany
DT:
Journal Article
JSC:
RN:
0037
Keywords
CT:
ANUS TUMOR/*drug therapy; EPITHELIUM TUMOR/*drug therapy; ADULT;
AGED; ARTICLE; BURNING SENSATION/side effect; CLINICAL ARTICLE;
ET:
TE:
CR:
AB:
AU:
AU:
AU:
CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED
STUDY; CYTOLOGY; DRUG DOSAGE FORM; EROSION/side effect;
ERYTHEMA/side effect; FOLLOW UP; HUMAN; HUMAN
IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION/side effect;
MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEXUAL
BEHAVIOR; TREATMENT RESPONSE; VIRUS TYPING; WART VIRUS;
IMIQUIMOD/adverse drug reaction; IMIQUIMOD/drug therapy;
IMIQUIMOD/pharmaceutics
Pharmacy; Gastroenterology
99011-02-6
Objective: To evaluate the treatment of anal intraepithelial neoplasia (AIN) with
the local immune response modifier imiquimod in human immunodeficiency
virus (HIV)-positive men who have sex with men (MSM). Design: Prospective,
nonrandomized, open-label pilot study, with a mean follow-up time of 91/2
months. Setting: Dermatology department of a university hospital. Patients:
Twenty-eight consecutive HIV-positive MSM with histologically confirmed
perianal (n=23) or intraanal (n=5) AIN. Intervention: Overnight treatment with
self-applied imiquimod cream (perianal AIN) or suppositories (intraanal AIN) 3
times a week for 16 weeks. Main Outcome Measures: Response to treatment was
documented using clinical, cytologic, and histologic criteria. Human
papillomavirus (HPV) typing and HPVDNA load determination for the high-risk
HPV types 16, 18, 31, and 33 were performed. Results: Seventeen (61%) of all 28
patients included in the study and 17 (77%) of the 22 patients with AIN, who
applied imiquimod as instructed, showed clinical and histologic clearance at the
end of therapy. Four patients had residual AIN and 1 patient did not improve.
Clinical response was accompanied by a sharp decline in HPV DNA loads and by
a reduction in the number of HPV types, but long-term HPV clearance was rarely
achieved. In the follow-up period, AIN cleared in 3 patients with residual AIN.
Fourteen (78%) of 18 imiquimod responders with at least 5 five months of
follow-up had a normal cytologic and clinical picture at the end of the follow-up
period. Three primary responders developed a recurrence. In 6 noncompliant
patients, there was no clinical or morphological improvement and the HPVDNA
loads remained high. Conclusions: Imiquimod appears to be a safe and effective
treatment option for AIN in HIV-positive MSM. Clinical response is accompanied
by a significant decrease in high-risk HPV DNA load. These results should
encourage controlled randomized studies of imiquimod treatment of AIN. Trial
Registration: clinicaltrials.gov Identifier: NCT00365729 ©2006 American
Medical Association. All rights reserved.
Wieland U
Wieland Ulrike
Institute of Virology, University of Cologne, Cologne
Brockmeyer NH
Department of Dermatology and Allergology, Ruhr University Bochum, Bochum,
Germany
Weissenborn SJ
AU:
AU:
AU:
AU:
AU:
AU:
CNOTE:
Hochdorfer B
Hochdorfer Bettina
Germany
Stücker M
Stücker Markus
Germany
Swoboda J
Swoboda Jochen
Institute of Cytology, Godesberg, Germany
Altmeyer P
Altmeyer Peter
Germany
Pfister H
Pfister Herbert
Kreuter A
Kreuter Alexander
Germany; Department of Dermatology and Allergology, Ruhr University
Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany
[email protected]
2/57 von 102
ND:
Autoren:
EM2006278290
Lévy A; Lebbe C
Titel:
Prise en charge des tumeurs de Buschke-Löwenstein
Buschke-Löwenstein tumour: diagnosis and treatment
Source:
DOI:
SU:
Sprache:
AL:
CY:
ISSN:
EISSN:
Annales d'Urologie; VOL: 40 (3); p. 175-178 /200606/
10.1016/j.anuro.2006.02.002
EMBASE
French
French; English
France
0003-4401
1768-3378
CO:
AUROA
PII:
S000344010600026X
Institution: Lévy A, Service de dermatologie, hôpital Saint-Louis, 1, avenue ClaudeVellefaux, 75010 Paris, France, [email protected]
COU:
France
DT:
Short Survey; Journal Article
JSC:
D.5 ... Urological Surgery
RN:
0018
Keywords
CT:
BUSCHKE LOWENSTEIN TUMOR/*diagnosis; BUSCHKE LOWENSTEIN
TUMOR/*drug therapy; BUSCHKE LOWENSTEIN TUMOR/*radiotherapy;
BUSCHKE LOWENSTEIN TUMOR/*surgery; VERRUCOUS
CARCINOMA/*diagnosis; VERRUCOUS CARCINOMA/*drug therapy;
VERRUCOUS CARCINOMA/*radiotherapy; VERRUCOUS
CARCINOMA/*surgery; BASEMENT MEMBRANE; CANCER
CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE;
CANCER SURGERY; CONDYLOMA ACUMINATUM; CRYOTHERAPY;
FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN
IMMUNE DEFICIENCY; MALE; PHYSICAL EXAMINATION; SHORT
SURVEY; ALPHA INTERFERON/drug therapy; BLEOMYCIN/drug therapy;
CISPLATIN/drug therapy; FLUOROURACIL/drug therapy; IMIQUIMOD/drug
therapy; METHOTREXATE/drug therapy; PODOPHYLLIN/drug therapy
ET:
Radiology; Cancer; Urology and Nephrology; Drug Literature Index;
Microbiology: Bacteriology, Mycology, Parasitology and Virology
TE:
bleomycin/11056-06-7; cisplatin/15663-27-1; cisplatin/26035-31-4;
cisplatin/96081-74-2; fluorouracil/51-21-8; imiquimod/99011-02-6;
methotrexate/15475-56-6; methotrexate/59-05-2; methotrexate/7413-34-5;
podophyllin/9000-55-9
CR:
11056-06-7; 15663-27-1; 26035-31-4; 96081-74-2; 51-21-8; 99011-02-6; 1547556-6; 59-05-2; 7413-34-5; 9000-55-9
AB:
Buschke-Löwenstein tumour is classified as a verrucous carcinoma. It presents
like an exophytic tumour of the genital or peri-anal area, with ulceration and
sometimes fistulae and sinuses. It is preferentially seen in men and
immunocompromised patients. Histological appearance is not far from condyloma
acuminata, but with a tendency to compress and displace deeper tissues, without
basement membrane disruption. HPV types 6 or 11 are regularly found in
association with this tumour. Other STI have to be searched. Physical examination
and precise imagery are useful to chose the right treatment regimen. Radical
excision is recommended to avoid malignant transformation, but has to be large
because of the high number of recurrences. Other treatment modalities such as
chemotherapy or imiquimod could be of interest to avoid mutilating surgical
interventions. A regular follow-up is necessary because of frequent recurrences
and possible malignant transformation. © 2006 Elsevier SAS. All rights reserved.
AU:
Lévy A
Lévy A
Paris, France
AU:
CNOTE:
[email protected]
Lebbe C
Lebbe C
Paris, France
2/58 von 102
ND:
Autoren:
EM2006092078
Kreuter A; Brockmeyer NH; Weissenborn SJ; Wafaisade A; Pfister H; Altmeyer
P; Wieland U
Titel:
5% Imiquimod suppositories decrease the DNA load of intra-anal
HPV types 6 and 11 in HIV-infected men after surgical ablation of
condylomata acuminata [1]
Source:
http://archderm.ama-assn.org/cgi/reprint/142/2/243
DOI:
10.1001/archderm.142.2.243
SU:
EMBASE
Sprache: English
CY:
United States
ISSN:
0003-987X
EISSN:
0003-987X
CO:
ARDEA
Institution: Kreuter A, Dr., Department of Dermatology, Ruhr-University Bochum,
Gudrunstrasse 56, D-44791 Bochum, Germany, [email protected]
COU:
Germany
DT:
Letter; Journal Article
JSC:
RN:
0008
Keywords
CT:
CAUTERIZATION/*; CONDYLOMA ACUMINATUM/*drug therapy;
CONDYLOMA ACUMINATUM/*surgery; HUMAN IMMUNODEFICIENCY
VIRUS INFECTION/*drug therapy; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/*etiology; SUPPOSITORY/*; VIRUS INFECTION/*drug therapy;
VIRUS INFECTION/*etiology; ADULT; CLINICAL ARTICLE; CLINICAL
TRIAL; CYTOPATHOLOGY; EROSION/side effect; ERYTHEMA/side effect;
FLU LIKE SYNDROME/side effect; HUMAN; HUMAN CELL; HUMAN
IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPE 6;
LETTER; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE
CHAIN REACTION; RECTOSCOPY; IMIQUIMOD/*adverse drug reaction;
IMIQUIMOD/*clinical trial; IMIQUIMOD/*drug therapy;
IMIQUIMOD/*pharmaceutics; IMIQUIMOD/*pharmacology;
ANTIRETROVIRUS AGENT/adverse drug reaction; ANTIRETROVIRUS
ET:
TE:
CR:
AU:
AU:
AU:
AU:
AU:
AU:
AU:
CNOTE:
AGENT/clinical trial; ANTIRETROVIRUS AGENT/drug therapy;
ANTIRETROVIRUS AGENT/pharmaceutics; ANTIRETROVIRUS
AGENT/pharmacology
Pharmacy; Microbiology: Bacteriology, Mycology, Parasitology and Virology
99011-02-6
Kreuter A
Kreuter Alexander
Department of Dermatology, Ruhr-University Bochum, Gudrunstrasse 56, D44791 Bochum, Germany
[email protected]
Brockmeyer NH
Weissenborn SJ
Wafaisade A
Wafaisade Arasch
Pfister H
Pfister Herbert
Altmeyer P
Altmeyer Peter
Wieland U
Wieland Ulrike
2/59 von 102
ND:
Autoren:
EM2006044659
Fox PA; Tung M-Y
Titel:
Human papillomavirus: Burden of illness and treatment cost considerations
Source:
American Journal of Clinical Dermatology; VOL: 6 (6); p. 365-381 /2005/
http://docstore.ingenta.com/cgibin/ds_deliver/1/u/d/ISIS/25358057.1/adis/derm/2005/00000006/00000006/art00004/A6BF32885
10.2165/00128071-200506060-00004
EMBASE
English
English
New Zealand
1175-0561
1175-0561
AJCDC
DOI:
SU:
Sprache:
AL:
CY:
ISSN:
EISSN:
CO:
Institution: Fox PA, Dr., Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, United
COU:
United Kingdom
DT:
JSC:
RN:
0136
Keywords
CT:
VERRUCA VULGARIS/*disease management; VERRUCA VULGARIS/*drug therapy; VERRU
INFECTION/*disease management; VIRUS INFECTION/*drug therapy; VIRUS INFECTION/*
NEOPLASIA; ANUS; BONE MARROW DEPRESSION/side effect; BOWENOID PAPULOSIS
CONDYLOMA/disease management; CONDYLOMA/drug therapy; CONDYLOMA/etiology; C
DRUG FATALITY/side effect; EDEMA/side effect; ELECTROSURGERY; ERYTHEMA/side e
EXTRAGENITAL WART/etiology; EXTRAGENITAL WART/surgery; EXTRAGENITAL WA
HEMATURIA/side effect; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PA
effect; LASER SURGERY; LOCAL SKIN REACTION/side effect; LUNG FIBROSIS/side effec
PAIN/side effect; POSTOPERATIVE COMPLICATION/complication; PREGNANCY; PRIORI
DEPRESSION/side effect; REVIEW; SCAR FORMATION/side effect; SKIN EROSION/side eff
CIRCULATION; TOXICITY/side effect; UTERINE CERVIX CARCINOMA IN SITU/drug ther
CHLORO 2,4 DINITROBENZENE/adverse drug reaction; 1 CHLORO 2,4 DINITROBENZENE
INTERFERON/drug comparison; ALPHA INTERFERON/drug therapy; ALPHA INTERFERON
INTERFERON/adverse drug reaction; ALPHA2B INTERFERON/drug therapy; ALPHA2B INTE
BLEOMYCIN/intralesional drug administration; BLEOMYCIN/pharmacology; CIDOFOVIR/adv
therapy; DIPHENCYPRONE/drug therapy; FLUOROURACIL/adverse drug reaction; FLUOROU
FORMALDEHYDE/drug therapy; GLUTARALDEHYDE/drug therapy; IMIQUIMOD/adverse
IMIQUIMOD/pharmacoeconomics; IMIQUIMOD/pharmacology; IMIQUIMOD/topical drug
combination; PODOPHYLLIN/drug comparison; PODOPHYLLIN/drug therapy; PODOPHYLLI
PODOPHYLLOTOXIN/drug comparison; PODOPHYLLOTOXIN/drug therapy; PODOPHYLLO
PODOPHYLLOTOXIN/topical drug administration; SALICYLIC ACID/adverse drug reaction; S
SALICYLIC ACID/topical drug administration; TRICHLOROACETIC ACID/adverse drug react
TRICHLOROACETIC ACID/pharmacoeconomics; WART VIRUS VACCINE/drug developmen
ET:
Dermatology and Venereology; Health Policy, Economics and Management; Drug Literature Inde
TE:
1 chloro 2,4 dinitrobenzene/25567-67-3; 1 chloro 2,4 dinitrobenzene/97-00-7; alpha2b interferon/
diphencyprone/886-38-4; fluorouracil/51-21-8; formaldehyde/50-00-0; glutaraldehyde/111-30-8;
podophyllotoxin/518-28-5; salicylic acid/63-36-5; salicylic acid/69-72-7; trichloroacetic acid/143
CR:
25567-67-3; 97-00-7; 99210-65-8; 11056-06-7; 113852-37-2; 51481-61-9; 70059-30-2; 886-38-4
14357-05-2; 76-03-9
AB:
The monetary and personal costs to society of human papillomavirus (HPV) infection are enormo
treatment from January 1966 to December 2003 using MEDLINE, with particular reference to pub
possibility of convenient and, on the whole, pain-free treatment. Podofilox (podophyllotoxin) and
cost-effective treatments and, on this basis, they are to be commended as appropriate first-line age
possible options include inosine pranobex with cryotherapy or electrosurgery, imiquimod with pa
for genital warts would be either some form of surgical removal or imiquimod. The first option m
comparative studies do not show any clear difference in efficacy between cryotherapy, trichloroac
effectiveness of these therapies is probably similar to that of imiquimod. Cryotherapy and trichlo
with certain exceptions, such as cryotherapy for meatal warts. The duration of treatment is signific
been present. For recalcitrant anogenital warts third-line treatment options that show promise inclu
easily be excised or physically ablated current treatment options include imiquimod and fluoroura
added to this list if it becomes commercially available, and that protective and therapeutic HPV va
reserved.
AU:
Fox PA
AU:
CNOTE:
Fox Paul A.
Chelsea and Westminster Hospital, London, United Kingdom; Ealing Hospital, Southall, Middles
Kingdom
[email protected]
Tung M-Y
Tung Mun-Yee
Chelsea and Westminster Hospital, London, United Kingdom
2/60 von 102
ND:
Autoren:
EM2006010974
Fox PA
Titel:
Human papillomavirus and anal intraepithelial neoplasia
Source:
Current Opinion in Infectious Diseases; VOL: 19 (1); p. 62-66 /200602/
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
0951-7375
CO:
COIDE
Institution: Fox PA, Dr., Department of HIV and Genitourinary Medicine, Chelsea and
Westminster Hospital, 369 Fulham Road, London SW10 9NH, United
COU:
United Kingdom
DT:
JSC:
RN:
0035
Keywords
CT:
ANUS INTRAEPITHELIAL NEOPLASM/*diagnosis; ANUS
INTRAEPITHELIAL NEOPLASM/*drug therapy; ANUS INTRAEPITHELIAL
NEOPLASM/*therapy; ANUS TUMOR/*diagnosis; ANUS TUMOR/*drug
therapy; ANUS TUMOR/*therapy; VIRUS INFECTION/*; AGE
DISTRIBUTION; AGEISM; ANUS CARCINOMA; ANUS INTERCOURSE;
CD4 LYMPHOCYTE COUNT; CREAM; CYTOLOGY; DIFFERENTIAL
DIAGNOSIS; DRUG EFFICACY; HETEROSEXUALITY; HUMAN; HUMAN
IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS
INFECTED PATIENT; INFRARED RADIATION; LOW LEVEL LASER
THERAPY; REVIEW; SEX ROLE; SEXUALITY; SMEAR; TREATMENT
OUTCOME; UTERINE CERVIX CARCINOMA IN SITU/diagnosis; UTERINE
CERVIX CYTOLOGY; VIRUS LOAD; WART VIRUS; CD4 ANTIGEN;
CIDOFOVIR/drug therapy; CIDOFOVIR/topical drug administration;
ET:
TE:
CR:
AB:
AU:
CNOTE:
Cancer; Drug Literature Index; Microbiology: Bacteriology, Mycology,
Parasitology and Virology; Gastroenterology
cidofovir/113852-37-2; imiquimod/99011-02-6; trichloroacetic acid/14357-05-2;
trichloroacetic acid/76-03-9
113852-37-2; 99011-02-6; 14357-05-2; 76-03-9
Purpose of review: A review of recent developments in the understanding of the
natural history of anal squamous carcinoma arising from areas of high-grade anal
intraepithelial neoplasia. Recent findings: Anal intraepithelial neoplasia is a
consequence of chronic human papillomavirus infection in the anal canal and
appears to be driven by high viral loads of human papillomavirus. In men who
have sex with men with multiple sexual partners prevalent human papillomavirus
infection does not decline with age, in contrast to heterosexual patients. Anal
intraepithelial neoplasia is equally prevalent in different age groups of men who
have sex with men, but in other respects what is known of its natural history
resembles that of cervical intraepithelial neoplasia. Low-grade lesions frequently
resolve, but high-grade lesions are much more stable. HIV-positives who practise
receptive anal intercourse are at highest risk of anal intraepithelial neoplasia.
Screening is easy to perform using cytology; the limitations of anal cytology
being similar to those of cervical cytology. Patients with any grade of cytological
abnormality require further investigation, ideally with high-resolution anoscopy,
every 6 months. Successful treatments for individual small to medium-sized highgrade lesions include trichloroacetic acid, infra-red coagulation and laser. In HIVpositive patients the development of new lesions elsewhere is very likely. Topical
agents for multifocal disease include imiquimod and cidofovir. Summary: There
is a need for large prospective cohort studies in men who have sex with men and
HIV-positive patients to further our understanding of this disease and to evaluate
treatment strategies. © 2006 Lippincott Williams & Wilkins.
Fox PA
Fox Paul A.
Department of HIV and Genitourinary Medicine, Chelsea and Westminster
Hospital, London, United Kingdom; Department of HIV and Genitourinary
Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10
9NH, United Kingdom
[email protected]
2/61 von 102
ND:
Autoren:
EM2005403864
Küppers V; Hampl M
Titel:
Gynäkologisch-onkologische probleme bei HIV-positiven
patientinnen
Gynecologic-oncologic problems in HIV-seropositive women
Source:
DOI:
SU:
Gynakologe; VOL: 38 (8); p. 680-687 /200508/
10.1007/s00129-005-1722-0
EMBASE
Sprache: German
AL:
English; German
CY:
Germany
ISSN:
0017-5994
CO:
GYNKA
Institution: Hampl M, Dr., Frauenklinik, Heinrich-Heine-Universität, Moorenstraße 5, 40225
Düsseldorf, Germany, [email protected]
COU:
Germany
DT:
JSC:
RN:
0034
Keywords
CT:
CANCER SUSCEPTIBILITY/*; GYNECOLOGIC CANCER/*; HUMAN
IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; HUMAN
IMMUNODEFICIENCY VIRUS INFECTION/*etiology; HUMAN
IMMUNODEFICIENCY VIRUS INFECTION/*surgery; ANUS CANCER;
CANCER INVASION; CANCER PREVENTION; CANCER RISK; CARBON
DIOXIDE LASER; COLPOSCOPY; CONDYLOMA/drug therapy;
CONDYLOMA/etiology; CONDYLOMA/surgery; EARLY DIAGNOSIS;
ELECTROSURGERY; GENITAL HERPES/drug therapy; GENITAL
HERPES/etiology; GENITAL HERPES/surgery; HUMAN; INFECTION RATE;
LEUKOCYTE COUNT; MEDICAL EXAMINATION; PAPANICOLAOU
TEST; PRECANCER/etiology; REVIEW; RISK ASSESSMENT; SCREENING
TEST; VIRUS IDENTIFICATION; VULVA CARCINOMA; WART VIRUS;
CARBON DIOXIDE; CD4 ANTIGEN; IMIQUIMOD/drug therapy;
PODOPHYLLOTOXIN/drug therapy
ET:
Obstetrics and Gynecology; Cancer; Biophysics, Bioengineering and Medical
Instrumentation; Drug Literature Index; Microbiology: Bacteriology, Mycology,
TE:
carbon dioxide/124-38-9; carbon dioxide/58561-67-4; imiquimod/99011-02-6;
CR:
124-38-9; 58561-67-4; 99011-02-6; 518-28-5
AB:
Among HIV-seropositive women there is a high prevalence of gynecological
infectious diseases: genital condidosis, genital herpes and anogenital human
papillomavirus (HPV) infection, inducing premalignant and malignant lesions of
vulva, vagina and cervix. The gynecological examination should include
colposcopy, a Pap smear test, secondary HPV testing and determination of
CD4+ T-lymphocyte counts. Treatment of choice for women with
benign external warts is the local application of Condylox®, Wartec
® or Aldara® or CO<inf>2</inf>-lasertreatment. The treatment of
cervical intraepithelial neoplasia (CIN) by CO<inf>2</inf>- laservaporisation,
Loop Electrosurgical Excision Procedure (LEEP) or cold knife conisation is based
on the localization of the lesion. Prior to the treatment of CIN it is mandatory to
exclude multicentric intraepithelial neoplasia by colposcopy. HIV infected women
are on an increased risk to develop invasive cervical, vulvar and anal cancer.
Since these diseases may be more aggressive and less responsive to treatment, the
early detection and prevention of these tumors is most important. © Springer
Medizin Verlag 2005.
AU:
AU:
CNOTE:
Küppers V
Küppers V
Gynäkologische Schwerpunktpraxis Dysplasie, Düsseldorf, Germany
Hampl M
Hampl M
Frauenklinik, Universität Düsseldorf; Frauenklinik, Heinrich-Heine-Universität,
Moorenstraße 5, 40225 Düsseldorf, Germany
[email protected]
2/62 von 102
ND:
Autoren:
EM2005360985
Chang LK; Gottesman L; Breen EL; Bleday R
Titel:
Anal dysplasia: Controversies in management
Source:
Seminars in Colon and Rectal Surgery; VOL: 15 (4 SPEC. ISS.); p. 233-238
/200512/
DOI:
10.1053/j.scrs.2005.03.005
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
1043-1489
CO:
SCRSF
PII:
S1043148905000151
Institution: Bleday R, Dr., Department of Surgery, Brigham and Women's Hospital, 75
Francis Street, Boston, MA 02115, United States, [email protected]
COU:
United States
DT:
JSC:
C.1.8 ... Gastroenterology; D.1 ... General & Abdominal Surgery
RN:
0086
Keywords
CT:
ANAL DYSPLASIA/*drug therapy; ANUS DISEASE/*drug therapy;
DYSPLASIA/*drug therapy; ANUS CANCER; CANCER RISK; CANCER
SCREENING; CONDYLOMA/drug therapy; HUMAN; INCIDENCE;
PAPANICOLAOU TEST; REVIEW; RISK FACTOR; SAFETY; UTERINE
CERVIX CARCINOMA IN SITU/drug therapy; UTERINE CERVIX
DYSPLASIA; FLUOROURACIL/drug therapy; FLUOROURACIL/topical drug
administration; IMIQUIMOD/drug therapy; IMIQUIMOD/pharmacology;
ET:
TE:
fluorouracil/51-21-8; imiquimod/99011-02-6
CR:
51-21-8; 99011-02-6
AB:
AU:
AU:
AU:
AU:
CNOTE:
There are several controversies in the management of anal dysplasia due to
uncertainty of its natural history and of its relationship to anal cancer. Different
screening recommendations can be found in the literature; however, not all are of
proven benefit and safety. Here we review the recent incidence of anal cancer,
present the scope of the problem, and offer a safe and effective screening program
to manage anal dysplasia, which may potentially counter the rising incidence of
anal cancer. © 2004 Elsevier Inc. All rights reserved.
Gottesman L
Gottesman L
Chang LK
Chang LK
Breen EL
Breen EL
Bleday R
Bleday R
Department of Surgery, Brigham and Women's Hospital, 75 Francis Street,
Boston, MA 02115, United States
[email protected]
2/63 von 102
ND:
Autoren:
EM2005360983
Berry JM; Jay N; Palefsky JM; Welton ML
Titel:
State-of-the-art of high-resolution anoscopy as a tool to manage
patients at risk for anal cancer
Source:
Seminars in Colon and Rectal Surgery; VOL: 15 (4 SPEC. ISS.); p. 218-226
/200512/
DOI:
10.1053/j.scrs.2005.05.001
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
1043-1489
CO:
SCRSF
PII:
S1043148905000345
Institution: Berry JM, Dr., Dysplasia Clinic, University of California, San Francisco School of
Medicine, 1600 Divisadero Street, San Francisco, CA 94143, United
COU:
United States
DT:
Journal Article
JSC:
RN:
0032
Keywords
CT:
ANOSCOPY/*; ANUS CANCER/*diagnosis; ANUS CANCER/*therapy;
CANCER DIAGNOSIS/*; CANCER RISK/*; DIAGNOSTIC PROCEDURE/*;
RISK ASSESSMENT/*; ADULT; ARTICLE; CANCER PATIENT; CANCER
SCREENING; CARCINOMA IN SITU/therapy; CASE REPORT;
COLPOSCOPY; CONDYLOMA/drug therapy; DIGITAL RECTAL
EXAMINATION; DYSPLASIA; HIGH RISK POPULATION; HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION/drug therapy;
INCIDENCE; MALE; OPERATING ROOM; PRECANCER; SQUAMOUS
CELL CARCINOMA; TRAINING; UTERINE CERVIX CANCER; UTERINE
CERVIX CYTOLOGY; ACICLOVIR/drug therapy; ANTIRETROVIRUS
AGENT/drug therapy; IMIQUIMOD/drug therapy; NITROGEN/drug therapy;
PODOPHYLLIN/drug therapy; PODOPHYLLOTOXIN/drug therapy
DN:
Aldara; Condylox
ET:
Cancer; Drug Literature Index; Gastroenterology; Surgery
TE:
aciclovir/59277-89-3; imiquimod/99011-02-6; nitrogen/7727-37-9;
podophyllin/9000-55-9; podophyllotoxin/518-28-5
CR:
59277-89-3; 99011-02-6; 7727-37-9; 9000-55-9; 518-28-5
AB:
Anal cancer is increasing in incidence in urban populations worldwide and
particularly in HIV-positive men who have sex with men (MSM). The etiologic
relationship of both anal and cervical cancer to human papillomavirus (HPV) is
well established. The incidence of cervical cancer has decreased significantly as a
result of an effective screening program. Women with abnormal cervical cytology
are referred for colposcopy, which is used to identify and eradicate the cervical
cancer precursors, cervical high-grade squamous intraepithelial lesions (HSIL).
High-resolution anoscopy (HRA) or colposcopy of the anus and perianal area is a
powerful tool to find and treat the precursors to anal cancer, anal HSIL. The
approach to management and treatment of anal HSIL at the UCSF Anal Dysplasia
Clinic using HRA in conjunction with anal cytology and digital rectal
examination (DRE) is presented as a means to prevent anal cancer and to facilitate
the early diagnosis of anal cancer. Principles of HRA, how to perform HRA,
findings during HRA, and the use of HRA in the operating room are described.
HRA coupled with DRE is an effective way to manage patients at risk for anal
cancer. Several cases are described illustrating the practical application of HRA in
managing patients with anal HSIL and diagnosing anal cancer. Increased
awareness and, at the very least, performance of regular DRE in patients at risk
and training more providers in HRA may help to decrease the incidence of anal
cancer in populations at risk. © 2004 Elsevier Inc. All rights reserved.
Berry JM
AU:
Berry J. Michael
Department of Medicine, Division of Hematology Oncology, University of
California San Francisco, San Francisco, CA, United States; Dysplasia Clinic,
University of California, San Francisco School of Medicine, 1600 Divisadero
Street, San Francisco, CA 94143, United States
[email protected]
AU:
Jay N
Jay Naomi
Department of Medicine, Division of Infectious Diseases, University of California
AU:
AU:
CNOTE:
San Francisco, San Francisco, CA, United States
Palefsky JM
Palefsky Joel M.
Department of Medicine, Division of Infectious Diseases, University of California
San Francisco, San Francisco, CA
Welton ML
Welton Mark Lane
Department of Surgery, Stanford University, Stanford University School of
Medicine, Stanford, CA, United States
2/64 von 102
ND:
Autoren:
EM2005345598
De Góis Speck NM; Costa RRL; Kesselring F; De Freitas VG; Ribalta JCL;
Kobata MP; Taha NS
Titel:
Grade 3 vulvar and anal intraepithelial neoplasia in a HIV
seropositive child - Therapeutic result: Case report
Source:
Clinical and Experimental Obstetrics and Gynecology; VOL: 32 (2); p. 138-140
/2005/
SU:
EMBASE
Sprache: English
AL:
English
CY:
Canada
ISSN:
0390-6663
CO:
CEOGA
Institution: De Góis Speck NM, Dr., Rua Gabriele D'Annunzio, 1400, 04619-005 São Paulo,
SP, Brazil
COU:
Brazil
DT:
Journal Article
JSC:
RN:
0013
Keywords
CT:
ANUS TUMOR/*disease management; ANUS TUMOR/*drug therapy; ANUS
TUMOR/*therapy; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/*disease management; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/*drug therapy; VULVA TUMOR/*disease management; VULVA
TUMOR/*drug therapy; VULVA TUMOR/*therapy; ANAMNESIS; ARTICLE;
CANCER GRADING; CARBON DIOXIDE LASER; CASE REPORT;
FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW LEVEL
LASER THERAPY; LYMPHOCYTE COUNT; ONSET AGE; PHYSICAL
EXAMINATION; RELAPSE; SCHOOL CHILD; TREATMENT FAILURE;
VAPORIZATION; VERTICAL TRANSMISSION; IMIQUIMOD/*drug
therapy; IMIQUIMOD/*topical drug administration; ANTIRETROVIRUS
ET:
TE:
CR:
AB:
AU:
AU:
AU:
AU:
AU:
AU:
AGENT/drug combination; ANTIRETROVIRUS AGENT/drug therapy;
INDINAVIR/drug combination; INDINAVIR/drug therapy;
PODOPHYLLOTOXIN/drug combination; PODOPHYLLOTOXIN/drug therapy;
PODOPHYLLOTOXIN/topical drug administration; ZIDOVUDINE/drug
combination; ZIDOVUDINE/drug therapy
Obstetrics and Gynecology; Drug Literature Index; Microbiology: Bacteriology,
Mycology, Parasitology and Virology; Gastroenterology; General Pathology and
imiquimod/99011-02-6; indinavir/150378-17-9; indinavir/157810-81-6;
indinavir/180683-37-8; podophyllotoxin/518-28-5; zidovudine/30516-87-1
99011-02-6; 150378-17-9; 157810-81-6; 180683-37-8; 518-28-5; 30516-87-1
A case report of a HIV seropositive 8-year-old child with vulvar and anal border
neoplasia, both grade 3, and the adopted therapeutic management are presented.
The mother reported the history of a progressively growing verrucous lesion in the
vulva since the age of three and a half years. On physical examination a
pigmented and elevated lesion was observed in the whole vulvar region extending
to the anal region and intergluteal sulcus. After biopsies and anatomic
pathological examination, antiretroviral therapy, adequate for age, and topical
application of podophyllotoxin associated with Thuya officinalis extract was
started. Three months afterwards vaporization and CO<inf>2</inf> laser excision
were performed in five sequential sessions, thereafter associated with topical
imiquimod application. After the first two sessions of laser therapy early relapses
occurred. After four weeks of imiquimod use, already a significant improvement
of the lesions was observed, making the following laser therapy sessions easier.
We conclude that antiretroviral therapy associated with podophyllotoxin and
Thuya was not effective regarding regression of the lesions. Laser therapy alone
led to early relapses. The local use of imiquimod associated with laser was
effective in decreasing and controling the lesions.
De Góis Speck NM
De Góis Speck NM
Department of Gynecology, UNIFESP, Hospital AC Camargo, São Paulo, Brazil;
Rua Gabriele D'Annunzio, 1400, 04619-005 São Paulo, SP, Brazil
Costa RRL
Costa RRL
Department of Gynecology, UNIFESP, Hospital AC Camargo, São Paulo, Brazil
Kesselring F
Kesselring F
De Freitas VG
De Freitas VG
Ribalta JCL
Ribalta JCL
Kobata MP
Kobata MP
AU:
CNOTE:
Taha NS
Taha NS
2/65 von 102
ND:
Autoren:
EM2005343655
Kong AP; Stamos MJ
Titel:
Anorectal complaints: Office diagnosis and treatment, part 2
Source:
Consultant; VOL: 45 (7); p. 735-739 /200506/
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
0010-7069
CO:
CNSLA
Institution: Kong AP, Dr., University of California, Irvine, CA, United States
COU:
United States
DT:
JSC:
RN:
0003
Keywords
CT:
ANORECTAL DISEASE/*diagnosis; ANORECTAL DISEASE/*drug therapy;
ANORECTAL DISEASE/*etiology; ANORECTAL DISEASE/*surgery;
ABSCESS DRAINAGE; ANUS FISTULA/complication; ANUS
FISTULA/surgery; ANUS PRURITUS/diagnosis; ANUS PRURITUS/drug
therapy; ANUS PRURITUS/etiology; ANUS PRURITUS/therapy; ANUS
TUMOR/diagnosis; ANUS TUMOR/radiotherapy; ANUS TUMOR/surgery;
BLEEDING; CANCER RADIOTHERAPY; CAUTERIZATION; CLINICAL
FEATURE; COLOSTOMY; CONDYLOMA ACUMINATUM/drug therapy;
CONDYLOMA ACUMINATUM/etiology; CONDYLOMA
CONSTIPATION; CRYOTHERAPY; ESTHETIC SURGERY; FECES
INCONTINENCE; HUMAN; HYGIENE; LOW LEVEL LASER THERAPY;
PERIANAL ABSCESS/etiology; PILONIDAL SINUS; PRIORITY JOURNAL;
RECTUM ABDOMINOPERINEAL RESECTION; RECTUM BIOPSY;
RECTUM FISTULA/complication; RECTUM FISTULA/surgery; RECTUM
MUCOSA; RECTUM PROLAPSE/diagnosis; RECTUM PROLAPSE/etiology;
RECTUM PROLAPSE/surgery; REVIEW; SIGMOIDOSCOPY; SKIN BIOPSY;
VIRUS INFECTION; WART VIRUS; ANALGESIC AGENT/drug therapy;
ANALGESIC AGENT/topical drug administration; ANESTHETIC AGENT/drug
therapy; ANESTHETIC AGENT/topical drug administration; BULKING
AGENT/drug therapy; FLUOROURACIL/drug therapy;
ET:
TE:
CR:
AB:
AU:
AU:
CNOTE:
HYDROCORTISONE/drug therapy; HYDROCORTISONE/topical drug
administration; IMIQUIMOD/drug therapy; INTERFERON/drug therapy;
ISPAGULA/drug therapy; PODOPHYLLIN/drug therapy; STARCH;
TRICHLOROACETIC ACID/drug therapy; VACCINE/drug therapy
Cancer; Drug Literature Index; Gastroenterology; General Pathology and
Pathological Anatomy; Surgery
fluorouracil/51-21-8; hydrocortisone/50-23-7; imiquimod/99011-02-6;
ispagula/77462-61-4; ispagula/8063-16-9; podophyllin/9000-55-9; starch/900525-8; starch/9005-84-9; trichloroacetic acid/14357-05-2; trichloroacetic acid/7603-9
51-21-8; 50-23-7; 99011-02-6; 77462-61-4; 8063-16-9; 9000-55-9; 9005-25-8;
9005-84-9; 14357-05-2; 76-03-9
Symptoms associated with anorectal abscesses include throbbing or aching pain,
swelling, drainage or bleeding, constipation, urinary difficulty, and fever.
Treatment is surgical drainage. About 50% of anorectal abscesses fail to heal after
drainage and result in fistulae. Characteristic findings in pilonidal disease include
a painful, fluctuant mass near the posterior midline at the superior aspect of the
buttocks and a sinus opening within the intergluteal fold. Treatment consists of
drainage of the abscess followed by light daily packing. Patients with rectal
prolapse may present with a protruding mass, a history of constipation and
incontinence, bleeding, discharge, or a sensation of incomplete emptying. Pruritus
ani can be caused by a number of anorectal disorders; however, in about 50% of
cases, it is idiopathic. Anal neoplasms appear as unusual masses that arise from
the anal or rectal mucosa; biopsy is often needed for diagnosis.
Kong AP
Kong Allen P.
University of California, Irvine, CA, United States; University of California,
Irvine Medical Center, Irvine, CA, United States
Stamos MJ
Stamos Michael J.
University of California, Irvine, CA, United States; Department of Clinical
Surgery, University of California, Irvine Medical Center, Irvine, CA, United
States
2/66 von 102
ND:
Autoren:
EM2005339380
Panther LA; Schlecht HP; Dezube BJ
Titel:
Spectrum of human papillomavirus-related dysplasia and carcinoma
of the anus in HIV-infected patients
Source:
SU:
Sprache:
AL:
AIDS Reader; VOL: 15 (2); p. 79-82+85-88+91 /200502/
EMBASE
English
English
CY:
United States
ISSN:
1053-0894
CO:
AIREF
Institution: Panther LA, Dr., Department of Medicine, Harvard Medical School, Boston, MA,
United States
COU:
United States
DT:
JSC:
C.0 ... Clinical Medicine; E.5.3 ... Virology
RN:
0054
Keywords
CT:
ANUS CARCINOMA/*complication; ANUS CARCINOMA/*diagnosis; ANUS
CARCINOMA/*drug therapy; ANUS CARCINOMA/*etiology; ANUS
CARCINOMA/*prevention; ANUS CARCINOMA/*radiotherapy; ANUS
CARCINOMA/*surgery; ANUS DISEASE/*complication; ANUS
DISEASE/*diagnosis; ANUS DISEASE/*drug therapy; ANUS
DISEASE/*etiology; ANUS DISEASE/*prevention; ANUS DISEASE/*surgery;
ANUS DYSPLASIA/*complication; ANUS DYSPLASIA/*diagnosis; ANUS
DYSPLASIA/*drug therapy; ANUS DYSPLASIA/*etiology; ANUS
DYSPLASIA/*prevention; ANUS DYSPLASIA/*surgery;
DYSPLASIA/*complication; DYSPLASIA/*diagnosis; DYSPLASIA/*drug
therapy; DYSPLASIA/*etiology; DYSPLASIA/*prevention;
DYSPLASIA/*surgery; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/*drug therapy; WART VIRUS/*; BONE MARROW
SUPPRESSION/side effect; CANCER INVASION; CLINICAL TRIAL;
DIAGNOSTIC TEST; DIARRHEA/side effect; FEMALE; HIGHLY ACTIVE
ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY
VIRUS; HUMAN TISSUE; IMMUNE DEFICIENCY; INCIDENCE;
LYMPHOCYTE COUNT; MALE; NONHUMAN; PAPANICOLAOU TEST;
PATHOGENESIS; PRECANCER/diagnosis; REVIEW; SKIN TOXICITY/side
effect; SQUAMOUS CELL CARCINOMA/complication; SQUAMOUS CELL
CARCINOMA/diagnosis; SQUAMOUS CELL CARCINOMA/drug therapy;
CARCINOMA/prevention; SQUAMOUS CELL CARCINOMA/radiotherapy;
SQUAMOUS CELL CARCINOMA/surgery; UTERINE CERVIX CANCER;
ANTIRETROVIRUS AGENT/drug therapy; CD4 ANTIGEN/endogenous
compound; CIDOFOVIR/drug therapy; CISPLATIN/adverse drug reaction;
CISPLATIN/drug combination; CISPLATIN/drug therapy;
FLUOROURACIL/adverse drug reaction; FLUOROURACIL/drug combination;
FLUOROURACIL/drug therapy; HEAT SHOCK PROTEIN 65/clinical trial;
HEAT SHOCK PROTEIN 65/drug combination; HEAT SHOCK PROTEIN
65/drug therapy; HEAT SHOCK PROTEIN 65/subcutaneous drug administration;
IMIQUIMOD/drug therapy; INTERFERON/drug therapy;
MITOMYCIN/adverse drug reaction; MITOMYCIN/drug combination;
MITOMYCIN/drug therapy; PROTEIN E7/clinical trial; PROTEIN E7/drug
combination; PROTEIN E7/drug therapy; PROTEIN E7/subcutaneous drug
administration; VIRUS VACCINE/clinical trial; VIRUS VACCINE/drug
combination; VIRUS VACCINE/drug therapy; VIRUS VACCINE/subcutaneous
drug administration; ZIDOVUDINE/adverse drug reaction; ZIDOVUDINE/drug
therapy
ET:
TE:
CR:
AB:
AU:
AU:
AU:
CNOTE:
Cancer; Drug Literature Index; Adverse Reactions Titles; Microbiology:
Bacteriology, Mycology, Parasitology and Virology; Gastroenterology
cidofovir/113852-37-2; cisplatin/15663-27-1; cisplatin/26035-31-4;
cisplatin/96081-74-2; fluorouracil/51-21-8; imiquimod/99011-02-6;
mitomycin/1404-00-8; zidovudine/30516-87-1
113852-37-2; 15663-27-1; 26035-31-4; 96081-74-2; 51-21-8; 99011-02-6; 140400-8; 30516-87-1
The incidence of human papillomavirus (HPV)-related anal squamous cell
carcinoma is increasing. It is likely that long-standing HIV-related
immunosuppression plays a significant role in the pathogenesis of anal
carcinoma; however, a direct HIV-HPV interaction has also been implicated.
Using cervical cancer prevention as a paradigm, anal Pap smear screening as part
of routine HIV preventive care has been proposed to detect and treat precancerous
anal lesions in the hope of decreasing anal cancer rates. All HIV-positive patients
with invasive cancer of the anal canal, particularly those with CD4+
cell counts greater than 200/ mu L and those receiving HAART, should be
managed in the same manner as their HIV-negative counterparts.
Panther LA
Panther Lori A.
Department of Medicine, Harvard Medical School, Boston, MA, United States
Schlecht HP
Schlecht Hans P.
Department of Internal Medicine, Division of Infectious Diseases, Harvard
Medical School, Boston, MA, United States
Dezube BJ
Dezube Bruce J.
Department of Internal Medicine, Division of Hematology/oncology, Harvard
Medical School, Boston, MA, United States; AIDS Malignancy Research and
Treatment Center, Beth Israel Deaconess Medical Center, Boston, MA, United
States
2/67 von 102
ND:
Autoren:
EM2005221876
Chin-Hong PV; Palefsky JM
Titel:
Human papillomavirus anogenital disease in HIV-infected
individuals
Source:
DOI:
SU:
Sprache:
AL:
CY:
Dermatologic Therapy; VOL: 18 (1); p. 67-76 /200501/
10.1111/j.1529-8019.2005.05009.x
EMBASE
English
English
United States
ISSN:
1396-0296
CO:
DETHF
Institution: Chin-Hong PV, Dr., Box 0654, University of California, San Francisco, 521
Parnassus Ave, San Francisco, CA 94143-0654, United
COU:
United States
DT:
RN:
0046
Keywords
CT:
ANUS DISEASE/*diagnosis; ANUS DISEASE/*drug therapy; ANUS
DISEASE/*etiology; ANUS DISEASE/*prevention; ANUS DISEASE/*surgery;
GENITAL SYSTEM DISEASE/*diagnosis; GENITAL SYSTEM
DISEASE/*drug therapy; GENITAL SYSTEM DISEASE/*etiology; GENITAL
SYSTEM DISEASE/*prevention; GENITAL SYSTEM DISEASE/*surgery;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*; ANUS
CANCER/epidemiology; CANCER SCREENING; COLPOSCOPY;
CONDYLOMA ACUMINATUM/drug therapy; DISEASE ASSOCIATION;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN;
IMMUNOSUPPRESSIVE TREATMENT; PAPANICOLAOU TEST;
PHYSICAL EXAMINATION; PREVALENCE; REVIEW; SKIN DISEASE;
UTERINE CERVIX CANCER/epidemiology; UTERINE CERVIX
CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS; 5
FLUOROTRYPTAMINE/drug therapy; ANTIRETROVIRUS AGENT/drug
therapy; CIDOFOVIR/drug therapy; IMIQUIMOD/drug therapy;
PODOPHYLLOTOXIN/drug therapy; TRICHLOROACETIC ACID/drug
therapy; VIRUS VACCINE/drug therapy
DN:
Aldara/3M, United States; Condylox/Watsons Pharmaceutical, United States
MN:
3M, United States; Watsons Pharmaceutical, United States
ET:
Obstetrics and Gynecology; Dermatology and Venereology; Urology and
Nephrology; Drug Literature Index; Microbiology: Bacteriology, Mycology,
TE:
5 fluorotryptamine/576-16-9; cidofovir/113852-37-2; imiquimod/99011-02-6;
acid/76-03-9
CR:
576-16-9; 113852-37-2; 99011-02-6; 518-28-5; 14357-05-2; 76-03-9
AB:
Human papillomavirus (HPV) is one of the most common sexually transmitted
infections and a significant cause of anogenital malignancies, precancer lesions,
and cutaneous disease. Human immunodeficiency virus (HIV)-positive
individuals have a higher prevalence of HPV infection and HPV-associated
anogenital disease compared to age-matched HIV-negative controls. Data suggest
that there has been little reduction in HPV-associated disease since the
introduction of highly active antiretroviral therapy (HAART). The authors believe
that cervical and anal cancer screening using Pap tests should be offered to all
HIV-positive individuals, but the infrastructure to identify (via colposcopy and
high-resolution anoscopy) and treat precancer lesions must be present. Treatment
of HPV-associated anogenital disease depends on the size, location, and grade of
the lesion, whereas a variety of ablative and excisional therapies are available.
Prophylactic and therapeutic HPV vaccines are promising as future interventions
AU:
AU:
CNOTE:
for disease control in at-risk populations such as HIV-infected women and men.
Copyright © Blackwell Publishing, Inc., 2005.
Chin-Hong PV
Chin-Hong Peter V.
Department of Medicine, University of California, San Francisco, CA, United
States; Box 0654, University of California, San Francisco, 521 Parnassus Ave,
San Francisco, CA 94143-0654, United States
[email protected]
Palefsky JM
Palefsky Joel M.
Department of Medicine, University of California, San Francisco, CA, United
States
2/68 von 102
ND:
Autoren:
EM2005158522
Weyandt GH; Benoit S; Becker JC; Bröcker E-B; Hamm H
Titel:
Kontrollierte schichtweise abtragung anogenitaler warzen mittels
argon-plasma-koagulation
Controlled layered removal of anogenital warts by argon-plasma
coagulation
Source:
/200504/
DOI:
10.1111/j.1610-0387.2005.04757.x
SU:
EMBASE
Sprache: German
AL:
English; German
CY:
United Kingdom
ISSN:
1610-0379
CO:
JJDDA
Institution: Weyandt GH, Dr., Klin./Poliklin. Haut-/G., Universität Würzburg, JosefSchneider-Str. 2, D-97080 Würzburg, Germany, [email protected]
COU:
Germany
DT:
Journal Article
JSC:
RN:
0016
Keywords
CT:
ARGON PLASMA COAGULATION/*; CONDYLOMA/*drug therapy;
CONDYLOMA/*therapy; ADULT; ARTICLE; COMBINATION
CHEMOTHERAPY; CREAM; DIATHERMY; FEMALE; HUMAN; MAJOR
CLINICAL STUDY; MALE; POSTOPERATIVE CARE; RECURRENT
ET:
TE:
CR:
AB:
AU:
AU:
AU:
AU:
AU:
CNOTE:
DISEASE; RISK FACTOR; TISSUE INJURY; TREATMENT OUTCOME;
IMIQUIMOD/drug therapy; IMIQUIMOD/pharmacology;
99011-02-6
Background: According to guidelines of the German STD Association,
appropriate treatment of extensive anogenital warts with comparable recurrence
rates includes cryotherapy, surgical excision, electrosurgery, CO<inf>2</inf>- and
Nd:YAG-laser vaporisation. All these procedures are associated with varying
degrees of risk for bleeding, release of potentially infectious aerosol, deep thermal
destruction, slow wound healing, and scarring. Methods: Using argon-plasma
coagulation anogenital warts can be removed in layers in a controlled manner.
High frequency current flows through the argon plasma to the tissue, allowing
well-controlled, superficial tissue destruction. Results: From January 2001 to
March 2003, 54 patients with extensive genital, anal or anogenital warts were
treated. After one treatment, 66% of the patients remained disease-free in the
following 4 months. Thirteen patients (24%) showed early recurrence after 4
weeks, five patients (9%) at a later date. In these patients, further treatment, in 9
cases combined with topical imiquimod cream, were necessary for complete
remission. Conclusion: Compared to other therapeutic procedures, argon-plasma
coagulation is a better controlled, quick and low-risk option for the treatment of
anogenital warts. Depending on the type of involvement and individual risk
factors, postoperative treatment with topical imiquimod cream may be useful.
Weyandt GH
Weyandt Gerhard H.
Klin./Poliklin. Haut-/G., Universität Würzburg, Würzburg, Germany;
Klin./Poliklin. Haut-/G., Universität Würzburg, Josef-Schneider-Str. 2, D-97080
Würzburg, Germany
[email protected]
Benoit S
Benoit Sandrine
Klin./Poliklin. Haut-/G., Universität Würzburg, Würzburg, Germany
Becker JC
Becker Jürgen C.
Bröcker E-B
Bröcker Eva-Bettina
Hamm H
Hamm Henning
2/69 von 102
ND:
Autoren:
EM2005147227
Abbasakoor F; Boulos PB
Titel:
Anal intraepithelial neoplasia
Source:
British Journal of Surgery; VOL: 92 (3); p. 277-290 /200503/
DOI:
10.1002/bjs.4967
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
0007-1323
CO:
BJSUA
Institution: Boulos PB, Prof., Colorectal Surgery Unit, Charles Bell House, 67-73 Riding
House Street, London W1W 7EJ, United Kingdom, [email protected]
COU:
United Kingdom
DT:
JSC:
RN:
0131
Keywords
CT:
NEOPLASIA/*epidemiology; ANAL INTRAEPITHELIAL
NEOPLASIA/*surgery; ANAL INTRAEPITHELIAL NEOPLASIA/*therapy;
ANUS TUMOR/*diagnosis; ANUS TUMOR/*drug therapy; ANUS
TUMOR/*epidemiology; ANUS TUMOR/*surgery; ANUS TUMOR/*therapy;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*etiology; ANUS
CANCER; ARGON LASER; BLISTER/side effect; CANCER GROWTH;
CANCER INCIDENCE; CANCER INVASION; CANCER RECURRENCE;
CANCER RISK; CANCER SURGERY; CLINICAL FEATURE; CLINICAL
TRIAL; COLONOSCOPY; CRYOTHERAPY; CYTOLOGY; DISEASE
ASSOCIATION; DISEASE COURSE; ERYTHEMA/side effect; FOLLOW UP;
HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY
VIRUS; IMMUNE DEFICIENCY; INFECTION/drug therapy; INFECTION/side
effect; LOW LEVEL LASER THERAPY; MEDLINE; PHOTODYNAMIC
THERAPY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN
IRRITATION/side effect; SQUAMOUS CELL CARCINOMA; VACCINATION;
VIRUS INFECTION/drug therapy; VIRUS INFECTION/etiology; VIRUS
INFECTION/prevention; WART VIRUS; FLUOROURACIL/*adverse drug
reaction; FLUOROURACIL/*drug combination; FLUOROURACIL/*drug
therapy; FLUOROURACIL/*topical drug administration;
IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*drug combination;
IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug administration;
PHOTOFRIN/*adverse drug reaction; PHOTOFRIN/*drug therapy;
PHOTOFRIN/*intravenous drug administration; PHOTOSENSITIZING
AGENT/*adverse drug reaction; PHOTOSENSITIZING AGENT/*drug therapy;
PHOTOSENSITIZING AGENT/*intravenous drug administration; VIRUS
DN:
ET:
TE:
CR:
AB:
AU:
AU:
CNOTE:
VACCINE/*clinical trial; VIRUS VACCINE/*drug therapy; VIRUS
VACCINE/*intramuscular drug administration; ZYC 101/*clinical trial; ZYC
101/*drug therapy; ZYC 101/*intramuscular drug administration;
AMINOLEVULINIC ACID/adverse drug reaction; AMINOLEVULINIC
ACID/drug therapy; ANTIBIOTIC AGENT/drug therapy; ANTIRETROVIRUS
AGENT/drug therapy; INDIGO CARMINE; PROTOPORPHYRIN;
UNCLASSIFIED DRUG
Zyc 101
Cancer; Public Health, Social Medicine and Epidemiology; Drug Literature Index;
Adverse Reactions Titles; Surgery
aminolevulinic acid/106-60-5; fluorouracil/51-21-8; imiquimod/99011-02-6;
indigo carmine/860-22-0; photofrin/85189-42-0; protoporphyrin/553-12-8
106-60-5; 51-21-8; 99011-02-6; 860-22-0; 85189-42-0; 553-12-8
Background: Anal intraepithelial neoplasia (AIN) is believed to be a precursor of
anal squamous cell cancer and its incidence is rising in high-risk groups,
particularly those infected with the human immunodeficiency virus (HIV). The
natural history of AIN is unclear and management strategies are lacking. Methods:
This review is based on a literature search (Medline and PubMed) with manual
cross-referencing of all articles related to AIN. Results and conclusions: The
aetiology of AIN is intricately linked with human papilloma viruses. The
pathological processes involved in the progression of AIN are becoming clearer
but the natural history, particularly the rate of progression to invasive cancer,
remains unknown. There is no standard management for AIN and this is mainly
due to difficulties in both diagnosis and treatment. A variety of treatment options
have been tried with varying success. Surgery is associated with significant
recurrence, particularly in HIV-positive patients. Non surgical approaches with
imiquimod, photodynamic therapy and vaccination are appealing, and further
work is required. Long-term follow-up of these patients is essential until the
natural history of AIN becomes clearer. Copyright © 2005 British Journal of
Surgery Society Ltd.
Abbasakoor F
Abbasakoor F
Department of Surgery, Roy. Free and Univ. Coll. Med. Sch., London, United
Kingdom
Boulos PB
Boulos PB
Department of Surgery, Roy. Free and Univ. Coll. Med. Sch., London, United
Kingdom; Colorectal Surgery Unit, Charles Bell House, 67-73 Riding House
Street, London W1W 7EJ, United Kingdom
[email protected]
2/70 von 102
ND:
Autoren:
EM2005140502
Leiman G
Titel:
Source:
Anal screening cytology
CytoJournal; VOL: 2 /20050216/
http://www.cytojournal.com/content/2/1/5
ANR:
5
DOI:
10.1186/1742-6413-2-5
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
1742-6413
EISSN:
1742-6413
Institution: Leiman G, University of Vermont, 111 Colchester Avenue, Burlington, VT
05446, United States, [email protected]
COU:
United States
DT:
JSC:
C.1.3.1 ... Clinical Oncology; C.11.2 ... Pathological Anatomy
RN:
0015
Keywords
CT:
ANUS/*; CYTOLOGY/*; SCREENING TEST/*; ACQUIRED IMMUNE
DEFICIENCY SYNDROME/drug therapy; ACQUIRED IMMUNE
DEFICIENCY SYNDROME/etiology; ANUS DISEASE/drug therapy; ANUS
DISEASE/etiology; ANUS DISEASE/surgery; ANUS DISEASE/therapy; ANUS
SURGERY; ANUS TUMOR/surgery; CANCER INCIDENCE; CANCER RISK;
CANCER SCREENING; CAUTERIZATION; CELL STRUCTURE;
COLPOSCOPY; CYTOPATHOLOGY; DISEASE CLASSIFICATION;
DISEASE COURSE; EPIDEMIC; EPIDEMIOLOGICAL DATA; EPITHELIUM
TUMOR/surgery; FATALITY; FOLLOW UP; HIGH RISK PATIENT; HIGHLY
ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY
VIRUS INFECTION/drug therapy; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/etiology; LOW LEVEL LASER THERAPY; MORBIDITY;
MORPHOLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW;
SAMPLE; STRUCTURE ANALYSIS; SURGICAL TECHNIQUE; UTERINE
CERVIX CANCER; WART VIRUS; ANTIRETROVIRUS AGENT/drug
therapy; IMIQUIMOD/drug therapy; INTERFERON/drug therapy;
PODOPHYLLOTOXIN/drug therapy
ET:
Drug Literature Index; Gastroenterology; General Pathology and Pathological
Anatomy
TE:
CR:
99011-02-6; 518-28-5
AB:
This issue of CytoJournal contains an article on screening for anal intraepithelial
neoplasia in high-risk male patients. This accompanying Editorial focuses on
current understanding of this relatively new disease entity, with insights as to the
potential role of screening cytopathology in the epidemiology, pathophysiology
and clinical management of this HIV and HPV related anal lesion, which
predominates in male patients living long-term with AIDS. Mention is made of
techniques of obtaining samples, methods of preparation, and morphologic
AU:
CNOTE:
classification. Issues of anoscopic confirmation, as well as topical and surgical
management are emphasized. The similarity of initial experiences in anal
screening to problems encountered early in cervical cancer screening programs
several decades ago, are highlighted. © 2005 Leiman; licensee BioMed Central
Ltd.
Leiman G
Leiman Gladwyn
University of Vermont, 111 Colchester Avenue, Burlington, VT 05446, United
States
[email protected]
2/71 von 102
ND:
Autoren:
EM2005112577
Lacey CJN
Titel:
Therapy for genital human papillomavirus-related disease
Source:
Journal of Clinical Virology; VOL: 32 (SUPPL.); p. S82-S90 /200503/
BTI:
Human Papillomaviruses
DOI:
10.1016/j.jcv.2004.10.020
SU:
EMBASE
Sprache: English
AL:
English
CY:
Netherlands
ISSN:
1386-6532
CO:
JCVIF
Institution: Lacey CJN, Hull York Medical School, University of York, Heslington, York
YO10 5DD, United Kingdom, [email protected]
COU:
United Kingdom
DT:
JSC:
E.5.3 ... Virology
RN:
0071
Keywords
CT:
CONDYLOMA/*drug therapy; CONDYLOMA/*etiology;
CONDYLOMA/*surgery; CONDYLOMA/*therapy; ANUS CANCER/drug
therapy; CANCER RISK; CLINICAL TRIAL; CONTACT ALLERGY; COST
EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DRUG SAFETY;
EDEMA/side effect; ELECTROSURGERY; EXCISION; HUMAN; INFECTION
RISK; INFLAMMATION/side effect; LARYNX PAPILLOMATOSIS/drug
therapy; LOW LEVEL LASER THERAPY; NEOPLASM; NONHUMAN;
PATHOPHYSIOLOGY; PENIS; PENIS CANCER/drug therapy;
PHOTODYNAMIC THERAPY; PREGNANCY; PRIORITY JOURNAL;
PSYCHOLOGICAL ASPECT; REVIEW; SCALPEL; SIDE EFFECT/side effect;
ULCER/side effect; UTERINE CERVIX CARCINOMA IN SITU/drug therapy;
MN:
ET:
TE:
CR:
AB:
AU:
CNOTE:
VAGINA CANCER/drug therapy; VULVA; VULVA CANCER/drug therapy;
WART VIRUS; 3 INDOLEMETHANOL/drug therapy; ANTIRETROVIRUS
AGENT/drug therapy; CIDOFOVIR/clinical trial; CIDOFOVIR/drug therapy;
CIDOFOVIR/intravenous drug administration;
CIDOFOVIR/pharmacoeconomics; CIDOFOVIR/pharmacology; DNA
VACCINE/clinical trial; DNA VACCINE/drug therapy; FLUOROURACIL/drug
therapy; FLUOROURACIL/pharmacology; IMIQUIMOD/adverse drug reaction;
IMIQUIMOD/drug therapy; INTERFERON/drug therapy;
PODOPHYLLIN/adverse drug reaction; PODOPHYLLIN/clinical trial;
PODOPHYLLIN/drug therapy; PODOPHYLLIN/drug toxicity;
PODOPHYLLIN/pharmacoeconomics; PODOPHYLLIN/pharmacology;
PODOPHYLLIN/topical drug administration; PODOPHYLLOTOXIN/clinical
trial; PODOPHYLLOTOXIN/drug therapy; PODOPHYLLOTOXIN/topical drug
administration; TRICHLOROACETIC ACID
Glaxo SmithKline
Health Policy, Economics and Management; Drug Literature Index; Adverse
Reactions Titles; Microbiology: Bacteriology, Mycology, Parasitology and
Virology; General Pathology and Pathological Anatomy
3 indolemethanol/700-06-1; cidofovir/113852-37-2; fluorouracil/51-21-8;
imiquimod/99011-02-6; podophyllin/9000-55-9; podophyllotoxin/518-28-5;
700-06-1; 113852-37-2; 51-21-8; 99011-02-6; 9000-55-9; 518-28-5; 14357-05-2;
76-03-9
Genital human papillomavirus (HPV) infection is very common, and often subclinical and usually resolves without any treatment. Genital warts are caused by
HPV 6/11 infection and are one of the commonest clinically recognised disease
manifestations of genital HPV. Subjects with genital warts usually perceive them
as cosmetically disfiguring, often leading to adverse psychological symptoms, and
most subjects with genital warts will present requesting treatment. A wide variety
of treatments are available including both provider- and patient-applied therapies.
Various individual subject and disease factors mediate appropriate therapy choice.
Some of the treatments that are used for genital warts can also be used for some
cases of intraepithelial neoplasia caused by high-oncogenic risk HPVs occurring at
vulval, anal or penile sites. Specific treatment considerations apply to genital
warts in pregnancy and laryngeal papillomatosis and these are also discussed. ©
2004 Elsevier B.V. All rights reserved.
Lacey CJN
Lacey Charles J.N.
Hull York Medical School, University of York, Heslington, York YO10 5DD,
United Kingdom
[email protected]
2/72 von 102
ND:
PMID:
EMM19281719
19281719
Autoren:
Krishna S
Titel:
Comparison of podophyllotoxin and imiquimod as anal condyloma
acuminata therapy.
Source:
Dermatology online journal; VOL: 15 (1); p. 14 /2009/
SU:
Medline
Sprache: English
AL:
English
CY:
United States
EISSN:
1087-2108
Institution: Krishna S,
DT:
Note; Journal Article
JSC:
Keywords
CT:
ANUS DISEASE/*drug therapy; CONDYLOMA ACUMINATUM/*drug
therapy; COMPARATIVE STUDY; HUMAN; NOTE; AMINOQUINOLINE
DERIVATIVE/*drug therapy; PODOPHYLLOTOXIN/*drug therapy;
IMIQUIMOD
TE:
CR:
518-28-5
AB:
imiquimod and podophyllotoxin for anal condyloma acuminata.
AU:
Krishna S
Krishna Sreedhar
CNOTE: MEDLINE® is the source for the citation and abstract of this record.
2/73 von 102
ND:
PMID:
Autoren:
EMM19265621
19265621
Dianzani C; Pierangeli A; Avola A; Borzomati D; Persichetti P; Degener AM
Titel:
Intra-anal condyloma: surgical or topical treatment?
Source:
Dermatology online journal; VOL: 14 (12); p. 8 /2008/
SU:
Medline
Sprache: English
AL:
English
CY:
United States
EISSN:
1087-2108
Institution: Dianzani C, Department of Dermatology, "Campus Biomedico," University of
Rome, Italy., [email protected]
DT:
Journal Article
JSC:
Keywords
CT:
TE:
CR:
AB:
AU:
AU:
AU:
AU:
AU:
AU:
CNOTE:
ANUS DISEASE/*drug therapy; ANUS DISEASE/*surgery; CONDYLOMA
ACUMINATUM/*drug therapy; CONDYLOMA ACUMINATUM/*surgery;
LOW LEVEL LASER THERAPY/*; SKIN DISEASE/*drug therapy; SKIN
DISEASE/*surgery; ADULT; ANAL CANAL; ARTICLE; CASE REPORT;
HUMAN; MALE; OINTMENT; PATHOLOGY; RETREATMENT; TOPICAL
DRUG ADMINISTRATION; TREATMENT OUTCOME; VIROLOGY;
AMINOQUINOLINE DERIVATIVE/*drug administration; IMIQUIMOD
99011-02-6
history of these lesions there is an increased risk of intraepithelial neoplasia and
cancer. Generally the lesions are not life-threatening, but they provoke significant
morbidity, are difficult to treat, and are a source of psychosocial stress. Thus,
condylomata represent not only a health problem for the patient but also an
economic burden for the society. Considering the individual episodes of care, men
experience a longer duration of the lesions and incur greater costs than women.
We report a case of a male patient with external and intra-anal condyloma
resistant to laser therapy. Initially, surgical intervention appeared required because
of florid and intra-anal growth. HPV DNA testing and sequencing revealed the
presence of HPV 6. After initial discomfort, the lesions were successfully cleared
with topical imiquimod 5 percent cream therapy.
Dianzani C
Dianzani Caterina
Pierangeli A
Pierangeli Alessandra
Avola A
Avola Alessandra
Borzomati D
Borzomati Domenico
Persichetti P
Persichetti Paolo
Degener AM
Degener Anna Marta
MEDLINE® is the source for the citation and abstract of this record.
2/74 von 102
ND:
PMID:
Autoren:
EMM17573882
17573882
Kreuter A; Wieland U; Gambichler T; Altmeyer P; Pfister H; Tenner-Racz K;
Racz P; Potthoff A; Brockmeyer NH
Titel:
p16ink4a expression decreases during imiquimod treatment of anal
intraepithelial neoplasia in human immunodeficiency virus-infected
men and correlates with the decline of lesional high-risk human
papillomavirus DNA load.
Source:
The British journal of dermatology; VOL: 157 (3); p. 523-530 /Sep 2007/
NCT:
SU:
Medline
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
0007-0963
Institution: Kreuter A, Department of Dermatology and Allergology, Ruhr-University
Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany., [email protected]
DT:
Journal Article
JSC:
Keywords
CT:
ANUS TUMOR/*drug therapy; CARCINOMA IN SITU/*drug therapy;
PRECANCER/*drug therapy; ADULT; AIDS RELATED
COMPLEX/complication; ARTICLE; GENETICS; HOMOSEXUALITY;
HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE;
METABOLISM; PAPILLOMA VIRUS; PILOT STUDY; VIROLOGY; VIRUS
INFECTION/complication; VIRUS LOAD; AMINOQUINOLINE
DERIVATIVE/*drug therapy; ANTINEOPLASTIC AGENT/*drug therapy;
CYCLIN DEPENDENT KINASE INHIBITOR 2A/*; IMIQUIMOD; KI 67
ANTIGEN; TUMOR MARKER; VIRUS DNA/drug analysis
TE:
CR:
99011-02-6
AB:
BACKGROUND: Human papillomavirus (HPV)-associated anogenital cancers
and their precursor lesions occur in excess in human immunodeficiency virus
(HIV)-infected patients despite the initiation of highly active antiretroviral
therapy. In this context, a drastically increased relative risk for anal intraepithelial
neoplasia (AIN) exists in HIV-infected men having sex with men (MSM). In a
pilot study, imiquimod, a topical immune response modifier, has been reported to
be beneficial in the treatment of AIN. OBJECTIVES: To investigate the role of
several biomarkers as potential adjuncts in the course of imiquimod treatment for
AIN, and to determine whether these markers correlate with the course of highrisk HPV DNA load during imiquimod therapy. METHODS:
Immunohistochemical staining was performed for p16(ink4a), minichromosome
maintenance protein (MCM), Ki67, proliferating cell nuclear antigen (PCNA) and
p21(waf1) expression before and after 16 weeks of imiquimod treatment for AIN.
High-risk HPV DNA load determinations were performed by real-time
polymerase chain reaction with type-specific primers and probes for HPV types
16, 18, 31 and 33. RESULTS: Histopathological and virological analyses were
AU:
AU:
AU:
AU:
AU:
AU:
AU:
AU:
performed in 21 HIV-infected MSM with histologically confirmed AIN. Eighteen
(86%) patients had a complete histological clearance of AIN after imiquimod
therapy. As previously shown, lesional high-risk HPV DNA load significantly
decreased during imiquimod therapy. Moreover, a significant decline of
p16(ink4a), Ki67, MCM and PCNA expression after treatment was observed,
while p21(waf1) expression changed nonsignificantly after imiquimod therapy. A
significant correlation between the course of high-risk HPV DNA load and
p16(ink4a) expression was observed during imiquimod treatment of AIN,
whereas the decline of high-risk HPV DNA load did not significantly correlate
with MCM, Ki67, PCNA or p21(waf1) expression. CONCLUSIONS: The
significant decrease in p16(ink4a) expression in correlation with the drop of
lesional high-risk HPV load suggests that p16(ink4a) may be a useful adjunct for
the evaluation of treatment response in HPV-associated malignancies and their
precursor lesions.
Kreuter A
Kreuter A
Gudrunstrasse 56, D-44791 Bochum, Germany.
Wieland U
Wieland U
Gambichler T
Gambichler T
Altmeyer P
Altmeyer P
Pfister H
Pfister H
Tenner-Racz K
Tenner-Racz K
Racz P
Racz P
Potthoff A
Potthoff A
AU:
CNOTE:
Brockmeyer NH
Brockmeyer NH
2/75 von 102
ND:
Autoren:
EM2004534385
Pelletier F; Drobacheff-Thiebaut C; Aubin F; Venier A-G; Mougin C; Laurent R
Titel:
Effects de l'imiquimod sur l'infection périanale latente à
papillomavirus humain chez des malades infectés par le virus de
l'immunodéficience humaine
Effects of imiquimod on latent human papillomavirus anal infection
in HIV-infected patients
Source:
Annales de Dermatologie et de Venereologie; VOL: 131 (11); p. 947-951
/200411/
SU:
EMBASE
Sprache: French
AL:
English; French
CY:
France
ISSN:
0151-9638
CO:
ADVED
Institution: Pelletier F, Service de Dermatologie, CHU Saint-Jacques, 2 place Saint-Jacques,
25030 Besançon Cedex, France
COU:
France
DT:
Journal Article
JSC:
RN:
0015
Keywords
CT:
HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*; VERRUCA
VULGARIS/*drug therapy; VERRUCA VULGARIS/*etiology; ADOLESCENT;
ADULT; AGED; ANAMNESIS; ANUS; ARTICLE; CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE
BLIND PROCEDURE; DRUG EFFECT; ERADICATION THERAPY;
FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE;
PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;
SEXUALLY TRANSMITTED DISEASE; TREATMENT OUTCOME; VIRUS
TRANSMISSION; WART VIRUS; IMIQUIMOD/*clinical trial;
IMIQUIMOD/*drug therapy; VIRUS DNA
ET:
Dermatology and Venereology; Drug Literature Index; Microbiology:
Bacteriology, Mycology, Parasitology and Virology
TE:
CR:
99011-02-6
AB:
AU:
AU:
AU:
AU:
AU:
AU:
CNOTE:
Introduction. High risk human papillomaviruses (HPV) have emerged as risk
factors for anal carcinoma particularly in HIV-infected patients who demonstrate
a high rate of anal HPV infection. Considering the relationship between the
presence of anal infection and the development of neoplastic lesions, we wished
to assess the capacity of imiquimod to eradicate latent HPV infection in HIVinfected patients. Patients and methods. We conducted a prospective, randomized,
double-blind and vehicle controlled study. Two consecutive anal swabs were
taken at 2 month intervals and only patients with two consecutive tests positive for
the detection of HPV-DNA (Hybrid Capture II®) were included. Patients with
persistent latent HPV infection were divided into 2 groups who applied
imiquimod versus vehicle during 6 weeks. HPV-DNA presence was then
investigated 2 and 4 months following the onset of treatment. Results. Among the
80 HIV-infected patients, 26 (32.5 p. 100) had 2 positive consecutive assays, and
19 patients were included in the study. After randomization, 9 patients received
imiquimod and 10 vehicle. There was no significant difference between treatment
groups according to the following criteria: gender, route of HIV transmission,
CDC stage, prior medical history of sexually transmitted diseases or anogenital
warts. 33.3 p. 100 (3/9) of patients treated with imiquimod were negative at M2,
whereas 100 p. 100 (10/10) vehicle treated-patients remained positive (p = 0.08).
Similar results were observed at the M4 visit. Discussion. Our study confirmed the
increased prevalence of latent HPV-DNA infection in HIV-infected patients. In
spite of the low number of treated patients, we did not observe a statistically
significant decrease in HPV-DNA in anal swabs from france imquimod-treated
patients as compared to placebo-treated patients.
Pelletier F
Pelletier F
Service de Dermatologie, CHU Saint-Jacques, Besançon, France; Service de
Dermatologie, CHU Saint-Jacques, 2 place Saint-Jacques, 25030 Besançon Cedex,
France
Drobacheff-Thiebaut C
Drobacheff-Thiebaut C
Service de Dermatologie, CHU Saint-Jacques, Besançon, France
Aubin F
Aubin F
Venier A-G
Venier A-G
Departement d'Information Medicine, CHU Saint-Jacques, Besançon, France
Mougin C
Mougin C
Lab. de Biol. Cell. et Moleculaire, CHU Jean Minjoz, Besançon, France
Laurent R
Laurent R
2/76 von 102
ND:
Autoren:
EM2004506141
Chang GJ; Welton ML
Titel:
Human papillomavirus, condylomata acuminata, and anal neoplasia
Source:
Clinics in Colon and Rectal Surgery; VOL: 17 (4); p. 221-230 /200411/
DOI:
10.1055/s-2004-836942
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
1531-0043
CO:
CCRSC
Institution: Chang GJ, Dr., Department of Surgical Oncology, Unit 444, U.T. M.D. Anderson
Cancer Center, 1400 Holcombe Blvd., Houston, TX 77230-1402, United
COU:
United States
DT:
JSC:
RN:
0095
Keywords
CT:
ANUS CANCER/*diagnosis; ANUS CANCER/*etiology; ANUS
CANCER/*surgery; CONDYLOMA ACUMINATUM/*diagnosis;
ACUMINATUM/*surgery; CONDYLOMA ACUMINATUM/*therapy; WART
VIRUS/*; ANUS DISEASE/diagnosis; ANUS DISEASE/drug therapy; ANUS
DISEASE/epidemiology; ANUS DISEASE/etiology; ANUS DISEASE/surgery;
ANUS DISEASE/therapy; ANUS FISTULA/side effect; ANUS SURGERY;
BOWEN DISEASE/etiology; CARBON DIOXIDE LASER; CAUTERIZATION;
CHILL/side effect; CONDYLOMA/diagnosis; CONDYLOMA/drug therapy;
CONDYLOMA/surgery; CONDYLOMA/therapy; CRYOTHERAPY;
DERMATITIS/side effect; DISEASE COURSE; ERYTHEMA/side effect;
EXCISION; FATIGUE/side effect; FETUS DEATH; FEVER/side effect;
HEADACHE/side effect; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/epidemiology; IMMUNOTHERAPY; LEUKOPENIA/side effect;
MYALGIA/side effect; NONHUMAN; PREVALENCE; RECURRENT
DISEASE; REVIEW; SCAR/side effect; SEXUALLY TRANSMITTED
DISEASE/diagnosis; SEXUALLY TRANSMITTED DISEASE/epidemiology;
SEXUALLY TRANSMITTED DISEASE/etiology; SIDE EFFECT/side effect;
SKIN NECROSIS/side effect; SYMPTOMATOLOGY;
TERATOGENICITY/side effect; UTERINE CERVIX CANCER/etiology;
UTERINE CERVIX DYSPLASIA/etiology; VIRUS INFECTION/diagnosis;
VIRUS INFECTION/epidemiology; VIRUS INFECTION/etiology;
DICHLOROACETIC ACID/*adverse drug reaction; DICHLOROACETIC
ACID/*drug administration; DICHLOROACETIC ACID/*drug therapy;
DICHLOROACETIC ACID/*topical drug administration;
FLUOROURACIL/*drug administration; FLUOROURACIL/*drug therapy;
ET:
TE:
CR:
FLUOROURACIL/*topical drug administration; IMIQUIMOD/*adverse drug
reaction; IMIQUIMOD/*drug administration; IMIQUIMOD/*drug therapy;
IMIQUIMOD/*topical drug administration; INTERFERON/*adverse drug
reaction; INTERFERON/*drug administration; INTERFERON/*drug therapy;
INTERFERON/*intralesional drug administration; INTERFERON/*intramuscular
drug administration; INTERFERON/*topical drug administration;
PODOPHYLLIN/*adverse drug reaction; PODOPHYLLIN/*drug administration;
PODOPHYLLIN/*drug therapy; PODOPHYLLIN/*topical drug administration;
TRICHLOROACETIC ACID/*drug administration; TRICHLOROACETIC
ACID/*drug therapy; TRICHLOROACETIC ACID/*topical drug administration;
1 CHLORO 2,4 DINITROBENZENE/drug administration; 1 CHLORO 2,4
DINITROBENZENE/drug therapy; 1 CHLORO 2,4 DINITROBENZENE/topical
drug administration; ANTINEOPLASTIC AGENT/drug administration;
ANTINEOPLASTIC AGENT/drug therapy; ANTINEOPLASTIC
AGENT/topical drug administration; BISMUTH DERIVATIVE/drug
administration; BISMUTH DERIVATIVE/drug therapy; BISMUTH
DERIVATIVE/topical drug administration; BLEOMYCIN/drug administration;
BLEOMYCIN/drug therapy; BLEOMYCIN/topical drug administration;
CANTHARIDIN/drug administration; CANTHARIDIN/drug therapy;
CANTHARIDIN/topical drug administration; COLCHICINE/drug administration;
COLCHICINE/drug therapy; COLCHICINE/topical drug administration;
DIMETHYL SULFOXIDE/drug administration; DIMETHYL SULFOXIDE/drug
therapy; DIMETHYL SULFOXIDE/topical drug administration;
IDOXURIDINE/drug administration; IDOXURIDINE/drug therapy;
IDOXURIDINE/topical drug administration; LIQUID NITROGEN;
MERCURY/drug administration; MERCURY/drug therapy; MERCURY/topical
drug administration; PHENOL DERIVATIVE/drug administration; PHENOL
DERIVATIVE/drug therapy; PHENOL DERIVATIVE/topical drug
administration; SALICYLIC ACID/drug administration; SALICYLIC ACID/drug
therapy; SALICYLIC ACID/topical drug administration; SOLCODERM/drug
administration; SOLCODERM/drug therapy; SOLCODERM/topical drug
administration; SULFONAMIDE/drug administration; SULFONAMIDE/drug
therapy; SULFONAMIDE/topical drug administration; TETRACYCLINE/drug
administration; TETRACYCLINE/drug therapy; TETRACYCLINE/topical drug
administration; THIOTEPA/drug administration; THIOTEPA/drug therapy;
THIOTEPA/topical drug administration; VIRUS DNA; VIRUS VACCINE/drug
therapy
Cancer; Drug Literature Index; Adverse Reactions Titles; Microbiology:
Bacteriology, Mycology, Parasitology and Virology; Surgery
1 chloro 2,4 dinitrobenzene/25567-67-3; 1 chloro 2,4 dinitrobenzene/97-00-7;
bleomycin/11056-06-7; cantharidin/56-25-7; colchicine/64-86-8; dichloroacetic
acid/13425-80-4; dichloroacetic acid/2156-56-1; dichloroacetic acid/79-43-6;
dimethyl sulfoxide/67-68-5; fluorouracil/51-21-8; idoxuridine/54-42-2;
imiquimod/99011-02-6; mercury/14302-87-5; mercury/7439-97-6;
podophyllin/9000-55-9; salicylic acid/63-36-5; salicylic acid/69-72-7;
tetracycline/23843-90-5; tetracycline/60-54-8; tetracycline/64-75-5; thiotepa/5224-4; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9
25567-67-3; 97-00-7; 11056-06-7; 56-25-7; 64-86-8; 13425-80-4; 2156-56-1; 7943-6; 67-68-5; 51-21-8; 54-42-2; 99011-02-6; 14302-87-5; 7439-97-6; 9000-55-9;
63-36-5; 69-72-7; 23843-90-5; 60-54-8; 64-75-5; 52-24-4; 14357-05-2; 76-03-9
AB:
AU:
AU:
CNOTE:
Genital human papillomavirus (HPV) infection is an increasingly common
sexually transmitted disease. This virus causes condylomata acuminata and is
associated with anal neoplasia. Management options are discussed.
Chang GJ
Chang George J.
Department of Surgical Oncology, Unit 444, U.T. M.D. Anderson Cancer Center,
1400 Holcombe Blvd., Houston, TX 77230-1402, United States; Department of
Surgical Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX, United
States
[email protected]
Welton ML
Welton Mark L.
Department of Surgery, Stanford University, School of Medicine, Stanford, CA,
United States
2/77 von 102
ND:
Autoren:
EM2004309751
Park JS; Kerner BA
Titel:
Perianal Paget's disease
Source:
Seminars in Colon and Rectal Surgery; VOL: 14 (4); p. 218-221 /200312/
DOI:
10.1053/j.scrs.2004.03.007
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
1043-1489
CO:
SCRSF
PII:
S1043148904000168
Institution: Kerner BA, Dr., 5965 East Broad Street, Suite 120, Columbus, OH, United
COU:
United States
DT:
JSC:
RN:
0016
Keywords
CT:
PAGET SKIN DISEASE/*diagnosis; PAGET SKIN DISEASE/*drug therapy;
PAGET SKIN DISEASE/*radiotherapy; PAGET SKIN DISEASE/*surgery;
ADENOCARCINOMA/surgery; CLINICAL FEATURE; DISEASE
ASSOCIATION; DISEASE COURSE; HUMAN;
IMMUNOHISTOCHEMISTRY; NECROSIS/complication; PHOTODYNAMIC
THERAPY; RECURRENT DISEASE/complication; REVIEW;
IMIQUIMOD/drug therapy; RETINOIC ACID/drug therapy
ET:
TE:
CR:
AB:
AU:
AU:
CNOTE:
Dermatology and Venereology; Drug Literature Index; Gastroenterology
imiquimod/99011-02-6; retinoic acid/302-79-4
99011-02-6; 302-79-4
Perianal Paget's disease is a rare intraepithelial adenocarcinoma of the anal
margin. Because of its rarity, delay in diagnosis is common and requires a high
index of suspicion. Although its etiology has never been definitively determined,
it now appears that 2 types of perianal Paget's disease exist. Primary perianal
Paget's disease likely represents intra-epithelial neoplasm from an apocrine
source, whereas secondary disease may represent "pagetoid" spread from an
anorectal malignancy. Diagnosis of the 2 types of disease can be established from
distinct immunohistochemical stain patterns. Wide local excision remains the
treatment of choice for primary disease, with or without local invasion. Although
local recurrence is high, re-excision can still be curative. Treatment of secondary
disease is less clear, though aggressive therapy appears indicated for curative
intent. Although adjuvant therapy is desirable, experience is still very limited. ©
2004 Elsevier Inc. All rights reserved.
Park JS
Park John S.
Grant Medical Center, Department of Surgery, Section of Colon and Rectal
Surgery, Columbus, OH, United States
Kerner BA
Kerner Bruce A.
Grant Medical Center, Department of Surgery, Section of Colon and Rectal
Surgery, Columbus, OH, United States; 5965 East Broad Street, Suite 120,
Columbus, OH, United States
[email protected]
2/78 von 102
ND:
Autoren:
EM2004308623
Hagensee ME; Cameron JE; Leigh JE; Clark RA
Titel:
Human papillomavirus infection and disease in HIV-infected
individuals
Source:
American Journal of the Medical Sciences; VOL: 328 (1); p. 57-63 /200407/
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
0002-9629
CO:
AJMSA
Institution: Hagensee ME, Dr., Department of Medicine, LSUHSC, 1542 Tulane Avenue,
New Orleans, LA 70112, United States, [email protected]
COU:
United States
DT:
JSC:
RN:
Keywords
CT:
ET:
TE:
CR:
AB:
AU:
0041
HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION/*epidemiology;
VERRUCA VULGARIS/*drug therapy; VERRUCA VULGARIS/*epidemiology;
VERRUCA VULGARIS/*etiology; VERRUCA VULGARIS/*side effect; ANUS
DISEASE/drug therapy; ANUS DISEASE/etiology; CARBON DIOXIDE
LASER; CLINICAL TRIAL; CONDYLOMA/drug therapy;
CONDYLOMA/etiology; CRYOSURGERY; DISEASE ASSOCIATION;
ELECTROSURGERY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN
IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION RISK; MOUTH
INFECTION/drug therapy; MOUTH INFECTION/etiology; MOUTH
INFECTION/side effect; MOUTH INFECTION/surgery;
PATHOPHYSIOLOGY; REVIEW; SEX DIFFERENCE; UTERINE CERVIX
DYSPLASIA/etiology; WART VIRUS; ANTIRETROVIRUS AGENT/adverse
drug reaction; ANTIRETROVIRUS AGENT/drug therapy;
FLUOROURACIL/clinical trial; FLUOROURACIL/drug therapy;
IMIQUIMOD/drug therapy; ISOTRETINOIN/clinical trial;
ISOTRETINOIN/drug therapy; ISOTRETINOIN/oral drug administration;
LIQUID NITROGEN/drug therapy; PODOPHYLLOTOXIN/drug therapy
Mycology, Parasitology and Virology; Internal Medicine
fluorouracil/51-21-8; imiquimod/99011-02-6; isotretinoin/4759-48-2;
51-21-8; 99011-02-6; 4759-48-2; 518-28-5
The possibility of increases in both oral and anogenital pathologic conditions due
to human papillomavirus (HPV) in patients infected with the human
immunodeficiency virus (HIV) is of concern and is the focus of numerous current
research studies. HIV-infected women are at higher risk for cervical HPV
detection, for infection with high-oncogenic-risk types of HPV, for persistent
HPV infection, for cervical cytologic abnormalities, and for cervical intraepithelial
neoplasms. HIV-infected men are at increased risk for anal HPV infection, for
anal infection with high oncogenic-risk types of HPV, for persistent anal HPV
infection, and for anal intraepithelial defects. Recent studies have shown an
increased risk of oral warts in HIV-infected individuals despite treatment with
highly active antiretroviral therapy (HAART). Oral HPV infection rates have not
declined since the initiation of HAART, and evidence suggests that the rates may
have actually increased in white HIV-infected males.
Hagensee ME
Hagensee Michael E.
Department of Medicine, LA State Univ. Health Science Center, New Orleans,
LA, United States; Dept. Microbio., Immunol./Parasitol., LA State Univ. Health
Science Center, New Orleans, LA, United States; Department of Medicine,
LSUHSC, 1542 Tulane Avenue, New Orleans, LA 70112, United States
[email protected]
AU:
AU:
AU:
CNOTE:
Cameron JE
Cameron Jennifer E.
Dept. Microbio., Immunol./Parasitol., LA State Univ. Health Science Center, New
Orleans, LA, United States
Leigh JE
Leigh Janet E.
School of Dentistry, LA State Univ. Health Science Center, New Orleans, LA,
United States
Clark RA
Clark Rebecca A.
Department of Medicine, LA State Univ. Health Science Center, New Orleans,
LA, United States
2/79 von 102
ND:
Autoren:
EM2004233715
Kreuter A; Hochdorfer B; Stücker M; Altmeyer P; Weiland U; Conant MA;
Brockmeyer NH
Titel:
Treatment of anal intraepithelial neoplasia in patients with acquired
HIV with imiquimod 5% cream [6]
Source:
Journal of the American Academy of Dermatology; VOL: 50 (6); p. 980-981
/200406/
SU:
EMBASE
Sprache: English
CY:
United States
ISSN:
0190-9622
CO:
JAADD
Institution: Network of Competence HIV/AIDS, Dept. of Dermatology and Allergology,
Ruhr-University Bochum, Germany
COU:
Germany
DT:
Letter; Journal Article
JSC:
RN:
0005
Keywords
CT:
ANUS TUMOR/*drug therapy; CARCINOMA IN SITU/*drug therapy; HUMAN
IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; BURNING
SENSATION/side effect; CLINICAL ARTICLE; ERYTHEMA/side effect;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY;
HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN
PAPILLOMAVIRUS TYPE 18; LETTER; MALE; PRIORITY JOURNAL;
REMISSION; WART VIRUS; IMIQUIMOD/*adverse drug reaction;
IMIQUIMOD/*drug therapy
ET:
TE:
CR:
AU:
AU:
AU:
AU:
AU:
AU:
AU:
CNOTE:
Mycology, Parasitology and Virology
99011-02-6
Weiland U
Weiland Ulrike
Kreuter A
Kreuter Alexander
Network of Competence HIV/AIDS, Dept. of Dermatology and Allergology,
Hochdorfer B
Hochdorfer Bettina
Stücker M
Stücker Markus
Altmeyer P
Altmeyer Peter
Conant MA
Conant Markus A.
Department of Dermatology, Univ. of California Medical Center, San Francisco,
CA, United States
Brockmeyer NH
Ruhr-University Bochum, Germany; Institute of Virology, University of Cologne,
Germany
2/80 von 102
ND:
Autoren:
EM2003421405
Majewski S; Pniewski T; Malejczyk M; Jablonska S
Titel:
Imiquimod is Highly Effective for Extensive, Hyperproliferative
Condyloma in Children
Source:
DOI:
SU:
Sprache:
AL:
Pediatric Dermatology; VOL: 20 (5); p. 440-442 /200309/
10.1046/j.1525-1470.2003.20516.x
EMBASE
English
English
CY:
United States
ISSN:
0736-8046
CO:
PEDRD
Institution: Jablonska S, Dr., Department of Dermatology, Warsaw School of Medicine,
Koszykowa 82A, 02-008 Warsaw, Poland, [email protected]
COU:
Poland
DT:
Journal Article
JSC:
C.5 ... Dermatology & Venereology; C.2 ... Pediatrics & Pediatric Surgery
RN:
0014
Keywords
CT:
CONDYLOMA/*etiology; ANUS; ARTICLE; CASE REPORT; CHILD
SEXUAL ABUSE; CLINICAL FEATURE; DRUG EFFICACY; DRUG
SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE;
INFLAMMATION; PREGNANCY; PRESCHOOL CHILD; PRIORITY
JOURNAL; TREATMENT OUTCOME; VERRUCA VULGARIS/diagnosis;
VERRUCA VULGARIS/drug therapy; VERRUCA VULGARIS/etiology; WART
VIRUS; IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug
administration
ET:
Dermatology and Venereology; Drug Literature Index; Microbiology:
Bacteriology, Mycology, Parasitology and Virology; Pediatrics and Pediatric
Surgery
TE:
CR:
99011-02-6
AB:
We describe a dramatic response to imiquimod of long-lasting, highly
proliferative extensive perianal condylomas involving the anal canal in a 19month-old girl. Her mother was free of condyloma and allegedly had no human
papillomavirus (HPV) infection during pregnancy. There was no evidence of
sexual abuse. Application of 5% imiquimod cream to the child every other day
for 3 weeks resulted in almost complete resolution of the warts, with total
clearance within another 2 weeks. The inflammatory reaction was moderate. Since
there is still discussion of whether imiquimod may be prescribed for small
children, this case of very extensive condyloma provides evidence that the
compound is safe and highly effective.
AU:
Majewski S
Majewski Slawomir
Dept. of Dermatology and Venereology, Warsaw School of Medicine, Warsaw,
Poland
AU:
Pniewski T
Pniewski Tomasz
Poland
AU:
Malejczyk M
Malejczyk Magdalena
Poland
AU:
CNOTE:
Jablonska S
Jablonska Stefania
Poland; Department of Dermatology, Warsaw School of Medicine, Koszykowa
82A, 02-008 Warsaw, Poland
[email protected]
2/81 von 102
ND:
Autoren:
EM2003379255
Bock J-U; Jongen J; Peleikis H-G; Stübinger SH
Titel:
Proktologische erkrankungen im urologischen alltag
Proctologic illnesses in daily urological practice
Source:
Urologe - Ausgabe A; VOL: 42 (8); p. 1105-1116 /20030801/
DOI:
10.1007/s00120-003-0410-8
SU:
EMBASE
Sprache: German
AL:
English; German
CY:
Germany
ISSN:
0340-2592
CO:
URGAB
Institution: Bock J-U, Dr., Proktologische Praxis, Beselerallee 67, 24105 Kiel,
Germany, [email protected]
COU:
Germany
DT:
JSC:
D.5 ... Urological Surgery
RN:
0024
Keywords
CT:
ANUS CARCINOMA/*diagnosis; ANUS CARCINOMA/*surgery; ANUS
DISEASE/*diagnosis; ANUS DISEASE/*drug therapy; ANUS
DISEASE/*surgery; ANUS FISSURE/*diagnosis; ANUS FISSURE/*drug
therapy; ANUS FISSURE/*surgery; HEMORRHOID/*diagnosis;
HEMORRHOID/*surgery; ADULT; ANUS FISTULA/diagnosis; ANUS
FISTULA/surgery; ANUS PRURITUS/etiology; ANUS SPHINCTER; ANUS
SURGERY; ARTERY LIGATION; BOWENOID PAPULOSIS/diagnosis;
CLINICAL PRACTICE; CONDYLOMA ACUMINATUM/diagnosis;
CONDYLOMA ACUMINATUM/drug therapy; CONDYLOMA
ACUMINATUM/surgery; CONSERVATIVE TREATMENT; DIFFERENTIAL
DIAGNOSIS; ECZEMA/etiology; ELECTROCOAGULATION; FECES
INCONTINENCE/etiology; FIBROMA/diagnosis; FIBROMA/surgery;
GONORRHEA/diagnosis; HEMORRHOIDECTOMY; HERPES
SIMPLEX/diagnosis; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/diagnosis; PAIN/etiology; PERIANAL ABSCESS/diagnosis;
PERIANAL ABSCESS/surgery; PRACTICE GUIDELINE;
ET:
TE:
CR:
AB:
AU:
AU:
AU:
AU:
CNOTE:
PROCTITIS/complication; PROCTITIS/diagnosis; RADIATION
INJURY/complication; RADIATION INJURY/diagnosis; RECTUM MUCOSA;
RECTUM PROLAPSE; REVIEW; SPHINCTEROTOMY; SYPHILIS/diagnosis;
THROMBOSIS/complication; BOTULINUM TOXIN/drug therapy; CALCIUM
ANTAGONIST/drug therapy; DILTIAZEM/drug therapy; GLYCERYL
TRINITRATE/drug therapy; IMIQUIMOD/drug therapy; IMIQUIMOD/topical
drug administration; NIFEDIPINE/drug therapy; PODOPHYLLOTOXIN/drug
therapy
Cancer; Urology and Nephrology; Drug Literature Index; Microbiology:
Bacteriology, Mycology, Parasitology and Virology; Surgery
diltiazem/33286-22-5; diltiazem/42399-41-7; glyceryl trinitrate/55-63-0;
imiquimod/99011-02-6; nifedipine/21829-25-4; podophyllotoxin/518-28-5
33286-22-5; 42399-41-7; 55-63-0; 99011-02-6; 21829-25-4; 518-28-5
Nearly two third of adults will suffer from proctologic complaints. The same
symptoms could also indicate or mask an anorectal carcinoma. Therefore, the first
priority should be to exclude the possibility of a neoplasm of the colon, rectum
and the anal canal. Knowledge of the specific anatomy of the anal canal and the
patient's history will lead to an exact proctologic diagnosis: perianal thrombosis,
acute thrombosed prolapsed haemorrhoidal plexus, an anal fissure, abscess and
fistula are located within the highly sensitive anoderma and are characterized by
pain. Perianal thrombosis, chronic fissure, abscess and fistula require surgery
Conservative treatment is the choice for an acute anal fissure, haemorrhoids grade
I-II. Haemorrhoids II-III require surgery, e.g. by haemorrhoidal artery ligation,
open or closed resection of the haemorrhoidal plexus, reconstruction of the anal
canal or stapled mucosectomy. Perianal diseases such as perianal tags, fibroma or
condylomata acuminata are easily diagnosed and treated. Secondary perianal
eczema requires treatment of the underlying proctologic disease. If it persists, a
biopsy is required.
Bock J-U
Bock J-U
Proktologische Praxis, Kiel, Germany; Anorektale Chirurgie, Park-Klinik, Kiel,
Germany; Proktologische Praxis, Beselerallee 67, 24105 Kiel, Germany
[email protected]
Jongen J
Jongen J
Proktologische Praxis, Kiel, Germany
Peleikis H-G
Peleikis H-G
Proktologische Praxis, Kiel, Germany
Stübinger SH
Stübinger SH
Klinik für Urologie, Univ. Klin. Schleswig-Holstein, Campus Kiel, Kiel, Germany
2/82 von 102
ND:
Autoren:
EM2003325726
Porter WM; Francis N; Hawkins D; Dinneen M; Bunker CB
Titel:
Penile intraepithelial neoplasia: Clinical spectrum and treatment of
35 cases
Source:
DOI:
10.1046/j.1365-2133.2002.05019.x
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
0007-0963
CO:
BJDEA
Institution: Porter WM, Dr., Department of Dermatology, Gloucestershire Royal Hospital,
Great Western Road, Gloucester GL1 3NN, United
COU:
United Kingdom
DT:
Journal Article
JSC:
RN:
0029
Keywords
CT:
CARCINOMA IN SITU/*diagnosis; CARCINOMA IN SITU/*drug therapy;
CARCINOMA IN SITU/*etiology; PENIS TUMOR/*diagnosis; PENIS
TUMOR/*drug therapy; PENIS TUMOR/*etiology; ADULT; AGED;
ANAMNESIS; ANUS CANCER; ARTICLE; BOWEN DISEASE; BOWENOID
PAPULOSIS; CIRCUMCISION; CLINICAL ARTICLE; CLINICAL FEATURE;
CLINICAL OBSERVATION; EROSION/side effect; ERYTHEMA/side effect;
ERYTHROPLASIA; FOLLOW UP; GENITAL TRACT INFECTION; HIGHLY
ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOSUPPRESSIVE
TREATMENT; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS;
MALE; PENIS DISEASE; PRIORITY JOURNAL; UTERINE CERVIX
CANCER; VIRUS INFECTION; WART VIRUS; FLUOROURACIL/*drug
therapy; FLUOROURACIL/*topical drug administration;
IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*drug therapy;
IMIQUIMOD/*topical drug administration; PREDNISOLONE/*drug therapy;
PREDNISOLONE/*oral drug administration; INTERLEUKIN 1/endogenous
compound; INTERLEUKIN 12/endogenous compound; INTERLEUKIN
6/endogenous compound; TUMOR NECROSIS FACTOR/endogenous compound
DN:
Efudix/ICN, United Kingdom
MN:
ICN, United Kingdom
ET:
Dermatology and Venereology; Cancer; Urology and Nephrology; Drug Literature
TE:
fluorouracil/51-21-8; imiquimod/99011-02-6; interleukin 12/138415-13-1;
prednisolone/50-24-8
CR:
51-21-8; 99011-02-6; 138415-13-1; 50-24-8
AB:
Background: Penile intraepithelial neoplasia (PIN) is the term used to describe
erythroplasia of Oueyrat (EQ), Bowen's disease (BD) and bowenoid papulosis
AU:
AU:
AU:
AU:
AU:
CNOTE:
(BP). These conditions are distinct clinical entities and have different
epidemiological and aetiological associations and prognostic implications.
Objectives: To describe the presentation and treatment of patients with PIN.
Methods: Thirty-five patients presenting with PIN over a 7-year period are
described. Results: Our observations include: (i) patients with BP are younger
than those with EQ or BD and sometimes have a history of immunosuppression;
(ii) patients with BP usually have a history or clinical evidence of previous genital
human papillomavirus infection; (iii) patients with EQ often have a concurrent
penile dermatosis (lichen sclerosus or lichen planus); (iv) patients with PIN are
usually uncircumcised; and (v) response to treatment of BP depends on the
integrity of the immune system. Conclusions: We recommend vigorous treatment
of all patients with PIN, including circumcision. Smoking should be actively
discouraged. Patients should have life-long follow-up and partners of patients with
BP should be screened for other forms of intraepithelial neoplasia (cervical and
anal).
Porter WM
Porter WM
Department of Dermatology, Chelsea and Westminster Hospital, Imperial College
School of Medicine, London SW10 9NH, United Kingdom; Department of
Dermatology, Gloucestershire Royal Hospital, Great Western Road, Gloucester
GL1 3NN, United Kingdom
[email protected]
Francis N
Francis N
Department of Histopathology, Chelsea and Westminster Hospital, Imperial
College School of Medicine, London SW10 9NH, United Kingdom
Hawkins D
Hawkins D
Department of Genitourinary Medicine, Chelsea and Westminster Hospital,
Imperial College School of Medicine, London SW10 9NH, United Kingdom
Dinneen M
Dinneen M
Department of Urology, Chelsea and Westminster Hospital, Imperial College
School of Medicine, London SW10 9NH, United Kingdom
Bunker CB
Bunker CB
Department of Dermatology, Chelsea and Westminster Hospital, Imperial College
School of Medicine, London SW10 9NH, United Kingdom
2/83 von 102
ND:
Autoren:
EM2003238428
Chu NR
Titel:
Therapeutic vaccination for the treatment of mucosotropic human
papillomavirus-associated disease
Source:
Expert Opinion on Biological Therapy; VOL: 3 (3); p. 477-486 /200306/
DOI:
10.1517/14712598.3.3.477
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
1471-2598
CO:
EOBTA
Institution: Chu NR, Stressgen Biotechnologies Corp., 350-4243 Glanford Ave., Victoria, BC
V8Z 4B9, Canada, [email protected]
COU:
Canada
DT:
JSC:
A.1 ... Pharmacology & Drug Therapy; E.0 ... Experimental Science
RN:
0107
Keywords
CT:
PAPILLOMA VIRUS/*; VACCINATION/*; VIRUS INFECTION/*drug
therapy; CHIMERA; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; FUSION
GENE; GENE DELIVERY SYSTEM; HUMAN; IMMUNIZATION;
IMMUNOGENICITY; IMMUNOTHERAPY; NONHUMAN; REVIEW; SIDE
EFFECT/side effect; TREATMENT INDICATION; VIRUS PARTICLE;
VACCINE/*drug therapy; VIRUS ANTIGEN/*drug therapy; WART VIRUS
VACCINE/*drug therapy; ADJUVANT; COVAL; CYTOTOXIC
AGENT/adverse drug reaction; CYTOTOXIC AGENT/drug therapy;
CYTOTOXIC AGENT/topical drug administration; HEAT SHOCK PROTEIN;
HEPATITIS B CORE ANTIGEN; HPV16 E7 VACCINE/drug therapy; HUMAN
PAPILLOMA VIRUS ANTIGEN/drug therapy; HYBRID PROTEIN;
IMIQUIMOD/adverse drug reaction; IMIQUIMOD/drug therapy;
IMIQUIMOD/topical drug administration; NUCLEOPROTEIN;
RECOMBINANT PROTEIN; UNCLASSIFIED DRUG
DN:
Coval/Stressgen Biotechnologies
MN:
Stressgen Biotechnologies
ET:
Immunology, Serology and Transplantation; Drug Literature Index; Adverse
Reactions Titles
TE:
CR:
99011-02-6
AB:
There is a high prevalence of diseases caused by human papillomavirus (HPV)
infection. Unfortunately, current treatments are inadequate. However, because
there is evidence to support a role for the immune system in host defence against
this virus, an immunotherapeutic approach is warranted. The existing
immunotherapies are not completely effective, nor are they durable. In addition,
natural history studies associated with spontaneous regression have provided little
guidance to the design of successful interventions. This state of knowledge has
encouraged efforts towards the development of novel immunotherapeutic
strategies. Successful preclinical studies of therapeutic vaccine candidates have
led to clinical studies for a variety of HPV-associated indications, such as
AU:
CNOTE:
anogenital warts and cervical and anal intraepithelial neoplasia. Immunisation
approaches such as adjuvanted peptides, virus-like particles and fusion constructs
are discussed. Specifically, chimaeric molecules comprised of mycobacterial heatshock proteins (Hsps) and HPV16 E7 appear promising.
Chu NR
Chu N. Randall
Stressgen Biotechnologies Corp., 350-4243 Glanford Ave., Victoria, BC V8Z
4B9, Canada
[email protected]
2/84 von 102
ND:
Autoren:
EM2003005992
Vukasin P
Titel:
Anal condyloma and HIV-associated anal disease
Source:
Surgical Clinics of North America; VOL: 82 (6); p. 1199-1211 /200212/
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
0039-6109
CO:
SCNAA
PII:
S0039610902000853
Institution: Vukasin P, Dr., Keck School of Medicine, University of Southern California,
1450 San Pablo Street, Los Angeles, CA 90033, United
COU:
United States
DT:
JSC:
RN:
0074
Keywords
CT:
ANUS CONDYLOMA/*drug therapy; ANUS CONDYLOMA/*epidemiology;
ANUS CONDYLOMA/*surgery; ANUS CONDYLOMA/*therapy; ANUS
DISEASE/*drug therapy; ANUS DISEASE/*etiology; ANUS
DISEASE/*surgery; ANUS ULCER/*drug therapy; ANUS ULCER/*etiology;
ANUS ULCER/*surgery; CONDYLOMA/*drug therapy;
CONDYLOMA/*epidemiology; CONDYLOMA/*surgery;
CONDYLOMA/*therapy; HUMAN IMMUNODEFICIENCY VIRUS/*; ANUS
CARCINOMA/epidemiology; ANUS CARCINOMA/etiology; CARCINOGENIC
ACTIVITY; DISEASE ASSOCIATION; ERYTHEMA/side effect; HUMAN;
PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE;
SKIN IRRITATION/side effect; ACICLOVIR/drug combination;
ACICLOVIR/drug therapy; ANTIBIOTIC AGENT/drug therapy; ANTIVIRUS
DN:
ET:
TE:
CR:
AB:
AU:
CNOTE:
AGENT/drug therapy; DICHLOROACETIC ACID/drug therapy;
DICHLOROACETIC ACID/topical drug administration; FLUOROURACIL/drug
therapy; FLUOROURACIL/topical drug administration; IMIQUIMOD/adverse
drug reaction; IMIQUIMOD/drug therapy; IMIQUIMOD/topical drug
administration; INTERFERON/drug therapy; INTERFERON/intralesional drug
administration; LIQUID NITROGEN; METRONIDAZOLE/drug combination;
METRONIDAZOLE/drug therapy; PODOPHYLLIN/adverse drug reaction;
PODOPHYLLIN/drug therapy; PODOPHYLLIN/topical drug administration;
STEROID/drug therapy; STEROID/intralesional drug administration
Aldara
Mycology, Parasitology and Virology; Gastroenterology; Surgery
aciclovir/59277-89-3; dichloroacetic acid/13425-80-4; dichloroacetic acid/215656-1; dichloroacetic acid/79-43-6; fluorouracil/51-21-8; imiquimod/99011-02-6;
metronidazole/39322-38-8; metronidazole/443-48-1; podophyllin/9000-55-9
59277-89-3; 13425-80-4; 2156-56-1; 79-43-6; 51-21-8; 99011-02-6; 39322-38-8;
443-48-1; 9000-55-9
Although there are a large variety of anal diagnoses associated with the HIV
population, anal condyloma and anal ulcerations make up the vast majority. A
large percentage of individuals having multiple concurrent pathologies should also
be noted. Thus, this article concentrates on anal condyloma, anal ulceration and
HIV, making note of other significant issues.
Vukasin P
Vukasin Petar
Keck School of Medicine, University of Southern California, 1450 San Pablo
Street, Los Angeles, CA 90033, United States
[email protected]
2/85 von 102
ND:
Autoren:
EM2002435253
Pigot F
Titel:
Condylomes anaux de l'adulte
Anal condyloma in adults
Source:
Hepato-Gastro; VOL: 9 (6); p. 409-415 /200211/
SU:
EMBASE
Sprache: French
CY:
France
ISSN:
1253-7020
CO:
HEGAF
Institution: Pigot F, Hôpital Bagatelle, 33401 Talence Cedex,
France, [email protected]
COU:
France
DT:
JSC:
RN:
0019
Keywords
CT:
ANUS DISEASE/*diagnosis; ANUS DISEASE/*drug therapy; ANUS
DISEASE/*etiology; ANUS DISEASE/*surgery; CONDYLOMA/*diagnosis;
CONDYLOMA/*drug therapy; CONDYLOMA/*etiology;
CONDYLOMA/*surgery; WART VIRUS/*; ADULT; ANUS
CANCER/diagnosis; ANUS CANCER/drug therapy; ANUS CANCER/etiology;
ANUS CANCER/surgery; CANCER RISK; CLINICAL FEATURE; CLINICAL
TRIAL; CONTROLLED STUDY; DYSPLASIA/etiology; FEMALE; GENITAL
TRACT INFECTION/diagnosis; GENITAL TRACT INFECTION/drug therapy;
GENITAL TRACT INFECTION/etiology; GENITAL TRACT
INFECTION/surgery; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS
INFECTION/drug therapy; IMMUNOMODULATION; MAJOR CLINICAL
STUDY; MALE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED
TRIAL; REVIEW; SEXUALLY TRANSMITTED DISEASE/diagnosis;
SEXUALLY TRANSMITTED DISEASE/drug therapy; SEXUALLY
TRANSMITTED DISEASE/etiology; SEXUALLY TRANSMITTED
DISEASE/surgery; SQUAMOUS CELL CARCINOMA/diagnosis; SQUAMOUS
CELL CARCINOMA/drug therapy; SQUAMOUS CELL
CARCINOMA/etiology; SQUAMOUS CELL CARCINOMA/surgery; VIRUS
CARCINOGENESIS; VIRUS TRANSMISSION; FLUOROURACIL/*drug
therapy; IMIQUIMOD/*clinical trial; IMIQUIMOD/*drug therapy;
IMIQUIMOD/*topical drug administration; IMMUNOMODULATING
AGENT/*clinical trial; IMMUNOMODULATING AGENT/*drug therapy;
IMMUNOMODULATING AGENT/*topical drug administration;
PODOPHYLLOTOXIN/*drug therapy; ANTIRETROVIRUS AGENT/drug
therapy
DN:
Aldara; Condyline; Efudix
ET:
Obstetrics and Gynecology; Cancer; Drug Literature Index; Microbiology:
TE:
fluorouracil/51-21-8; imiquimod/99011-02-6; podophyllotoxin/518-28-5
CR:
51-21-8; 99011-02-6; 518-28-5
AU:
Pigot F
Pigot François
Hôpital Bagatelle, 33401 Talence Cedex, France
[email protected]
2/86 von 102
ND:
Autoren:
EM2002403432
Kaspari M; Gutzmer R; Kaspari T; Kapp A; Brodersen JP
Titel:
Application of imiquimod by suppositories (anal tampons) efficiently
prevents recurrences after ablation of anal canal condyloma
Source:
DOI:
10.1046/j.1365-2133.2002.04979.x
SU:
EMBASE
Sprache: English
AL:
English
CY:
United Kingdom
ISSN:
0007-0963
CO:
BJDEA
Institution: Kaspari M, Department of Dermatology, Hannover Medical University,
Ricklinger Strasse 5, 30449 Hannover, Germany, [email protected]
COU:
Germany
DT:
Journal Article
JSC:
RN:
0011
Keywords
CT:
ANUS DISEASE/*drug therapy; ANUS DISEASE/*prevention; ANUS
DISEASE/*surgery; CONDYLOMA/*drug therapy; CONDYLOMA/*prevention;
CONDYLOMA/*surgery; INFECTION PREVENTION/*; SUPPOSITORY/*;
TAMPON/*; ADULT; ARTICLE; BURNING SENSATION/side effect;
CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG
EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP;
HUMAN; MALE; PRIORITY JOURNAL; PRURITUS/side effect;
RECURRENT DISEASE; SURGICAL TECHNIQUE; TREATMENT
OUTCOME; IMIQUIMOD/*adverse drug reaction; IMIQUIMOD/*drug
therapy; IMIQUIMOD/*pharmacology
DN:
Aldara
ET:
Gastroenterology
TE:
CR:
99011-02-6
AB:
Background: After surgical removal, anal canal condyloma (ACC) has a higher
risk of recurrence compared with extragenital warts. Objectives: To reduce local
recurrences of ACC using follow-up treatment with imiquimod-containing
suppositories (anal tampons). Methods: After ablation of ACC, 10 male patients
received treatment with imiquimod suppositories three times weekly for 3-4
months. Results: Treatment with imiquimod anal tampons was well tolerated.
Early initial recurrences in some patients cleared after treatment with the
imiquimod suppositories. Within a mean follow-up of 9 months no patient
demonstrated recurrence of ACC. Conclusions: These data suggest that
imiquimod anal tampons may represent a new therapeutic option to prevent
recurrences of ACC following ablative surgery.
AU:
Gutzmer R
Gutzmer R
Department of Dermatology, Hannover Medical University, Ricklinger Strasse 5,
30449 Hannover, Germany
AU:
Kaspari M
Kaspari Markus
AU:
AU:
AU:
CNOTE:
Kaspari T
Kaspari T
Kapp A
Kapp A
Brodersen JP
Brodersen JP
2/87 von 102
ND:
Autoren:
EM2002188385
Jayne CJ; Kaufman RH
Titel:
Treatment of vulvar intraepithelial neoplasia 2/3 with imiquimod
Source:
Journal of Reproductive Medicine for the Obstetrician and Gynecologist; VOL: 47
(5); p. 395-398 /2002/
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
0024-7758
CO:
JRPMA
Institution: Kaufman RH, Dr., 6624 Fannin, Houston, TX 77030, United
COU:
United States
DT:
Journal Article
JSC:
RN:
0011
Keywords
CT:
CARCINOMA IN SITU/*diagnosis; CARCINOMA IN SITU/*drug therapy;
VULVA CARCINOMA/*diagnosis; VULVA CARCINOMA/*drug therapy;
ADULT; AGED; ARTICLE; CANCER INVASION/complication; CANCER
REGRESSION; CLINICAL ARTICLE; CREAM; DIAGNOSTIC ACCURACY;
DRUG EFFICACY; EVALUATION; FEMALE; FOLLOW UP;
HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PATIENT CARE;
PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT
OUTCOME; TUMOR BIOPSY; IMIQUIMOD/*drug therapy;
ET:
TE:
CR:
AB:
AU:
AU:
CNOTE:
IMIQUIMOD/*pharmaceutics; IMIQUIMOD/*topical drug administration
Obstetrics and Gynecology; Cancer; Drug Literature Index; Pharmacy; General
Pathology and Pathological Anatomy
99011-02-6
OBJECTIVE: To retrospectively review the charts of 13 women diagnosed with
vulvar intraepithelial neoplasia (VIN) 2/3 treated with imiquimod and to evaluate
the efficacy of this treatment. STUDY DESIGN: Retrospective review. All 13
women were treated and evaluated by a single gynecologist. The extent of the
lesions prior to treatment and the extent and degree of improvement were
documented. Biopsy confirmation of disease was obtained for each individual.
Response to treatment was categorized as complete regression, at least 75%
regression or not improved. RESULTS: The mean duration of treatment was 3.3
months, and follow-up after completion of therapy was 5.5 months. Eight of the
13 women had complete regression of the VIN. Four patients demonstrated 75%
regression of disease, and in one diabetic woman no improvement was seen. In
two women demonstrating 75% lesion regression, invasive carcinoma of the vulva
was found in the area of residual disease. In one instance this was determined to
be superficially invasive squamous cell carcinoma (1 mm of invasion), and in the
second an anal tag was found to have invasive squamous cell carcinoma.
CONCLUSION: Medical management of VIN 2/3 with imiquimod is worth
considering. However, careful evaluation of the patient must be carried out prior
to the institution of therapy to exclude the presence of invasive squamous cell
carcinoma.
Jayne CJ
Jayne Christopher J.
6624 Fannin, Houston, TX 77030, United States
Kaufman RH
Kaufman Raymond H.
6624 Fannin, Houston, TX 77030, United States
2/88 von 102
ND:
Autoren:
EM2002110754
Mahé E; Descamps V
Titel:
Un nouvel anti-viral pour les condylomes ano-génitaux
A new antiviral for genito-anal condylomas
Source:
Presse Medicale; VOL: 31 (10); p. 449-450 /20020316/
SU:
EMBASE
Sprache: French
CY:
France
ISSN:
0755-4982
CO:
PRMEE
Institution: Mahé E, Serv. de Dermatol. du Pr Cricks, Hôpital Bichat-Claude Bernard, 75018
Paris, France
France
Note; Journal Article
0007
COU:
DT:
JSC:
RN:
Keywords
CT:
ANOGENITAL CONDYLOMA/*drug therapy; CONDYLOMA/*drug therapy;
CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE
BLIND PROCEDURE; DRUG EFFICACY; ERADICATION THERAPY;
HERPES VIRUS; HUMAN; IMMUNOCOMPETENCE;
NEPHROTOXICITY/side effect; NOTE; POLYMERASE CHAIN REACTION;
RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT
OUTCOME; CIDOFOVIR/*adverse drug reaction; CIDOFOVIR/*clinical trial;
CIDOFOVIR/*drug therapy; CIDOFOVIR/*intravenous drug administration;
IMIQUIMOD; PLACEBO
DN:
Aldara; Vistide
ET:
Public Health, Social Medicine and Epidemiology; Clinical and Experimental
Pharmacology; Drug Literature Index; Adverse Reactions Titles; Microbiology:
Bacteriology, Mycology, Parasitology and Virology
TE:
cidofovir/113852-37-2; imiquimod/99011-02-6
CR:
113852-37-2; 99011-02-6
AU:
Mahé E
Mahé E
Serv. de Dermatol. du Pr Cricks, Hôpital Bichat-Claude Bernard, 75018 Paris,
France
AU:
Descamps V
Descamps V
Serv. de Dermatol. du Pr Cricks, Hôpital Bichat-Claude Bernard, 75018 Paris,
France
2/89 von 102
ND:
Autoren:
EM2002032801
Pfenninger JL; Zainea GG
Titel:
Common anorectal conditions
Source:
DOI:
SU:
Sprache:
AL:
CY:
ISSN:
Obstetrics and Gynecology; VOL: 98 (6); p. 1130-1139 /2001/
10.1016/S0029-7844(01)01687-8
EMBASE
English
English
United States
0029-7844
CO:
OBGNA
PII:
S0029784401016878
Institution: Pfenninger JL, Dr., Natl. Procedures Inst., Midland, MI, Midland, MI, United
States
COU:
United States
DT:
Journal Article
JSC:
RN:
0033
Keywords
CT:
ANORECTAL DISEASE/*disease management; ANORECTAL DISEASE/*drug
therapy; ANORECTAL DISEASE/*surgery; ANORECTAL DISEASE/*therapy;
ANUS CANCER/drug therapy; ANUS CANCER/radiotherapy; ANUS
FISSURE/drug therapy; ANUS FISTULA/surgery; ARTICLE; CANCER
SCREENING; CLINICAL FEATURE; COLORECTAL CANCER/surgery;
CONDYLOMA ACUMINATUM; ENTERITIS; FAMILY HISTORY;
GENERAL PRACTITIONER; HEMORRHOID/surgery;
HEMORRHOID/therapy; HUMAN; PAPILLOMA VIRUS; PERIANAL
ABSCESS/surgery; POLYP; PRIORITY JOURNAL; RECTUM
PROLAPSE/surgery; SEPSIS/drug therapy; SEPSIS/surgery; SEXUALITY;
STENOSIS/surgery; ULCER; VIRUS INFECTION; ANESTHETIC
AGENT/drug therapy; ANTIBIOTIC AGENT/drug therapy; BOTULINUM
TOXIN/drug therapy; BOTULINUM TOXIN/pharmacoeconomics;
CORTICOSTEROID/drug therapy; DILTIAZEM/drug therapy;
FLUOROURACIL/drug therapy; GLYCERYL TRINITRATE/drug therapy;
IMIQUIMOD/drug therapy; IMIQUIMOD/pharmacoeconomics;
INTERFERON/drug therapy; LIDOCAINE/drug therapy; LIDOCAINE/topical
drug administration; MISOPROSTOL/drug therapy; NIFEDIPINE/drug therapy;
NIFEDIPINE/topical drug administration; PHENYTOIN/drug therapy;
PODOPHYLLOTOXIN/drug therapy;
PODOPHYLLOTOXIN/pharmacoeconomics; SUPPOSITORY BASE/drug
therapy; SUPPOSITORY BASE/rectal drug administration;
ET:
Cancer; Health Policy, Economics and Management; Drug Literature Index;
Gastroenterology
TE:
diltiazem/33286-22-5; diltiazem/42399-41-7; fluorouracil/51-21-8; glyceryl
trinitrate/55-63-0; imiquimod/99011-02-6; lidocaine/137-58-6; lidocaine/2484767-4; lidocaine/56934-02-2; lidocaine/73-78-9; misoprostol/59122-46-2;
misoprostol/59122-48-4; nifedipine/21829-25-4; phenytoin/57-41-0;
phenytoin/630-93-3; podophyllotoxin/518-28-5; trichloroacetic acid/14357-05-2;
trichloroacetic acid/76-03-9
CR:
33286-22-5; 42399-41-7; 51-21-8; 55-63-0; 99011-02-6; 137-58-6; 24847-67-4;
56934-02-2; 73-78-9; 59122-46-2; 59122-48-4; 21829-25-4; 57-41-0; 630-93-3;
518-28-5; 14357-05-2; 76-03-9
AB:
Patients with a wide variety of anorectal lesions present to family physicians.
Most can be successfully managed in the office setting. A high index of suspicion
for cancer should be maintained and all patients should be questioned about
relevant family history or other indications for cancer screening. Patients with
condylomata acuminata must be examined for human papillomavirus infection
AU:
AU:
CNOTE:
elsewhere after treatment of the presenting lesions. Their sexual partners should
also be counseled and screened. Both surgical and nonsurgical treatments are
available for the pain of anal fissure. Infection in the anorectal area may present
as different types of abscesses, cryptitis, fistulae or perineal sepsis. Fistulae may
result from localized infection or indicate inflammatory bowel disease. Protrusion
of tissue through the anus may be due to hemorrhoids, mucosal prolapse, polyps
or other lesions.
Pfenninger JL
Pfenninger John L
National Procedures Institute, Midland, MI, United States
Zainea GG
Zainea George G
2/90 von 102
ND:
Autoren:
EM2001248617
Pfenninger JL; Zainea GG
Titel:
Common anorectal conditions: Part II. Lesions
Source:
American Family Physician; VOL: 64 (1); p. 77-88 /20010701/
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
0002-838X
CO:
AFPYA
Institution: Pfenninger JL, Dr., National Procedures Institute, Midland, MI, United States
COU:
United States
DT:
Journal Article
JSC:
RN:
0033
Keywords
CT:
ANORECTAL DISEASE/*diagnosis; ANORECTAL DISEASE/*disease
management; ANORECTAL DISEASE/*drug therapy; ANORECTAL
DISEASE/*etiology; ANORECTAL DISEASE/*surgery; ANUS
CANCER/surgery; ANUS FISSURE/drug therapy; ANUS FISSURE/surgery;
ANUS FISTULA/etiology; ANUS FISTULA/surgery; ARTICLE; CANCER
SCREENING; COLORECTAL CANCER/diagnosis; CONDYLOMA
ACUMINATUM/disease management; CONDYLOMA ACUMINATUM/drug
therapy; CONDYLOMA ACUMINATUM/etiology; CONDYLOMA
ACUMINATUM/surgery; FAMILY HISTORY; HEMORRHOID/surgery;
HUMAN; INFECTION/surgery; PERIANAL ABSCESS/etiology; PERIANAL
ABSCESS/surgery; PROCTITIS/etiology; RECTUM CANCER/surgery;
RECTUM POLYP/diagnosis; RECTUM PROLAPSE/surgery;
STENOSIS/surgery; WART VIRUS; FLUOROURACIL/*drug therapy;
FLUOROURACIL/*pharmacoeconomics; INTERFERON/*drug therapy;
INTERFERON/*pharmacoeconomics; TRICHLOROACETIC ACID/*drug
therapy; TRICHLOROACETIC ACID/*pharmacoeconomics; DILTIAZEM/drug
therapy; GLYCERYL TRINITRATE/drug therapy; GLYCERYL
TRINITRATE/topical drug administration; IMIQUIMOD/drug therapy;
IMIQUIMOD/pharmacoeconomics; LIDOCAINE/drug therapy;
LIDOCAINE/topical drug administration; NIFEDIPINE/drug therapy;
PODOPHYLLOTOXIN/drug therapy;
PODOPHYLLOTOXIN/pharmacoeconomics; STEROID/drug therapy;
STEROID/topical drug administration
Aldara; Condylox; Efudex
Health Policy, Economics and Management; Drug Literature Index;
Gastroenterology; Internal Medicine
diltiazem/33286-22-5; diltiazem/42399-41-7; fluorouracil/51-21-8; glyceryl
trinitrate/55-63-0; imiquimod/99011-02-6; lidocaine/137-58-6; lidocaine/2484767-4; lidocaine/56934-02-2; lidocaine/73-78-9; nifedipine/21829-25-4;
acid/76-03-9
33286-22-5; 42399-41-7; 51-21-8; 55-63-0; 99011-02-6; 137-58-6; 24847-67-4;
56934-02-2; 73-78-9; 21829-25-4; 518-28-5; 14357-05-2; 76-03-9
Patients with a wide variety of anorectal lesions present to family physicians.
Most can be successfully managed in the office setting. A high index of suspicion
for cancer should be maintained and all patients should be questioned about
relevant family history or other indications for cancer screening. Patients with
condylomata acuminata must be examined for human papillomavirus infection
elsewhere after treatment of the presenting lesions. Their sexual partners should
also be counseled and screened. Both surgical and nonsurgical treatments are
available for the pain of anal fissure. Infection in the anorectal area may present
as different types of abscesses, cryptitis, fistulae or perineal sepsis. Fistulae may
result from localized infection or indicate inflammatory bowel disease. Protrusion
of tissue through the anus may be due to hemorrhoids, mucosal prolapse, polyps
or other lesions.
Pfenninger JL
Pfenninger JL
Zainea GG
Zainea GG
DN:
ET:
TE:
CR:
AB:
AU:
AU:
CNOTE:
2/91 von 102
ND:
EM2001181833
Autoren: Menz J
Titel:
Pruritus ani: Some answers for that maddening itch!
Source: Medicine Today; VOL: 2 (5); p. 67-73 /2001/
SU:
EMBASE
Sprache: English
AL:
English
CY:
Australia
ISSN: 1443-430X
CO:
MTNBC
DT:
JSC:
Keywords
CT:
ANUS PRURITUS/*drug therapy; ANUS PRURITUS/*etiology; ANUS
PRURITUS/*surgery; ANUS PRURITUS/*therapy; ANAMNESIS; ANUS
FISSURE; ATOPIC DERMATITIS/drug therapy; BOWEN DISEASE; CANCER;
CANDIDIASIS; CLEANING; CLOTHING; CONTACT DERMATITIS;
CONTAMINATION; CRYOTHERAPY; DIET THERAPY; DISEASE
PREDISPOSITION; ENTEROBIUS VERMICULARIS; FECES; GENERAL
PRACTITIONER; HEMORRHOID/surgery; HEMORRHOIDECTOMY;
HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
HYPEREMIA; INFECTION; LICHEN SCLEROSUS ET ATROPHICUS; PAGET
SKIN DISEASE; PERSONAL HYGIENE; PODOPHYLLUM/drug therapy;
PODOPHYLLUM/topical drug administration; PSORIASIS; PSYCHOLOGICAL
ASPECT; RECTUM PROLAPSE; REVIEW; SEBORRHEIC DERMATITIS/drug
therapy; SKIN CANCER; SKIN DISEASE/drug therapy; SQUAMOUS CELL
CARCINOMA; SWEATING; SYMPTOM; TINEA; ULTRAPROCT; WART
VIRUS; ANTHELMINTIC AGENT/drug therapy; ANTIHISTAMINIC
AGENT/drug therapy; ANTIINFECTIVE AGENT/drug therapy; ANUSOL;
CLOTRIMAZOLE/drug therapy; CLOTRIMAZOLE/topical drug administration;
COMBANTRIN 1; CONDYLINE PAINT; DOXEPIN/drug therapy;
FEXOFENADINE/drug therapy; FULCHIN; GLYCERYL TRINITRATE;
GRISEOFULVIN/drug therapy; GRISEOFULVIN/oral drug administration;
HEMOCAINE; HYDROCORTISONE/drug therapy; HYDROCORTISONE/topical
drug administration; HYDROCORTISONE ACETATE/drug therapy;
HYDROCORTISONE ACETATE/topical drug administration; IMIQUIMOD/drug
therapy; IMIQUIMOD/topical drug administration; LIQUID PARAFFIN/drug
therapy; LORASTYNE; LORATADINE/drug therapy; MEBENDAZOLE/drug
therapy; MENTHOL/drug therapy; MICONAZOLE/drug therapy;
MICONAZOLE/topical drug administration; POSALFILIN; PREPARATION H;
PROCTOSEDYL; PYRANTEL EMBONATE/drug therapy; RECTINOL; SAMA
LOTION; SCHERIPROCT; UNCLASSIFIED DRUG; XYLOPROCT/drug
therapy; XYLOPROCT/topical drug administration; ZINC/drug therapy
DN:
Aldara; Anusol; Canesten; Claratyne; Combantrin 1; Condyline Paint; Daktarin;
Deptran; Fulchin; Griseostatin; Grisovin; Hemocaine; Lorastyne; Posalfilin;
Preparation H; Proctosedyl; Rectinol; Rectogesic; Sama Lotion; Scheriproct;
Sigmacort; Sinequan; Telfast; Ultraproct; Xyloproct
ET:
Dermatology and Venereology; Cancer; Drug Literature Index; Microbiology:
TE:
anusol/8053-45-0; clotrimazole/23593-75-1; doxepin/1229-29-4; doxepin/1668-195; fexofenadine/138452-21-8; glyceryl trinitrate/55-63-0; griseofulvin/126-07-8;
hydrocortisone acetate/50-03-3; hydrocortisone/50-23-7; imiquimod/99011-02-6;
liquid paraffin/8012-95-1; loratadine/79794-75-5; mebendazole/31431-39-7;
menthol/1490-04-6; menthol/89-78-1; miconazole/22916-47-8; proctosedyl/805805-7; pyrantel embonate/22204-24-6; zinc/7440-66-6
CR:
8053-45-0; 23593-75-1; 1229-29-4; 1668-19-5; 138452-21-8; 55-63-0; 126-07-8;
50-03-3; 50-23-7; 99011-02-6; 8012-95-1; 79794-75-5; 31431-39-7; 1490-04-6; 8978-1; 22916-47-8; 8058-05-7; 22204-24-6; 7440-66-6
AB:
Pruritus ani is a common condition and is more frequent in men than women.
Pruritus ani is a symptom rather than a diagnosis. Faecal contamination is a
predisposing factor. Local hygiene problems frequently contribute to faecal
contamination, and surgical problems such as haemorrhoids, fissures, mucosal
prolapse or scars may be causes of anal leakage. Dermatoses, infections or cancers
are other possible underlying causes. With the removal of underlying pathology, the
itch often resolves. Patients are often reticent in discussing the condition and the
general practitioner has an important role to play in supporting the patient.
AU:
Menz J
Menz J
2/92 von 102
ND:
Autoren:
EM2001104477
Smith LE; Hyman N; Savoca P; Simmang C; Stratton M
Titel:
Potions and lotions
Source:
Perspectives in Colon and Rectal Surgery; VOL: 13 (2); p. 17-30 /2000/
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
0894-8054
CO:
PCRSF
Institution: Smith LE, Dr., Section of Colon and Rectal Surgery, Washington Hospital Center,
Washington, DC, United States
COU:
United States
DT:
Keywords
CT:
HEMORRHOID/*drug therapy; HEMORRHOID/*therapy; LOTION/*; ANUS
FISSURE/drug therapy; ANUS FISSURE/therapy; CONDYLOMA/drug therapy;
CREAM; DRUG EFFECT; DRUG USE; DYSPLASIA; HERPES; HUMAN;
ILEITIS; MEDICAL PRACTICE; OINTMENT; PILONIDAL SINUS/drug
therapy; PILONIDAL SINUS/therapy; PROCTITIS/drug therapy; REVIEW;
SIDE EFFECT/side effect; SUPPOSITORY; ULCERATIVE COLITIS;
ANALPRAM; ANUSOL; BENZOCAINE; DICHLOROACETIC ACID/drug
therapy; DICHLOROACETIC ACID/topical drug administration;
ENEMA/adverse drug reaction; GLYCERYL TRINITRATE/adverse drug
DN:
ET:
TE:
CR:
AB:
reaction; GLYCERYL TRINITRATE/drug therapy; GLYCERYL
TRINITRATE/topical drug administration; HYDROCORTISONE/adverse drug
reaction; HYDROCORTISONE/drug therapy; HYDROCORTISONE/topical drug
administration; HYDROCORTISONE ACETATE/drug combination;
HYDROCORTISONE ACETATE/drug therapy; HYDROCORTISONE
ACETATE/topical drug administration; IMIQUIMOD/drug therapy;
LIDOCAINE; MINERAL OIL/drug therapy; NEOSPORIN/drug therapy; NON
PRESCRIPTION DRUG/adverse drug reaction; NON PRESCRIPTION
DRUG/drug therapy; PETROLATUM/drug therapy; PLACEBO;
PODOPHYLLIN/drug therapy; PODOPHYLLOTOXIN/drug therapy;
POLYSPORIN/drug therapy; PRAMOCAINE/drug combination;
PRAMOCAINE/drug therapy; PRAMOCAINE/topical drug administration;
SILVER NITRATE/drug therapy; SILVER NITRATE/topical drug
administration; TANNIN/drug therapy; TANNIN/topical drug administration;
drug administration; VANCOMYCIN/drug therapy; VANCOMYCIN/oral drug
administration
Americaine; Analpram; Anusol; Balneol; Condylox; Cortifoam
Public Health, Social Medicine and Epidemiology; Drug Literature Index;
anusol/8053-45-0; benzocaine/1333-08-0; benzocaine/94-09-7; dichloroacetic
acid/13425-80-4; dichloroacetic acid/2156-56-1; dichloroacetic acid/79-43-6;
glyceryl trinitrate/55-63-0; hydrocortisone acetate/50-03-3; hydrocortisone/50-237; imiquimod/99011-02-6; lidocaine/137-58-6; lidocaine/24847-67-4;
lidocaine/56934-02-2; lidocaine/73-78-9; neosporin/8057-37-2; petrolatum/800903-8; podophyllin/9000-55-9; podophyllotoxin/518-28-5; polysporin/118933-134; pramocaine/140-65-8; pramocaine/637-58-1; silver nitrate/7761-88-8;
tannin/1401-55-4; trichloroacetic acid/14357-05-2; trichloroacetic acid/76-03-9;
vancomycin/1404-90-6; vancomycin/1404-93-9
8053-45-0; 1333-08-0; 94-09-7; 13425-80-4; 2156-56-1; 79-43-6; 55-63-0; 50-033; 50-23-7; 99011-02-6; 137-58-6; 24847-67-4; 56934-02-2; 73-78-9; 8057-37-2;
8009-03-8; 9000-55-9; 518-28-5; 118933-13-4; 140-65-8; 637-58-1; 7761-88-8;
1401-55-4; 14357-05-2; 76-03-9; 1404-90-6; 1404-93-9
Many of the topical ointments, creams, suppositories, and enemas that we use
have been formulated by someone with good intentions, but without the benefit of
scientific scrutiny. This is not to say that certain remedies and herbs from doctors
of old and even contemporaries do not obtain some sort of reaction or response.
However, many of these items that are promoted by our mentors have been
handed down to their students and residents as the answer for specific ailments.
We are the disciples who have gathered for discussion of the products and
compounds that we have adopted into our personal practices. It is important for us
to insert disclaimers that these products have often been created without absolute
scientific certainty, and that they will list the intended results. Like various acrossthe-counter medications, many have caused no harm, but also have yielded no
effects. However, calming the patient's anxiety is worthwhile. During this
discussion, our experts will point out those medications that have merit and those
that may have placebo effect. Our first topic is the treatment of hemorrhoidal
symptoms without significant procedures; the benefit of suppositories or other
topical remedies. We will also cover medications for anal fissures: selection,
application, components of, and benefits or side effects. Pilonidal sinuses care will
AU:
AU:
AU:
AU:
AU:
CNOTE:
be addressed by our panelists, including the use of silver nitrate. Options for
identifying and treating condyloma, dysplasia, and herpes are reviewed; muscle
problems such as proctalgia fugax and levator syndrome; suggestions for
ulcerative proctitis and pouchitis; and other conditions of interest to our readers
will be examined by our group of panelists.
Smith LE
Smith LE
Section of Colon and Rectal Surgery, Washington Hospital Center, Washington,
DC, United States
Hyman N
Hyman N
DC, United States
Savoca P
Savoca P
DC, United States
Simmang C
Simmang C
DC, United States
Stratton M
Stratton M
DC, United States
2/93 von 102
ND:
Autoren:
EM2001041907
Michel C; Schubert B
Titel:
Maladies sexuellement transmises de l'anus
Anal sexually transmitted diseases
Source:
Revue du Praticien; VOL: 51 (1); p. 50-53 /20010115/
SU:
EMBASE
Sprache: French
AL:
English; French
CY:
France
ISSN:
0035-2640
CO:
REPRA
Institution: Michel C, Service de Dermatologie, Centre Hospitalier de Mulhouse, 68070
Mulhouse Cedex, France, [email protected]
COU:
France
DT:
JSC:
RN:
Keywords
CT:
DN:
ET:
TE:
CR:
AB:
AU:
AU:
0015
ANUS DISEASE/*drug therapy; ANUS DISEASE/*etiology; SEXUALLY
TRANSMITTED DISEASE/*diagnosis; SEXUALLY TRANSMITTED
DISEASE/*etiology; CONDYLOMA/drug therapy; CONDYLOMA/etiology;
GENITAL HERPES/drug therapy; GENITAL HERPES/etiology; GENOTYPE;
GONORRHEA/drug therapy; GONORRHEA/etiology; HUMAN; HUMAN
CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE;
REVIEW; SYPHILIS/drug therapy; SYPHILIS/etiology; VIRUS
TRANSMISSION; BENZATHINE PENICILLIN/*drug therapy; BENZATHINE
PENICILLIN/*intramuscular drug administration; CEFTRIAXONE/*drug
therapy; CEFTRIAXONE/*intramuscular drug administration;
CIPROFLOXACIN/*drug therapy; PENICILLIN DERIVATIVE/*drug therapy;
SPECTINOMYCIN/*drug therapy; SPECTINOMYCIN/*intramuscular drug
administration; AZITHROMYCIN/drug therapy; COTRIMOXAZOLE;
DOXYCYCLINE/drug therapy; DOXYCYCLINE/oral drug administration;
FAMCICLOVIR/drug therapy; IMIQUIMOD/drug therapy;
VALACICLOVIR/drug therapy
Aldara; Bactrim Forte; Ciflox; Extencilline; Oravir; Rocephine; Trobicin; Zelitrex;
Zithromax
Drug Literature Index; Microbiology: Bacteriology, Mycology, Parasitology and
Virology; Gastroenterology
azithromycin/83905-01-5; benzathine penicillin/1538-09-6; ceftriaxone/73384-595; ceftriaxone/74578-69-1; ciprofloxacin/85721-33-1; cotrimoxazole/8064-90-2;
doxycycline/10592-13-9; doxycycline/17086-28-1; doxycycline/564-25-0;
famciclovir/104227-87-4; imiquimod/99011-02-6; spectinomycin/1695-77-8;
spectinomycin/21736-83-4; spectinomycin/23312-56-3; valaciclovir/124832-26-4
83905-01-5; 1538-09-6; 73384-59-5; 74578-69-1; 85721-33-1; 8064-90-2; 1059213-9; 17086-28-1; 564-25-0; 104227-87-4; 99011-02-6; 1695-77-8; 21736-83-4;
23312-56-3; 124832-26-4
Sexually transmitted diseases, despite vigorous efforts in prevention, are still
existing and may provide portal of entry for human immunodeficiency virus
transmission. Syphilis and gonococcal infection are decreasing but remain a
problem in developing countries and their return cannot be excluded, despite
active therapy. In industrial countries, viral infections are expanding. Herpes
genitalis is the most common cause of genito-anal ulceration and anogenital warts
have been steadily rising in the past decades. Some human papillomavirus
genotypes are oncogenic. No treatment is able to eradicate them.
Michel C
Michel C
Service de Dermatologie, Centre Hospitalier de Mulhouse, 68070 Mulhouse
Cedex, France
Schubert B
Schubert B
Service de Dermatologie, Centre Hospitalier de Mulhouse, 68070 Mulhouse
Cedex, France
CNOTE:
2/94 von 102
ND:
Autoren:
EM2001036716
Pehoushek J; Smith KJ
Titel:
Imiquimod and 5% fluorouracil therapy for anal and perianal
squamous cell carcinoma in situ in an HIV-1-positive man
Source:
SU:
EMBASE
Sprache: English
CY:
United States
ISSN:
0003-987X
CO:
ARDEA
Institution: Smith KJ, Department Dermatology/Pathology, National Naval Medical Center,
Bethesda, MD 20889-5600, United States, [email protected]
COU:
United States
DT:
Journal Article
JSC:
RN:
0020
Keywords
CT:
ANUS CARCINOMA/*drug therapy; CARCINOMA IN SITU/*drug therapy;
HUMAN IMMUNODEFICIENCY VIRUS 1/*; HUMAN
IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; SQUAMOUS
CELL CARCINOMA/*drug therapy; ADULT; ARTICLE; CANCER
COMBINATION CHEMOTHERAPY; CASE REPORT; CREAM; DNA
PROBE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY
JOURNAL; SKIN BIOPSY; TREATMENT OUTCOME; ANTIVIRUS
AGENT/*drug combination; ANTIVIRUS AGENT/*drug therapy;
FLUOROURACIL/*drug combination; FLUOROURACIL/*drug therapy;
FLUOROURACIL/*topical drug administration; IMIQUIMOD/*drug
combination; IMIQUIMOD/*drug therapy; IMIQUIMOD/*topical drug
administration; INDINAVIR/drug combination; INDINAVIR/drug therapy;
LAMIVUDINE/drug therapy; NELFINAVIR/drug combination;
NELFINAVIR/drug therapy; STAVUDINE/drug combination;
STAVUDINE/drug therapy
ET:
Dermatology and Venereology; Cancer; Drug Literature Index
TE:
fluorouracil/51-21-8; imiquimod/99011-02-6; indinavir/150378-17-9;
indinavir/157810-81-6; indinavir/180683-37-8; lamivudine/134678-17-4;
lamivudine/134680-32-3; nelfinavir/159989-64-7; nelfinavir/159989-65-8;
stavudine/3056-17-5
CR:
51-21-8; 99011-02-6; 150378-17-9; 157810-81-6; 180683-37-8; 134678-17-4;
134680-32-3; 159989-64-7; 159989-65-8; 3056-17-5
AU:
Pehoushek J
Pehoushek J
AU:
CNOTE:
Department Dermatology/Pathology, National Naval Medical Center, Bethesda,
MD 20889-5600, United States
Smith KJ
Smith KJ
Department Dermatology/Pathology, National Naval Medical Center, Bethesda,
MD 20889-5600, United States
2/95 von 102
ND:
Autoren:
EM2000375758
Maw R; Von Krogh G
Titel:
The management of anal warts: Topical self treatment, ablative
therapy, and counselling should all be available
Source:
British Medical Journal; VOL: 321 (7266); p. 910-911 /20001014/
SU:
EMBASE
Sprache: English
CY:
United Kingdom
ISSN:
0959-8146
CO:
BMJOA
Institution: Maw R, Royal Victoria Hospital, Belfast BT12 6BA, United
COU:
United Kingdom
DT:
Editorial; Journal Article
JSC:
RN:
0013
Keywords
CT:
CONDYLOMA ACUMINATUM/*drug therapy; CRYOTHERAPY; DRUG
EFFICACY; EDITORIAL; ELECTROSURGERY; HUMAN; MEDICAL
DECISION MAKING; PRIORITY JOURNAL; SEXUALLY TRANSMITTED
DISEASE; TREATMENT PLANNING; IMIQUIMOD/*drug therapy;
IMIQUIMOD/*topical drug administration; PODOPHYLLOTOXIN/*drug
therapy; PODOPHYLLOTOXIN/*topical drug administration
ET:
TE:
CR:
99011-02-6; 518-28-5
AU:
Maw R
Maw R
Royal Victoria Hospital, Belfast BT12 6BA, United Kingdom
AU:
Von Krogh G
Von Krogh G
Royal Victoria Hospital, Belfast BT12 6BA, United Kingdom
2/96 von 102
ND:
PMID:
Autoren:
EMM14610898
14610898
Gross G
Titel:
Humane Papillomaviren.
Human papillomaviruses
Source:
Therapeutische Umschau. Revue therapeutique; VOL: 60 (10); p. 595-604 /Oct
2003/
SU:
Medline
Sprache: German
AL:
English
CY:
Switzerland
ISSN:
0040-5930
Institution: Gross G, Klinik und Poliklinik fur Dermatologie und Venerologie, Universitat
Rostock, Deutschland., [email protected]
DT:
Journal Article
JSC:
Keywords
CT:
PAPILLOMA VIRUS/*; SKIN TUMOR/*diagnosis; SKIN TUMOR/*therapy;
VIRAL SKIN DISEASE/*diagnosis; VIRAL SKIN DISEASE/*therapy; VIRUS
INFECTION/*diagnosis; VIRUS INFECTION/*therapy; ADOLESCENT;
ADULT; ANUS TUMOR/diagnosis; ANUS TUMOR/therapy; ARTICLE;
BIOPSY; CONDYLOMA ACUMINATUM/diagnosis; CONDYLOMA
ACUMINATUM/therapy; FEMALE; HUMAN; MALE; MIDDLE AGED;
PATHOLOGY; SKIN; UROGENITAL TRACT TUMOR/diagnosis;
UROGENITAL TRACT TUMOR/therapy; VERRUCA VULGARIS/diagnosis;
VERRUCA VULGARIS/therapy
AB:
Human papillomaviruses (HPV) infect exclusively the basal cells of the skin and
of mucosal epithelia adjacent to the skin such as the mouth, the upper respiratory
tract, the lower genital tract and the anal canal. HPV does not lead to a viremia.
Basically there are three different types of HPV infection: Clinically visible
lesions, subclinical HPV infections and latent HPV infections. Distinct HPV types
induce morphologically and prognostically different clinical pictures. The most
common HPV associated benign tumor of the skin is the common wart. Infections
of the urogenitoanal tract with specific HPV-types are recognised as the most
frequent sexually transmitted viral infections. So-called "high-risk" HPV-types
(HPV16, 18 and others) are regarded by the world health organisation as
important risk-factors for the development of genital cancer (mainly cervical
cancer), anal cancer and upper respiratory tract cancer in both genders. Antiviral
substances with a specific anti-HPV effect are so far unknown. Conventional
therapies of benign skin warts and of mucosal warts are mainly nonspecific. They
comprise tissue-destroying therapies such as electrocautery, cryotherapy and laser.
In addition cytotoxic substances such as podophyllotoxin and systemic therapy
with retinoids are in use. Systemically and topically administered
AU:
CNOTE:
immunotherapies represent a new approach for treatment. Both interferons and
particularly the recently developed imiquimod, an interferon-alpha and cytokineinductor lead to better results and are better tolerated then conventional therapies.
HPV-specific vaccines have been developed in the last 5 years and will be used in
future for prevention and treatment of benign and malignant HPV-associated
tumors of the genitoanal tract in both sexes.
Gross G
Gross G
Klinik und Poliklinik fur Dermatologie und Venerologie, Universitat Rostock,
Deutschland.
2/97 von 102
ND:
PMID:
Autoren:
EMM12835572
12835572
Heinzerling LM; Kempf W; Kamarashev J; Hafner J; Nestle FO
Titel:
Treatment of verrucous carcinoma with imiquimod and CO2 laser
ablation.
Source:
Dermatology (Basel, Switzerland); VOL: 207 (1); p. 119-122 /2003/
SU:
Medline
Sprache: English
AL:
English
CY:
Switzerland
ISSN:
1018-8665
Institution: Heinzerling LM, University Hospital Zurich, Zurich, Switzerland.
DT:
Journal Article
Keywords
CT:
LASER/*drug therapy; SKIN TUMOR/*therapy; VERRUCOUS
CARCINOMA/*therapy; AGED; ARTICLE; CANCER STAGING; CASE
REPORT; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY;
MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; PATHOLOGY;
RISK ASSESSMENT; TREATMENT OUTCOME; AMINOQUINOLINE
DERIVATIVE/*drug administration; CARBON DIOXIDE; IMIQUIMOD
TE:
carbon dioxide/124-38-9; imiquimod/99011-02-6
CR:
124-38-9; 99011-02-6
AB:
An 82-year-old female patient presented with a large perianal hyperkeratotic
tumor extending into the anal canal. Staging did not reveal any metastatic spread.
Diagnosis of verrucous carcinoma or Buschke-Lowenstein tumor, respectively,
was based on typical clinical and histologic features. Moreover, human
papillomavirus 6b DNA sequences could be detected by PCR. Surgical excision
could not be performed due to the general health status of the patient; thus,
alternative therapy methods were necessary. Treatment with imiquimod cream
5% (Aldara), a topical immune response modifier applied once a day and left for
12 h, led to significant partial tumor regression and clear demarcation of the
AU:
AU:
AU:
AU:
AU:
CNOTE:
tumor. The remaining tumor, now feasible for treatment with CO2 laser, was
removed in two sessions in local anesthesia. In a third session, tumor parts in the
anal canal were vaporized. This case demonstrates that the combination of
imiquimod and CO2 laser ablation is an effective treatment option for verrucous
carcinoma. Copyright 2003 S. Karger AG, Basel
Heinzerling LM
Heinzerling LM
University Hospital Zurich, Zurich, Switzerland.
Kempf W
Kempf W
Kamarashev J
Kamarashev J
Hafner J
Hafner J
Nestle FO
Nestle FO
2/98 von 102
ND:
PMID:
Autoren:
EMM12903534
12903534
Bertagni A; Vagliasindi A; Ascari Raccagni A; Valmori L; Verdecchia GM
Titel:
Perianal Bowen's disease: a case report and review of the literature.
Perianal Bowen's disease: a case report and review of the literature
Source:
Tumori; VOL: 89 (4 Suppl); p. 16-18 /2003 Jul-Aug/
SU:
Medline
Sprache: Italian
AL:
English
CY:
Italy
ISSN:
0300-8916
Institution: Bertagni A, UO di Chirurgia Generale II, Unita di Chirurgia Oncologica, Ospedale
GB Morgagni-L Pierantoni, Forli.
DT:
JSC:
C.1.3 ... Oncology
RN:
0012
Keywords
CT:
ANUS TUMOR/*complication; ANUS TUMOR/*drug therapy; ANUS
TE:
CR:
AB:
AU:
AU:
AU:
AU:
TUMOR/*radiotherapy; ANUS TUMOR/*surgery; BOWEN
DISEASE/*complication; BOWEN DISEASE/*drug therapy; BOWEN
DISEASE/*radiotherapy; BOWEN DISEASE/*surgery; SKIN
TUMOR/*complication; SKIN TUMOR/*drug therapy; SKIN
TUMOR/*radiotherapy; SKIN TUMOR/*surgery; ADJUVANT
CHEMOTHERAPY; ADJUVANT THERAPY; CASE REPORT; FEMALE;
GASTROINTESTINAL HEMORRHAGE/etiology; HUMAN; ISOLATION
AND PURIFICATION; MIDDLE AGED; MULTIMODALITY CANCER
THERAPY; PAIN/etiology; PAPILLOMA VIRUS; PATHOLOGY;
PRURITUS/etiology; REVIEW; VIROLOGY; VIRUS INFECTION;
VULVITIS/complication; ANTINEOPLASTIC AGENT/drug therapy;
FLUOROURACIL/drug administration; MITOMYCIN/drug administration
mitomycin/1404-00-8
1404-00-8
Perianal Bowen's disease is a uncommon, slow growing, intraepidermal
squamous-cell carcinoma (carcinoma in situ) of the anal region and may be a
precursor to squamous carcinoma of the anus. It is associated with cervical and
vulvar intraepithelial neoplasia and have human papillomavirus as a common
cause. Both sexes and all races are affected, with the highest prevalence in patients
aged 20 to 45 years. The symptoms of anal Bowen's disease are unspecific and the
clinical findings are uncharacteristic and include pain, itching, bleeding and a
disturbing lump. Biopsy and histopathologic examination is required for diagnosis
and to distinguish other perianal dermatoses; thus an anogenital warts that fail to
respond to conventional therapy, or change in appearance, warrant a biopsy and,
where the technique is available, DNA typing to identify the viral pathogen. Infact
the etiologic agent, the human papillomavirus (HPV), has been classified by DNA
techniques into at least 42 types, of which 16 and 18 are considered to carry a high
risk for cancer. The intraoperative findings is a lesion at the anocutaneous line:
perianal or intra-anal tumor, erosion or ulceration as well as lichenoid lesion or
hyperpigmentation. The disease has a proclivity for recurrence and there are many
controversies concerning treatment that effectiveness remains uncertain and range
from aggressive wide local excision with skin grafting when necessary to laser
vaporization (argon or CO2), radiotherapy or a new immune response modifier
(Imiquimod). We report a case of a 50-years-old woman with recurrence of
Bowen's disease associated with vulvar HPV infection and review the literature.
Bertagni A
Bertagni A
UO di Chirurgia Generale II, Unita di Chirurgia Oncologica, Ospedale GB
Morgagni-L Pierantoni, Forli.
Vagliasindi A
Vagliasindi A
Ascari Raccagni A
Ascari Raccagni A
Valmori L
AU:
CNOTE:
Valmori L
Verdecchia GM
Verdecchia GM
2/99 von 102
ND:
PMID:
Autoren:
EMM11894692
11894692
Sultan S
Titel:
Condylomes anaux: une prise en charge encore difficile.
Anal condyloma: its management is still difficult
Source:
Journal de chirurgie; VOL: 138 (5); p. 277-280 /Oct 2001/
SU:
Medline
Sprache: French
AL:
English
CY:
France
ISSN:
0021-7697
Institution: Sultan S, Service de Coloproctologie, Hopital des Diaconesses, 18, rue du
Sergent-Bauchat, F 75012 Paris.
DT:
JSC:
RN:
0037
Keywords
CT:
ANUS DISEASE/*diagnosis; ANUS DISEASE/*therapy; CONDYLOMA
ACUMINATUM/*diagnosis; CONDYLOMA ACUMINATUM/*therapy;
HUMAN; REVIEW; VIROLOGY
AB:
Anal condylomas result from papillomavirus infection, the most common sexually
transmitted disease. The principal risk is the development of cancer of the anal
canal. The risk of contamination is high, even after a single sexual contact. No
specific antiviral treatment is available and no consensus has been reached on the
appropriate treatment of anal condylomas. Despite the development of various
methods (interferon, imiquimod), electrocoagulation remains the treatment of
choice. Finally, regular follow-up and treatment of the partner(s) are essential.
AU:
Sultan S
Sultan S
Service de Coloproctologie, Hopital des Diaconesses, 18, rue du Sergent-Bauchat,
F 75012 Paris.
2/100 von 102
ND:
Autoren:
EM1998212508
Fleshner PR
Titel:
Management of anal diseases in the patient infected with human
immunodeficiency virus
Source:
Seminars in Colon and Rectal Surgery; VOL: 9 (2); p. 90-93 /1998/
SU:
EMBASE
Sprache: English
AL:
English
CY:
United States
ISSN:
1043-1489
CO:
SCRSF
Institution: Fleshner PR, Dr., 8737 Beverly Blvd, Los Angeles, CA 90048, United States
COU:
United States
DT:
JSC:
RN:
0032
Keywords
CT:
ANUS DISEASE/*surgery; ANUS DISEASE/*therapy; HUMAN
IMMUNODEFICIENCY VIRUS INFECTION/*drug therapy; ANUS
FISSURE/drug therapy; ANUS FISSURE/surgery; ANUS FISSURE/therapy;
ANUS FISTULA/surgery; ANUS FISTULA/therapy; ANUS SPHINCTER;
CAUTERIZATION; CONDYLOMA/drug therapy; CONDYLOMA/surgery;
CONDYLOMA/therapy; ERADICATION THERAPY; EXCISION;
HEMORRHOID/surgery; HEMORRHOID/therapy; HEMORRHOIDECTOMY;
HUMAN; ORAL DRUG ADMINISTRATION; PERIANAL ABSCESS/drug
therapy; PERIANAL ABSCESS/surgery; PERIANAL ABSCESS/therapy;
REVIEW; TOPICAL DRUG ADMINISTRATION; ANTI HUMAN
IMMUNODEFICIENCY VIRUS AGENT/*drug therapy; ANTIRETROVIRUS
AGENT/*drug therapy; ACICLOVIR/drug therapy; ANTIBIOTIC AGENT/drug
therapy; BOTULINUM TOXIN; CHLOROACETIC ACID/drug therapy;
FLUOROURACIL/drug therapy; GLYCERYL TRINITRATE;
IMIQUIMOD/drug therapy; LAXATIVE; PODOPHYLLOTOXIN/drug therapy
DN:
Aldara; Condylox
ET:
Immunology, Serology and Transplantation; Drug Literature Index;
Gastroenterology; Surgery
TE:
aciclovir/59277-89-3; chloroacetic acid/14526-03-5; chloroacetic acid/79-11-8;
fluorouracil/51-21-8; glyceryl trinitrate/55-63-0; imiquimod/99011-02-6;
CR:
59277-89-3; 14526-03-5; 79-11-8; 51-21-8; 55-63-0; 99011-02-6; 518-28-5
AB:
Anorectal diseases observed in the general population are common in human
AU:
CNOTE:
immunodeficiency virus-infected (HIV+) patients and may be the primary reason
they seek medical care. As more individuals contract the disease and those already
infected live longer because of improved antiviral therapy, colorectal surgeons
will frequently be involved in the care of these patients. Selective surgical
management based on the principles of correct diagnosis will result in low
operative morbidity with a high rate of symptom relief and eradication of these
anorectal diseases.
Fleshner PR
Fleshner PR
8737 Beverly Blvd, Los Angeles, CA 90048, United States
2/101 von 102
ND:
PMID:
EMM11363030
11363030
Titel:
Warts treatment.
Source: Treatment review (no 20); p. 7 /Nov 1995/
SU:
Medline
Sprache: English
CY:
United States
DT:
Journal Article
Keywords
CT:
CONDYLOMA ACUMINATUM/*drug therapy; ANAL CANAL; ARTICLE;
BIOSYNTHESIS; GENITAL SYSTEM; HUMAN; PATHOLOGY; ALPHA
INTERFERON/*; AMINOQUINOLINE DERIVATIVE/*drug therapy;
AMINOQUINOLINE DERIVATIVE/*pharmacology; ANTIVIRUS AGENT/*drug
therapy; ANTIVIRUS AGENT/*pharmacology; INTERFERON INDUCING
AGENT/*drug therapy; INTERFERON INDUCING AGENT/*pharmacology;
IMIQUIMOD
TE:
CR:
99011-02-6
2/102 von 102
DIMDI: EMBASE Alert (EA08) © 2011 Elsevier B.V.
ND:
Autoren:
EA2010704199
Newsom-Davis T; Bower M
Titel:
HIV-associated anal cancer
Source:
F1000 Medicine Reports; VOL: 2 (1) /20101208/
http://f1000.com/reports/m/2/85/pdf
M2-85
10.3410/M2-85
ANR:
DOI:
PU:
Faculty of 1000 Ltd
Sprache: English
AL:
English
CY:
United Kingdom
EISSN:
1757-5931
Institution: Bower M, Department of Oncology, Chelsea, Westminster Hospital NHS
Foundation Trust, 369 Fulham Road, London SW10 9NH, United
COU:
United Kingdom
DT:
Journal Article
RN:
0041
AB:
HIV-associated anal carcinoma, a non-AIDS-defining cancer, is a human
papillomavirus-associated malignancy with a spectrum of preinvasive changes.
The standardized incidence ratio for anal cancer in patients with HIV/AIDS is 2050. Algorithms for anal cancer screening include anal cytology followed by highresolution anoscopy for those with abnormal findings. Outpatient topical
treatments for anal intraepithelial neoplasia include infrared coagulation therapy,
trichloroacetic acid, and imiquimod. The development of cost-effective national
screening programs for HIV-associated anal cancer remains a challenge. © 2010
Faculty of 1000 Ltd.
AU:
Newsom-Davis T
Newsom-Davis Thomas
AU:
Bower M
Bower Mark
[email protected]
PU:
Faculty of 1000 Ltd
34-42 Cleveland Street, London, W1T 4LB, United Kingdom
javascript: window.close()
Anlage 4 - 24.08.2012

Anlage 2

Transcription

Similar documents